# ESC Guidelines: Peripheral Arterial Aortic (2024)

**Source**: `2024_Peripheral_Arterial_Aortic.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 163

---

## Table of Contents

- [2024 ESC Guidelines for the management of peripheral arterial and aortic diseases](#2024-esc-guidelines-for-the-management-of-peripher) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 10)*
  - [2. Introduction](#2-introduction) *(p. 11)*
  - [3. What is new](#3-what-is-new) *(p. 13)*
  - [4. Epidemiology and risk factors](#4-epidemiology-and-risk-factors) *(p. 21)*
    - [4.1. Epidemiology](#41-epidemiology) *(p. 21)*
    - [4.2. Risk factors](#42-risk-factors) *(p. 22)*
  - [5. Evaluation of peripheral arteries and aorta](#5-evaluation-of-peripheral-arteries-and-aorta) *(p. 23)*
    - [5.1. Clinical history and examination, and laboratory assessment, in patients with peripheral arterial and aortic diseases](#51-clinical-history-and-examination,-and-laborator) *(p. 23)*
    - [5.2. Functional and quality of life assessment in patients with peripheral arterial and aortic diseases](#52-functional-and-quality-of-life-assessment-in-pa) *(p. 23)*
    - [5.3. Vascular examination of peripheral arteries](#53-vascular-examination-of-peripheral-arteries) *(p. 24)*
      - [5.3.1. Duplex ultrasound](#531-duplex-ultrasound) *(p. 25)*
      - [5.3.2. Digital subtraction angiography, computed tomography angiography, and magnetic resonance angiography](#532-digital-subtraction-angiography,-computed-tomo) *(p. 25)*
    - [5.4. Evaluation of the aorta](#54-evaluation-of-the-aorta) *(p. 25)*
      - [5.4.1. Aortic measurements](#541-aortic-measurements) *(p. 25)*
      - [5.4.2. Normal aortic values](#542-normal-aortic-values) *(p. 28)*
      - [5.4.3. Chest X-ray and electrocardiogram](#543-chest-x-ray-and-electrocardiogram) *(p. 28)*
      - [5.4.4. Echocardiography](#544-echocardiography) *(p. 28)*
      - [5.4.5. Duplex ultrasound imaging of the abdominal aorta](#545-duplex-ultrasound-imaging-of-the-abdominal-aor) *(p. 29)*
      - [5.4.6. Cardiovascular computed tomography](#546-cardiovascular-computed-tomography) *(p. 29)*
      - [5.4.7. Cardiovascular magnetic resonance](#547-cardiovascular-magnetic-resonance) *(p. 29)*
      - [5.4.8. Positron emission tomography](#548-positron-emission-tomography) *(p. 29)*
      - [5.4.9. Intravascular ultrasound](#549-intravascular-ultrasound) *(p. 30)*
      - [5.4.10. Digital subtraction aortography](#5410-digital-subtraction-aortography) *(p. 30)*
  - [6. Screening for carotid, peripheral arterial, and aortic diseases](#6-screening-for-carotid,-peripheral-arterial,-and-) *(p. 30)*
    - [6.1. Screening for carotid and peripheral arterial diseases](#61-screening-for-carotid-and-peripheral-arterial-d) *(p. 30)*
      - [6.1.1. Lower-extremity peripheral arterial disease](#611-lower-extremity-peripheral-arterial-disease) *(p. 30)*
      - [6.1.2. Carotid artery stenosis](#612-carotid-artery-stenosis) *(p. 30)*
      - [6.1.3. Multisite artery disease](#613-multisite-artery-disease) *(p. 30)*
    - [6.2. Screening for aortic diseases](#62-screening-for-aortic-diseases) *(p. 31)*
      - [6.2.1. Screening for abdominal aortic aneurysm](#621-screening-for-abdominal-aortic-aneurysm) *(p. 31)*
      - [6.2.2. Screening for thoracic aortic aneurysm](#622-screening-for-thoracic-aortic-aneurysm) *(p. 31)*
  - [7. Optimal medical treatment](#7-optimal-medical-treatment) *(p. 31)*
    - [7.1. Lifestyle, exercise, patient education](#71-lifestyle,-exercise,-patient-education) *(p. 31)*
      - [7.1.1. Diet](#711-diet) *(p. 31)*
      - [7.1.2. Physical activity](#712-physical-activity) *(p. 32)*
      - [7.1.3. Smoking](#713-smoking) *(p. 33)*
      - [7.1.4. Patient education](#714-patient-education) *(p. 33)*
      - [7.1.5. Risk scoring models in secondary prevention](#715-risk-scoring-models-in-secondary-prevention) *(p. 33)*
    - [7.2. Principles of pharmacological medical therapy](#72-principles-of-pharmacological-medical-therapy) *(p. 34)*
      - [7.2.1. Antithrombotic therapy](#721-antithrombotic-therapy) *(p. 34)*
      - [7.2.2. Antihypertensive therapy](#722-antihypertensive-therapy) *(p. 34)*
        - [7.2.2.1. Renovascular hypertension](#7221-renovascular-hypertension) *(p. 34)*
      - [7.2.3. Lipid-lowering therapy](#723-lipid-lowering-therapy) *(p. 35)*
        - [7.2.3.1. Statins](#7231-statins) *(p. 35)*
        - [7.2.3.2. Ezetimibe](#7232-ezetimibe) *(p. 35)*
        - [7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors](#7233-proprotein-convertase-subtilisin/kexin-type-9) *(p. 35)*
        - [7.2.3.4. Bempedoic acid](#7234-bempedoic-acid) *(p. 35)*
        - [7.2.3.5. Hypertriglyceridaemia](#7235-hypertriglyceridaemia) *(p. 35)*
      - [7.2.4. Diabetes and pre-diabetes conditions](#724-diabetes-and-pre-diabetes-conditions) *(p. 36)*
      - [7.2.5. Other pharmacological therapy](#725-other-pharmacological-therapy) *(p. 37)*
  - [8. Peripheral arterial disease](#8-peripheral-arterial-disease) *(p. 37)*
    - [8.1. Lower-extremity peripheral arterial disease](#81-lower-extremity-peripheral-arterial-disease) *(p. 37)*
      - [8.1.1. Peripheral arterial disease syndromes](#811-peripheral-arterial-disease-syndromes) *(p. 37)*
        - [8.1.1.1. Clinical presentation and diagnosis](#8111-clinical-presentation-and-diagnosis) *(p. 37)*
          - [8.1.1.1.1. Diagnostic tests](#81111-diagnostic-tests) *(p. 38)*
          - [8.1.1.1.2. Imaging methods](#81112-imaging-methods) *(p. 39)*
        - [8.1.1.2. Medical treatment](#8112-medical-treatment) *(p. 41)*
          - [8.1.1.2.1. Exercise therapy](#81121-exercise-therapy) *(p. 41)*
          - [8.1.1.2.2. Pharmacological treatment](#81122-pharmacological-treatment) *(p. 45)*
          - [8.1.1.2.3. Aorto-iliac lesion revascularization](#81123-aorto-iliac-lesion-revascularization) *(p. 46)*
          - [8.1.1.2.4. Femoro-popliteal lesion revascularization](#81124-femoro-popliteal-lesion-revascularization) *(p. 47)*
          - [8.1.1.2.5. Below-the-knee artery revascularization](#81125-below-the-knee-artery-revascularization) *(p. 47)*
        - [8.1.1.3. Follow-up](#8113-follow-up) *(p. 48)*
      - [8.1.2. Chronic limb-threatening ischaemia](#812-chronic-limb-threatening-ischaemia) *(p. 48)*
        - [8.1.2.1. Clinical presentation and diagnosis](#8121-clinical-presentation-and-diagnosis) *(p. 48)*
          - [8.1.2.1.1. Definition](#81211-definition) *(p. 48)*
          - [8.1.2.1.2. Initial assessment and risk of amputation](#81212-initial-assessment-and-risk-of-amputation) *(p. 48)*
          - [8.1.2.1.3. Imaging](#81213-imaging) *(p. 48)*
          - [8.1.2.1.4. Mortality risk assessment](#81214-mortality-risk-assessment) *(p. 48)*
        - [8.1.2.2. Medical treatment](#8122-medical-treatment) *(p. 49)*
        - [8.1.2.3. Interventional treatment](#8123-interventional-treatment) *(p. 49)*
          - [8.1.2.3.1. Revascularization](#81231-revascularization) *(p. 49)*
          - [8.1.2.3.2. Spinal cord stimulation](#81232-spinal-cord-stimulation) *(p. 50)*
          - [8.1.2.3.3. Amputation](#81233-amputation) *(p. 50)*
        - [8.1.2.4. Follow-up](#8124-follow-up) *(p. 50)*
      - [8.1.3. Acute limb ischaemia](#813-acute-limb-ischaemia) *(p. 50)*
        - [8.1.3.1. Clinical presentation and diagnosis](#8131-clinical-presentation-and-diagnosis) *(p. 50)*
          - [8.1.3.1.1. Clinical examination](#81311-clinical-examination) *(p. 51)*
          - [8.1.3.1.2. Imaging and functional tests](#81312-imaging-and-functional-tests) *(p. 51)*
        - [8.1.3.2. Medical treatment](#8132-medical-treatment) *(p. 51)*
        - [8.1.3.3. Surgical and interventional treatment](#8133-surgical-and-interventional-treatment) *(p. 51)*
        - [8.1.3.4. Follow-up](#8134-follow-up) *(p. 53)*
    - [8.2. Extracranial carotid and vertebral artery disease](#82-extracranial-carotid-and-vertebral-artery-disea) *(p. 53)*
      - [8.2.1. Clinical presentation and diagnosis](#821-clinical-presentation-and-diagnosis) *(p. 53)*
        - [8.2.1.1. Clinical presentation](#8211-clinical-presentation) *(p. 53)*
        - [8.2.1.2. Diagnosis](#8212-diagnosis) *(p. 53)*
      - [8.2.2. Asymptomatic carotid artery stenosis](#822-asymptomatic-carotid-artery-stenosis) *(p. 54)*
        - [8.2.2.1. Medical treatment](#8221-medical-treatment) *(p. 54)*
          - [8.2.2.1.1. Lipid-lowering therapy](#82211-lipid-lowering-therapy) *(p. 54)*
          - [8.2.2.1.2. Antihypertensive therapy](#82212-antihypertensive-therapy) *(p. 54)*
          - [8.2.2.1.3. Glucose-lowering therapy](#82213-glucose-lowering-therapy) *(p. 54)*
          - [8.2.2.1.4. Antithrombotic therapy](#82214-antithrombotic-therapy) *(p. 54)*
        - [8.2.2.2. Interventional treatment](#8222-interventional-treatment) *(p. 55)*
          - [8.2.2.2.1. Open surgery vs. medical therapy](#82221-open-surgery-vs-medical-therapy) *(p. 55)*
          - [8.2.2.2.2. Carotid revascularization: surgery vs. stenting](#82222-carotid-revascularization:-surgery-vs-stenti) *(p. 55)*
      - [8.2.3. Symptomatic carotid artery stenosis](#823-symptomatic-carotid-artery-stenosis) *(p. 57)*
        - [8.2.3.1. Medical treatment](#8231-medical-treatment) *(p. 57)*
          - [8.2.3.1.1. Lipid-lowering therapy](#82311-lipid-lowering-therapy) *(p. 57)*
          - [8.2.3.1.2. Antihypertensive therapy](#82312-antihypertensive-therapy) *(p. 57)*
          - [8.2.3.1.3. Glucose-lowering therapy](#82313-glucose-lowering-therapy) *(p. 57)*
          - [8.2.3.1.4. Antithrombotic therapy](#82314-antithrombotic-therapy) *(p. 57)*
        - [8.2.3.2. Interventional treatment](#8232-interventional-treatment) *(p. 58)*
          - [8.2.3.2.1. Open surgery](#82321-open-surgery) *(p. 58)*
          - [8.2.3.2.2. Endovascular therapy vs. open surgery](#82322-endovascular-therapy-vs-open-surgery) *(p. 58)*
          - [8.2.3.2.3. Vertebral arteries](#82323-vertebral-arteries) *(p. 58)*
        - [8.2.3.3. Follow-up](#8233-follow-up) *(p. 59)*
    - [8.3. Other arterial locations](#83-other-arterial-locations) *(p. 59)*
      - [8.3.1. Subclavian artery disease](#831-subclavian-artery-disease) *(p. 59)*
        - [8.3.1.1. Clinical presentation and diagnosis](#8311-clinical-presentation-and-diagnosis) *(p. 59)*
        - [8.3.1.2. Treatment strategy (medical and interventional)](#8312-treatment-strategy-(medical-and-interventiona) *(p. 60)*
        - [8.3.1.3. Follow-up](#8313-follow-up) *(p. 60)*
      - [8.3.2. Renal artery disease](#832-renal-artery-disease) *(p. 61)*
        - [8.3.2.1. Clinical presentation and diagnosis](#8321-clinical-presentation-and-diagnosis) *(p. 61)*
          - [8.3.2.1.1. Epidemiology](#83211-epidemiology) *(p. 61)*
          - [8.3.2.1.2. Clinical presentation](#83212-clinical-presentation) *(p. 61)*
          - [8.3.2.1.3. Diagnosis of renal artery disease](#83213-diagnosis-of-renal-artery-disease) *(p. 61)*
          - [8.3.2.1.4. Prognosis](#83214-prognosis) *(p. 61)*
        - [8.3.2.2. Treatment strategy (medical and interventional)](#8322-treatment-strategy-(medical-and-interventiona) *(p. 61)*
          - [8.3.2.2.1. Medical therapy](#83221-medical-therapy) *(p. 61)*
          - [8.3.2.2.2. Revascularization](#83222-revascularization) *(p. 61)*
        - [8.3.2.3. Follow-up](#8323-follow-up) *(p. 63)*
      - [8.3.3. Visceral artery disease](#833-visceral-artery-disease) *(p. 63)*
        - [8.3.3.1. Acute mesenteric ischaemia](#8331-acute-mesenteric-ischaemia) *(p. 63)*
          - [8.3.3.1.1. Clinical presentation and diagnosis](#83311-clinical-presentation-and-diagnosis) *(p. 63)*
          - [8.3.3.1.2. Treatment strategy](#83312-treatment-strategy) *(p. 63)*
          - [8.3.3.1.3. Follow-up](#83313-follow-up) *(p. 64)*
        - [8.3.3.2. Chronic mesenteric artery disease](#8332-chronic-mesenteric-artery-disease) *(p. 64)*
          - [8.3.3.2.1. Clinical presentation and diagnosis](#83321-clinical-presentation-and-diagnosis) *(p. 64)*
          - [8.3.3.2.2. Treatment strategy](#83322-treatment-strategy) *(p. 65)*
          - [8.3.3.2.3. Follow-up](#83323-follow-up) *(p. 65)*
  - [9. Aorta](#9-aorta) *(p. 65)*
    - [9.1. Atheromatous disease of the aorta](#91-atheromatous-disease-of-the-aorta) *(p. 65)*
      - [9.1.1. General concepts](#911-general-concepts) *(p. 65)*
      - [9.1.2. Treatment](#912-treatment) *(p. 65)*
        - [9.1.2.1. Primary prevention](#9121-primary-prevention) *(p. 65)*
        - [9.1.2.2. Secondary prevention](#9122-secondary-prevention) *(p. 65)*
    - [9.2. Aortic aneurysms](#92-aortic-aneurysms) *(p. 66)*
      - [9.2.1. General concepts](#921-general-concepts) *(p. 66)*
        - [9.2.1.1. Definitions](#9211-definitions) *(p. 66)*
      - [9.2.2. Thoracic aortic aneurysms](#922-thoracic-aortic-aneurysms) *(p. 66)*
        - [9.2.2.1. Aetiology, risk factors, and natural history](#9221-aetiology,-risk-factors,-and-natural-history) *(p. 66)*
        - [9.2.2.2. Ascending thoracic aorta and arch aneurysms](#9222-ascending-thoracic-aorta-and-arch-aneurysms) *(p. 66)*
        - [9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta aneurysms](#9223-descending-thoracic-aorta-and-thoracoabdomina) *(p. 67)*
        - [9.2.2.4. Surveillance](#9224-surveillance) *(p. 70)*
      - [9.2.3. Abdominal aortic aneurysms](#923-abdominal-aortic-aneurysms) *(p. 70)*
        - [9.2.3.1. General concepts](#9231-general-concepts) *(p. 70)*
        - [9.2.3.2. Aetiology, risk factors, and natural history](#9232-aetiology,-risk-factors,-and-natural-history) *(p. 70)*
        - [9.2.3.3. Surveillance](#9233-surveillance) *(p. 70)*
      - [9.2.4. Optimal medical treatment of aortic aneurysms](#924-optimal-medical-treatment-of-aortic-aneurysms) *(p. 72)*
      - [9.2.5. Surgical management of aortic aneurysms](#925-surgical-management-of-aortic-aneurysms) *(p. 72)*
        - [9.2.5.1. Surgical treatment of aortic root and ascending aorta](#9251-surgical-treatment-of-aortic-root-and-ascendi) *(p. 72)*
        - [9.2.5.2. Surgical treatment of aortic arch aneurysms](#9252-surgical-treatment-of-aortic-arch-aneurysms) *(p. 74)*
        - [9.2.5.3. Surgical treatment of the thoracic descending aorta](#9253-surgical-treatment-of-the-thoracic-descending) *(p. 75)*
          - [9.2.5.3.1. General considerations](#92531-general-considerations) *(p. 75)*
          - [9.2.5.3.2. Open repair](#92532-open-repair) *(p. 75)*
          - [9.2.5.3.3. Endovascular repair](#92533-endovascular-repair) *(p. 75)*
        - [9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms](#9254-surgical-treatment-of-thoracoabdominal-aorta-) *(p. 75)*
          - [9.2.5.4.1. General considerations](#92541-general-considerations) *(p. 75)*
          - [9.2.5.4.2. Open repair](#92542-open-repair) *(p. 75)*
          - [9.2.5.4.3. Endovascular repair](#92543-endovascular-repair) *(p. 75)*
        - [9.2.5.5. Surgical treatment of abdominal aorta aneurysms](#9255-surgical-treatment-of-abdominal-aorta-aneurys) *(p. 76)*
          - [9.2.5.5.1. General considerations](#92551-general-considerations) *(p. 76)*
          - [9.2.5.5.2. Pre-operative cardiovascular evaluation and choice of treatment](#92552-pre-operative-cardiovascular-evaluation-and-) *(p. 76)*
          - [9.2.5.5.3. Open abdominal aorta aneurysm repair](#92553-open-abdominal-aorta-aneurysm-repair) *(p. 78)*
          - [9.2.5.5.4. Endovascular abdominal aorta aneurysm repair](#92554-endovascular-abdominal-aorta-aneurysm-repair) *(p. 78)*
      - [9.2.6. Endoleaks](#926-endoleaks) *(p. 78)*
      - [9.2.7. Long-term follow-up after aortic repair](#927-long-term-follow-up-after-aortic-repair) *(p. 80)*
        - [9.2.7.1. Follow-up after thoracic aortic aneurysm treatment](#9271-follow-up-after-thoracic-aortic-aneurysm-trea) *(p. 80)*
        - [9.2.7.2. Follow-up after abdominal aortic aneurysm treatment](#9272-follow-up-after-abdominal-aortic-aneurysm-tre) *(p. 80)*
    - [9.3. Acute thoracic aortic syndromes](#93-acute-thoracic-aortic-syndromes) *(p. 81)*
      - [9.3.1. General concepts](#931-general-concepts) *(p. 81)*
        - [9.3.1.1. Epidemiology and risk factors](#9311-epidemiology-and-risk-factors) *(p. 81)*
          - [9.3.1.1.1. Sex differences](#93111-sex-differences) *(p. 83)*
          - [9.3.1.1.2. Chronobiology](#93112-chronobiology) *(p. 84)*
          - [9.3.1.1.3. Outcomes](#93113-outcomes) *(p. 84)*
        - [9.3.1.2. Clinical presentation](#9312-clinical-presentation) *(p. 85)*
        - [9.3.1.3. Diagnostic work-up](#9313-diagnostic-work-up) *(p. 85)*
        - [9.3.1.4. Therapeutic intervention in acute aortic dissection](#9314-therapeutic-intervention-in-acute-aortic-diss) *(p. 85)*
          - [9.3.1.4.1. Initial treatment](#93141-initial-treatment) *(p. 85)*
          - [9.3.1.4.2. Type A aortic dissection interventional treatment](#93142-type-a-aortic-dissection-interventional-trea) *(p. 86)*
          - [9.3.1.4.3. Acute type B aortic dissection interventional treatment](#93143-acute-type-b-aortic-dissection-interventiona) *(p. 91)*
          - [9.3.1.4.4. Chronic type B aortic dissection interventional treatment](#93144-chronic-type-b-aortic-dissection-interventio) *(p. 92)*
          - [9.3.1.4.5. Management during pregnancy](#93145-management-during-pregnancy) *(p. 92)*
      - [9.3.2. Intramural haematoma](#932-intramural-haematoma) *(p. 93)*
        - [9.3.2.1. Diagnostic work-up](#9321-diagnostic-work-up) *(p. 93)*
        - [9.3.2.2. Clinical outcomes](#9322-clinical-outcomes) *(p. 93)*
        - [9.3.2.3. Geographical variations](#9323-geographical-variations) *(p. 93)*
        - [9.3.2.4. Management](#9324-management) *(p. 93)*
          - [9.3.2.4.1. Type A intramural haematoma](#93241-type-a-intramural-haematoma) *(p. 93)*
          - [9.3.2.4.2. Type B intramural haematoma](#93242-type-b-intramural-haematoma) *(p. 93)*
      - [9.3.3. Penetrating atherosclerotic ulcer](#933-penetrating-atherosclerotic-ulcer) *(p. 94)*
        - [9.3.3.1. Diagnosis](#9331-diagnosis) *(p. 94)*
        - [9.3.3.2. Treatment](#9332-treatment) *(p. 94)*
      - [9.3.4. Aortic pseudo-aneurysm](#934-aortic-pseudo-aneurysm) *(p. 95)*
      - [9.3.5. Traumatic aortic injury](#935-traumatic-aortic-injury) *(p. 96)*
        - [9.3.5.1. Diagnosis and therapeutic interventions](#9351-diagnosis-and-therapeutic-interventions) *(p. 96)*
        - [9.3.5.2. Long-term surveillance in traumatic aortic injury](#9352-long-term-surveillance-in-traumatic-aortic-in) *(p. 96)*
      - [9.3.6. Iatrogenic aortic injuries](#936-iatrogenic-aortic-injuries) *(p. 96)*
      - [9.3.7. Long-term follow-up of acute aortic syndrome](#937-long-term-follow-up-of-acute-aortic-syndrome) *(p. 96)*
        - [9.3.7.1. Follow-up after invasive treatment](#9371-follow-up-after-invasive-treatment) *(p. 97)*
        - [9.3.7.2. Follow-up under medical treatment (chronic type B aortic dissection, intramural haematoma, penetrating atherosclerotic ulcer)](#9372-follow-up-under-medical-treatment-(chronic-ty) *(p. 99)*
  - [10. Genetic and congenital diseases of the aorta](#10-genetic-and-congenital-diseases-of-the-aorta) *(p. 100)*
    - [10.1. Genetic and chromosomal diseases](#101-genetic-and-chromosomal-diseases) *(p. 100)*
      - [10.1.1. Turner syndrome](#1011-turner-syndrome) *(p. 101)*
        - [10.1.1.1. Diagnosis, clinical presentation, and natural history](#10111-diagnosis,-clinical-presentation,-and-natura) *(p. 101)*
        - [10.1.1.2. Medical treatment](#10112-medical-treatment) *(p. 103)*
        - [10.1.1.3. Surgery of aortic aneurysms](#10113-surgery-of-aortic-aneurysms) *(p. 103)*
        - [10.1.1.4. Pregnancy and physical exercise](#10114-pregnancy-and-physical-exercise) *(p. 103)*
      - [10.1.2. Vascular Ehlers–Danlos syndrome](#1012-vascular-ehlers–danlos-syndrome) *(p. 104)*
        - [10.1.2.1. Diagnosis, clinical presentation, and natural history](#10121-diagnosis,-clinical-presentation,-and-natura) *(p. 104)*
        - [10.1.2.2. Surveillance and imaging](#10122-surveillance-and-imaging) *(p. 104)*
        - [10.1.2.3. Medical treatment](#10123-medical-treatment) *(p. 104)*
        - [10.1.2.4. Surgical treatment](#10124-surgical-treatment) *(p. 104)*
        - [10.1.2.5. Pregnancy](#10125-pregnancy) *(p. 104)*
      - [10.1.3. Marfan syndrome](#1013-marfan-syndrome) *(p. 104)*
        - [10.1.3.1. Diagnosis, clinical presentation, and natural history](#10131-diagnosis,-clinical-presentation,-and-natura) *(p. 104)*
        - [10.1.3.2. Imaging surveillance](#10132-imaging-surveillance) *(p. 104)*
        - [10.1.3.3. Medical treatment](#10133-medical-treatment) *(p. 105)*
        - [10.1.3.4. Aortic surgery](#10134-aortic-surgery) *(p. 105)*
        - [10.1.3.5. Pregnancy and physical exercise](#10135-pregnancy-and-physical-exercise) *(p. 106)*
      - [10.1.4. Other syndromic and non-syndromic heritable thoracic aortic diseases and/or arterial disorders](#1014-other-syndromic-and-non-syndromic-heritable-t) *(p. 106)*
        - [10.1.4.1. Loeys–Dietz syndrome](#10141-loeys–dietz-syndrome) *(p. 106)*
          - [10.1.4.1.1. Diagnosis, clinical presentation, and natural evolution](#101411-diagnosis,-clinical-presentation,-and-natur) *(p. 106)*
        - [10.1.4.2. ACTA2-related heritable thoracic aortic disease](#10142-acta2-related-heritable-thoracic-aortic-dise) *(p. 108)*
    - [10.2. Aortic disease associated with bicuspid aortic valves](#102-aortic-disease-associated-with-bicuspid-aortic) *(p. 109)*
    - [10.3. Coarctation of the aorta and aortic arch variants](#103-coarctation-of-the-aorta-and-aortic-arch-varia) *(p. 111)*
      - [10.3.1. Coarctation of the aorta](#1031-coarctation-of-the-aorta) *(p. 111)*
        - [10.3.1.1. Diagnostic work-up](#10311-diagnostic-work-up) *(p. 111)*
        - [10.3.1.2. Treatment and follow-up](#10312-treatment-and-follow-up) *(p. 111)*
      - [10.3.2. Aortic arch anatomic variants](#1032-aortic-arch-anatomic-variants) *(p. 113)*
      - [10.3.3. Aberrant subclavian artery and Kommerell’s diverticulum](#1033-aberrant-subclavian-artery-and-kommerell’s-di) *(p. 113)*
  - [11. Polyvascular peripheral arterial disease and peripheral arterial disease in patients with cardiac diseases](#11-polyvascular-peripheral-arterial-disease-and-pe) *(p. 113)*
    - [11.1. Polyvascular disease](#111-polyvascular-disease) *(p. 113)*
      - [11.1.1. Epidemiology and prognosis](#1111-epidemiology-and-prognosis) *(p. 113)*
      - [11.1.2. Screening for atherosclerosis in other arterial territories](#1112-screening-for-atherosclerosis-in-other-arteri) *(p. 113)*
        - [11.1.2.1. Screening for coronary artery disease in patients with symptomatic peripheral arterial disease](#11121-screening-for-coronary-artery-disease-in-pat) *(p. 114)*
        - [11.1.2.2. Screening for peripheral arterial disease in patients with coronary artery disease](#11122-screening-for-peripheral-arterial-disease-in) *(p. 114)*
        - [11.1.2.3. Screening for coronary artery disease in patients with carotid stenosis](#11123-screening-for-coronary-artery-disease-in-pat) *(p. 114)*
        - [11.1.2.4. Screening for carotid stenosis in patients with coronary artery disease](#11124-screening-for-carotid-stenosis-in-patients-w) *(p. 114)*
      - [11.1.3. Management of patients with polyvascular disease](#1113-management-of-patients-with-polyvascular-dise) *(p. 114)*
    - [11.2. Peripheral arterial disease and heart failure](#112-peripheral-arterial-disease-and-heart-failure) *(p. 114)*
    - [11.3. Peripheral arterial disease and AF](#113-peripheral-arterial-disease-and-af) *(p. 115)*
    - [11.4. Peripheral arterial disease and aortic stenosis](#114-peripheral-arterial-disease-and-aortic-stenosi) *(p. 115)*
  - [12. Key messages](#12-key-messages) *(p. 115)*
  - [13. Gaps in evidence](#13-gaps-in-evidence) *(p. 116)*
  - [14. Sex differences](#14-sex-differences) *(p. 116)*
  - [15. ‘What to do’ and ‘What not to do’ messages from the guidelines](#15-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 116)*
  - [16. Evidence tables](#16-evidence-tables) *(p. 124)*
  - [17. Data availability statement](#17-data-availability-statement) *(p. 124)*
  - [18. Author information](#18-author-information) *(p. 124)*
  - [Appendix](#appendix) *(p. 125)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management 
of peripheral arterial and aortic diseases
Developed by the task force on the management of peripheral arterial 
and aortic diseases of the European Society of Cardiology (ESC)  
Endorsed by the European Association for Cardio-Thoracic Surgery 
(EACTS), the European Reference Network on Rare Multisystemic 
Vascular Diseases (VASCERN), and the European Society of Vascular 
Medicine (ESVM)  
Authors/Task Force Members: Lucia Mazzolai  *†, (Chairperson) (Switzerland), 
Gisela Teixido-Tura  
‡, (Task Force Co-ordinator) (Spain), Stefano Lanzi  
‡, 
(Task Force Co-ordinator) (Switzerland), Vinko Boc  
(Slovenia), 
Eduardo Bossone  
(Italy), Marianne Brodmann  
1 (Austria), 
Alessandra Bura-Rivière  
(France), Julie De Backer  
2 (Belgium), 
Sebastien Deglise  
(Switzerland), Alessandro Della Corte  
(Italy), 
Christian Heiss  
(United Kingdom), Marta Kałużna-Oleksy  
(Poland), 
Donata Kurpas  
(Poland), Carmel M. McEniery  
(United Kingdom), 
Tristan Mirault  
(France), Agnes A. Pasquet  
(Belgium), Alex Pitcher  
(United Kingdom), Hannah A.I. Schaubroeck  
(Belgium), Oliver Schlager  
(Austria), Per Anton Sirnes  
(Norway), Muriel G. Sprynger  
(Belgium), 
Eugenio Stabile  
(Italy), Françoise Steinbach (France), Matthias Thielmann  
(Germany), Roland R.J. van Kimmenade  
(Netherlands), Maarit Venermo  
(Finland), Jose F. Rodriguez-Palomares  *†, (Chairperson) (Spain), 
and ESC Scientific Document Group
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
*  Corresponding authors: Lucia Mazzolai, Department of Angiology, Lausanne University Hospital (CHUV), and Medical School, Lausanne University (UNIL) Lausanne, Switzerland. Tel: +41 
(0)21 314 0750. Email: Lucia.Mazzolai@chuv.ch; and Jose F. Rodriguez-Palomares, Cardiovascular Imaging Section and Aortic Diseases Unit (VASCERN), Department of Cardiology, Vall 
d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Centro de Investigación Biomédica en Red de 
Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain, and Department of Medicine, Universitat Autònoma de Barcelona, Spain. Tel: +34 93 882 3881. Email: 
josefernando.rodriguez@vallhebron.cat
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Society of Vascular Medicine (ESVM)
2 Representing the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Surgery, Thrombosis.
Patient Forum
https://doi.org/10.1093/eurheartj/ehae179
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Alessia Gimelli, (CPG Review Co-ordinator) (Italy), Jean-Baptiste Ricco, (CPG Review 
Co-ordinator) (France), Elena Arbelo (Spain), Christian-Alexander Behrendt (Germany), Michael Böhm 
(Germany), Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio Buccheri (Sweden), 
Gill Louise Buchanan (United Kingdom), Christina Christersson (Sweden), Gert J. de Borst (Netherlands), 
Marco De Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United Kingdom), Lynne Hinterbuchner (Austria), 
Borja Ibanez (Spain), Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan (Sweden), 
Klaus Kallenbach2 (Luxemburg), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Juraj Madaric1 
(Slovakia), Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer (Israel), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen (Denmark), 
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Barbara Rantner (Germany), Bianca Rocca (Italy), 
Xavier Rossello (Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland), Sabine Steiner (Germany), 
Isabella Sudano (Switzerland), Martin Teraa (Netherlands), Ilonca Vaartjes (Netherlands), Rafael Vidal-Perez (Spain), 
Christiaan Vrints (Belgium), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest which 
are reported in a supplementary document to the guidelines. See the European Heart Journal online or  
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and 
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, 
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant 
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged 
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do 
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated 
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s 
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC 
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational 
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written 
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of 
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Acute aortic syndrome • Aortic aneurysm • Aortic atherosclerosis • Aortic dissection • Aortic surgery 
• Carotid artery disease • Chronic limb-threatening ischaemia • Endovascular repair • Exercise • Genetic aortic 
diseases • Intramural haematoma • Lower extremity artery disease • Penetrating atherosclerotic ulcer • Peripheral 
arterial disease • Polyvascular disease • Renal artery disease
ESC Guidelines                                                                                                                                                                                          3539


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble .............................................................................................................. 3547
2. Introduction ....................................................................................................... 3548
3. What is new ....................................................................................................... 3550
4. Epidemiology and risk factors ..................................................................... 3558
4.1. Epidemiology ............................................................................................
3558
4.2. Risk factors ................................................................................................
3559
5. Evaluation of peripheral arteries and aorta .......................................... 3560
5.1. Clinical history and examination, and laboratory assessment, 
in patients with peripheral arterial and aortic diseases ..................
3560
5.2. Functional and quality of life assessment in patients with 
peripheral arterial and aortic diseases ...................................................
3560
5.3. Vascular examination of peripheral arteries ...............................
3561
5.3.1. Duplex ultrasound ......................................................................... 3562
5.3.2. Digital subtraction angiography, computed tomography 
angiography, and magnetic resonance angiography ..................... 3562
5.4. Evaluation of the aorta .........................................................................
3562
5.4.1. Aortic measurements ................................................................... 3562
5.4.2. Normal aortic values ..................................................................... 3565
5.4.3. Chest X-ray and electrocardiogram ....................................... 3565
5.4.4. Echocardiography ........................................................................... 3565
5.4.5. Duplex ultrasound imaging of the abdominal aorta ........ 3566
5.4.6. Cardiovascular computed tomography ................................ 3566
5.4.7. Cardiovascular magnetic resonance ....................................... 3566
5.4.8. Positron emission tomography ................................................. 3566
5.4.9. Intravascular ultrasound ............................................................... 3567
5.4.10. Digital subtraction aortography ............................................. 3567
6. Screening for carotid, peripheral arterial, and aortic diseases ..... 3567
6.1. Screening for carotid and peripheral arterial diseases ...........
3567
6.1.1. Lower-extremity peripheral arterial disease ....................... 3567
6.1.2. Carotid artery stenosis ................................................................ 3567
6.1.3. Multisite artery disease ................................................................. 3567
6.2. Screening for aortic diseases .............................................................
3568
6.2.1. Screening for abdominal aortic aneurysm ........................... 3568
6.2.2. Screening for thoracic aortic aneurysm ................................ 3568
7. Optimal medical treatment ......................................................................... 3568
7.1. Lifestyle, exercise, patient education .............................................
3568
7.1.1. Diet ....................................................................................................... 3568
7.1.2. Physical activity ................................................................................ 3569
7.1.3. Smoking ............................................................................................... 3570
7.1.4. Patient education ............................................................................ 3570
7.1.5. Risk scoring models in secondary prevention .................... 3570
7.2. Principles of pharmacological medical therapy ..........................
3571
7.2.1. Antithrombotic therapy ............................................................... 3571
7.2.2. Antihypertensive therapy ............................................................ 3571
7.2.2.1. Renovascular hypertension ................................................
3571
7.2.3. Lipid-lowering therapy ................................................................. 3572
7.2.3.1. Statins ..........................................................................................
3572
7.2.3.2. Ezetimibe ...................................................................................
3572
7.2.3.3. Proprotein convertase subtilisin/kexin type 9 
inhibitors ....................................................................................................
3572
7.2.3.4. Bempedoic acid .......................................................................
3572
7.2.3.5. Hypertriglyceridaemia ..........................................................
3572
7.2.4. Diabetes and pre-diabetes conditions ................................... 3573
7.2.5. Other pharmacological therapy ............................................... 3574
8. Peripheral arterial disease ............................................................................ 3574
8.1. Lower-extremity peripheral arterial disease ..............................
3574
8.1.1. Peripheral arterial disease syndromes ................................... 3574
8.1.1.1. Clinical presentation and diagnosis .................................
3574
8.1.1.1.1. Diagnostic tests ..............................................................
3575
8.1.1.1.2. Imaging methods ............................................................
3576
8.1.1.2. Medical treatment ..................................................................
3578
8.1.1.2.1. Exercise therapy ............................................................
3578
8.1.1.2.2. Pharmacological treatment .......................................
3582
8.1.1.2.3. Aorto-iliac lesion revascularization ........................
3583
8.1.1.2.4. Femoro-popliteal lesion revascularization ..........
3584
8.1.1.2.5. Below-the-knee artery revascularization ...........
3584
8.1.1.3. Follow-up ...................................................................................
3585
8.1.2. Chronic limb-threatening ischaemia ....................................... 3585
8.1.2.1. Clinical presentation and diagnosis .................................
3585
8.1.2.1.1. Definition ..........................................................................
3585
8.1.2.1.2. Initial assessment and risk of amputation ...........
3585
8.1.2.1.3. Imaging ...............................................................................
3585
8.1.2.1.4. Mortality risk assessment ...........................................
3585
8.1.2.2. Medical treatment ..................................................................
3586
8.1.2.3. Interventional treatment .....................................................
3586
8.1.2.3.1. Revascularization ............................................................
3586
8.1.2.3.2. Spinal cord stimulation ................................................
3587
8.1.2.3.3. Amputation ......................................................................
3587
8.1.2.4. Follow-up ...................................................................................
3587
8.1.3. Acute limb ischaemia .................................................................... 3587
8.1.3.1. Clinical presentation and diagnosis .................................
3587
8.1.3.1.1. Clinical examination .....................................................
3588
8.1.3.1.2. Imaging and functional tests ......................................
3588
8.1.3.2. Medical treatment ..................................................................
3588
8.1.3.3. Surgical and interventional treatment ...........................
3588
8.1.3.4. Follow-up ...................................................................................
3590
8.2. Extracranial carotid and vertebral artery disease .....................
3590
8.2.1. Clinical presentation and diagnosis ......................................... 3590
8.2.1.1. Clinical presentation .............................................................
3590
8.2.1.2. Diagnosis ....................................................................................
3590
8.2.2. Asymptomatic carotid artery stenosis .................................. 3591
8.2.2.1. Medical treatment ..................................................................
3591
8.2.2.1.1. Lipid-lowering therapy ................................................
3591
8.2.2.1.2. Antihypertensive therapy ...........................................
3591
8.2.2.1.3. Glucose-lowering therapy .........................................
3591
8.2.2.1.4. Antithrombotic therapy .............................................
3591
8.2.2.2. Interventional treatment .....................................................
3592
8.2.2.2.1. Open surgery vs. medical therapy .........................
3592
8.2.2.2.2. Carotid revascularization: surgery vs. stenting .
3592
8.2.3. Symptomatic carotid artery stenosis ..................................... 3594
8.2.3.1. Medical treatment ..................................................................
3594
8.2.3.1.1. Lipid-lowering therapy ................................................
3594
8.2.3.1.2. Antihypertensive therapy ...........................................
3594
8.2.3.1.3. Glucose-lowering therapy .........................................
3594
8.2.3.1.4. Antithrombotic therapy .............................................
3594
8.2.3.2. Interventional treatment .....................................................
3595
8.2.3.2.1. Open surgery ..................................................................
3595
8.2.3.2.2. Endovascular therapy vs. open surgery ................
3595
8.2.3.2.3. Vertebral arteries ..........................................................
3595
8.2.3.3. Follow-up ...................................................................................
3596
8.3. Other arterial locations .......................................................................
3596
8.3.1. Subclavian artery disease ............................................................. 3596
8.3.1.1. Clinical presentation and diagnosis .................................
3596
8.3.1.2. Treatment strategy (medical and interventional) .....
3597
8.3.1.3. Follow-up ...................................................................................
3597
8.3.2. Renal artery disease ....................................................................... 3598


<!-- PAGE 4 -->

### Page 4

8.3.2.1. Clinical presentation and diagnosis .................................
3598
8.3.2.1.1. Epidemiology ...................................................................
3598
8.3.2.1.2. Clinical presentation .....................................................
3598
8.3.2.1.3. Diagnosis of renal artery disease ............................
3598
8.3.2.1.4. Prognosis ...........................................................................
3598
8.3.2.2. Treatment strategy (medical and interventional) .....
3598
8.3.2.2.1. Medical therapy ..............................................................
3598
8.3.2.2.2. Revascularization ............................................................
3598
8.3.2.3. Follow-up ...................................................................................
3600
8.3.3. Visceral artery disease .................................................................. 3600
8.3.3.1. Acute mesenteric ischaemia ..............................................
3600
8.3.3.1.1. Clinical presentation and diagnosis ........................
3600
8.3.3.1.2. Treatment strategy .......................................................
3600
8.3.3.1.3. Follow-up ..........................................................................
3601
8.3.3.2. Chronic mesenteric artery disease .................................
3601
8.3.3.2.1. Clinical presentation and diagnosis ........................
3601
8.3.3.2.2. Treatment strategy .......................................................
3602
8.3.3.2.3. Follow-up ..........................................................................
3602
9. Aorta ..................................................................................................................... 3602
9.1. Atheromatous disease of the aorta ...............................................
3602
9.1.1. General concepts ............................................................................ 3602
9.1.2. Treatment .......................................................................................... 3602
9.1.2.1. Primary prevention ................................................................
3602
9.1.2.2. Secondary prevention ..........................................................
3602
9.2. Aortic aneurysms ...................................................................................
3603
9.2.1. General concepts ............................................................................ 3603
9.2.1.1. Definitions .................................................................................
3603
9.2.2. Thoracic aortic aneurysms ......................................................... 3603
9.2.2.1. Aetiology, risk factors, and natural history .................
3603
9.2.2.2. Ascending thoracic aorta and arch aneurysms .........
3603
9.2.2.3. Descending thoracic aorta and thoracoabdominal 
aorta aneurysms .....................................................................................
3604
9.2.2.4. Surveillance ...............................................................................
3607
9.2.3. Abdominal aortic aneurysms ..................................................... 3607
9.2.3.1. General concepts ...................................................................
3607
9.2.3.2. Aetiology, risk factors, and natural history .................
3607
9.2.3.3. Surveillance ...............................................................................
3607
9.2.4. Optimal medical treatment of aortic aneurysms .............. 3609
9.2.5. Surgical management of aortic aneurysms .......................... 3609
9.2.5.1. Surgical treatment of aortic root and ascending 
aorta ............................................................................................................
3609
9.2.5.2. Surgical treatment of aortic arch aneurysms .............
3611
9.2.5.3. Surgical treatment of the thoracic descending aorta
3612
9.2.5.3.1. General considerations ...............................................
3612
9.2.5.3.2. Open repair .....................................................................
3612
9.2.5.3.3. Endovascular repair ......................................................
3612
9.2.5.4. Surgical treatment of thoracoabdominal aorta 
aneurysms .................................................................................................
3612
9.2.5.4.1. General considerations ...............................................
3612
9.2.5.4.2. Open repair .....................................................................
3612
9.2.5.4.3. Endovascular repair ......................................................
3612
9.2.5.5. Surgical treatment of abdominal aorta aneurysms ..
3613
9.2.5.5.1. General considerations ...............................................
3613
9.2.5.5.2. Pre-operative cardiovascular evaluation and 
choice of treatment .........................................................................
3613
9.2.5.5.3. Open abdominal aorta aneurysm repair .............
3615
9.2.5.5.4. Endovascular abdominal aorta aneurysm repair
3615
9.2.6. Endoleaks ........................................................................................... 3615
9.2.7. Long-term follow-up after aortic repair ............................... 3617
9.2.7.1. Follow-up after thoracic aortic aneurysm treatment
3617
9.2.7.2. Follow-up after abdominal aortic aneurysm 
treatment ...................................................................................................
3617
9.3. Acute thoracic aortic syndromes ....................................................
3618
9.3.1. General concepts ............................................................................ 3618
9.3.1.1. Epidemiology and risk factors ...........................................
3618
9.3.1.1.1. Sex differences ................................................................
3620
9.3.1.1.2. Chronobiology ................................................................
3621
9.3.1.1.3. Outcomes .........................................................................
3621
9.3.1.2. Clinical presentation .............................................................
3622
9.3.1.3. Diagnostic work-up ...............................................................
3622
9.3.1.4. Therapeutic intervention in acute aortic dissection
3622
9.3.1.4.1. Initial treatment ..............................................................
3622
9.3.1.4.2. Type A aortic dissection interventional 
treatment ..............................................................................................
3623
9.3.1.4.3. Acute type B aortic dissection interventional 
treatment ..............................................................................................
3628
9.3.1.4.4. Chronic type B aortic dissection interventional 
treatment ..............................................................................................
3629
9.3.1.4.5. Management during pregnancy ................................
3629
9.3.2. Intramural haematoma ................................................................. 3630
9.3.2.1. Diagnostic work-up ...............................................................
3630
9.3.2.2. Clinical outcomes ...................................................................
3630
9.3.2.3. Geographical variations .......................................................
3630
9.3.2.4. Management .............................................................................
3630
9.3.2.4.1. Type A intramural haematoma ...............................
3630
9.3.2.4.2. Type B intramural haematoma ................................
3630
9.3.3. Penetrating atherosclerotic ulcer ............................................ 3631
9.3.3.1. Diagnosis ....................................................................................
3631
9.3.3.2. Treatment .................................................................................
3631
9.3.4. Aortic pseudo-aneurysm ............................................................. 3632
9.3.5. Traumatic aortic injury ................................................................. 3633
9.3.5.1. Diagnosis and therapeutic interventions ......................
3633
9.3.5.2. Long-term surveillance in traumatic aortic injury ....
3633
9.3.6. Iatrogenic aortic injuries .............................................................. 3633
9.3.7. Long-term follow-up of acute aortic syndrome ............... 3633
9.3.7.1. Follow-up after invasive treatment ................................
3634
9.3.7.2. Follow-up under medical treatment (chronic type B 
aortic dissection, intramural haematoma, penetrating 
atherosclerotic ulcer) ...........................................................................
3636
10. Genetic and congenital diseases of the aorta ................................... 3637
10.1. Genetic and chromosomal diseases ............................................
3637
10.1.1. Turner syndrome ......................................................................... 3638
10.1.1.1. Diagnosis, clinical presentation, and natural history
3638
10.1.1.2. Medical treatment ...............................................................
3640
10.1.1.3. Surgery of aortic aneurysms ...........................................
3640
10.1.1.4. Pregnancy and physical exercise ...................................
3640
10.1.2. Vascular Ehlers–Danlos syndrome ....................................... 3641
10.1.2.1. Diagnosis, clinical presentation, and natural history
3641
10.1.2.2. Surveillance and imaging ...................................................
3641
10.1.2.3. Medical treatment ...............................................................
3641
10.1.2.4. Surgical treatment ...............................................................
3641
10.1.2.5. Pregnancy ................................................................................
3641
10.1.3. Marfan syndrome ......................................................................... 3641
10.1.3.1. Diagnosis, clinical presentation, and natural history
3641
10.1.3.2. Imaging surveillance ............................................................
3641
10.1.3.3. Medical treatment ...............................................................
3642
10.1.3.4. Aortic surgery .......................................................................
3642
10.1.3.5. Pregnancy and physical exercise ...................................


<!-- PAGE 5 -->

### Page 5

10.1.4. Other syndromic and non-syndromic heritable thoracic 
aortic diseases and/or arterial disorders ........................................... 3643
10.1.4.1. Loeys–Dietz syndrome .....................................................
3643
10.1.4.1.1. Diagnosis, clinical presentation, and natural 
evolution ...............................................................................................
3643
10.1.4.2. ACTA2-related heritable thoracic aortic disease ....
3645
10.2. Aortic disease associated with bicuspid aortic valves ..........
3646
10.3. Coarctation of the aorta and aortic arch variants ................
3648
10.3.1. Coarctation of the aorta ........................................................... 3648
10.3.1.1. Diagnostic work-up ............................................................
3648
10.3.1.2. Treatment and follow-up .................................................
3648
10.3.2. Aortic arch anatomic variants ................................................ 3650
10.3.3. Aberrant subclavian artery and Kommerell’s 
diverticulum ................................................................................................... 3650
11. Polyvascular peripheral arterial disease and peripheral arterial 
disease in patients with cardiac diseases ..................................................... 3650
11.1. Polyvascular disease ............................................................................
3650
11.1.1. Epidemiology and prognosis .................................................... 3650
11.1.2. Screening for atherosclerosis in other arterial 
territories ....................................................................................................... 3650
11.1.2.1. Screening for coronary artery disease in patients 
with symptomatic peripheral arterial disease ............................
3651
11.1.2.2. Screening for peripheral arterial disease in patients 
with coronary artery disease ............................................................
3651
11.1.2.3. Screening for coronary artery disease in patients 
with carotid stenosis ............................................................................
3651
11.1.2.4. Screening for carotid stenosis in patients with 
coronary artery disease .......................................................................
3651
11.1.3. Management of patients with polyvascular disease ....... 3651
11.2. Peripheral arterial disease and heart failure .............................
3651
11.3. Peripheral arterial disease and AF ................................................
3652
11.4. Peripheral arterial disease and aortic stenosis ........................
3652
12. Key messages .................................................................................................. 3652
13. Gaps in evidence ............................................................................................ 3653
14. Sex differences ............................................................................................... 3653
15. ‘What to do’ and ‘What not to do’ messages from the 
guidelines .................................................................................................................. 3653
16. Evidence tables ............................................................................................... 3661
17. Data availability statement ......................................................................... 3661
18. Author information ...................................................................................... 3661
19. Appendix ........................................................................................................... 3662
Tables of Recommendations
Recommendation Table 1 — Recommendations for clinical and 
laboratory, and for functional and quality of life, assessment in patients 
with peripheral arterial and aortic disease (see also Evidence Table 1)
3560
Recommendation Table 2 — Recommendations for diagnostic tests 
in patients with peripheral arterial disease ................................................ 3562
Recommendation Table 3 — Recommendations for imaging of the 
aorta (see also Evidence Table 2) .................................................................. 3565
Recommendation Table 4 — Recommendations for thoracic aortic 
measurements ........................................................................................................ 3566
Recommendation Table 5 — Recommendations for peripheral 
arterial disease screening (see also Evidence Table 3) .......................... 3568
Recommendation Table 6 — Recommendations for abdominal 
aortic aneurysm screening ................................................................................ 3568
Recommendation Table 7 — Recommendations for lifestyle, 
physical activity, and patient education (see also Evidence Table 4)
3570
Recommendation Table 8 — Recommendations for 
antihypertensive therapy in patients with peripheral and aortic 
disease ........................................................................................................................ 3571
Recommendation Table 9 — Recommendations for lipid-lowering 
therapy in patients with peripheral arterial and aortic diseases ....... 3572
Recommendation Table 10 — Recommendations for the medical 
management of patients with peripheral arterial and aortic diseases 
and diabetes ............................................................................................................ 3573
Recommendation Table 11 — Recommendations for diagnostic 
tests in patients with peripheral arterial disease and diabetes, renal 
failure, and wounds .............................................................................................. 3577
Recommendation Table 12 — Recommendations for imaging in 
patients with peripheral arterial disease ..................................................... 3577
Recommendation Table 13 — Recommendations for exercise 
therapy in patients with peripheral arterial disease (see also Evidence 
Table 5) ..................................................................................................................... 3582
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with peripheral arterial disease 
(see also Evidence Table 6) .............................................................................. 3582
Recommendation Table 15 — Recommendations for interventional 
treatment of asymptomatic and symptomatic peripheral arterial 
disease (general) .................................................................................................... 3584
Recommendation Table 16 — Recommendations for interventional 
treatment of patients with symptomatic peripheral arterial disease 
(per arterial bed) ................................................................................................... 3585
Recommendation Table 17 — Recommendations in patients with 
peripheral arterial disease: follow-up of patients with peripheral 
arterial disease ........................................................................................................ 3585
Recommendation Table 18 — Recommendations for the 
management of chronic limb-threatening ischaemia ............................. 3586
Recommendation Table 19 — Recommendations for medical 
treatment in patients with chronic limb-threatening ischaemia (see 
also Evidence Table 7) ........................................................................................ 3586
Recommendation Table 20 — Recommendations for interventional 
treatment of chronic limb-threatening ischaemia ................................... 3587
Recommendation Table 21 — Recommendations for follow-up in 
patients with chronic limb-threatening ischaemia .................................. 3587
Recommendation Table 22 — Recommendations for the 
management of patients presenting with acute limb ischaemia (see 
also Evidence Table 8) ........................................................................................ 3590
Recommendation Table 23 — Recommendations for carotid artery 
stenosis assessment ............................................................................................. 3590
Recommendation Table 24 — Recommendations for 
antithrombotic treatment in patients with carotid stenosis .............. 3592
Recommendation Table 25 — Recommendations for interventional 
treatment in patients with asymptomatic carotid artery stenosis ... 3594
Recommendation Table 26 — Recommendations for evaluation and 
medical treatment in patients with symptomatic carotid artery 
stenosis ...................................................................................................................... 3594
Recommendation Table 27 — Recommendations for interventions 
in patients with symptomatic carotid artery stenosis ........................... 3596
Recommendation Table 28 — Recommendations for follow-up in 
patients with carotid artery stenosis ............................................................ 3596
Recommendation Table 29 — Recommendations for the 
management of subclavian artery stenosis (see also Evidence 
Table 9) ..................................................................................................................... 3597
Recommendation Table 30 — Recommendations for diagnostic 
strategies for renal artery disease .................................................................. 3600


<!-- PAGE 6 -->

### Page 6

Recommendation Table 31 — Recommendations for treatment 
strategies for renal artery disease (see also Evidence Table 10) ...... 3600
Recommendation Table 32 — Recommendations in patients with 
visceral artery stenosis ........................................................................................ 3602
Recommendation Table 33 — Recommendations for primary and 
secondary prevention in aortic atheromatous plaques ........................ 3602
Recommendation Table 34 — Recommendations for initial 
evaluation of thoracic aortic aneurysm and abdominal aortic 
aneurysm .................................................................................................................. 3603
Recommendation Table 35 — Recommendation for the surveillance 
of patients with thoracic aortic aneurysms (non-heritable thoracic 
aortic disease) ......................................................................................................... 3607
Recommendation Table 36 — Recommendations for surveillance of 
patients with abdominal aortic aneurysm .................................................. 3609
Recommendation Table 37 — Recommendations for medical 
treatment in patients with thoracic aorta or abdominal aortic 
aneurysms ................................................................................................................ 3609
Recommendation Table 38 — Recommendations for surgery in 
aortic root and ascending aorta dilatation associated with tricuspid 
aortic valve (see also Evidence Table 11) ................................................... 3611
Recommendation Table 39 — Recommendations for surgery in 
aortic arch aneurysms ......................................................................................... 3611
Recommendation Table 40 — Recommendations for the 
management of patients presenting with descending thoracic aortic 
and thoracoabdominal aortic aneurysms ................................................... 3613
Recommendation Table 41 — Recommendations for the 
management of patients presenting with abdominal aortic 
aneurysm .................................................................................................................. 3615
Recommendation Table 42 — Recommendations for the 
management of patients presenting with endoleaks ............................. 3617
Recommendation Table 43 — Recommendations for follow-up 
after treatment of aortic aneurysms (see also Evidence Table 12)
3618
Recommendation Table 44 — Recommendations for diagnostic 
work-up of acute aortic syndromes ............................................................. 3622
Recommendation Table 45 — Recommendation for medical 
treatment in acute aortic syndromes ........................................................... 3623
Recommendation Table 46 — Recommendations for intervention 
in type A acute aortic dissection .................................................................... 3624
Recommendation Table 47 — Recommendations for aortic repair 
strategies in type A acute aortic dissection ............................................... 3624
Recommendation Table 48 — Recommendations for the 
management of malperfusion in the setting of acute aortic 
dissection .................................................................................................................. 3628
Recommendation Table 49 — Recommendations for the 
management of patients presenting with acute type B aortic 
dissection .................................................................................................................. 3629
Recommendation Table 50 — Recommendations for the 
management of patients presenting with chronic type B aortic 
dissection .................................................................................................................. 3629
Recommendation Table 51 — Recommendations for the 
management of intramural haematoma ...................................................... 3631
Recommendation Table 52 — Recommendations for the 
management of penetrating atherosclerotic ulcer ................................. 3631
Recommendation Table 53 — Recommendations for traumatic 
aortic injury .............................................................................................................. 3633
Recommendation Table 54 — Recommendations for follow-up 
after treatment of acute aortic syndrome ................................................. 3637
Recommendation Table 55 — Recommendations for the 
management of patients with heritable thoracic aortic disease ....... 3637
Recommendation Table 56 — Recommendations for genetic testing 
and aortic screening in aortic disease .......................................................... 3638
Recommendation Table 57 — Recommendations for imaging in 
women with Turner syndrome ...................................................................... 3638
Recommendation Table 58 — Recommendations for aortic surgery 
in women with Turner syndrome ................................................................. 3640
Recommendation Table 59 — Recommendations for medical 
treatment in patients with vascular Ehlers–Danlos syndrome (see 
also Evidence Table 13) ...................................................................................... 3641
Recommendation Table 60 — Recommendations for vascular 
imaging in Marfan syndrome ............................................................................ 3642
Recommendation Table 61 — Recommendations for medical 
treatment in Marfan syndrome (see also Evidence Table 14) ........... 3642
Recommendation Table 62 — Recommendations for aortic surgery 
in Marfan syndrome ............................................................................................. 3642
Recommendation Table 63 — Recommendations for pregnancy in 
women with Marfan syndrome ...................................................................... 3643
Recommendation Table 64 — Recommendations for physical 
exercise in patients with Marfan syndrome .............................................. 3643
Recommendation Table 65 — Recommendations for imaging 
follow-up in Loeys–Dietz syndrome ............................................................ 3644
Recommendation Table 66 — Recommendations for aortic root 
surgery in Loeys–Dietz syndrome ................................................................. 3644
Recommendation Table 67 — Recommendations for imaging and 
surgery in ACTA2-related heritable thoracic aortic disease (see also 
Evidence Table 11) ............................................................................................... 3645
Recommendation Table 68 — Recommendations for bicuspid aortic 
valve-associated aortopathy management ........................................................
3647
Recommendation Table 69 — Recommendations for evaluation and 
medical treatment of patients with coarctation of the aorta ............ 3648
Recommendation Table 70 — Recommendations for screening and 
management of polyvascular disease and peripheral arterial disease 
with cardiac diseases (see also Evidence Table 15) ............................... 3652
List of tables
Table 1 Classes of recommendations .......................................................... 3547
Table 2 Levels of evidence ................................................................................ 3548
Table 3 New recommendations .................................................................... 3550
Table 4 Revised recommendations ............................................................... 3555
Table 5 Main aortic imaging techniques ...................................................... 3564
Table 6 High-risk populations for carotid artery stenosis .................. 3567
Table 7 Peripheral arterial disease categorized according to clinical 
presentation ............................................................................................................ 3574
Table 8 Assessment of the risk of amputation: the Wound, 
Ischaemia, and foot Infection classification ................................................ 3577
Table 9 Clinical categories of acute limb ischaemia ............................... 3588
Table 10 Peak systolic velocity criteria for grading internal carotid 
artery stenosis ........................................................................................................ 3591
Table 11 High-risk features associated with increased risk of stroke 
in patients with asymptomatic internal carotid artery stenosis on 
optimal medical treatment ................................................................................ 3592
Table 12 High-risk peri-operative features for carotid 
endarterectomy ..................................................................................................... 3595
Table 13 Clinical signs suggestive of renal artery disease .................... 3598
Table 14 Grading of atherosclerotic aortic plaques .............................. 3603
Table 15 Overview of factors favouring open vs. endovascular repair 
in thoracoabdominal aortic aneurysm ......................................................... 3613
Table 16 High-risk features of intramural haematoma type A and B
3630
Table 17 Need for assessment of associated atherosclerotic disease in 
additional vascular territories in symptomatic patients with coronary 
artery disease, peripheral arterial disease, or carotid stenosis ...............
3651
Table 18 ‘What to do’ and ‘What not to do’ .......................................... 3654
ESC Guidelines                                                                                                                                                                                          3543


<!-- PAGE 7 -->

### Page 7

List of figures
Figure 1 Central illustration: from diagnosis to treatment, a holistic 
multidisciplinary peripheral arterial and aortic diseases approach .. 3549
Figure 2 Estimated specific prevalence of peripheral arterial disease, 
by sex, in people aged 40 years and older ................................................. 3558
Figure 3 Main risk factors associated with atherosclerosis in 
peripheral arterial and aortic diseases ......................................................... 3559
Figure 4 Haemodynamic assessment of peripheral arterial disease
3561
Figure 5 Anatomy and aortic segments and upper normal values for 
aortic dimensions .................................................................................................. 3563
Figure 6 Conventional measurements of the aorta at different 
levels by echocardiography or duplex ultrasound (A, B, C), 
cardiovascular computed tomography or cardiovascular magnetic 
resonance (D, E, F) ......................................................................................... 3564
Figure 7 Cardiovascular risk modification and healthy lifestyle 
interventions and targets in patients with peripheral arterial and 
aortic diseases ........................................................................................................ 3569
Figure 8 Cardiovascular risk in patients with peripheral arterial disease
3575
Figure 9 Diagnostic algorithm for peripheral arterial disease ............ 3576
Figure 10 Optimal medical treatment in patients with peripheral 
arterial disease ........................................................................................................ 3578
Figure 11 Treatment algorithm in peripheral arterial disease without 
wounds ................................................................................................................................
3579
Figure 12 Treatment algorithm in peripheral arterial disease with 
wounds ...................................................................................................................... 3580
Figure 13 Exercise training characteristics and benefits in patients 
with peripheral arterial disease ....................................................................... 3581
Figure 14 Long-term antithrombotic therapy in patients with 
symptomatic peripheral arterial disease ..........................................................
3583
Figure 15 Patients with chronic symptomatic PAD after 
endovascular revascularization ........................................................................ 3584
Figure 16 Management of acute limb ischaemia ...................................... 3589
Figure 17 North American Symptomatic Carotid Endarterectomy 
Trial/European Carotid Surgery Trial methods ....................................... 3591
Figure 18 Algorithm of carotid artery stenosis management ............ 3593
Figure 19 Diagnostic and treatment algorithm for renal artery 
stenosis ...................................................................................................................... 3599
Figure 20 Algorithm of chronic mesenteric ischaemia management
3601
Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, 
screening and diagnostic methods ................................................................. 3604
Figure 22 Classification of thoracoabdominal and abdominal aortic 
aneurysms ................................................................................................................ 3605
Figure 23 Risk factors for thoracic and abdominal aneurysm rupture
3606
Figure 24 Surveillance of patients with non-heritable thoracic 
aortic disease and abdominal aortic aneurysms ...................................... 3608
Figure 25 Peri-operative algorithm for the management of patients 
with surgically treated aortic root and ascending aortic aneurysm
3610
Figure 26 Algorithm for individual decision-making process in the 
treatment of patients with abdominal aortic aneurysm ...................... 3614
Figure 27 Algorithm for follow-up after thoracic endovascular aortic 
aneurysm repair, and management of endoleaks and their classification
3616
Figure 28 Anatomical and temporal classification of acute aortic 
syndrome .................................................................................................................. 3619
Figure 29 Aortic dissection classification system based on the 2020 
Society for Vascular Surgery/Society of Thoracic Surgeons 
Reporting Standards and the European update of the Stanford 
classification—Type Entry Malperfusion classification .......................... 3620
Figure 30 Multiparametric diagnostic work-up of acute aortic 
syndrome .................................................................................................................. 3621
Figure 31 Medical management of acute aortic syndrome ................. 3623
Figure 32 Complications in acute aortic syndromes, clinical evidence 
associated with malperfusion syndrome, and in-hospital mortality 
associated with these complications ............................................................ 3625
Figure 33 Interventional treatment algorithm in acute aortic 
dissection .................................................................................................................. 3626
Figure 34 Mechanisms and clinical management of aortic branch 
obstruction in acute aortic dissection .......................................................... 3627
Figure 35 High-risk features in penetrating atherosclerotic ulcer and 
management of patients with type B penetrating atherosclerotic 
ulcer ............................................................................................................................ 3632
Figure 36 Classification and treatment of traumatic aortic injuries
3634
Figure 37 Aetiology, risk factors, and classification of iatrogenic 
aortic injuries .......................................................................................................... 3635
Figure 38 Algorithm for follow-up after acute aortic syndrome ..... 3636
Figure 39 Algorithm for genetic and imaging screening in patients 
with thoracic aortic disease .............................................................................. 3639
Figure 40 Algorithm for surveillance in women (≥15 years) with 
Turner syndrome .................................................................................................. 3640
Figure 41 Algorithm for imaging surveillance in patients with 
syndromic and non-syndromic heritable thoracic aortic disease ..... 3644
Figure 42 Suggested thresholds for prophylactic aortic root/ 
ascending replacement in Loeys–Dietz syndrome ................................. 3645
Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature . 3646
Figure 44 Criteria for significant coarctation/re-coarctation of the 
aorta and management algorithm .................................................................. 3649
Figure 45 Reported rate ranges of other localizations of 
atherosclerosis in patients with a specific arterial disease .................. 3650
Abbreviations and acronyms
18F–NaF
Fluorine-18–sodium fluoride
6MWD
Six-minute walking distance
6MWT
Six-minute walk test
AA
Abdominal aorta
AAA
Abdominal aortic aneurysm
AAD
Acute aortic dissection
AAE
Aortic adverse events
AAL
Ascending aortic length
AAS
Acute aortic syndrome
ABI
Ankle–brachial index
ACAS
Asymptomatic Carotid Atherosclerosis Study
ACB
Asymptomatic Cervical Bruit Study
ACC/AHA
American College of Cardiology and American 
Heart Association
ACEI
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
ACST
Asymptomatic Carotid Surgery Trial
ACTA2
Alpha-actin gene
AD
Aortic dissection
ADAM
American Aneurysm Detection and Management
ADD-RS
Aortic dissection detection-risk score
AF
Atrial fibrillation
AHI
Aortic height index
ALI
Acute limb ischaemia
AMI
Acute mesenteric ischaemia
AP
Antero-posterior
ARB
Angiotensin receptor blocker
ARR
Absolute risk reduction
ASCVD
Atherosclerotic cardiovascular disease
ASE
American Society of Echocardiography


<!-- PAGE 8 -->

### Page 8

ASI
Aortic size index
BASIL
Bypass versus Angioplasty in Severe Ischaemia of 
the Leg trial
BAV
Bicuspid aortic valve
BB
Beta-blocker
BEST-CLI
Best Endovascular versus Best Surgical Therapy for 
Patients with Critical Limb Ischemia trial b.i.d.
Bis in die (twice daily)
BMI
Body mass index
BP
Blood pressure b.p.m.
Beats per minute
BSA
Body surface area
BTK
Below-the-knee
CABG
Coronary artery bypass grafting
CAD
Coronary artery disease
CANTOS
Canakinumab Anti-Inflammatory Thrombosis 
Outcomes Study
CANVAS
Canagliflozin Cardiovascular Assessment Study
CAS
Carotid artery stenting
CCA
Common carotid artery
CCB
Calcium channel blocker
CCT
Cardiovascular computed tomography
CDT
Catheter-based thrombectomy cdTLR
Clinically driven target lesion revascularization
CEA
Carotid endarterectomy
CEUS
Contrast-enhanced ultrasound
CHA2DS2-VASc
Congestive heart failure, hypertension, age ≥75 
(doubled), diabetes, stroke (doubled), vascular 
disease, age 65 to 74 and sex category (female)
CI
Confidence interval cIMT
Carotid intima media thickness
CK
Creatinine kinase
CKD
Chronic kidney disease
CLTI
Chronic limb-threatening ischaemia
CMI
Chronic mesenteric ischaemia
CMR
Cardiovascular magnetic resonance
CoA
Coarctation of the aorta
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COPD
Chronic obstructive pulmonary disease
CP
Carotid plaque
CREDENCE
Canagliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evaluation
CREST-2
Carotid Revascularization Endartectomy vs. 
Stenting Trial 2
CRP
C-reactive protein
CS
Carotid artery stenosis
CSA/h
Cross-sectional area-to-height ratio
CT
Computed tomography
CTA
Computed tomography angiography
CV
Cardiovascular
CVD
Cardiovascular disease
CVRF
Cardiovascular risk factor
DAPT
Dual antiplatelet therapy
DBP
Diastolic blood pressure
DD
D-dimer
DISSECT
Duration, Intimal tear, Size, Segmental Extent, 
Clinical complications, Thrombosis
DPI
Dual pathway inhibition
DSA
Digital subtraction angiography
DTA
Descending thoracic aorta
DUS
Duplex ultrasound
DWI
Diffusion-weighted imaging
ECG
Electrocardiogram
ECST
European Carotid Surgery Trial eGFR
Estimated glomerular filtration rate
EMPA-REG 
OUTCOME
(Empagliflozin) Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients
ESC
European Society of Cardiology
ESH
European Society of Hypertension
ESRD
End-stage renal disease
EUCLID
Examining Use of tiCagreLor In peripheral artery 
Disease
FDA
(United States) Food and Drug Administration
FDG
Fluorodeoxyglucose
FDR
First-degree relative
FET
Frozen elephant trunk
FID
Focal intimal disruption
FL
False lumen
GERAADA
German Registry of Acute Aortic Dissection Type 
A
GFR
Glomerular filtration rate
GLP-1RA
Glucagon-like peptide-1 receptor agonist
GSV
Great saphenous vein
HADS
Hospital anxiety and depression score
HbA1c
Glycated haemoglobin
HBET
Home-based exercise training
HF
Heart failure
HITS
High-intensity transient signal
HOME
Hyperinsulinaemia: the Outcomes of its Metabolic 
Effects
HR
Hazard ratio
HRQoL
Health-related quality of life hs-CRP
High-sensitivity C-reactive protein
HSR
High surgical risk
HTAD
Heritable thoracic aortic disease
IC
Intermittent claudication
ICA
Internal carotid artery
ID
Intimal disruption
IL
Interleukin
ILT
Intensive lipid-lowering therapy
IMA
Inferior mesenteric artery
IMH
Intramural haematoma
IMPROVE-AD
The Improving outcomes in vascular disease— 
aortic dissection trial
IMPROVE-IT
IMProved Reduction of Outcomes: Vytorin 
Efficacy International Trial
IPE
Icosapent ethyl
IRAD
International Registry of Acute Aortic Dissection
ISTH
International Society on Thrombosis and 
Haemostasis i.v.
Intravenous
IVUS
Intravascular ultrasound
LDL-C
Low-density lipoprotein cholesterol
LEADER
Liraglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome Results 
trial
LSA
Left subclavian artery
LV
Left ventricular
MACE
Major adverse cardiac event
ESC Guidelines                                                                                                                                                                                          3545


<!-- PAGE 9 -->

### Page 9

MAD
Multisite artery disease
MALE
Major adverse limb event
MAP
Mean arterial pressure
MESA
Multi-Ethnic Study of Atherosclerosis
MFS
Marfan syndrome
MHV
Mechanical heart valve
MI
Myocardial infarction
MRA
Magnetic resonance angiography
MRI
Magnetic resonance imaging
MWD
Maximal walking distance
NASCET
North American Symptomatic Carotid 
Endarterectomy Trial
OAC
Oral anticoagulation o.d.
Once daily
OMT
Optimal medical treatment
OR
Odds ratio
PAAD
Peripheral arterial and aortic diseases
PA
Popliteal aneurysm
PAD
Peripheral arterial disease
PAU
Penetrating atherosclerotic ulcer
PC-AKI
Post-contrast acute kidney injury
PCSK9
Proprotein convertase subtilisin/kexin type 9
PET
Positron emission tomography
PET-CT
PET-computed tomography
PFWD
Pain-free walking distance
PROM
Patient-reported outcome measure
PSV
Peak systolic velocity
PSVr
Peak systolic velocity ratio
PVD
Polyvascular disease
QoL
Quality of life
RAR
Renal-aortic peak flow velocity ratio
RAS
Renal artery stenosis
RCT
Randomized controlled trial
REACH
The REduction of Atherothrombosis for 
Continued Health
REDUCE-IT
Reduction of Cardiovascular Events With 
Icosapent Ethyl–Intervention Trial
ROMS
Retrograde open mesenteric stenting
ROPAC
Registry Of Pregnancy And Cardiac disease
RPE
Rate of perceived exertion
RR
Relative risk
SAMMPRIS
Stenting and Aggressive Medical Management for 
Preventing Recurrent Stroke in Intracranial 
Stenosis trial
SAPPHIRE
Stenting and Angioplasty with Protection in 
Patients at High Risk for Endarterectomy trial
SAPT
Single antiplatelet therapy
SBP
Systolic blood pressure
SCI
Spinal cord ischaemia
SCS
Spinal cord stimulation
SET
Supervised exercise training
SF-36
Short-form 36-item health questionnaire
SGLT2i
Sodium-glucose co-transporter-2 inhibitor
SMA
Superior mesenteric artery
SMART
Secondary Manifestation of ARTerial disease
SOCRATES
Acute Stroke or Transient Ischaemic Attack 
Treated with Aspirin or Ticagrelor and Patient 
Outcomes trial
SCORE2
Systematic Coronary Risk Evaluation 2
SCORE2-Diabetes
Systematic Coronary Risk Evaluation 2 - diabetes
SCORE2-OP
Systematic Coronary Risk Evaluation 2–Older 
Persons
SPACE-2
Stent Protected Angioplasty versus Carotid 
Endarterectomy study
SPPB
Short physical performance battery
SRUCC
Society of Radiologists in Ultrasound
SS
Subclavian stenosis
SSFP
Steady-state free precession
STJ
Sinotubular junction
STS/AATS
Society of Thoracic Surgeons/American 
Association for Thoracic Surgery
SUSTAIN-6
Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes with Semaglutide in 
Subjects with Type 2 Diabetes
SVS
Society for Vascular Surgery
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TAA
Thoracic aortic aneurysm
TAAA
Thoracoabdominal aortic aneurysm
TAAD
Type A aortic dissection
TAD
Thoracic aortic disease
TAI
Traumatic aortic injury
TAV
Tricuspid aortic valve
TAVI
Transcatheter aortic valve implantation
TBAD
Type B aortic dissection
TBI
Toe–brachial index
TCAR
Transcarotid artery revascularization
TcPO2
Transcutaneous oxygen pressure
TOE
Transoesophageal echocardiography
TEM
Type entry malperfusion classification
TEVAR/EVAR
Thoracic endovascular aortic aneurysm  
repair
TFCAS
Transfemoral carotid artery stenting
THALES
Acute Stroke or Transient Ischaemic Attack 
Treated with Ticagrelor and acetylsalicylic acid for 
Prevention of Stroke and Death trial
TIA
Transient ischaemic attack
TIMI
Thrombolysis in myocardial infarction
TP
Toe pressure
TS
Turner syndrome
TTE
Transthoracic echocardiography
UEAD
Upper-limb artery disease
UKPDS
United Kingdom Prospective Diabetes Study: 
clinical and therapeutic implications for type 2 
diabetes uTBAD
Uncomplicated type B aortic dissection
VascuQoL
Vascular quality of life questionnaire
VAST
Vertebral Artery Stenting Trial vEDS
Vascular Ehlers–Danlos syndrome
VIST
Vertebral Artery Ischaemia Stenting Trial
VKA
Vitamin K antagonist
WELCH
Walking Estimated Limitation Calculated by 
History
WIfI
Wound, Ischaemia, foot Infection classification
WIQ
Walking Impairment Questionnaire


<!-- PAGE 10 -->

### Page 10

### 1 Preamble

Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeutic 
approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription and to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated when warranted by new evidence. ESC 
Policies and Procedures for formulating and issuing ESC Guidelines can 
be found on the ESC website (https://www.escardio.org/Guidelines/ 
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- 
Guidelines). This guideline updates and replaces the previous periph­
eral arterial disease and aortic disease guidelines from 2017 and 
2014, respectively.
The Members of this task force were selected by the ESC to include 
professionals involved with the medical care of patients with this path­
ology as well as patient representatives and methodologists. The selec­
tion procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
and inclusion, notably with respect to gender and country of origin. 
The task force performed a critical review and evaluation of the pub­
lished literature on diagnostic and therapeutic approaches including as­
sessment of the risk–benefit ratio. The strength of every 
recommendation and the level of evidence supporting them were 
weighed and scored according to pre-defined scales as outlined in 
Tables 1 and 2 below. Patient-reported outcome measures (PROMs) 
and patient-reported experience measures (PREMs) were also evalu­
ated as the basis for recommendations and/or discussion in these 
guidelines. The task force followed ESC voting procedures and all ap­
proved recommendations were subject to a vote and achieved at least 
75% agreement among voting members. Members of the task force 
with declared interests on specific topics were asked to abstain from 
voting on related recommendations.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules which 
can be found on the ESC website (http://www.escardio.org/guidelines) 
and have been compiled in a report published in a supplementary docu­
ment with the guidelines. Funding for the development of ESC 
Guidelines is derived entirely from the ESC with no involvement of 
the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
for the approval process. In addition to review by the CPG 
Committee, ESC Guidelines undergo multiple rounds of double-blind 
peer review by external experts, including members from across the 
whole of the ESC region, all National Cardiac Societies of the ESC 
and from relevant ESC Subspecialty Communities. After appropriate 
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
ESC Guidelines                                                                                                                                                                                          3547


<!-- PAGE 11 -->

### Page 11

revisions, the guidelines are signed off by all the experts in the task 
force. The finalized document is signed off by the CPG Committee 
for publication in the European Heart Journal.
ESC Guidelines are based on analyses of published evidence, chiefly 
on clinical trials and meta-analyses of trials, but potentially including 
other types of studies. Evidence tables summarizing key information 
from relevant studies are generated early in the guideline development 
process to facilitate the formulation of recommendations, to enhance 
comprehension of recommendations after publication, and reinforce 
transparency in the guidelines development process. The tables are 
published in their own section of ESC Guidelines and reference specific 
recommendation tables.
Off-label use of medication may be presented in this guideline if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Peripheral arterial and aortic diseases (PAAD) are highly prevalent 
and significantly increase cardiovascular (CV) mortality and 
morbidity in the general population,1,2 consequently, intensive pre­
ventive strategies are needed. However, patients with PAAD are 
generally underdiagnosed and undertreated3,4 compared with pa­
tients with coronary artery disease (CAD).5 Common risk factors 
in PAAD often coexist, requiring a multidisciplinary approach for ef­
fective management.5 Early diagnosis is crucial for better outcomes. 
These guidelines address PAAD, updating and merging the 2017 
peripheral arterial diseases and 2014 aortic diseases guidelines. 
The focus is primarily on atherosclerotic arterial diseases, but 
they also address some non-atherosclerotic genetic conditions. 
While not exhaustive, these 2024 guidelines offer guidance on 
diagnosis, surveillance, and treatment. A number of new and revised 
recommendations are summarized in Tables 3 and 4, respectively. 
Readers should consider non-atherosclerotic conditions and refer 
to specific documents.6–9
A general approach to PAAD is provided in the central illustration 
(Figure 1).
In the management of PAAD, the following aspects must be 
highlighted: 
• Shared 
decision-making 
to 
involve 
patients, 
explore 
treatment options, assess patient values, and reach decisions 
collaboratively.
• Multidisciplinary approach (Figure 1) in expert and high-volume 
PAAD centres for complex patients or procedures. These centres 
provide diverse services, including diagnosis, treatment planning, 
minimally invasive procedures, open surgery, post-operative and out­
patient care, and ideally, research and innovation. They should provide 
continuous clinical service (24/7) and have access to digital imaging. 
These guidelines recognize variations in healthcare systems, population 
sizes, and needs, impacting the definition of ‘high volume’ in PAAD care 
across countries.
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024


<!-- PAGE 12 -->

### Page 12

Diagnosis
Cardiologist
Angiologist
Vascular surgeon
Geneticist
Cardiac surgeon
CV radiologist
CV intensive care specialist
Neurologist
Anaesthetist
Nurse
Nephrologist
Exercise therapist
Follow-up
Treatment
Prevention
Goals
Initial steps
Clinical assessment
Functional assessment
QoL assessment
Use of non-invasive tools
Imaging, if appropriate
Optimal medical treatment
Patient education
CVRFs control
Exercise/rehabilitation programmes
Need for intervention/
surgery?
Regular follow-up
Optimal medical treatment
CVRFs management
Patient education
Patient’s tailored targets and goals
Family screening, if appropriate
Increase awareness
CVRFs management
Screening
Genetic counselling
Prevent development of peripheral and aortic atherosclerosis
Prevent aortic dilation or lesions
Improve patients’ QoL and functioning
Reduce risk of MACE and MALE
Improve survival
Reduce the risk of hospitalization
Reduce the need for intervention/surgery
Screen patients at risk of PAAD
Enable early access to treatment
Ensure optimal medical treatment
Figure 1 Central illustration: from diagnosis to treatment, a holistic multidisciplinary peripheral arterial and aortic diseases approach. CV, cardiovas­
cular; CVRFs, cardiovascular risk factors; MACE, major adverse cardiac event; MALE, major adverse limb event; PAAD, peripheral arterial and aortic 
diseases; QoL, quality of life.
ESC Guidelines                                                                                                                                                                                          3549


<!-- PAGE 13 -->

### Page 13

### 3 What is new

Table 3 New recommendations
Recommendations
Class
Level
Recommendations for clinical and laboratory, and for functional quality of life, assessment in patients with peripheral arterial and aortic 
disease
When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of arterial circulation.
I
B
Recommendations for peripheral arterial disease screening
In patients with AAA, femoro-popliteal aneurysm screening with DUS should be considered.
IIa
C
In patients needing intervention with transfemoral access, screening for iliofemoral artery disease may be considered.
IIb
C
In patients with two or more CVRFs, screening for asymptomatic CS may be considered.
IIb
C
Recommendations for abdominal aortic aneurysm screening
Opportunistic AAA screening with DUS should be considered in symptomatic/asymptomatic PAD patients.
IIa
B
Recommendations for lifestyle, physical activity, and patient education
Use of web- or app-based secondary prevention risk calculators should be considered in the shared decision-making to improve patient 
adherence to treatment and lifestyle changes.
IIa
C
E-cigarettes may be considered as an aid to quitting tobacco smoking, but it is advisable to limit their use and avoid simultaneous use with 
conventional cigarettes due to unknown long-term effects.
IIb
C
Recommendations for lipid-lowering therapy in patients with peripheral arterial and aortic diseases
In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended.
I
A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with 
atherosclerotic PAAD.
I
A
If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in 
patients with atherosclerotic PAAD, to achieve target values.
I
A
If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to achieve 
the given target values.
I
B
For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is 
recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.
I
B
Statins for the reduction of growth and rupture of AAA should be considered.
IIa
B
Statins for the reduction of growth and rupture of TAA may be considered.
IIb
B
In high-risk patients with PAAD and triglycerides >1.5 mmol/L despite lifestyle measures and statin therapy, icosapent ethyl 2 g b.i.d. may be 
considered in addition to a statin.
IIb
B
Fibrates are not recommended for cholesterol lowering.
III
B
Recommendations for exercise therapy in patients with peripheral arterial disease
In patients with symptomatic PAD, SET is recommended.
I
A
In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy.
I
A
When SET is not available or feasible, a structured and monitored (calls, logbooks, connected devices) HBET programme should be 
considered.
IIa
A
Walking should be considered as the first-line training modality. When walking exercise is not an option, alternative exercise modes (strength 
training, arm cranking, cycling, and combinations of different training modes) should also be considered.
IIa
A
Walking training performed at high intensity (77%–95% of maximal heart rate or 14–17 self-perceived exertion on Borg’s scale) should be 
considered to improve walking performance, and high-intensity exercise training (various aerobic training modes) should be considered to 
improve cardiorespiratory fitness.
IIa
A
Training frequency of at least three times per week, training session duration of at least 30 min, and training programme duration of at least 12 
weeks should be considered.
IIa
B
In patients with PAD, exercise training to moderate-severe claudication pain may be considered to improve walking performance. However, 
improvements are also achievable with lesser claudication pain severities (low-mild pain or pain-free).
IIb
B
Based on patient’s tolerance, a progressive increase (every 1–2 weeks) in exercise training load may be considered.
IIb
C
Continued


<!-- PAGE 14 -->

### Page 14

Recommendations for antithrombotic therapy in patients with peripheral arterial disease
Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD and high 
ischaemic risk, and non-high bleeding risk.
IIa
A
Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD and non-high 
bleeding risk following lower-limb revascularization.
IIa
B
Aspirin (75–100 mg) for primary prevention may be considered in patients with asymptomatic PAD and DM, in the absence of 
contraindications.
IIb
A
Recommendations for interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)
In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended.
I
B
It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general 
patient condition.
I
C
In patients with symptomatic PAD and impaired PAD-related QoL after a 3 month period of OMT and exercise therapy, revascularization 
may be considered.
IIb
B
In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI.
III
B
In patients with asymptomatic PAD, revascularization is not recommended.
III
C
Recommendations for interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed)
In femoro-popliteal lesions, drug-eluting treatment should be considered as the first-choice strategy.
IIa
A
In femoro-popliteal lesions, if revascularization is indicated, an open surgical approach should be considered when an autologous vein (e.g. 
GSV) is available in patients with low surgical risk.
IIa
C
In patients with severe IC undergoing endovascular femoro-popliteal revascularization, treatment of BTK arteries may be considered in the 
same intervention.
IIb
C
Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease
It is recommended to regularly, at least once a year, follow-up patients with PAD, assessing clinical and functional status, medication 
adherence, limb symptoms, and CVRFs, with DUS assessment as needed.
I
C
Recommendations for the management of chronic limb-threatening ischaemia
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage.
I
C
Recommendations for medical treatment in patients with chronic limb-threatening ischaemia
It is recommended that patients with CLTI are managed by a vascular team.
I
C
In patients with CLTI and ulcers, offloading mechanical tissue stress is indicated to allow wound healing.
I
C
Lower-limb exercise training is not recommended in patients with CLTI and wounds.
III
C
Recommendations for interventional treatment of chronic limb-threatening ischaemia
In CLTI patients, it is recommended to perform revascularization as soon as possible.
I
B
In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery.
I
B
In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions.
I
C
In CLTI patients with good autologous veins and low surgical risk (<5% peri-operative mortality, >50% 2 year survival), infra-inguinal bypass 
may be considered.
IIb
B
In CLTI patients, endovascular treatment may be considered as first-line therapy, especially in patients with increased surgical risk or 
inadequate autologous veins.
IIb
B
Recommendations for follow-up in patients with chronic limb-threatening ischaemia
In patients with CLTI, following revascularization it is recommended to follow-up patients on a regular basis.
I
C
At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs.
I
C
Recommendations for carotid artery stenosis assessment
It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis.
I
B
It is not recommended to use the ECST method for ICA stenosis assessment.
III
C
Recommendations for the management of subclavian artery stenosis
Bilateral arm BP measurement is recommended for all patients with PAAD.
I
B
Endovascular revascularization may be considered over surgery, despite similar long-term outcomes, due to lower complication rates.
IIb
B
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended.
III
C
Recommendations for diagnostic strategies for renal artery disease
DUS is recommended as the first-line imaging modality in patients with suspicion of RAS.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3551


<!-- PAGE 15 -->

### Page 15

Recommendations for treatment strategies for renal artery disease
Revascularization
In patients with atherosclerotic unilateral >70% RAS, concomitant high-risk features, and signs of kidney viability, renal artery revascularization 
should be considered after OMT has been established.
IIa
B
In patients with atherosclerotic bilateral (>70%) RAS or RAS in a solitary kidney, concomitant high risk features, and signs of kidney viability, 
renal artery revascularization should be considered.
IIa
B
In patients with hypertension and/or signs of renal dysfunction due to RAS caused by fibromuscular dysplasia, concomitant high-risk features, 
and signs of kidney viability, revascularization with primary balloon angioplasty and bailout stenting should be considered.
IIa
B
In patients with an indication for renal artery revascularization and complex anatomy, or after failed endovascular revascularization, open 
surgical revascularization should be considered.
IIa
B
In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended.
III
A
Recommendations in patients with visceral artery stenosis
In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended.
I
C
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended.
III
C
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
In patients with dilatation of the tubular ascending aorta who can be offered surgery with low predicted risk, ascending aortic replacement 
should be considered at a maximum diameter >52 mm.
IIa
B
In patients undergoing surgery for tricuspid aortic valve disease who have concomitant dilatation of the aortic root or ascending tubular aorta, 
and low predicted surgical risk, ascending aorta or root replacement should be considered at a maximum diameter ≥45 mm, otherwise 
≥50 mm.
IIa
B
SAPT with low-dose aspirin (75–100 mg/day) should be considered for the first 3 months after valve-sparing aortic surgery when there are no 
other baseline indications for OAC.
IIa
C
In patients undergoing non-aortic-valve cardiac surgery who have concomitant dilatation of the ascending aorta or aortic root with a 
maximum diameter ≥50 mm, concomitant aortic surgery should be considered.
IIa
C
Recommendations for surgery in aortic arch aneurysms
In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to 
non-aortic causes, open surgical replacement of the arch is recommended.
I
C
In patients undergoing open surgical repair of an aortic arch aneurysm, an elephant trunk or frozen elephant trunk procedure should be 
considered if the aneurysmal disease extends into the proximal descending thoracic aorta.
IIa
C
Recommendations for follow-up after treatment of aortic aneurysms
After open repair of TAA, an early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years 
and every 5 years thereafter is recommended if findings are stable.
I
B
After 5 post-operative years without complications, continuing long-term follow-up of TEVAR by CCT every 5 years should be considered.
IIa
B
If growth of the excluded aneurysm is observed, without evidence of type I or III endoleak, repeating CCT every 6–12 months, depending on 
the growth rate observed, should be considered.
IIa
C
In low-risk patients, from 1 year post-operatively after EVAR, repeating DUS/CEUS every 2 years should be considered.
IIa
B
If any abnormality during DUS/CEUS is found, confirmation should be considered using additional CCT or CMR (based on potential artefacts).
IIa
B
Recommendations for diagnostic work-up of acute aortic syndrome
CCT from neck to pelvis is recommended as the first-line imaging technique in patients with suspected AAS since it is widely available, 
accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).
I
C
In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications.
I
C
Recommendations for medical treatment in acute aortic syndromes
In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching to 
oral BBs and, if necessary, up-titration of other BP-lowering agents is recommended after 24 h if gastrointestinal transit is preserved.
I
B
If the patient has a contraindication for BBs, a non-dihydropyridine calcium blocker should be considered.
IIa
B
Recommendations for intervention in type A acute aortic dissection
In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic 
root replacement is recommended with a mechanical or biological valved conduit.
I
B
In patients presenting with acute TAAD, transfer from a low- to a high-volume aortic centre with the presence of a multidisciplinary team 
should be considered to improve survival if transfer can be accomplished without significant delay in surgery.
IIa
B
In selected patients, a valve-sparing root repair may be considered, when performed by experienced surgeons.
IIb
B
Continued


<!-- PAGE 16 -->

### Page 16

Recommendations for aortic repair strategies in type A acute aortic dissection
In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is 
recommended over valve replacement.
I
B
In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL 
thrombosis rates.
I
B
In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more 
extensive arch replacement.
I
B
In patients with acute TAAD and a secondary intimal tear in the arch or proximal DTA, extended aortic repair with stenting of the proximal 
DTA (e.g. by the frozen elephant technique) may be considered to reduce late distal aortic complications (e.g. aneurysm evolution of the 
remaining dissected descending aorta).
IIb
C
Recommendations for the management of malperfusion in the setting of acute aortic dissection
In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is 
recommended.
I
B
In patients with acute TAAD presenting with cerebral malperfusion or non-haemorrhagic stroke, immediate aortic surgery should be 
considered to improve neurological outcome and reduce mortality.
IIa
B
In patients with acute TAAD presenting with clinically significant mesenteric malperfusion syndrome, immediate invasive angiographic 
diagnostics to evaluate percutaneous malperfusion repair before or directly after aortic surgery, in aortic centres with expertise, should be 
considered.
IIa
C
Recommendations for the management of patients presenting with acute type B aortic dissection
In patients with uncomplicated acute TBAD, TEVAR in the subacute phase (between 14 and 90 days) should be considered in selected 
patients with high-risk features to prevent aortic complications.
IIa
B
Recommendations for the management of patients presenting with chronic type B aortic dissection
In chronic TBAD and with a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable surgical risk.
I
B
In patients with chronic TBAD and a descending thoracic aortic diameter ≥55 mm, an indication for intervention should be considered in 
patients with low procedural risk.
IIa
C
In patients with chronic post-dissection thoracoabdominal aortic aneurysms, the use of fenestrated/branched stent grafts may be considered, 
when treatment is indicated.
IIb
C
Recommendations for the management of penetrating atherosclerotic ulcer
In uncomplicated type B PAU with high-risk imaging features, endovascular treatment should be considered.
IIa
C
Recommendations for traumatic aortic injury
In cases of severe aortic injury (grade 4), immediate repair is recommended.
I
A
In minimal aortic injury (grades 1 or 2), initial medical therapy under careful clinical and imaging surveillance should be considered.
IIa
C
In cases of progression of the IMH (grade 2), semi-elective repair (within 24–72 h) should be considered.
IIa
C
Recommendations for follow-up after treatment of acute aortic syndrome
In medically treated type B AAS or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging findings 
are stable.
I
C
In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable.
I
C
After open surgery for AAS, follow-up imaging by CCT and TTE within 6 months, then CCT at 12 months and then yearly if findings are stable, 
should be considered.
IIa
B
If no complications occur within the first 5 years, CCT every 2 years thereafter should be considered.
IIa
B
If no residual patent FL is documented for 3 post-operative years, subsequent surveillance by CCT every 2–3 years should be considered.
IIa
C
In the follow-up of medically treated PAU, after 2 years of imaging stability, larger intervals should be considered in low-risk patients.
IIa
C
Recommendations for the management of patients with heritable thoracic aortic disease
It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making.
I
C
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in 
the care of this patient group.
I
C
Recommendations for genetic testing and aortic screening in aortic disease
In patients with HTAD, guidance of clinical management by the underlying gene/variant, when known, should be considered.
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3553


<!-- PAGE 17 -->

### Page 17

Recommendations for imaging in women with Turner syndrome
To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to BSA 
[m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and assess 
the risk of aortic dissection.
I
C
It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending 
ASI and concomitant lesions.
I
C
Recommendations for aortic surgery in women with Turner syndrome
Elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered in women with TS who are ≥15 years of age, 
have an ascending ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, and have associated risk factors for aortic dissection or are planning 
pregnancy.
IIa
C
Elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women with TS who are ≥15 years of age, 
have an ascending ASI >25 mm/m2, an AHI >25 mm/m, a z-score >4, and who do not have associated risk factors for aortic dissection.
IIb
C
Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome
In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended.
I
C
Treatment with celiprolol should be considered in patients with vEDS.
IIa
B
Recommendations for vascular imaging in Marfan syndrome
In patients with MFS, TTE is recommended: 
• At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factors
• At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factors
• At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factors
I
C
In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aortic imaging by CMR or CCT and DUS is 
recommended at the first evaluation, and subsequently every 3–5 years if stable.
I
C
Recommendations for medical treatment in Marfan syndrome
In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to reduce 
the rate of aortic dilatation.
I
A
In patients with MFS, the use of both a BB and an ARB, in maximally tolerated doses (unless contraindicated), should be considered to reduce 
the rate of aortic dilatation.
IIa
A
Recommendations for pregnancy in women with Marfan syndrome
It is recommended that all women with MFS: 
• Have a pre-conception evaluation to address the risks of maternal CV and other complications
• Have follow-up in a centre with access to a pregnancy heart and vessel team
I
C
It is recommended that couples in which a partner has or is at risk of HTAD be offered pre-conception genetic counselling.
I
C
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy.
I
C
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth.
I
C
Intake of BBs during pregnancy is recommended.
I
C
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm.
I
C
Prophylactic aortic root surgery may be considered in women desiring pregnancy with aortic diameters of 40–45 mm.
IIb
C
Recommendations for physical exercise in patients with Marfan syndrome
It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and 
pre-existing fitness.
I
C
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS.
I
C
For patients who present with aortic dissection and/or have undergone aortic surgery, post-operative cardiac rehabilitation aiming at 
improving both physical and mental health should be considered.
IIa
B
Recommendations for imaging follow-up in Loeys–Dietz syndrome
In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth, is 
recommended.
I
C
In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance 
with CMR or CCT or DUS every 1–3 years is recommended.
I
C
Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease
Annual monitoring of the aortic root/ascending aorta with TTE to evaluate for aortic root/ascending aorta enlargement is recommended.
I
C
Imaging of the aorta with CMR/CCT every 3–5 years is recommended.
I
C
Prophylactic aortic root surgery should be considered with a diameter ≥45 mm, or lower in cases with other risk factors.
IIa
C
Continued


<!-- PAGE 18 -->

### Page 18

Recommendations for bicuspid aortic valve-associated aortopathy management
Surgery for bicuspid aortopathy of the root phenotype is recommended when the maximum aortic diameter is ≥50 mm.
I
B
Screening by TTE in FDRs of BAV patients with root phenotype aortopathy and/or isolated aortic regurgitation is recommended.
I
C
In patients with low surgical risk, surgery for bicuspid aortopathy of ascending phenotype should be considered when the maximum aortic 
diameter is >52 mm.
IIa
B
Recommendations for evaluation and medical treatment of patients with coarctation of the aorta
In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR 
every 3–5 years (adapted to clinical status and previous imaging findings).
I
B
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.
I
A
In patients with stable PVD who are symptomatic in at least one territory and without high bleeding risk, treatment with a combination of 
rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered.
IIa
A
© ESC 2024
AAA, abdominal aortic aneurysm; AAD, acute aortic dissection; AAS, acute aortic syndrome; AHI, aortic height index; ARB, angiotensin receptor blocker; ASI, aortic size index; BAV, bicuspid 
aortic valve; BB, beta-blocker; b.i.d., twice daily; BP, blood pressure; BTK, below-the-knee; BSA, body surface area; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced 
ultrasound; CLTI, chronic limb-threatening ischaemia; CMR, cardiovascular magnetic resonance; CS, carotid artery stenosis; CV, cardiovascular; CVRFs, cardiovascular risk factors; DM, 
diabetes mellitus; DTA, descending thoracic aorta; DUS, duplex ultrasound; ECST, European Carotid Surgery Trial; FDR, first-degree relative; FL, false lumen; GSV, great saphenous vein; 
HBET, home-based exercise training; HTAD, heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; IC, intermittent claudication; i.v., intravenous; 
LDL-C, low-density lipoprotein cholesterol; MFS, Marfan syndrome; NASCET, North American Symptomatic Carotid Endarterectomy Trial; OAC, oral anticoagulation; o.d., once daily; 
OMT, optimal medical treatment; PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; PVD, polyvascular disease; 
QoL, quality of life; RAS, renal artery stenosis; SAPT, single antiplatelet therapy; SET, supervised exercise training; TAA, thoracic aortic aneurysm; TAAD, type A aortic dissection; 
TBAD, type B aortic dissection; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TS, Turner syndrome; TTE, transthoracic 
echocardiography; vEDS, vascular Ehlers–Danlos syndrome.
Table 4 Revised recommendations
Recommendations in 2017 (PAD) and 2014 
(Aortic)
Class
Level
Recommendations in 2024
Class
Level
Recommendations for abdominal aortic aneurysm screening
Screening for AAA with DUS
Is recommended in all men >65 years of age.
I
A
Is recommended in men aged ≥65 years with a history of 
smoking to reduce the risk of death from ruptured AAA.
I
A
(i) May be considered in women >65 years of age with 
history of current/past smoking.
IIb
C
May be considered in men aged ≥75 years (irrespective of 
smoking history) or in women aged ≥75 years who are 
current smokers, hypertensive, or both.
IIb
C
(ii) Is not recommended in female non-smokers without 
familial history.
III
C
Family AAA screening with DUS
Targeted screening for AAA with ultrasound should be 
considered in first-degree siblings of a patient with AAA.
IIa
B
Is recommended for FDRs of patients with AAA aged 
≥50, unless an acquired cause can be clearly identified.
I
C
Opportunistic AAA screening with DUS
Targeted screening for AAA with ultrasound should be 
considered in first-degree siblings of patients with AAA.
IIa
B
Should be considered in men ≥65 years and in women 
aged ≥75 years during TTE.
IIa
B
Recommendations for antihypertensive therapy in patients with peripheral and aortic disease
In patients with PAD and hypertension, it is recommended 
to control blood pressure at <140/90 mmHg
I
A
In patients with PAAD and hypertension an SBP target 
towards 120–129 mmHg, if tolerated, is recommended.
I
A
ACEIs or ARBs should be considered as first-line therapy 
in patients with PAD and hypertension.
IIa
B
ACEIs/ARBs may be considered in all patients with PAD, 
regardless of BP levels, in the absence of contraindications.
IIb
B
Recommendations for lipid-lowering therapy for patients with peripheral arterial and aortic diseases
In patients with PAD, it is recommended to reduce LDL-C 
to <1.8 mmol/L (70 mg/dL) or decrease it by >50% if 
baseline values are 1.8–3.5 mmol/L (70–135 mg/dL).
I
C
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a 
>50% reduction in LDL-C vs. baseline are recommended 
in patients with atherosclerotic PAAD.
I
A
Recommendations for carotid artery stenosis assessment
DUS (as first-line imaging), CTA, and/or MRA are 
recommended for evaluating the extent and severity of 
extracranial carotid stenosis.
I
B
It is recommended to use DUS as first-line imaging to 
diagnose ICA stenosis.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3555


<!-- PAGE 19 -->

### Page 19

Recommendations in patients with visceral artery stenosis
In patients with acute embolic occlusion of the SMA, both 
endovascular and open surgery therapy should be 
considered.
IIa
B
In patients with acute mesenteric ischaemia due to acute 
occlusion of the SMA, endovascular revascularization is 
recommended.
I
B
Recommendations for surveillance of patients with abdominal aorta aneurysm
In patients with small (30–55 mm) AAA, the following 
time interval should be considered: 
• Every 3 years for AAA of 30–39 mm diameter
• Every 2 years for AAA of 40–44 mm diameter
• Every year for AAA >45 mm diameter.
IIa
B
DUS surveillance should be considered annually in women 
with AAA of 40–45 mm and in men with AAA of 40– 
49 mm.
IIa
B
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
Surgery should be considered in patients who have 
isolated aortic arch aneurysm with a maximal diameter 
≥55 mm.
IIa
C
Surgery is recommended in patients with dilatation of the 
aortic root or ascending aorta with a tricuspid aortic valve 
and a maximum diameter of ≥55 mm.
I
B
Aortic valve repair using the reimplantation technique or 
remodelling with aortic annuloplasty is recommended in 
young patients with aortic root dilation and tricuspid 
aortic valves.
I
C
Valve-sparing aortic root replacement is recommended in 
patients with aortic root dilatation if performed in 
experienced centres and durable results are expected.
I
B
Lower thresholds for intervention may be considered 
according to BSA in patients with small stature or in the 
case of rapid progression, aortic valve regurgitation, 
planned pregnancy, and patient’s preference.
IIb
C
Ascending aortic or root replacement may be considered 
at a maximum diameter of ≥50 mm in patients with 
proximal aorta dilatation who can be offered surgery with 
low predicted risk and present with any of the following: 
• Growth of the aortic diameter ≥3 mm per year
• Resistant hypertension
• Short stature (<1.69 m)
• Root phenotype
• Aortic length >11 cm
• Age <50 years
• Desire for pregnancy
• Aortic coarctation.
IIb
B
Recommendations for surgery in aortic arch aneurysms
Aortic arch repair may be considered in patients with 
aortic arch aneurysm who already have an indication for 
surgery of an adjacent aneurysm located in the ascending 
or descending aorta.
IIb
C
In patients undergoing open surgical repair of an ascending 
aortic aneurysm, concomitant hemi-arch replacement 
should be considered if the dilatation extends into the 
proximal aortic arch (>50 mm).
IIa
C
Recommendations for follow-up after treatment of aortic aneurysms
After TEVAR or EVAR, surveillance is recommended after 
1, 6, and 12 months and then yearly. Shorter intervals can 
be proposed in the event of abnormal findings requiring 
closer surveillance.
I
C
After TEVAR, follow-up imaging is recommended at 1 and 
12 months post-operatively, then yearly until the fifth 
post-operative year if no abnormalities are documented.
I
B
Long-term surveillance of open abdominal aortic repair 
may be considered at loose (5 year) intervals using colour 
DUS or CCT imaging.
IIb
C
After open repair of AAA, first follow-up imaging is 
recommended within 1 post-operative year, and every 5 
years thereafter if findings are stable.
I
A
If neither endoleak nor AAA sac enlargement is 
documented during first year after EVAR, then colour 
DUS, with or without contrast agents, should be 
considered for annual post-operative surveillance, with 
non-contrast CT imaging every 5 years.
IIa
C
After EVAR, follow-up imaging is recommended with CCT 
(or CMR) and DUS/CEUS at 1 month and 12 months 
post-operatively, then, if no abnormalities are documented, 
DUS/CEUS is recommended every year, repeating CCT or 
CMR (based on potential artefacts) every 5 years.
I
A
Recommendations for diagnostic work-up of acute aortic syndrome
TTE is recommended as an initial imaging investigation. 
In stable patients with a suspicion of AAS, the following 
imaging modalities are recommended (or should be 
considered according to local availability and expertise):
I
C
In patients with suspected AAS, focused TTE (with use of 
contrast if feasible) is recommended during the initial 
evaluation.
I
C
MRI
I
C
In patients with suspected AAS, CMR should be 
considered as an alternative imaging technique if CCT is 
not available.
IIa
C
Continued


<!-- PAGE 20 -->

### Page 20

TOE
IIa
C
In patients with suspected AAS, TOE is recommended to 
guide peri-operative management and detect 
complications.
I
C
Recommendations for medical treatment in acute aortic syndromes
In all patients with AD, medical therapy, including pain 
relief and blood pressure control, is recommended.
I
C
Invasive monitoring with an arterial line and continuous 
three-lead ECG recording, as well as admission to an 
intensive care unit, is recommended.
I
B
Recommendations for the management of patients presenting with acute type B aortic dissection
In complicated TBAD, TEVAR is recommended.
I
C
In patients with complicated acute TBAD, emergency 
intervention is recommended.
I
B
In complicated TBAD, surgery may be considered.
IIb
C
In complicated TBAD, TEVAR may be recommended.
IIb
C
In patients with complicated acute TBAD, TEVAR is 
recommended as the first-line therapy.
I
B
In complicated TBAD, surgery may be considered.
IIb
C
Recommendations for the management of intramural haematoma
In complicated type B IMH, TEVAR should be considered.
IIa
C
In complicated type B IMH, TEVAR is recommended.
I
C
Recommendations for the management of penetrating atherosclerotic ulcer
In the case of type A PAU, surgery should be considered.
IIa
C
In the case of type A PAU, surgery is recommended.
I
C
In complicated type B PAU, TEVAR should be considered.
IIa
C
In complicated type B PAU, endovascular treatment is 
recommended.
I
C
Recommendations for traumatic aortic injury
In cases of TAI with suitable anatomy requiring 
intervention, TEVAR should be preferred to surgery.
IIa
C
In cases of TAI with suitable anatomy requiring 
intervention, TEVAR is recommended over open surgery.
I
A
Recommendations for genetic testing and aortic screening in aortic disease
It is recommended to investigate FDRs (siblings and 
parents) of a subject with TAAD to identify a familial form 
in which relatives all have a 50% chance of carrying the 
family mutation/disease.
I
C
Imaging screening of family members of patients with 
TAD with risk factors for HTAD in whom no (likely) 
pathogenic variant is identified should be considered 
starting at age 25, or 10 years below the youngest case, 
whichever is younger. If the initial screening is normal, 
continued screening every 5 years until the age of 60 
should be considered.
IIa
C
Recommendations for bicuspid aortic valve-associated aortopathy management
Cardiac MRI or CT is indicated in patients with BAV when 
the morphology of the aortic root and the ascending aorta 
cannot be accurately assessed by TTE.
I
C
CCT or CMR of the entire thoracic aorta is 
recommended at first diagnosis and when important 
discrepancies in measurements are found between 
subsequent TTE controls during surveillance, or when the 
diameter of the aorta exceeds 45 mm.
I
C
In the case of aortic diameter >50 mm or an increase of 
>3 mm per year measured by echocardiography, 
confirmation of the measurement is indicated, using 
another imaging modality (CT or MRI).
I
C
In the case of a diameter of the aortic root or the 
ascending aorta >45 mm or an increase of >3 mm per 
year measured by echocardiography, annual 
measurement of aortic diameter is indicated.
I
C
Surveillance serial imaging by TTE is recommended in BAV 
patients with a maximum aortic diameter >40 mm, either 
with no indication for surgery or after isolated aortic valve 
surgery, after 1 year, then if stability is observed, every 2–3 
years.
I
C
In cases of BAV, surgery of the ascending aorta is indicated 
in the case of: 
• Aortic root or ascending aortic diameter >50 mm in the 
presence of other risk factors (coarctation of the aorta, 
systemic hypertension, family history of dissection, or 
increase in aortic diameter of >3 mm per year).
I
C
In patients with low surgical risk and ascending phenotype 
bicuspid aortopathy, surgery should be considered at a 
maximum diameter ≥50 mm if any of the following is the 
case: 
• Age <50 years
• Short stature
• Ascending aortic length ≥11 cm
• Aortic diameter growth rate >3 mm per year
• Family history of acute aortic syndrome
• Aortic coarctation
• Resistant hypertension
• Concomitant non-aortic-valve cardiac surgery
• Desire for pregnancy
IIa
C
Continued 
ESC Guidelines                                                                                                                                                                                          3557


<!-- PAGE 21 -->

### Page 21

### 4 Epidemiology and risk factors

4.1. Epidemiology
Peripheral arterial disease (PAD) is prevalent worldwide and affects 113 
million people aged 40 and older, of which 42.6% are in countries with a 
low-to-middle sociodemographic index. Global prevalence is 1.52%, in­
creases with age (14.91% in those aged 80–84 years), and is higher in 
females than in males (18.03% vs. 10.56%, in the same age group).10–13
PAD prevalence rose by 72% from 1990 to 2019, considering a 
45% growth rate in the world population.10,11,14 The overall global 
age-standardized prevalence is about 1470 per 100 000 persons (Figure 2).14
Ischaemic cerebral disease, mainly linked to carotid stenosis (65% of 
cases), has a prevalence of 77.19 million, marking a 95% increase from 
1990 to 2019.15
The overall prevalence of aortic disease including aneurysm and 
dissections is estimated at around 1% to 3% in the general population, 
with up to 10% prevalence in older age groups. European studies show 
a decrease in abdominal aortic aneurysm (AAA) prevalence in screened 
men >65 years of age, at 1.3%–3.3%,16,17 contrasting with the United 
States of America’s 5% found in screened male smokers.16,17
Globally, in 2019, there were 172 000 aortic aneurysm-related deaths 
(82.1% increase from 1990).10
In cases of BAV, surgery of the ascending aorta is indicated 
in the case of: 
• Aortic root or ascending aortic diameter >45 mm 
when surgical aortic valve replacement is scheduled.
I
C
Surgery for bicuspid aortopathy in patients undergoing 
aortic valve surgery should be considered at a root or 
ascending diameter ≥45 mm.
IIa
C
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients undergoing CABG, DUS is recommended in 
patients with a recent (<6 months) history of TIA/stroke.
I
B
Carotid DUS should be considered for stable patients 
scheduled for CABG with TIA/stroke within the past 6 
months without carotid revascularization.
IIa
B
© ESC 2024
AAA, abdominal aortic aneurysm; AAS, acute aortic syndrome; ACEI, angiotensin-converting enzyme inhibitor; AD, aortic dissection; ARB, angiotensin receptor blocker; BAV, bicuspid aortic 
valve; BP, blood pressure; BSA, body surface area; CABG, coronary artery bypass grafting; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced ultrasound; CMR, 
cardiovascular magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; DUS, duplex ultrasound; ECG, electrocardiogram; FDR, first-degree relative; 
HTAD, heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; LDL-C, low-density lipoprotein cholesterol; MRA, magnetic resonance angiography; 
MRI, magnetic resonance imaging; PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; SBP, systolic blood pressure; 
SMA, superior mesenteric artery; TAAD, type A aortic dissection; TAD, thoracic aortic disease; TAI, traumatic aortic injury; TBAD, type B aortic dissection; TOE, transoesophageal 
echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TIA, transient ischaemic attack; TTE, transthoracic echocardiography.
30 000
25 000
20 000
15 000
10 000
5000
0
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
Female
Male
Age (years)
Prevalence rate (per 100 000 population)
Figure 2 Estimated specific prevalence of peripheral arterial disease, by sex, in people aged 40 years and older. Adapted from12 under the terms of the 
Open access Creative Commons CC-BY license.


<!-- PAGE 22 -->

### Page 22

4.2. Risk factors
Main PAAD risk factors are summarized in Figure 3. Traditional risk factors 
in tools like Framingham, Reynolds, Atherosclerotic Cardiovascular Disease 
(ASCVD) risk estimator Plus (United States of America), SCORE2 
(Systematic Coronary Risk Evaluation 2, age 40–69 years), SCORE2- 
Diabetes (Systematic Coronary Risk Evaluation 2 - diabetes), and 
SCORE2-OP (Systematic Coronary Risk Evaluation 2–Older Persons) 
(Europe)18 also contribute to PAAD’s pathophysiology and development. 
More details are available in Supplementary data online, Section 1.1, and the 
Low-density lipoprotein cholesterol (LDL-C) is a pivotal factor in 
atherosclerosis,19 with diabetes and tobacco exposure significantly 
A
t h
e r
o s
c l
e r
o t
i c
 
P
A
A
D
Traditional risk factors
Non-traditional risk factors
Female-specific risk factors
Non-modifiable risk factors
Modifiable risk factors
Overweight
Sedentary lifestyle
Sleep disorders
Apolipoproteins
Environmental pollution
Socio-economic status
Menopause
Pregnancy-induced hypertension/
diabetes
Polygenic and family inheritance
Sex
Age
Tobacco
Diabetes
Lipids
Hypertension
Stressful lifestyle
Alcohol
Diet
Inﬂammation
Autoimmune disease
Figure 3 Main risk factors associated with atherosclerosis in peripheral arterial and aortic diseases. PAAD, peripheral arterial and aortic diseases.
ESC Guidelines                                                                                                                                                                                          3559


<!-- PAGE 23 -->

### Page 23

amplifying PAD risk by 2–4 times each.20 Both men and women face a 
similar risk of PAD, but women have distinct risk factors (Figure 3).21
Hypertension and male sex are major risk factors for AAA, whereas dia­
betes mellitus lowers its incidence by 25%.22–24 Thoracic aortic aneurysm 
(TAA) or dissection share atherosclerotic risk factors, yet monogenic or 
polygenic diseases like Marfan syndrome (MFS), more prevalent in young­
er individuals, also contribute.24,25 Inflammation as a risk factor can be ob­
served in PAAD26 and the potential for inflammation to be a modifiable 
risk factor is indicated by research related to colchicine and the effects 
demonstrated by canakinumab (a monoclonal antibody that reduces in­
flammation by inhibiting interleukin-1 beta).27,28
5. Evaluation of peripheral arteries 
and aorta
To be consistent with existing literature, the term PAD is used to refer 
to lower-extremity atherosclerotic arterial disease.
5.1. Clinical history and examination, and 
laboratory assessment, in patients with 
peripheral arterial and aortic diseases
Clinical evaluation encompassing history (including family history), 
review of symptoms, and physical examination are the first steps 
in diagnosing and assessing patients with PAAD. Pulse palpation, 
femoral, carotid, and abdominal bruit auscultation, heart ausculta­
tion, and observation of the legs and feet need to be part of the vas­
cular examination.
Clinical signs, beyond aiding diagnosis, offer prognostic insights. 
Carotid bruits double the risk of myocardial infarction (MI) and CV 
death,29,30 while a brachial systolic blood pressure (SBP) difference of 
more than 15 mmHg raises CV death risk by 50%.31 Hence, bilateral 
arm blood pressure (BP) measurement is recommended.32 Lab assess­
ments should include lipid profile (including lipoprotein[a] at least once 
in a lifetime),33 fasting glycaemia, glycated haemoglobin (HbA1c), renal 
function, blood count, coagulation studies, liver function, electrolytes, 
and inflammatory markers (C-reactive protein [CRP] and erythrocyte 
sedimentation rate). Additional evaluations, like thyroid function tests, 
are advised as needed.
5.2. Functional and quality of life 
assessment in patients with peripheral 
arterial and aortic diseases
Patients with PAD have decreased walking performance and self- 
reported physical and mental health-related quality of life 
(HRQoL).34–40 Muscle strength and balance are also impaired,41–45
leading to a faster decline in functional (physical functioning) perform­
ance in both symptomatic and asymptomatic patients.46,47 Depression 
is associated with greater impairment in functional performance.48,49
Impaired functional status is related to decreased self-reported 
HRQoL,50,51 and predicts further mobility loss and CV mortality.52,53
Very poor HRQoL has been found in patients with chronic limb- 
threatening ischaemia (CLTI).54
Different questionnaires are available assessing different facets (func­
tional, mental, and social status) of patient-reported outcome measures 
(PROMs).34–36,38 The Short-form 36-item health questionnaire (SF-36) 
(including physical- and mental health-related items) is the most used 
generic questionnaire in PAD.35,36,38 The Edinburgh Claudication 
Questionnaire is a modified version of the initially developed Rose ques­
tionnaire and has a sensitivity of 91% and a specificity of 99% in compari­
son with a physician-based diagnosis.55,56 The Walking Impairment 
Questionnaire (WIQ), the Walking Estimated Limitation Calculated by 
History (WELCH), and the Vascular quality of life (VascuQoL) question­
naire are the most used PAD-specific questionnaires.34–36,38
Treadmill testing, using standardized criteria, is the gold standard to as­
sess walking performance.37,57–62 Patients are asked to walk until max­
imal pain levels, defining the maximal walking distance (MWD). 
Patients are also asked to indicate the point at which pain begins, defining 
the pain-free walking distance (PFWD). Constant-load protocols have 
poorer reliability than graded protocols.60–64 Additionally, the six-minute 
walk test (6MWT) should be performed to assess functional walking per­
formance.62,65 For muscular lower-limb strength assessment,66 isokinetic 
dynamometry has good test–retest reliability.67 Alternatively, the Short 
physical performance battery (SPPB) test should be used.62,64,68,69 The 
SPPB has good test–retest reliability.64
Few data exist on HRQoL, functional assessment, and exercise cap­
acity in patients with aortic diseases.70,71 Those with acute aortic dis­
section (AAD), as well as patients who had aortic valve or thoracic 
aortic surgery, may present with depression and anxiety, leading to 
mental health issues72,73 that can also be assessed with the SF-36 ques­
tionnaire or the hospital anxiety and depression score (HADS).72
Patients with MFS have reduced HRQoL and a significant decline 
over time in physical HRQoL.74,75 Assessing HRQoL in aortic disease 
patients is crucial for understanding well-being, disease impact, and 
treatment effects. This involves PROMs, including surveys, symptom 
assessment, functional evaluation, psychological well-being (HADS), 
social and occupational function, and medication/treatment side effects. 
It also covers healthcare utilization and patient satisfaction, informing 
care and enhancing aortic disease management.
Recommendation Table 1 — Recommendations for clin­
ical and laboratory, and for functional and quality of life, as­
sessment in patients with peripheral arterial and aortic 
disease (see also Evidence Table 1)
Recommendations
Classa
Levelb
When managing PAAD, it is recommended to adopt 
a comprehensive approach that addresses the 
entirety of the arterial circulation.76
I
B
To assess PAAD, it is recommended to perform 
thorough clinical, vascular, and CVRFs laboratory 
evaluation.77
I
C
Overall evaluation of functional (physical functioning) 
performance with objective tests should be 
considered in patients with symptomatic and 
asymptomatic chronic PAD.57,61,63
IIa
B
Overall evaluation of self-reported (i.e. by 
questionnaire) physical and mental/social HRQoL 
should be considered in patients with  
PAAD.34–36,38,72
IIa
B
© ESC 2024
CVRFs, cardiovascular risk factors; HRQoL, health-related quality of life; PAAD, peripheral 
arterial and aortic diseases; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 24 -->

### Page 24

5.3. Vascular examination of peripheral 
arteries
The ankle-brachial index (ABI)78,79 is a low-cost, easy, and largely used 
tool, used both at rest or after exercise80–84 for PAD diagnosis and sur­
veillance (Figure 4). Both oscillometric and Doppler methods have 
shown good concordance.78
Resting ABI has a 68%–84% sensitivity and an 84%–99% specificity 
for PAD diagnosis (Figure 4).79 An ABI ≤0.90 confirms PAD 
diagnosis.79,85–87 For values >1.40, the term ‘non-compressible arteries’ 
should be used.
Ankle–brachial index >1.40, seen in arterial stiffness (diabetes, 
severe kidney failure, or advanced age), correlates with increased CV 
events and mortality risk.88,89 For ABI >1.40, assessing resting toe– 
brachial index (TBI) is recommended.79,90–95
Toe–brachial index addresses medium-calibre artery rigidity96 measur­
ing pressure on the hallux, second, or third toe using laser Doppler probe 
or plethysmography.97,98 Sensitivity and specificity for PAD diagnosis 
Ankle-brachial index (ABI)
Haemodynamic criteria for PAD
Haemodynamic criteria for CLTI
Higher systolic ankle pressure of target leg
(posterior tibial or dorsalis pedis artery)
Higher systolic brachial pressure, 
irrespective of target leg
Toe-brachial index (TBI)
Toe pressure of target leg
Higher systolic brachial pressure, 
irrespective of target leg
Borderline ABI
0.90
1.0
0.70
1.40
Abnormal low ABI
Abnormal low TBI
Abnormal high ABI
Normal
ABI
Normal
TBI
Ankle pressure <50 mmHg
How to measure
Transcutaneous oxygen partial pressure (TcPO2)
Toe pressure <30 mmHg
TcPO2 <30 mmHg
In supine position, 5–10 min resting, constant room temperature
ABI and ankle pressure: cuffs on upper arms and lower limbs (just above the ankle)
TBI and toe pressure: cuffs on upper arms and photoplethysmography probe on distal pulp of first or second toe
TcPO2: preferred position of measurement electrode at first intermetatarsal position
Figure 4 Haemodynamic assessment of peripheral arterial disease. ABI, ankle–brachial index; CLTI, chronic limb-threatening ischaemia; PAD, 
peripheral arterial disease; TBI, toe–brachial index; TcPO2, transcutaneous oxygen pressure.
ESC Guidelines                                                                                                                                                                                          3561


<!-- PAGE 25 -->

### Page 25

range from 45% to 100% and 17% to 100%, respectively.91 The usual 
pathological threshold for TBI is ≤0.70 (Figure 4).99
Used within the Framingham risk score, ABI enables the upgrading of 
risk estimation in ‘low-risk’ women and men,77,88 it allows CV risk as­
sessment in diverse ethnic groups independently of risk factors,77,89
and is inexpensive and minimally time-consuming.100 Trained physicians 
have better reproducibility than inexperienced ones.101,102
In patients with exertional limb pain relieved by rest and a resting 
ABI >0.90, exercise testing with post-exercise ABI measurements 
or exercise oximetry has been proposed to diagnose lower-limb ar­
terial stenoses.103–105
The post-exercise ABI is determined 1 min after the cessation of 
a standardized treadmill exercise.106 The physician measures bilat­
eral ankle BP, starting with the symptomatic leg, using the ankle ar­
tery used for the reference resting ABI measurement. Brachial SBP 
should simultaneously be measured to enable calculation of the 
post-exercise ABI.104
Discrepancies in PAD diagnosis exist between exercise criteria, such 
as a fall in absolute ankle BP >30 mmHg or a drop of >20% in the post- 
exercise ABI.104 Recent studies identified numerous false positives in a 
healthy population when using a post-exercise ABI drop of >20% as the 
diagnostic threshold, as commonly proposed.103
Measurement of transcutaneous oxygen pressure (TcPO2) is a 
means of evaluating tissue viability and is proposed as a diagnostic cri­
terion of CLTI (Figure 4).107 TcPO2 is affected by local and general fac­
tors such as skin thickness, probe temperature, inflammation, and 
oedema,108,109 resulting in misleading values.
Resting TcPO2 >30 mmHg is a favourable indicator of wound heal­
ing;110–112 however, resting TcPO2 <10 mmHg is associated with bad 
prognosis for wound healing and amputation in CLTI patients treated 
with bone marrow-derived stem cells.107 When performed at succes­
sive levels on an ischaemic limb, TcPO2 measurement may help to de­
termine amputation level.113–115
Exercise transcutaneous oximetry has also been proposed.116,117
This seems of interest to detect proximal (buttock) claudication105
or unsuspected exercise-induced hypoxaemia118 in patients with inter­
mittent claudication (IC).117
5.3.1. Duplex ultrasound
Duplex ultrasound (DUS) is a first step in the vascular work-up for PAD 
screening and diagnosis, allowing a dynamic, non-invasive, radiation- and 
contrast-free examination. It localizes vascular lesions and quantifies 
their extent and severity through velocity criteria.119–121 In combin­
ation with ABI or TBI, DUS permits determining the haemodynamic 
relevance of arterial lesions122,123 and estimation of ABI.124 DUS has 
a sensitivity of 88% and specificity of 95% for >50% stenosis detec­
tion.125 Post-exercise DUS can reveal borderline arterial lesions if initial 
findings are inconclusive.122,126,127
Duplex ultrasound distinguishes atherosclerotic (even subclinical dis­
ease) from non-atherosclerotic lesions, but its reliability relies on the 
sonographer’s expertise.122 Cross-sectional imaging is advisable for re­
vascularization planning. ABI and DUS are recommended for PAD pa­
tient follow-up post-revascularization.128
More recent techniques, such as flow imaging, 3D echography, ultra­
fast ultrasound, and shear wave elastography, as well as the use of 
contrast-enhanced ultrasound (CEUS), could further improve DUS 
performance.129
5.3.2. Digital subtraction angiography, computed 
tomography angiography, and magnetic resonance 
angiography
Detailed information about these techniques can be found in the 
Supplementary data online, Section 1.2 (Table S1). Digital subtraction 
angiography (DSA) remains mostly limited to revascularization proce­
dures. Computed tomography angiography (CTA) offers better spatial 
resolution than magnetic resonance angiography (MRA) and better cal­
cification visualization; however, it can also overestimate stenosis sever­
ity due to the blooming effect. MRA allows arterial wall and lumen 
assessment as well as tissue and organ perfusion distal to or surround­
ing the explored arterial territory.
5.4. Evaluation of the aorta
The aorta can be divided into different anatomical regions (from prox­
imal to distal) for reporting purposes. The main anatomical aortic re­
gions are the aortic root, ascending aorta, aortic arch, descending 
thoracic aorta (DTA), abdominal aorta (AA), infrarenal aorta, and the 
iliac arteries (Figure 5).134,135
5.4.1. Aortic measurements
The main imaging techniques used for aortic evaluation are illustrated in 
Table 5.
Evaluating aortic dilation and progression depends on standardized 
measurements. In echocardiography, aortic diameters should be mea­
sured using the leading-to-leading edge method during end-diastole 
(as systole sees about a 2 mm aortic expansion) in all segments 
(Figure 6).137,138
Most studies supporting prophylactic surgery have used this ap­
proach. Furthermore, better agreement exists between echo’s 
leading-to-leading edge and cardiovascular computed tomography 
(CCT)/cardiovascular magnetic resonance (CMR)’s inner-to-inner 
edge during end-diastole.137,139,140 However, when the aortic wall 
thickens (e.g. atheroma, thrombus, intramural haematoma [IMH], or 
aortitis) or in cases of aortic dissection (AD), also report the 
outer-to-outer diameter (Figure 6).
Recommendation Table 2 — Recommendations for 
diagnostic tests in patients with peripheral arterial 
disease
Recommendations
Classa
Levelb
Measurement of the ABI is recommended as the 
first-line non-invasive test for screening and diagnosis 
of PAD, using an ABI ≤0.90 as a diagnostic 
criterion.79,90,130,131
I
B
In the case of non-compressible ankle arteries or ABI 
>1.40, additional methods such as TP, TBI or 
Doppler waveform analysis are 
recommended.90,91,124,132,133
I
B
© ESC 2024
ABI, ankle–brachial index; PAD, peripheral arterial disease; TBI, toe–brachial index; TP, toe 
pressure. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 26 -->

### Page 26

Distal descending aorta
Aortic arch
Thoracic descending aorta
Mid aortic arch
Proximal aortic arch
Ascending aorta
37 mm
40 mm
34 mm
36 mm
Sinotubular junction
Sinus of Valsalva
(<22 mm/m2)
38 mm
40 mm
33 mm
34 mm
0
1 23
4
5
6
7
8
9
10
11
29 mm 26 mm
23 mm 20 mm
34 mm 31 mm
Abdominal aorta
23 mm 19 mm
Proximal descending aorta
Figure 5 Anatomy and aortic segments and upper normal values for aortic dimensions. Numbers represent the 11 aortic segments based on the 
Society for Vascular  Surgery/Society of Thoracic Surgeons (SVS/STS) classification for surgical and endovascular purposes.136 Z-scores can be calcu­
lated for aortic root and ascending aorta. Calculation of z-scores can be performed following these links: https://www.marfan.fr/accueil/z-score-calculus/
or https://marfan.org/dx/z-score-adults.
ESC Guidelines                                                                                                                                                                                          3563


<!-- PAGE 27 -->

### Page 27

Table 5 Main aortic imaging techniques
TTE/DUS
TOE
CCT
CMR
Availability
++++
+++
++
+
Cost
+
++
+++
++++
Time requirement
+
+++
+++
++++
Radiation
0
0
+++
0
Spatial resolution
1 mm
1 mm
0.6 mm
1–2 mm
Temporal resolution
20 msec
20 msec
80 msec
30 msec
Nephrotoxicity
0
0
+++
+
Accuracy
++
++++
++++
++++
Serial examination
++++
++
++
++++
Aortic wall visualization
++
+++
++++
++++
Aortic valve function
+++
++++
+
++++
RV/LV function
+++
+++
+++a
++++
Aortic root assessment
+++
+++
++++
++++
Aortic arch assessment
++
+++
++++
++++
Thoracic aorta assessment
+
++
++++
++++
Abdominal aorta assessment
+++
-
++++
++++
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; LV, left ventricle; RV right ventricle; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography. 
aCCT can be used to evaluate left and right ventricular function only if retrospective gating is used.
A
B
C
D
E
F
AoR ASC
Figure 6 Conventional measurements of the aorta at different levels by echocardiography or duplex ultrasound (A, B, C), cardiovascular computed 
tomography or cardiovascular magnetic resonance (D, E, F). (A) Echocardiographic measurements of the aortic root and ascending aorta using the 
leading-to-leading edge methodology. (B) The outer-to-outer convention in the abdominal aorta in cases with aortic wall disease in a longitudinal 
view. This method can be used in a non-circular section as an alternative. (C) The outer-to-outer antero-posterior diameter of the abdominal aorta 
in a cross-sectional view. Evaluation of the aortic root using the cusp-to-cusp diameter (D) and the cusp-to-commissure convention (E); (F) meas­
urement of the ascending aorta and the descending aorta with the double-oblique technique. AoR, aortic root; ASC, proximal ascending aorta.


<!-- PAGE 28 -->

### Page 28

Given the high incidence of atherosclerotic plaques/thrombi in the 
AA, the outer-to-outer convention should be preferred (also present­
ing the best agreement with CCT and CMR) (Figure 6).141,142
Regarding CCT and CMR, measurements must be performed using 
the inner-to-inner edge method (Figure 6) in end-diastole (fewer mo­
tion artefacts).137,143,144
The aortic root is measured in the parasternal long axis by transthor­
acic echocardiography (TTE),137,139,140,145 since the short axis underesti­
mates the diameter due to possible plane obliquity. By CMR or CCT, the 
cusp-to-cusp diameter best correlates with echocardiography (Figure 6). 
A diameter difference >5 mm (among root diameters within the same 
imaging modality) indicates root asymmetry, frequent in bicuspid aortic 
valve (BAV) or genetic aortopathies, which is important to be determined 
since it generates underestimations.146 While 3D echocardiography is a 
potential surveillance alternative in these cases (especially if CMR/CCT 
is limited for serial follow-up), validation studies are lacking.147
In end-diastole, measure the ascending aorta by moving the transducer 
1–2 intercostal spaces up in the parasternal long axis. Echocardiography 
provides information on aortic arch or DTA enlargement, but diagnostic 
certainty (precise measurement of the diameters) is lacking. CCT or 
CMR uses the double-oblique technique to measure aortic diameters, re­
porting antero-posterior and perpendicular dimensions for accurate as­
sessment.148 It is recommended to report aortic measurements by 
specific segments based on anatomical landmarks and to relate the largest 
diameter to a nearby anatomical structure for reference.
Changes in aortic diameter require a ≥3 mm increase in echocardi­
ography, which should be confirmed with CCT/CMR and compared 
with baseline measurements. For accurate assessment, stick to the 
same imaging technique, centre, methodology, and side-by-side 
comparisons.137,140
5.4.2. Normal aortic values
When evaluating aortic dimensions and clinical relevance, consider fac­
tors like aortic region, anthropometric measurements, patient history, 
and underlying medical conditions. Factors influencing aortic and per­
ipheral artery size in the normal population include age, sex, ethnicity, 
body surface area (BSA), and, particularly, height.149
Body surface area is the most used method to normalize aortic dimen­
sions based on an individual’s body size, thus an ascending thoracic aorta 
>22 mm/m2 or a DTA >16 mm/m2 is considered aortic dilatation.150–152
However, extremes of low or high body weight pose limitations. In such 
cases, surgical thresholds may involve indexing aortic diameter by height 
(an aorta height index >32.1 mm/m is associated with a 12% yearly risk 
of aortic adverse events [AAE]),153 aortic cross-sectional area to patient 
height (a ratio ≥10 cm2/m implies reduced long-term survival),154 or aor­
tic length (from the aortic annulus to the innominate artery, considering a 
length >11 cm a threshold for surgery).155
To correlate measured diameter with the expected one based on 
age, sex, and body surface, use nomograms or z-score calculation for­
mulas, especially in heritable thoracic aortic disease (HTAD). 
Supplementary data online, Figure S1 and Table S2, presents nomo­
grams developed for echocardiography, applicable also to CCT 
and CMR.156,157 Calculation of z-scores can be performed following 
these links: https://www.marfan.fr/accueil/z-score-calculus/ or https:// 
marfan.org/dx/z-score-adults/; reference values used for their esti­
mation may vary depending on age and other factors. However, 
z-scores are limited by the fact that not all ethnic groups are equally 
represented (mostly white) and over- or underweight can lead to an 
over- or underestimation.158
Moreover, with ageing and loss of elastic properties, the aorta tends 
to enlarge. Aortic growth in adults is about 0.9 mm per 10 years in 
males and 0.7 mm per 10 years in females, which may be influenced 
by BP, physical activity, and genetic factors.
5.4.3. Chest X-ray and electrocardiogram
Chest X-ray obtained for other indications in asymptomatic patients or 
in cases of acute aortic syndrome (AAS) suspicion may detect abnor­
malities of aortic size/contour that need to be confirmed by another im­
aging technique. It presents limited sensitivity (64%) and specificity 
(86%) in the diagnosis of aortic diseases;162 thus, a normal chest 
X-ray may not rule out the diagnosis of AAS.162–164 On the contrary, 
chest X-ray may identify other causes of chest pain (e.g. pleural effusion 
or pneumothorax).
Electrocardiogram (ECG) might be useful to rule out other causes of 
chest pain (e.g. MI) or AAS complications (coronary occlusion/dissec­
tion) but it is not useful for AAS diagnosis.
5.4.4. Echocardiography
It is considered the first-line imaging technique in the evaluation of aor­
tic disease, assessing all echocardiographic windows and the aortic 
valve. It provides key anatomic information (i.e. dilatation, atheroscler­
otic lesions, or dissection) for the ascending aorta, arch, and AA; how­
ever, it is not useful to assess the exact diameters of the aortic arch and 
DTA (requiring confirmation with CCT/CMR). Also, the distal ascend­
ing aorta and proximal arch (blind spot) are inadequately visualized due 
to left mainstem bronchus interposition.
Transthoracic echocardiography can identify AAS complications (e.g. 
aortic regurgitation, tamponade, or wall motion abnormalities), but its 
diagnostic accuracy for AAS is limited (sensitivity: 78%–100% for type 
A, 31%–55% for type B). Contrast enhancement improves diagnosis.165
Recommendation Table 3 — Recommendations for 
imaging of the aorta (see also Evidence Table 2)
Recommendations
Classa
Levelb
It is recommended that aortic diameters are 
measured at pre-specified anatomical landmarks, and 
the largest diameter of the section be perpendicular 
to the longitudinal axis.134,135
I
C
It is recommended in cases of serial imaging of the 
aorta over time to use the same imaging modality 
with the same measurement method.159
I
C
It is recommended to consider renal function, 
pregnancy, age, and history of allergy to contrast 
media to select the optimal imaging modality with 
minimal radiation exposure and lowest iatrogenic 
risk, except for emergency cases.159–161
I
C
Indexing aortic diameters to BSA, along with the use 
of nomograms, z-scores, or other indexing methods, 
should be considered for more accurate assessment 
of aortic size, especially for body sizes at the lower 
end of the normal distribution.156–158
IIa
B
© ESC 2024
BSA, body surface area. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3565


<!-- PAGE 29 -->

### Page 29

Transoesophageal echocardiography (TOE) is highly accurate (sensitiv­
ity: up to 99%, specificity: 89% for AAS), except with absolute contra­
indications like oesophageal issues, bleeding, recent gastro-oesophageal 
surgery, or respiratory distress. TOE is convenient for bedside and in­
traoperative use but less suitable for long-term surveillance, which re­
quires evaluation with CCT/CMR.
5.4.5. Duplex ultrasound imaging of the abdominal 
aorta
After scanning both transversally and longitudinally, the antero- 
posterior (AP) diameter in a cross-sectional view of the AA should 
be measured. Ensure the DUS beam is perpendicular to the AA axis, 
forming a circular vessel section. If the AA is sinuous or dilated, achiev­
ing equal AP and transverse diameters may be challenging. In such in­
stances, calculate the mean ellipse diameter or measure the AA 
diameter in a clear longitudinal view with a perpendicular diameter 
(Figure 6).122 The outer-to-outer (Figure 6) method is the one 
recommended by the American Institute of Ultrasound in Medicine, 
the American College of Cardiology/American Heart Association 
(ACC/AHA), and the European Society of Cardiology (ESC), since it 
is more reliable in cases of atherosclerotic plaque or intravascular 
thrombus and best correlates with CCT and CMR. However, the 
most effective methodology is under debate and further studies are 
needed to determine the best convention.169
Normal diameters of the AA are reported in Figure 5 and 
Supplementary data online, Section 1.3.
5.4.6. Cardiovascular computed tomography
Cardiovascular computed tomography, due to its quick acquisition, 
wide availability, high reproducibility, and suitability for emergency de­
partments, is the primary imaging method for aortic disease diagnosis, 
prognosis, and therapy planning (sensitivity 100%, specificity 98% for 
AAS).170–172 ‘Double or triple rule-out’ protocols concurrently assess 
the aorta, pulmonary, and coronary arteries.173,174
Electrocardiogram triggering is crucial to prevent motion artefacts 
(especially in the aortic root and ascending aorta), which can distort 
measurements or resemble dissection flaps, facilitating coronary artery 
assessment. The standard protocol comprises non-enhanced scans (for 
calcification, IMH, or surgical material), contrast-enhanced CCT angiog­
raphy, and a late scan (to visualize contrast leakage or aortic wall late 
enhancement suggestive of inflammation or infection).175
Iodinated contrast agents carry potential allergic reactions and post- 
contrast acute kidney injury (PC-AKI) risks.176 In these cases, opt for 
contrast-free CCT for accurate aortic diameter measurement (also 
for CMR-intolerant patients). Moreover, excessive radiation caution 
is crucial, particularly in young females, when performing CCT for mon­
itoring chronic aortic diseases.177
5.4.7. Cardiovascular magnetic resonance
Cardiovascular magnetic resonance comprehensively evaluates the 
aorta, including shape, diameter, tissue characteristics (inflammation, in­
fection, atheroma, bleeding),178 lesion extent, side branches, adjacent 
structures, and mural thrombus. It assesses ventricular and valve func­
tion, quantifies flow, and employs cine steady-state free precession 
(SSFP) or ECG-gated angio-CMR for the aortic root, while non-gated 
sequences suffice for the rest. Recently, 4D flow sequences179 have 
been developed to evaluate complex intravascular flows,180,181 com­
plex flow parameters (wall shear stress, pulse wave velocity, or kinetic 
energy), or flow quantification at different levels in one unique acquisi­
tion (useful in AD or congenital diseases).182,183
Cardiovascular magnetic resonance obviates ionizing radiation and 
iodinated contrast (3D contrast CMR), making it ideal for young pa­
tients, women, and pregnancy. Caution is warranted, especially with 
non-macrocyclic gadolinium, for estimated glomerular filtration 
rate (eGFR) <30 mL/min/1.73 m² (Supplementary data online, 
Section 1.2). CMR is increasingly used in patients with intracardiac de­
vices (pacemakers/implantable cardioverter defibrillators, CMR- and 
non-CMR-compatible devices) with proper monitoring, but not for 
those with cochlear implants or intracranial clips.184,185
In the acute setting, CMR use is limited because of low availability, dif­
ficulties in monitoring unstable patients, and longer acquisition 
times.166,186
5.4.8. Positron emission tomography
Positron emission tomography (PET) usually uses 18F-fluorodeoxyglucose 
(FDG), allowing non-invasive assessments of metabolic activity 
Recommendation Table 4 — Recommendations for 
thoracic aortic measurements
Recommendations
Classa
Levelb
TTE is recommended as the first-line imaging 
technique in evaluating thoracic aortic diseases.159,165
I
B
It is recommended to report aortic diameters using 
the leading-to-leading edge convention in 
end-diastole by echocardiography.137,139,140,159
I
C
It is recommended to report aortic diameters using 
the inner-to-inner edge convention in end-diastole 
by CCT or CMR.137,143,144,159
I
C
It is recommended to report aortic diameters from 
images obtained with the double-oblique technique 
(not axial images) by CCT or CMR.148
I
C
ECG-triggered CCT is recommended for 
comprehensive diagnosis, follow-up, and pre-invasive 
treatment assessment of the entire aorta, particularly 
the root and ascending aorta.159
I
C
CMR is recommended for diagnosis and follow-up of 
thoracic aortic diseases, especially when chronic 
follow-up is required.166–168
I
C
The aortic root should be measured using the 
cusp-to-cusp distance. Also, the presence of 
asymmetry (>5 mm) among distances should be 
reported.137,146
IIa
C
If an increase of ≥3 mm per year in aortic diameters 
by TTE is observed, confirmation by CCT/CMR 
should be considered.137,159
IIa
C
Chest X-ray may be considered in cases of low 
clinical probability of AAS; however, a negative 
exploration should not delay dedicated aortic 
imaging in high-risk patients.162–164
IIb
C
© ESC 2024
AAS, acute aortic syndrome; CCT, cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; ECG, electrocardiogram; TTE, transthoracic 
echocardiography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 30 -->

### Page 30

(inflammation/infection) and treatment response.187,188 Although differ­
ent tracers have been tested to identify calcification, fibrosis and/or 
thrombus formation, most PET studies have focused on vasculitis.
The relationship between FDG-PET images and AAA progression is 
controversial. However, fluorine-18–sodium fluoride (18F–NaF) 
PET-computed tomography (PET-CT), a marker of active vascular cal­
cification and high-risk plaques, has shown a correlation between in­
creased tracer uptake, AAA growth, and CV events.189
PET-CT has shown better diagnostic accuracy in identifying lesions 
and detecting graft infection or infectious aortic diseases.190–193 High 
radiation exposure, high costs, and limited availability are the main lim­
itations of PET.
5.4.9. Intravascular ultrasound
Intravascular ultrasound (IVUS) provides high-resolution imaging for ar­
tery and vein diseases, aiding complex aortic disease management by 
distinguishing true and false lumens and guiding stent placement. It is 
operator-dependent, costly, and less accessible, but seems to provide 
better measurements for acute aortic syndromes.194
5.4.10. Digital subtraction aortography
Non-invasive imaging modalities have replaced DSA in first-line 
diagnostic testing, both in suspected AAS or known chronic AD; 
however, DSA might be useful if findings in non-invasive techniques 
are ambiguous or incomplete. It is primarily used for the percutan­
eous treatment of CAD, aortic visceral branches, or for monitoring 
thoracic endovascular aortic aneurysm repair (TEVAR/EVAR) 
implantation.
6. Screening for carotid, 
peripheral arterial, and aortic 
diseases
6.1. Screening for carotid and peripheral 
arterial diseases
6.1.1. Lower-extremity peripheral arterial disease
Due to elevated CV risk in chronic PAD, early diagnosis, preven­
tion, and robust cardiovascular risk factor (CVRF) control are es­
sential, even in asymptomatic cases. ‘Intermediary CV risk’ 
individuals may be reclassified as ‘high or very high risk’, prompting 
adapted prevention. ABI is the preferred first-line test for asymp­
tomatic individuals aged ≥65 years,14,195 especially women.196
Screening might also be beneficial at a younger age in case of 
CVRFs, but data are still lacking. Clinical examination, functional 
status, and walking capacity assessment are recommended to de­
tect ‘masked PAD’.77
In diabetes, early PAD (and foot neuropathy) diagnosis is crucial. 
Effective CVRF management and treatment can prevent CV disease, 
foot wounds, and amputation.197 In patients with diabetes and normal 
resting ABI, TBI measurement should be considered.
The prevalence of popliteal aneurysms (PAs) is high in patients with 
AAA and subaneurysmal aortic dilatation, warranting screening. PAs 
are correlated with iliac and femoral artery diameters.76 In patients 
needing transfemoral access, screening for iliofemoral artery disease 
may be considered.198
6.1.2. Carotid artery stenosis
Due to the low prevalence of ≥70% asymptomatic carotid artery 
stenosis (CS) in the general population (0%–3.1%), widespread 
screening is not recommended since it does not reduce stroke 
risk and might lead to inappropriate stress and invasive proce­
dures.199,200 Conversely, screening for significant CS in a highly se­
lected population might be cost-effective, especially if prevalence is 
≥20% (Table 6).201 When the degree of asymptomatic CS is ≥70%, 
the 5 year ipsilateral stroke risk is significantly increased (14.6%) and 
revascularization may be beneficial.202 Selective screening aims to 
prevent CV events, rather than identifying candidates for an 
intervention.203
6.1.3. Multisite artery disease
Multisite artery disease (MAD) is defined as the presence of athero­
sclerosis in two or more vascular beds.204 This is a common condition 
in patients with atherosclerotic diseases. Although associated with 
worse clinical outcomes, screening for asymptomatic disease in add­
itional vascular sites did not seem to improve outcomes.77 More re­
cently, screening for coronary calcifications (coronary artery calcium 
[CAC] score) and screening for carotid and femoral plaques have 
Table 6 High-risk populations for carotid artery 
stenosis
Population
Prevalence of carotid stenosis 
(%)
>60 years + CVRFs (hypertension, 
CAD, current smoking, 
first-degree family history of 
stroke)210
Two CVRFs: 14% 
Three CVRFs: 16% 
Four CVRFs: 67%
Hypertension + cardiac disease211
22%
HD212
• In HD patients, prevalence of 
carotid stenosis is high, and is 
associated with high 
peri-operative and long-term 
stroke or death rates
• Carotid stenosis is a predictor of 
death in patients with long-term 
dialysis and aged ≥70 years at time 
of surgery
• Lower risk if previous renal 
transplant.
PAD213
23.2%
Severe CAD (before CABG)
• Almost 20%214
• Carotid bruit and T2DM: 
increased predictive value215
• Carotid stenosis = risk factors for 
peri-operative stroke.215
Carotid bruit216
31%
Previous neck irradiation217
21.7% (70%–99% stenosis)
© ESC 2024
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVRFs, 
cardiovascular risk factors; HD, haemodialysis; PAD, peripheral arterial disease; T2DM, 
type 2 diabetes mellitus.
ESC Guidelines                                                                                                                                                                                          3567


<!-- PAGE 31 -->

### Page 31

been shown to be of potential assistance in CV risk reclassification of 
‘presumed moderate-risk patients’ into a higher-risk category, leading 
to more aggressive prevention strategies.205–209
6.2. Screening for aortic diseases
6.2.1. Screening for abdominal aortic aneurysm
Abdominal aortic aneurysm screening by DUS is effective in reducing 
rupture-related mortality in populations with high AAA prevalence (es­
pecially male smokers aged ≥65 years).221–224 However, no such effect 
has been found in a single large study in which AAA prevalence was low 
(current or former smoking women aged 65–74 years, or with a history 
of CAD).225
Screening for AAA by non-contrast computed tomography (CT) 
was not found to be effective over 5 years in males aged 65–74 years 
in a Danish trial.226 Longer-term follow-up is planned, and as the tech­
nique involves ionizing radiation, no recommendation is made in rela­
tion to CT at present.
Screening may be considered in populations at intermediate risk, 
such as men aged >75 years, or women aged >75 years who are hyper­
tensive, smokers, or both, since almost all women in a contemporary 
population-based study who had ruptured AAA and were aged 
>75 years were either smokers or hypertensive.227,228
Screening for AAA is recommended in first-degree relatives (FDRs) of 
patients with AAA (especially siblings), as they are at increased risk of 
AAA when >50 years of age.229 The risk associated with family history 
is uncertain, but a population-based study estimated a relative risk of 
around 2.230 Screening should be repeated periodically if initial assessment 
is reassuring and performed at a relatively young age.231
Opportunistic screening (during TTE) identified AAA in about 2% of 
subjects, thus it may be considered in high-prevalence populations 
(males ≥65 or women ≥75 years of age).232 Additionally, opportunistic 
screening detects AAA in patients with symptomatic/asymptomatic 
PAD (with a 12% cumulative incidence in symptomatic PAD), making 
it worthwhile in this population.233
6.2.2. Screening for thoracic aortic aneurysm
Screening for TAA is described in detail in Section 10.1 and Section 10.2.
7. Optimal medical treatment
Optimal medical treatment (OMT), including lifestyle measures and 
pharmacological treatment, is recommended for all patients with 
PAAD (Figure 7).
7.1. Lifestyle, exercise, patient education
Apart from genetic-related TAA, hypertension and ASCVD are the 
main causative factors for PAAD. As lifestyle factors are strongly re­
lated to ASCVD,11 patients with PAAD should strive to maintain a 
healthy lifestyle. The 2021 ESC Guidelines on cardiovascular prevention19
give comprehensive guidance on risk factors for ASCVD and their 
treatment.
7.1.1. Diet
A Mediterranean diet rich in legumes, dietary fibre, nuts, fruits, and 
vegetables proves crucial and efficacious for primary and CV pre­
vention in PAAD.238 It has demonstrated notable reductions in chol­
esterol and BP,239–247 and holds potential protective benefits against 
PAAD development.248,249 In a large cohort with 17.5 years of 
follow-up, adherence to a Mediterranean diet was associated with 
reduced AAA risk in current and ex-smokers.249,250 Malnutrition 
and metabolic disorders can complicate post-invasive procedure re­
covery and nutritional support may improve nutritional status and 
HRQoL.251
Recommendation Table 5 — Recommendations for 
peripheral arterial disease screening (see also Evidence 
Table 3)
Recommendations
Classa
Levelb
In patients with diabetes or chronic kidney disease, 
and normal resting ABI, TBI measurement should be 
considered.
IIa
B
In patients ≥65 years of age with CVRFs, screening 
for PAD by ABI or TBI should be considered.77,218,219
IIa
C
In patients with AAA, femoro-popliteal aneurysm 
screening with DUS should be considered.76
IIa
C
In patients ≥65 years without CVRFs, screening for 
PAD by ABI or TBI may be considered.220
IIb
C
In patients needing intervention with transfemoral 
access, screening for iliofemoral artery disease may 
be considered.198
IIb
C
In patients with two or more CVRFs, screening for 
CS may be considered.201,203,210
IIb
C
© ESC 2024
AAA, abdominal aortic aneurysm; ABI, ankle–brachial index; CS, carotid artery stenosis; 
CVRFs, cardiovascular risk factors; DUS, duplex ultrasound; PAD, peripheral arterial 
disease; TBI, toe–brachial index. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 6 — Recommendations for 
abdominal aortic aneurysm screening
Recommendations
Classa
Levelb
Screening for AAA with DUS:
Is recommended in men aged ≥65 years with a 
history of smoking to reduce the risk of death from 
ruptured AAA.221–224,234
I
A
May be considered in men aged ≥75 years 
(irrespective of smoking history) or in women aged 
≥75 years who are current smokers, hypertensive, 
or both.227,228,235–237
IIb
C
Family AAA screening with DUS:
Is recommended for FDRs of patients with AAA aged 
≥50, unless an acquired cause can be clearly 
identified.231
I
C
Opportunistic AAA screening with DUS:
Should be considered in symptomatic/asymptomatic 
PAD patients.233
IIa
B
Should be considered in men aged ≥65 years and in 
women aged ≥75 years during TTE.232
IIa
B
© ESC 2024
AAA, abdominal aortic aneurysm; FDR, first-degree relative; DUS, duplex ultrasound; PAD, 
peripheral arterial disease; TTE, transthoracic echocardiography. 
Smoking is defined as lifetime smoking of >100 cigarettes or equivalent. This threshold is 
used to distinguish between substantial exposure and occasional use. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 32 -->

### Page 32

7.1.2. Physical activity
Few patients with chronic symptomatic PAD meet the physical activity guide­
lines252 for reducing the risk of major adverse cardiac events (MACE).253,254
Better ambulation, HRQoL, and vascular outcomes have been observed in 
patients meeting the physical activity time-intensity guidelines.19,255 Regular 
physical activity is also relevant in patients with aortic diseases70,71,256–259
and lowers resting heart rate and BP, thus decreasing the risk of aortic com­
plications.256,259 Few data exist on the practice of exercise and sports in pa­
tients with aortic diseases.70,71,256–259 Recommendations should be 
individualized and based on risk stratification.71
Medications
Lifestyle
Targets
Targets
Systolic blood pressure
≤120–129 mmHg
Beta-blockers
ACEi or ARB
Calcium channel blockers
Antiplatelet therapy
Statins
Ezetimibe
PCSK9i
Bempedoic acid
Reducing risk of atherothrombosis
Optimal glucose control (HbA1c <7%)
Educational programmes
Psychological support
Genetic counselling
Supervised exercise training
LDL <55 mg/dL (<1.4 mmol/L)
Healthy diet
BMI 20–25 kg/m2
Waist: <94 cm men; <80 cm women
Low-to-moderate exercise training
Limit isometric exercise in aortic diseases
Avoid excessive alcohol intake
Avoid smoking/smoking cessation
Avoid cocaine and stimulating drugs
Glucose-lowering agents
Diastolic blood pressure 
≤70–79 mmHg
Anticoagulants
Figure 7 Cardiovascular risk modification and healthy lifestyle interventions and targets in patients with peripheral arterial and aortic diseases. ACEi, 
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; LDL, low-density lipoprotein; PCSK9i, proprotein 
convertase subtilisin/kexin type 9 inhibitor; HbA1c, glycated haemoglobin.
ESC Guidelines                                                                                                                                                                                          3569


<!-- PAGE 33 -->

### Page 33

7.1.3. Smoking
Patients with PAAD who smoke should strongly be advised to quit (see 
Supplementary data online, Section 1.1.5). Complete smoking cessation 
and avoiding second-hand smoke or environmental particle air pollu­
tion are crucial in patients with PAAD to reduce the risk of death, 
AD, acute mesenteric ischaemia (AMI), AAA, and PAD.119,260–267
Smokers should be offered structural follow-up support, including nico­
tine replacement therapy, varenicline, and bupropion, individually or in 
combination.19,268,269 Smoking avoidance also includes cannabis, asso­
ciated with premature ASCVD.266
Vaping and e-cigarette use has surged in the past decade, viewed by 
some as a healthier option than smoked tobacco, though long-term 
health effects remain unknown.270 E-cigarettes may be considered as 
an aid to quit tobacco smoking, as a recent Cochrane review found 
that they increase quit rates as compared with nicotine replacement 
therapy,271 but their use has been associated with adverse effects on 
CV, respiratory, immunological, and periodontal health compared with 
non-users, but with a milder impact than smoked cigarettes.272–274
However, their use should be brief and preferably not concurrent with 
traditional cigarettes.271,275
The main limitation of the evidence base remains imprecision due to 
the small number of randomized controlled trials (RCTs), often with 
low event rates and follow-up limited to 2 years.
7.1.4. Patient education
While detailed explanations of CVRFs might not always inspire lifestyle 
changes,276 providing plain language and visual aids is essential for pa­
tient understanding.277 Structured programmes, incorporating psycho­
logical and behavioural aspects, are pivotal in fostering desired 
changes.276 Engaging patients’ families, friends, and support networks 
significantly contributes to perpetuating these changes (particularly in 
self-care),276 and increases treatment compliance and self-efficacy, re­
ducing hospitalization risk and enriching patient HRQoL.278,279 When 
caregivers disconnect from healthcare professionals, they should be re­
cognised to receive better support systems.280,281 Psychosocial inter­
ventions are crucial to navigating complexities with resilience.282
Advocating active involvement, education, clear communication, and 
shared decision-making is key for achieving optimal patient out­
comes.276–283
7.1.5. Risk scoring models in secondary prevention
Recent ESC CV prevention guidelines discuss risk models for develop­
ing vascular disease in healthy individuals and ASCVD patients.19
Several registries enabling risk prediction in ASCVD have been 
developed: REACH (The REduction of Atherothrombosis for 
Continued Health)284 and SMART (Secondary Manifestation of 
ARTerial disease)285 which use clinical parameters such as medical his­
tory, SBP, and common biomarkers. Addition of carotid ultrasound 
did not improve the model.286 A new algorithm combining the 
SMART and REACH models287 enables calculation of lifetime risk 
and treatment effects. The SMART model has recently been updated 
and validated288,289 with the SMART-2 algorithm. These tools are avail­
able online as clinical risk calculators (see www.u-preveotnt.com) and 
smartphone apps on the ESC website (https://www.escardio.org/ 
Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/SMART- 
Risk-Score).
Recommendation Table 7 — Recommendations for 
lifestyle, physical activity, and patient education (see 
also Evidence Table 4)
Recommendations
Classa
Levelb
In patients with PAAD, cessation and abstinence from 
smoking of any kind is recommended to reduce the 
risk of AD, MI, death, and limb ischaemia.119,261–267
I
A
A healthy diet rich in legumes, dietary fibre, nuts, 
fruits, and vegetables, with a high flavonoid intake 
(Mediterranean diet), is recommended for CV 
disease prevention in patients with PAAD.239– 
241,249,290–293
I
A
Low- to moderate-intensity (or high if tolerated)c 
aerobic activities are recommended in patients with 
PAD to increase overall and pain-free walking 
distance.37,294
I
A
In patients with PAAD, behavioural counselling to 
promote healthy diet, smoking cessation, and 
physical activity is recommended to improve the CV 
risk profile.241,249,253,295
I
B
It is recommended to promote patient and 
caregivers’ education and empowerment through 
tailored guidance on lifestyle adjustments and the 
importance of regular physical activity.276,277,283
I
C
In patients with PAAD, avoidance of exposure to 
second-hand smoke and air pollution should be 
considered.261
IIa
C
Physical exercise and sports activities should be 
considered in patients with aortic diseases based on 
prior risk stratification (based on the extent of the 
aneurysm, risk of dissection, and BP control).71
IIa
C
Use of web- or app-based secondary prevention risk 
calculators should be considered in the shared 
decision-making to improve patient adherence to 
treatment and lifestyle changes.288,289
IIa
C
E-cigarettes may be considered as an aid to quit 
tobacco smoking, but it is advisable to limit their use 
and avoid simultaneous use with conventional 
cigarettes due to unknown long-term 
effects.119,271,296,297
IIb
C
© ESC 2024
AD, aortic dissection; BP, blood pressure; CV, cardiovascular; MI, myocardial infarction; 
PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence. 
cLow intensity refers to an exercising heart rate (HR) of 57%–63% HRmax or a rate of 
perceived exertion (RPE) on the Borg’s scale of 9–11. Moderate intensity refers to an 
exercising heart rate of 64%–76% HRmax or RPE of 12–13. Vigorous intensity refers to 
an exercising heart rate of 77%–95% HRmax or RPE of 14–17.298


<!-- PAGE 34 -->

### Page 34

7.2. Principles of pharmacological medical 
therapy
7.2.1. Antithrombotic therapy
Antithrombotic therapy is crucial for patients with symptomatic PAAD at 
high CV risk. While trials are fewer than in CAD, recent evidence should 
guide practice. In the absence of specific indications for chronic oral antic­
oagulation (OAC) in concomitant CV disease, a single antiplatelet agent is 
the primary long-term treatment for patients with symptomatic PAAD. 
Combining it with another antiplatelet agent or low-dose anticoagulants 
depends on the patient’s ischaemic and bleeding risk, as well as therapeutic 
paths (e.g. endovascular therapy). Recent guidelines299 propose a tool for 
bleeding risk assessment in PAD patients (OAC3 PAD score).
Antithrombotic strategy is detailed in Sections 8 and 9 for each arter­
ial territory.
7.2.2. Antihypertensive therapy
New 2024 ESC Guidelines on hypertension are currently published and 
should be reviewed for further details.300 Patients with hypertension 
and PAAD are considered to have target organ damage and are at 
high CV risk.300
Different meta-analyses showed that systolic BP treatments reduce 
CV risk in all ages up to 85 years down to a level of 120– 
129 mmHg.301,302 There is no need to increase the BP target in healthy 
patients up to the age of 85 years.303,304 To reduce cardiovascular disease 
(CVD) risk, it is recommended that treated SBP values in most adults be 
targeted to 120–129 mmHg, provided the treatment is well tolerated. 
However, in cases where BP-lowering treatment is poorly tolerated 
and achieving an SBP of 120–129 mmHg is not possible, it is recom­
mended to target an SBP level that is ‘as low as reasonably achievable’ 
(ALARA principle).301,302,305 To avoid overtreatment, out-of-office BP 
measurements may be helpful when pursuing this target.
If on-treatment SBP is on target, but diastolic blood pressure (DBP) 
is ≥80 mmHg, intensified treatment may be considered to further re­
duce the CV risk.306
Because the CVD benefit of an on-treatment BP target of 120– 
129 mmHg may not generalize to some groups, setting personalized 
and more lenient BP targets (e.g. <140/90 mmHg) has to be considered 
in patients with pre-treatment orthostatic hypotension, age ≥85 years, 
clinically significant frailty at any age, or a limited lifespan (<3 years).301
Patients with both PAAD and hypertension face a high or very high 
CV risk. Antihypertensive medications such as diuretics, beta-blockers 
(BBs), calcium channel blockers (CCBs), angiotensin-converting en­
zyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) 
are all appropriate options for managing hypertension in PAAD. 
These agents can be used as monotherapy or in various combinations 
(excluding ARBs+ACEIs), considering individual patients’ conditions. It 
is often necessary to implement combination therapy, preferably in 
the form of a single pill, to effectively achieve the recommended treat­
ment goals. However, ACEIs or ARBs should be considered as first-line 
antihypertensive therapy to reduce CV events.300,307–312
Regardless of BP levels and in the absence of contraindications, 
ACEIs/ARBs may be considered in all patients with PAD to reduce car­
diovascular events.312,313 A meta-analysis suggests that antihypertensive 
treatment may improve mean walking distance in patients with PAD.310
Beta-blockers can be prescribed, if necessary, to patients with inter­
mittent claudication, since they do not worsen walking capacity or limb 
events.314 There is some evidence suggesting a higher amputation 
rate315 or increased rate of re-intervention316 in patients with CLTI 
treated with ACEIs, although in one smaller study no effect on 
limb-related outcomes was observed.317 Thus, they remain a treatment 
option in hypertensive patients with PAD, especially in those with con­
comitant CAD.318 BBs were not associated with worsened clinical out­
comes in a retrospective study319 on CLTI patients, but it seems 
prudent to avoid excessively low heart rates in these patients.
7.2.2.1. Renovascular hypertension
Angiotensin-converting enzyme inhibitors and ARBs effectively manage 
unilateral renal artery stenosis (RAS) by blocking the renin–angiotensin 
system, potentially reducing renal capillary perfusion pressure.320–322
This transiently lowers glomerular filtration rate (GFR) and raises ser­
um creatinine. For bilateral RAS, regular follow-up assessments of renal 
function and kidney perfusion are advised.
Angiotensin-converting enzyme inhibitors and ARBs additionally 
(combined with hydrochlorothiazide and/or CCBs if needed) contrib­
ute to CV risk reduction in patients with atherosclerotic disease and re­
duced eGFR.307,323,324
Recommendation Table 8 — Recommendations for 
antihypertensive therapy in patients with peripheral 
and aortic disease
Recommendations
Classa
Levelb
In patients with PAAD and hypertension an SBP 
target towards 120–129 mmHg, if tolerated, is 
recommended.301–305,325
I
A
In unilateral RAS patients, it is recommended that 
antihypertensive medication include ACEIs/ 
ARBs.307,320–323
I
B
In patients with PAAD and hypertension, ACEIs or 
ARBs should be considered as first-line 
antihypertensive therapy.307,312
IIa
B
In RAS-related hypertension, the combination of 
ACEIs/ARBs with diuretics and/or calcium channel 
blockers should be considered.324
IIa
B
An individualized, more lenient BP goal (e.g. <140/ 
90 mmHg) should be considered in:301
• Age ≥85 years
• Residential care
• Symptomatic orthostatic hypotension
IIa
C
An individualized, more lenient BP goal (e.g. <140/ 
90 mmHg) may be considered in:301
• Clinically severe frailty at any age
• Limited life expectancy (<3 years)
IIb
C
In patients with bilateral RAS, antihypertensive 
medication including ACEIs/ARBs may be considered 
if close patient monitoring (renal function) is 
feasible.321
IIb
B
ACEIs/ARBs may be considered in all patients with 
PAD, regardless of BP levels, in the absence of 
contraindications.312,313
IIb
B
Continued 
ESC Guidelines                                                                                                                                                                                          3571


<!-- PAGE 35 -->

### Page 35

7.2.3. Lipid-lowering therapy
Patients with symptomatic PAAD are at very high CV risk but are usually 
inadequately managed compared with patients with CAD.5,247,326–332
Both LDL-C reduction by ≥50% from baseline and an LDL-C goal of 
<1.4 mmol/L (<55 mg/dL) are recommended to obtain a reduction in 
CV death, MI, and stroke, and to improve walking distance.242,333–336
7.2.3.1. Statins
Statins demonstrate mortality and CV event reduction in RCTs for 
PAD, CS, and severe aortic arch plaques.243–245 Even in advanced dis­
ease stages, they are linked to lower MACE and mortality.246
Statins significantly improve CV outcomes in patients with PAD, redu­
cing major adverse limb events (MALE).244,327–329,337,338 Meta-analyses 
show enhanced walking distances.244,338,339
For CS, statin pre-treatment lowers recurrent stroke risk post- 
transient ischaemic attack (TIA).19,340–343 While lacking RCTs in reno­
vascular or visceral artery disease, statins benefit cardiorenal events and 
post-RAS stenting prognosis.344–346
Mixed evidence suggests statins may mitigate AAA and TAA 
growth.347–352 However, since most patients with AAA or TAA pre­
sent with associated CVRFs, liberal use of lipid-lowering treatment19
should be considered, using an individualized approach with shared 
decision-making and considering residual CV risk.353 Pre-operative sta­
tin use links to increased 5 year survival after TEVAR.19
Statin use was associated with a mean AAA growth rate reduction 
and a lower rupture risk.347–349,352,354
Some evidence suggests that statins may reduce TAA growth rate 
and risk of rupture.350,351,355
No benefit on AAA or TAA growth rate was shown with fenofibrate 
therapy.356,357
7.2.3.2. Ezetimibe
Ezetimibe combined with statins benefits selected patients with 
PAAD, particularly when the target LDL-C level is not met.335 In 
an IMProved Reduction of Outcomes: Vytorin Efficacy International 
Trial (IMPROVE-IT) subanalysis, involving acute coronary syndrome 
(ACS) patients with PAD, ezetimibe consistently reduced CV risk, espe­
cially in high-risk subgroups.247,331
7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in addition 
to statins, reduce CV events in symptomatic atherosclerotic disease patients 
with LDL-C ≥1.8 mmol/L.336 Adding them to statins further reduces MACE 
and MALE risk in patients with PAD and improves walking distance;333 how­
ever, their potential in TAA/AAA is an emerging area of research.247
Inclisiran, administered semi-annually, has proved a notable 26% 
MACE risk reduction in a pooled phase III analysis,358 but its role in 
PAAD is not firmly established and ongoing RCTs including PAD parti­
cipants (e.g. ClinicalTrials.gov NCT05030428) aim to provide insights.
7.2.3.4. Bempedoic acid
Bempedoic acid, acting upstream of statins in cholesterol metabolism, 
has been shown to reduce cholesterol levels by 17%–28%359,360 and 
demonstrated a decrease in the incidence of MACE in statin-intolerant 
PAD patients.361 However, its impact on aortic diseases and AAA still 
requires further research.
7.2.3.5. Hypertriglyceridaemia
Beyond LDL-C, evidence shows insulin resistance, elevated triglycer­
ides, and remnant lipoproteins are associated with ASCVD, particularly 
in PAD.362–365 However, in a meta-analysis and an RCT, fibrates 
showed no benefit over placebo in reducing MACE in patients with 
PAD for a composite outcome of non-fatal stroke, non-fatal MI, and 
vascular death.366 Fibrates showed no benefit over placebo in reducing 
coronary and cerebrovascular events in patients with PAD in an 
RCT.367 While the relationship between triglycerides and aortic dis­
eases is complex and not fully understood, some evidence suggests 
that triglyceride levels may contribute to the development and progres­
sion of aortic diseases.
In contrast, icosapent ethyl (IPE) demonstrated a reduction 
in mortality and morbidity among individuals with hypertrigly­
ceridaemia in the Reduction of Cardiovascular Events With 
Icosapent Ethyl–Intervention Trial (REDUCE-IT).368 Its impact 
on patients with PAAD is unexplored,369 although a small pilot 
RCT suggested an improved ABI in hyperglycaemic haemodialysis 
patients.370
In cases where on-treatment SBP is at or below 
target (120–129 mmHg) but DBP is not at target 
(≥80 mmHg), intensifying BP-lowering treatment to 
achieve an on-treatment DBP of 70–79 mmHg may 
be considered to reduce CVD risk.306
IIb
C
© ESC 2024
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BP, 
blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; PAAD, 
peripheral arterial and aortic diseases; PAD, peripheral arterial disease; RAS, renal artery 
stenosis; SBP, systolic blood pressure. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 9 — Recommendations for 
lipid-lowering therapy in patients with peripheral 
arterial and aortic diseases
Recommendations
Classa
Levelb
In patients with atherosclerotic PAAD, lipid-lowering 
therapy is recommended.242,334–336
I
A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) 
and a >50% reduction in LDL-C vs. baseline are 
recommended in patients with atherosclerotic 
PAAD.19,242,246,300,335
I
A
Statins are recommended in all patients with 
PAD.328,329,337,371
I
A
If the target LDL-C level is not achieved on maximally 
tolerated statins and ezetimibe, treatment with a 
PCSK9 inhibitor is recommended in patients with 
atherosclerotic PAAD, to achieve target 
values.372,373
I
A
If the target LDL-C level is not achieved, a 
combination of statins and ezetimibe is indicated in 
patients with atherosclerotic PAAD, to achieve the 
given target values.247
I
B
For statin-intolerant patients with atherosclerotic 
PAAD, at high CV risk, who do not achieve their 
LDL-C goal on ezetimibe, it is recommended to add 
bempedoic acid either alone or in combination with a 
PCSK9 inhibitor.361
I
B
Statins for the reduction of growth and rupture of 
AAA should be considered.347–349,352,354
IIa
B
Continued


<!-- PAGE 36 -->

### Page 36

7.2.4. Diabetes and pre-diabetes conditions
Screening for diabetes or pre-diabetes is recommended in PAAD. Recent 
ESC Guidelines on diabetes and CVD374 provide detailed diagnostic cri­
teria and underscore the importance of diagnosing diabetes in ASCVD pa­
tients and vice versa. Both Type 1 (T1DM) and Type 2 (T2DM) diabetes 
mellitus imply significantly increased risk of PAD, carotid stenosis, and 
polyvascular disease, depending on disease duration and the status 
of other CVRFs. Diabetes is present in 30% of patients with IC and 
50%–70% of those with CLTI.375,376 Although the prevalence of PAD 
in patients with diabetes is 20%–30%, only half of them are symptomatic 
because of peripheral neuropathy with decreased pain sensitivity.377 As 
already detailed in Section 4, diabetes implies reduced risk of TAA, 
AAA, or aortic dissection. However, patients with T2DM and PAAD 
are in the very high-risk group for stroke, MI, and CV death,374 and for 
T1DM, an online risk prediction tool has recently been developed.377–380
For non-pregnant PAAD patients, aiming for an HbA1c level of 
<53 mmol/mol (7%) to avoid significant hypoglycaemia is appropriate. 
Consider a higher threshold (<69 mmol/mol [8.5%]) for limited life ex­
pectancy or when treatment risks outweigh benefits.374
In PAAD, it is recommended to aim for tight glycaemic control, pref­
erably with agents with proven CV benefits such as sodium-glucose 
co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 re­
ceptor agonists (GLP-1RA), adding metformin and other glucose- 
lowering agents as necessary.374,381–384
The Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results (LEADER) trial and Trial to Evaluate 
Cardiovascular and Other Long-term Outcomes with Semaglutide 
in Subjects with Type 2 Diabetes (SUSTAIN-6) investigated subcutane­
ous GLP-1RAs liraglutide (≤1.8 mg/day) and semaglutide (0.5 or 
1.0 mg/week), respectively, vs. placebo in T2DM patients with high CV 
risk. Overall, 12.7% of patients in LEADER and 14.0% in SUSTAIN-6 pre­
sented with PAD at baseline. Although non-statistically significant due to 
a lack of power, the effects on MACE showed a consistently beneficial 
trend in PAD: liraglutide (hazard ratio (HR), 0.77; 95% confidence interval 
(CI), 0.58–1.01) and semaglutide (HR, 0.61; 95% CI, 0.33–1.13).381
The (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 
Diabetes Mellitus Patients (EMPA-REG OUTCOME) investigated the 
SGLT2i empagliflozin (10 mg or 25 mg per day) vs. placebo in patients 
with T2DM and high CV risk. Overall, 20.8% of patients presented 
with PAD at baseline. In these patients, empagliflozin reduced CV death 
(HR, 0.57; 95% CI, 0.37–0.88) and all-cause mortality (HR, 0.62; 95% CI, 
0.44–0.88), and there was a non-significant reduction in limb amputa­
tion: 5.5% with empagliflozin vs. 6.3% with placebo (HR, 0.84; 95% CI, 
0.54–1.32).382 In the Canagliflozin Cardiovascular Assessment Study 
(CANVAS)385 investigating canagliflozin, there was an increased risk of 
amputation, but this was not confirmed in the Canagliflozin and Renal 
Events in Diabetes with Established Nephropathy Clinical Evaluation 
(CREDENCE) trial investigating canagliflozin in patients with T2DM 
and chronic kidney disease (CKD).386 Still, the use of other SLGT2is 
seems reasonable in PAD patients.
Patients with carotid stenosis were included in trials testing GLP-1RA 
and SGLT2i, but no analysis on this subpopulation was performed. A 
meta-analysis of eight trials investigating GLP-1RAs vs. placebo in pa­
tients with T2DM reported a reduction in all strokes (HR, 0.84; 95% 
CI, 0.75–0.93).387 Among patients with T2DM and prior history of MI 
or non-fatal stroke, GLP-1RAs reduced the incidence of recurrent 
MACE (HR, 0.86; 95% CI, 0.8–0.92).388 SGLT2is do not appear to re­
duce stroke in patients with T2DM, but patients with a stroke history 
experienced similar cardiorenal benefits as the rest of the population.389
Before the era of GLP-1RAs and SGLT2is, different studies (United 
Kingdom 
Prospective 
Diabetes 
Study 
[UKPDS] 
34390
and 
Hyperinsulinaemia: the Outcomes of its Metabolic Effects [HOME] 
trials391) showed that metformin reduced the risk of MALE and 
MACE in patients with PAD.391,392 But a recent study with GLP-1RA 
dulaglutide found the same risk reduction in MACE between patients 
with and without baseline metformin, calling into question its add-on 
value.384,393 However, there are studies suggesting that metformin 
may reduce AAA growth (see Section 9.2.4).
Statins for the reduction of growth and rupture of 
TAA may be considered.350,351,355
IIb
B
In high-risk patients with PAAD and triglycerides 
>1.5 mmol/L despite lifestyle measures and statin 
therapy, icosapent ethyl 2 g b.i.d. may be considered 
in addition to a statin.368
IIb
B
Fibrates are not recommended for cholesterol 
lowering.367
III
B
© ESC 2024
AAA, abdominal aortic aneurysm; b.i.d., twice daily; CV, cardiovascular; LDL-C, low-density 
lipoprotein cholesterol; PAAD, peripheral arterial and aortic diseases; PAD, peripheral 
arterial disease; PCSK9, proprotein convertase subtilisin/kexin type 9; TAA, thoracic 
aortic aneurysm. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 10 — Recommendations for 
the medical management of patients with peripheral 
arterial and aortic diseases and diabetes
Recommendations
Classa
Levelb
It is recommended to apply tight glycaemic control 
(HbA1c <53 mmol/mol [7%]) to reduce microvascular 
complications in patients with PAAD.374,394–397
I
A
SGLT2i with proven CV benefit are recommended 
in patients with T2DM and PAAD to reduce CV 
events, independent of baseline or target HbA1c 
and concomitant glucose-lowering 
medication.382,386,398–402
I
A
GLP-1RAs with proven CV benefit are 
recommended in patients with T2DM and PAAD to 
reduce CV events, independent of baseline or target 
HbA1c and concomitant glucose-lowering 
medication.381,403–407
I
A
It is recommended to avoid hypoglycaemia in 
patients with PAAD.374,408–412
I
B
It is recommended to individualize HbA1c targets 
according to comorbidities, diabetes duration, and 
life expectancy.408,411
I
C
It is recommended to prioritize the use of 
glucose-lowering agents with proven CV benefits,c,d 
followed by agents with proven CV safety,e over 
agents without proven CV benefit or safety.374
I
C
If additional glucose control is needed, metformin 
should be considered in patients with T2DM and 
PAAD.374,384,393
IIa
B
© ESC 2024
CV, cardiovascular; GLP-1RAs, glucagon-like peptide-1 receptor agonists; HbA1c, glycated 
haemoglobin; PAAD, peripheral arterial and aortic diseases; SGLT2i, sodium-glucose 
co-transporter-2 inhibitors; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cEmpagliflozin, canagliflozin, dapagliflozin, sotagliflozin. 
dLiraglutide, semaglutide subcutaneous, dulaglutide, efpeglenatide. 
eMetformin, pioglitazone, dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, alogliptin, 
linagliptin), glimepiride, gliclazide, insulin glargine, insulin degludec, ertugliflozin, 
lixisenatide, exenatide (extended release), oral semaglutide.
ESC Guidelines                                                                                                                                                                                          3573


<!-- PAGE 37 -->

### Page 37

7.2.5. Other pharmacological therapy
Increased attention is focused on inflammation in ASCVD,413 sup­
ported by the Canakinumab Anti-Inflammatory Thrombosis 
Outcomes Study (CANTOS),414 which showed that canakinumab, 
a monoclonal antibody targeting interleukin (IL)-1β, reduced MACE 
in high-risk patients with previous MI and increased high-sensitivity 
(hs)-CRP. Data for patients with PAAD are not reported. 
Furthermore, low-dose colchicine (0.5 mg/day) has been shown to 
reduce MACE among those with stable atherosclerosis after recent 
MI.415 However, the effect of colchicine and other anti-inflammatory 
drugs in PAAD remains unproven.416
8. Peripheral arterial disease
8.1. Lower-extremity peripheral arterial 
disease
8.1.1. Peripheral arterial disease syndromes
8.1.1.1. Clinical presentation and diagnosis
Atheromatous lower-extremity PAD is a chronic disease with different 
clinical manifestations. PAD may be symptomatic or asymptomatic and 
may or may not be associated with limb wounds. Wound healing and 
amputation risk may be affected by the concomitant presence of 
PAD, diabetes, and/or infection;417 therefore, amputation risk assess­
ment should be systematically performed using the Wound, 
Ischaemia, and foot Infection (WIfI) classification.
PAD presents as: 
• Asymptomatic PAD: suspected by lower-limb pulse abolition or im­
aging studies performed for other purposes and detected by patho­
logical ABI or TBI.418,419 These patients do not present with IC or 
atypical effort-related symptoms. However, attention should be 
paid to those with wounds, with masked effort-related symptoms 
due to reduced walking capacity (for reasons other than PAD), or re­
duced pain sensitivity. ‘Masked PAD’ is defined as PAD without pro­
voked leg pain because of reduced walking capacity for other reasons 
or reduced pain sensitivity.420
• Symptomatic (effort-related) PAD: patients with pathological ABI or 
TBI, presenting with IC, atypical effort-related symptoms, or chronic 
lower-limb wounds (diabetic foot or non-healing ulceration/gangrene 
≥2 weeks) without critically reduced limb perfusion.417,421 In these 
patients, IC is characterized by exertional muscle pain and dysfunc­
tion in the supply area of the obstructed arterial segment, which is 
relieved at rest.422 Some patients may present with atypical 
symptoms or with ‘masked PAD’.420,423 In women, the prevalence 
of IC is lower than in men, while atypical symptoms are more 
common.424
• CLTI represents the more severe chronic PAD presentation and un­
derlies poor limb outcomes without intervention. In addition to com­
mon signs of chronic PAD, patients with CLTI present with a critical 
haemodynamic status (ankle pressure <50 mmHg, toe pressure [TP] 
<30 mmHg, or TcPO2 <30 mmHg) responsible for ischaemic rest 
pain, non-healing chronic (>2 weeks of duration) ulceration, or 
foot gangrene.425,426
PAD syndromes can be categorized according to their clinical presen­
tation (Table 7). 
The 5 year cumulative incidence of clinical deterioration from 
asymptomatic PAD to IC is 7%, and 21% from IC to CLTI.427 All pa­
tients with PAD are at high risk of MACE, cerebrovascular disease, 
and MALE (Figure 8).428–430 The 5 year cumulative incidence of CV 
mortality is 9% in asymptomatic PAD and 13% in symptomatic pa­
tients. In comparison with symptomatic PAD, CLTI further increases 
all-cause mortality risk (relative risk [RR] 2.26) and the risk of MACE 
(RR 1.73).431 Health insurance data reveal a major amputation rate of 
9% in patients with CLTI and 1% in patients with IC, while consider­
ably higher amputation rates were reported in trials and registries 
data focusing on patients with CLTI.432–435 Among patients with 
PAD, development of MALE is associated with poor prognosis, 
with a three-fold increase in death and a 200-fold increase in subse­
quent lower-extremity amputation.429
Prevention of MALE is crucial, and the risk of MACE/MALE increases 
with the increased number of arterial beds involved.
Table 7 Peripheral arterial disease categorized according to clinical presentation
Clinical characteristics of PAD
Rutherford classification
Fontaine classification
Category
Signs and symptoms
Stage
Signs and symptoms
Asymptomatic PAD
0
Asymptomatic
I
Asymptomatic
Symptomatic (effort-related) PAD
1
Mild claudication
IIa
Non-disabling intermittent claudication
2
Moderate claudication
IIb
Disabling intermittent claudication
3
Severe claudication
Chronic limb-threatening Ischaemia
4
Ischaemic rest pain
III
Ischaemic rest pain
5
Minor tissue loss
IV
Ischaemic ulceration or gangrene
6
Major tissue loss
© ESC 2024
PAD, peripheral arterial disease.


<!-- PAGE 38 -->

### Page 38

8.1.1.1.1. Diagnostic tests. Vascular assessment: ABI, TBI, TcPO2 
measurements (refer to Section 5.3)
Ankle–brachial index is the proposed initial non-invasive diagnostic 
test to confirm lower-limb decreased perfusion status90,436,437 and 
needs to be reported separately for each leg (see Recommendation 
Table 2). An ABI ≤0.90 confirms PAD diagnosis.90,436,437 In cases of 
an ABI >0.90 and clinical suspicion of PAD, post-exercise ABI measure­
ments should be considered, along with imaging studies (preferably by 
treadmill). A post-exercise ABI decrease of >20% may serve as a PAD 
diagnostic criterion.438,439
In cases of abnormally high ABI values (ABI >1.4; see 
Recommendation Table 2) and patients with CLTI and diabetes440
(see Recommendation Table 11), TP measurements, the calculation 
of TBI and TcPO2, as well as pulse volume recordings or analysis of dis­
tal arterial Doppler waveforms, should be considered,90,91,132,133,441
and ABI can be estimated from distal Doppler waveforms independent 
of diabetes and media sclerosis.124
Apart from the assessment of limb perfusion, ABI serves as a surro­
gate marker for CV and all-cause mortality.88,442,443 A diagnostic PAD 
algorithm is depicted in Figure 9.
4–5x increased risk of
CV events compared with patients without PAD
Cardiac disease (MACE):
Cerebrovascular disease
Lower limb disease (MALE):
CV mortality
Myocardial infarction
Coronary revascularization
Hospitalization for heart failure
Amputation
Chronic or acute lower limb ischaemia
Lower limb revascularization
Increased death and vascular amputation risk
Figure 8 Cardiovascular risk in patients with peripheral arterial disease. CV, cardiovascular; MACE, major adverse cardiac event; MALE, major adverse limb 
event; PAD, peripheral arterial disease.
ESC Guidelines                                                                                                                                                                                          3575


<!-- PAGE 39 -->

### Page 39

Walking impairment questionnaires, assessment of functional and 
walking capacity
Determining walking impairment, capacity, and functional status in all 
patients with PAD is mandatory (refer to Section 5.2).
Assessment of amputation risk
In patients with PAD and chronic lower-limb wounds (diabetic 
foot ulcer, non-healing lower-limb ulceration, or gangrene of ≥2 
weeks of duration), even without haemodynamic parameters of 
critical limb perfusion, the additional presence of comorbidities 
such as diabetes and/or wound infection may contribute to an 
increased risk of amputation. The WIfI classification system takes 
the patients’ limb perfusion, wound size, and the extent of foot 
infection into account to determine the amputation risk 
(Table 8).417,444–446
8.1.1.1.2. Imaging methods. Duplex ultrasound is recommended as 
the first-line imaging method for PAD screening and diagnosis. CTA 
and/or MRA are recommended as adjuvant imaging. For details refer 
to Supplementary data online, Section 1.4.
Suspicion of PAD
Clinical assessment (personal history, physical examination),
 walking impairment assessment (questionnaire, treadmill),
 and functional assessment (6MWT, SPPB)
Haemodynamic/vascular assessment
 (ABI, AP, TP, TcPO2, DUS), 
wound assessment (WIfl)
PAD
Y
Typical symptoms
Y
N
Ischaemic rest pain or gangrene
 or non-healing chronic wound and critical limb perfusion
 (AP <50 mmHg, TP <30 mmHg or TcPO2 <30 mmHg)
N
Masked PAD
N
Asymptomatic PAD
 with or without wound
N
Symptomatic PAD
 with or without wound
Y
Chronic limb-threatening ischaemia
Other diagnosis
Figure 9 Diagnostic algorithm for peripheral arterial disease. 6MWT, six-minute walk test; ABI, ankle–brachial index; AP, ankle pressure; DUS, duplex 
ultrasound; PAD, peripheral arterial disease; SPPB, short physical performance battery; TcPO2, transcutaneous oxygen pressure; TP, toe pressure; WIfI, 
Wound, Ischaemia, and foot Infection classification.


<!-- PAGE 40 -->

### Page 40

Table 8 Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification
Component
Score
Description
W (Wound)
0
No ulcer (ischaemic rest pain)
1
Small, shallow ulcer on distal leg or foot without gangrene
2
Deeper ulcer with exposed bone, joint or tendon ± gangrenous changes limited to toes
3
Extensive deep ulcer, full thickness heel ulcer ± calcaneal involvement ± extensive gangrene
I (Ischaemia)
ABI
Ankle pressure (mmHg)
Toe pressure or TcPO2
0
≥0.80
>100
≥60
1
0.60–0.79
70–100
40–59
2
0.40–0.59
50–70
30–39
3
<0.40
<50
<30
fl (foot infection)
0
No symptoms/signs of infection
1
Local infection involving only skin and subcutaneous tissue
2
Local infection involving deeper than skin/subcutaneous tissue
3
Systemic inflammatory response syndrome
Ischaemia – 0
Ischaemia – 1
Ischaemia – 2
Ischaemia – 3
W–0
VL
VL
VL
VL
VL
L
L
M
L
L
M
M
M
H
H
H
W–1
VL
VL
VL
VL
L
M
M
M
M
H
H
H
H
H
H
H
W–2
VL
VL
VL
VL
M
M
H
H
H
H
H
H
H
H
H
H
W–3
VL
VL
VL
VL
M
M
M
H
H
H
H
H
H
H
H
H
fl–0
fl–1
fl–2
fl–3
fl–0
fl–1
fl–2
fl–3
fl–0
fl–1
fl–2
fl–3
fl–0
fl–1
fl–2
fl–3
© ESC 2024
Very low (green) = VL = clinical stage 1; low (yellow) = L = clinical stage 2; moderate (orange) = M = clinical stage 3; high (red) = H = clinical stage 4. 
ABI, ankle–brachial index; TcPO2, transcutaneous oxygen pressure. 
The Wound, Ischaemia and foot Infection (WIfI) classification allows the assessment of the individual risk of amputation in PAD patients: it comprises scores for wound size (W), degree of 
ischaemia (I), as assessed by the ABI, ankle pressure, and toe pressure or TcPO2, and extent of foot infection (fI) as depicted in the respective table. The combination of all three components 
results in the amputation risk stratification (VL = very low, L = low, M = moderate, H = high). Table reproduced with permission from.417
Recommendation Table 11 — Recommendations for 
diagnostic tests in patients with peripheral arterial dis­
ease and diabetes, renal failure, and wounds
Recommendations
Classa
Levelb
Measuring TP or TBI is recommended in patients 
with diabetes or renal failure if resting ABI is 
normal.90,91,94,440
I
C
In patients with PAD and chronic wounds, the WIfI 
classification system should be considered to 
estimate individual risk of amputation.417,444–446
IIa
C
© ESC 2024
ABI, ankle–brachial index; PAD, peripheral arterial disease; TBI, toe–brachial index; TP, toe 
pressure; WIfI, Wound, Ischaemia, and foot Infection classification. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 12 — Recommendations for 
imaging in patients with peripheral arterial disease
Recommendations
Classa
Levelb
DUS is recommended as the first-line imaging 
method to confirm PAD lesions.122,123,447
I
C
In symptomatic patients with aorto-iliac or 
multisegmental/complex disease, CTA and/or MRA 
are recommended as adjuvant imaging techniques for 
preparation of revascularization procedures.448,449
I
C
Analysis of anatomical imaging tests in conjunction 
with symptoms and haemodynamic tests prior to an 
invasive procedure is recommended.426
I
C
© ESC 2024
CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic 
resonance angiography; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3577


<!-- PAGE 41 -->

### Page 41

8.1.1.2. Medical treatment
Patients with PAD should receive comprehensive OMT, including 
supervised exercise training and lifestyle modification (Figures 10–
12). A personalized programme of guidelines-guided pharmacother­
apy to reduce MACE and MALE should be prescribed and tightly 
followed.
Patients with PAD are less likely to receive OMT than patients with 
CAD.450–452 For general lifestyle and pharmacological therapy see 
Section 7.
8.1.1.2.1. Exercise therapy. A consensus document on exercise and 
PAD has been published recently.62 Symptomatic patients should be 
medically screened before any supervised exercise training (SET) pro­
gramme initiation.37,62 In patients with symptomatic PAD, SET is safe 
and improves treadmill PFWD, MWD, functional walking as measured 
by six-minute walking distance (6MWD), HRQoL, and cardiorespira­
tory fitness (Figure 13).294,453–463 Exercise has not been found to 
improve ABI.457,458 Ideally, SET should be co-ordinated by vascular 
physicians, and training sessions supervised by clinical exercise 
physiologists or physiotherapists.62
In Europe, SET is usually 
underused.464,465
When SET is not available, home-based exercise training (HBET) 
should be proposed (Figure 13), although it is inferior with regard to im­
proving walking performance.466–469 HBET is safe and its inferiority is 
reduced if monitoring is implemented.469,470 Compared with no exer­
cise, HBET improves walking performance.471 SET training frequency 
should be at least three times per week, for 30–60 min, and the pro­
gramme last for at least 12 weeks.37,58,59,454,472,473 Patients should ex­
ercise to moderate-severe claudication pain to improve walking 
performance.37,294,453,454,456–458,474 However, prescribing high-pain 
exercise may hinder programme uptake and adherence. Additionally, 
it has been reported that improvements in walking performance may 
be obtained with less severe claudication pain.455,460 Therefore, a 
flexible approach is recommended, considering the patient’s needs 
Optimal medical treatment
Address lower limbs-related symptoms
Improve quality of life
Address general CV risk prevention
Smoking cessation
Weight loss
Healthy diet
Supervised exercise training
Antihypertensive drugs
Optimal glucose control in diabetics
Cholesterol-lowering drugs
Antithrombotic drugs
+
Figure 10 Optimal medical treatment in patients with peripheral arterial disease. CV, cardiovascular.


<!-- PAGE 42 -->

### Page 42

and preferences.62 Alternative training modalities, such as strength 
training, arm cranking, cycling, and combinations of different modes, 
have proven effective in improving walking performance compared 
with traditional walking training, with limited evidence for HRQoL.475
However, this evidence is low due to small sample size and risk of 
bias.475 Vigorous intensity exercise training (77%–95% of maximal heart 
rate or 14–17 on the rate of perceived exertion on Borg’s scale) has 
been shown to induce the best walking and cardiorespiratory fitness 
improvements.294,457
Training 
programmes 
should 
begin 
at 
low-to-moderate intensity, gradually advancing to vigorous exercise if 
well tolerated.62 This approach assesses patient response and mini­
mizes complications.37,62
N
N
Chronic PAD syndromes (without wounds)
Vascular follow-up (clinical, physical, functional, vascular assessment)
Asymptomatic PAD
Symptomatic PAD
CLTI
Optimal medical treatment
Optimal medical treatment
Optimal medical treatment
Vascular team assessment
Revascularization feasible
Supervised or structured home-based exercise training
Vascular team assessment
Improved PAD-related symptoms
Revascularization indicated and reasonable
Revascularization indicated and reasonable
Revascularization and supervised or structured
 home-based exercise training
Supervised or structured
 home-based
 exercise training
Evaluate alternative
 treatment strategy
(pharmacological,
amputation)
Revascularization feasible
Revascularization
Y
Y
Y
N
N
Y
Y
N
Figure 11 Treatment algorithm in peripheral arterial disease without wounds. CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.
ESC Guidelines                                                                                                                                                                                          3579


<!-- PAGE 43 -->

### Page 43

N
N
N
N
N
N
N
Chronic PAD syndromes (with wounds)
Vascular follow-up (clinical, physical, functional, vascular assessment)
Asymptomatic PAD
Symptomatic PAD
CLTI
Optimal medical treatment
Optimal medical treatment
Optimal medical treatment
Wound care
Wound care
Wound care
Healing
Healing
Vascular team assessment
Revascularization feasible
Supervised or structured home-based exercise training
Vascular team assessment
Vascular team assessment
Improved PAD-related symptoms
Revascularization indicated and reasonable
Revascularization indicated and reasonable
Revascularization and
Wound care
Revascularization and
Wound care
Evaluate alternative
 treatment strategy
(pharmacological,
amputation)
Revascularization and supervised or structured home-based exercise training
Supervised or structured home-based exercise training
Revascularization feasible
Revascularization indicated and reasonable
Y
Revascularization feasible
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Figure 12 Treatment algorithm in peripheral arterial disease with wounds. CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.


<!-- PAGE 44 -->

### Page 44

Data on the efficacy of exercise therapy in women compared with 
men are scarce. Women may respond less well than men,476,477 al­
though discrepancies among studies exist.478–481
SET combined with endovascular revascularization significantly improves 
walking performance, HRQoL, and reduces future revascularization.482,483
An exercise therapy algorithm in PAD has been recently described.62
Supervised hospital-based exercise programmes
Supervised home-based exercise programmes
Training characteristics
Training benefits
Potential involved mechanisms
Mitochondrial content/function
Symptoms
Quality of life
Walking performance
Patient awareness
 CVR
Functional status
Arteriogenesis
 
Endothelial function
Myofibre size
Inflammation
Supervised group sessions
Different training modes
Remote monitoring,
logbook and connected devices
At least three times per week
Different levels of elicited pain
Low-to-moderate exercise intensity (or high if tolerated)
Session duration of at least
30 min. Programmes duration of at least 12 weeks.
Figure 13 Exercise training characteristics and benefits in patients with peripheral arterial disease. CVR, cardiovascular risk.
ESC Guidelines                                                                                                                                                                                          3581


<!-- PAGE 45 -->

### Page 45

8.1.1.2.2. Pharmacological treatment. Antithrombotic therapy
Asymptomatic PAD
Although patients with PAD are at very high CV risk,404,484 a trial 
evaluating the effect of antiplatelet agents in asymptomatic patients 
with an ABI ≤0.95 did not show an effect on MACE or revasculariza­
tion.485 Another trial on patients with an ABI ≤0.99 and diabetes also 
failed to show any difference in MACE or amputation.486 However, 
these data were not powered to analyse subgroups and do not rule 
out the possibility that aspirin could provide a benefit in subjects at in­
creased risk of CV events. In a randomized trial evaluating aspirin in the 
prevention of cancer and CVD in patients with diabetes without known 
arterial disease, MACE occurred in a significantly lower percentage of 
participants in the aspirin group than in the placebo group, with 
more major bleeding events in the aspirin group.487 The effect of antith­
rombotics in patients with higher-risk PAD (i.e. ABI <0.90 and other 
CV risk factors) has not been evaluated in randomized trials. 
Antithrombotic therapy should not be systematically administered in 
patients with asymptomatic PAD.
Symptomatic PAD
In patients with symptomatic PAD, antithrombotic therapy improves 
CV prognosis.488–492 Clopidogrel may have a modest advantage over 
aspirin (Figure 14).493,494 In the Examining Use of tiCagreLor In periph­
eral artery Disease (EUCLID) trial, single antiplatelet therapy (SAPT) 
with ticagrelor showed no superior benefit in the reduction of 
MACE or major bleeding compared with clopidogrel.495–497
Dual antithrombotic therapy with aspirin and vascular-dose rivarox­
aban (2.5 mg b.i.d.) in patients with PAD is more effective than aspirin 
alone, reducing MACE, MALE, and preventing acute limb ischaemia 
(ALI), but with increased major bleeding risk.429,430,498,499 Patients 
with high-risk limb presentation (CLTI, previous amputation, or revas­
cularization) or high-risk comorbidities (heart failure [HF], diabetes, or 
polyvascular disease [PVD]) benefit the most.498
After endovascular therapy, dual antiplatelet therapy (DAPT) for 1–3 
months is supported by rare randomized studies.500,501 DAPT is not asso­
ciated with reduced CV mortality or MACE,501 but seems to improve 
patency without increasing bleeding (Figure 15).502–504 The combination 
of aspirin 100 mg and vascular-dose rivaroxaban (2.5 mg b.i.d.), started 
post-revascularization, showed a moderate but significantly lower incidence 
of MALE and MACE compared with aspirin alone,490,505without an increase 
in thrombolysis in myocardial infarction (TIMI) major bleedings, but with an 
increase in International Society on Thrombosis and Haemostasis (ISTH) 
major bleedings, especially when clopidogrel was given for >1 month.506
Patients with CLTI are at high risk of MACE and MALE.429,431,507
Among CLTI patients, there is no robust evidence favouring a specific an­
tithrombotic strategy for vein graft maintenance. DAPT with clopidogrel 
and aspirin is not superior to aspirin alone in below-the-knee (BTK) by­
pass grafts.508–510 Vitamin K antagonists (VKAs) may be considered for 
high-risk conduits with low bleeding risk.509
Dual antiplatelet therapy could confer benefit for prosthetic conduit 
(occlusion, revascularization, amputation, or death), without increasing 
major bleeding.510 VKAs with an international normalized ratio (INR) of 
3–4.5 are slightly beneficial in venous conduits, but with a 1.9-fold and 
1.3-fold increase in major and fatal bleedings, respectively.509 A study 
suggested that VKAs could be associated with prolonged patency of 
at-risk prosthetic grafts due to poor run-off.511
In patients with another indication for OAC (such as atrial fibrillation 
[AF] or mechanic valve replacement) and PAD, anticoagulation is war­
ranted.512 Additional SAPT post-endovascular therapy should be brief.
Recommendation Table 13 — Recommendations for 
exercise therapy in patients with peripheral arterial 
disease (see also Evidence Table 5)
Recommendations
Classa
Levelb
In patients with symptomatic PAD, SET is 
recommended.294,453,456–458,462
I
A
In those patients undergoing endovascular 
revascularization, SET is recommended as an 
adjuvant therapy.482,483
I
A
When SET is not available or feasible, a structured 
and monitored (calls, logbooks, connected devices) 
HBET programme should be considered.468,469,471
IIa
A
Walking should be considered as a first-line training 
modality. When walking exercise is not an option, 
alternative exercise modes (strength training, arm 
cranking, cycling, and combinations of different 
training modes) should also be considered.475
IIa
A
Walking training performed at high intensity (77%– 
95% of maximal heart rate or 14–17 self-perceived 
exertion on Borg’s scale) should be considered to 
improve walking performance,294 and high-intensity 
exercise training (various aerobic training modes) 
should be considered to improve cardiorespiratory 
fitness.294,457
IIa
A
Training frequency of at least three times per week, 
training session duration of at least 30 min, and 
training programme duration of at least 12 weeks 
should be considered.472
IIa
B
In patients with PAD, exercise training to 
moderate-severe claudication pain may be 
considered to improve walking 
performance.37,454,456,458 However, improvements 
are also achievable with lesser claudication pain 
severities (low-mild pain or pain-free).455,460
IIb
B
Based on patient’s tolerance, a progressive increase 
(every 1–2 weeks) in exercise training load may be 
considered.37,62
IIb
C
© ESC 2024
HBET, home-based exercise training; PAD, peripheral arterial disease; SET, supervised 
exercise training. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with peripheral 
arterial disease (see also Evidence Table 6)
Recommendations
Classa
Levelb
Use of antiplatelet therapy with aspirin alone (range 
75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is 
recommended for the reduction of MACE in patients 
with symptomatic PAD.488–490
I
A
Treatment with combination rivaroxaban (2.5 mg 
b.i.d.) and aspirin (100 mg o.d.) should be considered 
for patients with PAD, high ischaemic risk,c and 
non-high bleeding risk.d,429,498,499
IIa
A
Continued


<!-- PAGE 46 -->

### Page 46

Pharmacotherapy to decrease walking impairment
Verapamil,516 statins,517,518 antiplatelet agents, and prostanoids 
(prostaglandins I2 and E1)519 can alleviate walking impairment in patients 
with symptomatic PAD. However, drugs like cilostazol, naftidrofuryl, 
pentoxifylline, buflomedil, carnitine, and propionyl-L-carnitine are sug­
gested to increase walking distance in patients with IC without impact­
ing CV health.339,520 Their objective benefit is generally limited, ranging 
from mild to moderate, with considerable variability.339 The additional 
benefit of these drugs alongside antithrombotics, antihypertensives, and 
statins remains unknown.
Cilostazol, a phosphodiesterase type III inhibitor, improved MWD 
compared with placebo and pentoxifylline.520–522 In a Cochrane analysis, 
100 mg twice daily increased MWD by 76%,521 while another review re­
ported a 25% average improvement.520 Cilostazol also has antiplatelet ef­
fects, requiring cautious combination with other anticoagulant and 
antiplatelet treatments.522 Notably, it increases bleeding complications.523
Naftidrofuryl oxalate, tested for IC,524 demonstrated a 74% average 
increase in MWD and improved HRQoL.524,525 In a systematic review, 
the average MWD improvement was 60% compared with placebo.520
However, inconsistent results for other medications, such as prosta­
noids, pentoxifylline, L-arginine, buflomedil, or Gingko biloba, preclude 
their recommendation for patients with IC.519,526,527
8.1.1.2.3. Aorto-iliac lesion revascularization. Aorto-iliac lesions can 
be treated by either an endovascular or a surgical approach according 
to the lesion morphology and patient risk. Long-term patency with a 
low risk of complications can be achieved by balloon angioplasty with 
or without stenting in external iliac arteries or primary stenting in com­
mon iliac arteries.528 A meta-analysis evaluated outcomes of open surgery 
vs. an endovascular approach in aorto-iliac lesions (TASC II C-D) and 
found that short-term morbidity and mortality favours the endovascular 
approach, but early and mid-term primary patency favours open surgery; 
however, secondary patency is comparable in all groups.
Treatment with combination rivaroxaban (2.5 mg 
b.i.d.) and aspirin (100 mg o.d.) should be considered 
for patients with PAD and non-high bleeding risk 
following lower-limb revascularization.490,505
IIa
B
Use of antiplatelet therapy with clopidogrel alone 
(75 mg o.d.) may be considered over aspirin to 
reduce MI, stroke, and vascular death.493,494
IIb
B
Aspirin (75–100 mg) for primary prevention may be 
considered in patients with asymptomatic PAD and 
DM, in the absence of contraindications.419,487
IIb
A
DAPT for at least 1 month after revascularization 
may be considered to reduce limb 
events.500,501,503,513,514
IIb
B
Long-term DAPT in patients with PAD is not 
recommended.489
III
A
Oral anticoagulant monotherapy for PAD (unless for 
another indication) is not recommended.515
III
A
The routine use of ticagrelor in patients with PAD is 
not recommended.495
III
A
It is not recommended to systematically treat 
patients with asymptomatic PAD without any sign of 
clinically relevant ASCVD with antiplatelet drugs.485
III
B
© ESC 2024
ASCVD, atherosclerotic cardiovascular disease; DAPT, dual antiplatelet therapy; DM, 
diabetes mellitus; MACE, major adverse cardiovascular events; MI, myocardial infarction; 
o.d., once daily; PAD, peripheral arterial disease. 
aClass of recommendation. 
bLevel of evidence. 
cHigh ischaemic risk: previous amputation, critical limb threatening ischaemia, previous 
revascularization, high-risk comorbidities (heart failure, diabetes, vascular disease in two 
or more vascular beds), eGFR <60 mL/min/1.73 m2.498
dHigh bleeding risk: dialysis or renal impairment GFR <15 mL/min/1.73 m2, acute coronary 
syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically 
significant bleeding.
Patients with chronic symptomatic PAD
Assess risk level at every follow-up
High-risk limb presentation
 or high-risk comorbiditiesa without high bleeding risk
Non high-risk limb presentation
 or high-risk comorbiditiesa
Single antiplatelet therapy
 (ASA or clopidogrel)
(Class I)
ASA
 and 2.5 mg rivaroxaban b.i.d.
(Class IIa)
Single OAC
monotherapy
(Class IIb)
Patients requiring
 long-term anticoagulation
Figure 14 Long-term antithrombotic therapy in patients with symptomatic peripheral arterial disease. b.i.d., twice daily; OAC, oral anticoagulant; PAD, 
peripheral arterial disease; ASA, aspirin aHigh-risk limb presentation: previous amputation, chronic limb-threatening ischaemia, previous revascularization, 
high-risk comorbidities: heart failure, diabetes, vascular disease in two or more vascular beds, moderate kidney dysfunction; eGFR <60 mL/min/1.73 m2.
ESC Guidelines                                                                                                                                                                                          3583


<!-- PAGE 47 -->

### Page 47

8.1.1.2.4. Femoro-popliteal lesion revascularization. If revasculariza­
tion is indicated, endovascular therapy should be the first choice 
even for complex lesions, especially in surgical high-risk pa­
tients.119,529–531
Endovascular therapy faces the challenge of sustaining long-term 
patency and durability in the femoro-popliteal region, particularly 
post-stent placement in a highly mobile artery. Drug-eluting balloons 
have improved long-term patency in complex patient cohorts and le­
sions.532 With regard to paclitaxel-coated devices, a meta-analysis 
caused a decline in their usage, especially as the United States 
Food and Drug Administration (FDA) reacted and restricted their 
use.533 Consequently, data from large national databases were eval­
uated and the mortality signal could not be confirmed. The FDA re­
vised its position, and drug-eluting treatment is now deemed to be 
a safe and efficient treatment strategy for femoro-popliteal 
lesions.534–538
An open surgical approach in femoro-popliteal lesions should be 
considered when an autologous vein (e.g. great saphenous vein 
[GSV]) is available and the patient shows low surgical risk, and in com­
plex lesions after an interdisciplinary team discussion.
8.1.1.2.5. Below-the-knee artery revascularization. In patients with 
severe IC in whom endovascular femoro-popliteal treatment is per­
formed, BTK arteries can be treated in the same intervention if there 
is substantially impaired outflow.539
N
Y
Patients with chronic symptomatic PAD after endovascular revascularization
Long-term anticoagulation required
Bleeding risk
No high bleeding risk
High bleeding riska
No high bleeding risk
High bleeding riska
Bleeding risk
ASA and 2.5 mg rivaroxaban b.i.d. +/- clopidogrel for 1 month
(Class IIa)
ASA + 2.5 mg rivaroxaban b.i.d.
(Class IIa)
OAC
 monotherapy
(Class IIa)
OAC
 monotherapy
(Class IIa)
SAPT
(ASA or clopidogrel)
(Class I)
DAPT
1–3 months
(Class IIa)
SAPT 1–3 months
 and OAC
(Class IIa)
Figure 15 Patients with chronic symptomatic PAD after endovascular revascularization. b.i.d., twice daily; DAPT, dual antiplatelet therapy; OAC, oral 
anticoagulant; PAD, peripheral arterial disease; ASA, aspirin; SAPT, single antiplatelet therapy aHigh bleeding risk: dialysis or a renal impairment glom­
erular filtration rate <15 mL/min/1.73 m2, acute coronary syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically 
significant bleeding.
Recommendation Table 15 — Recommendations for 
interventional treatment of asymptomatic and symp­
tomatic peripheral arterial disease (general)
Recommendations
Classa
Levelb
In patients with symptomatic PAD, after a 3 month 
period of OMT and exercise therapy, PAD-related 
QoL assessment is recommended.119
I
B
It is recommended to adapt the mode and type of 
revascularization options to anatomical lesion location, 
lesion morphology, and general patient condition.119
I
C
In patients with symptomatic PAD and impaired 
PAD-related quality of life after a 3 month period of 
OMT and exercise therapy, revascularization may be 
considered.465,540
IIb
B
In patients with PAD, revascularization is not 
recommended if the reason is to solely prevent 
progression to CLTI.541–544
III
B
In patients with asymptomatic PAD, 
revascularization is not recommended.119,529
III
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia; OMT, optimal medical treatment; PAD, 
peripheral arterial disease; QoL, quality of life. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

8.1.1.3. Follow-up
Asymptomatic and symptomatic PAD are at increased risk of leg symp­
tom worsening427 and of CV mortality and morbidity.419,431,551
Follow-up post-revascularization is crucial to ensure perfusion improve­
ment, address CVRFs, optimize pharmacological treatment adherence, 
identify disease progression, and evaluate mental health and functional 
capacity. Experienced vascular care physicians should conduct follow-up, 
although specific protocols are currently undefined.128,552 Data on asymp­
tomatic PAD follow-up are limited.553 For symptomatic PAD or post- 
intervention, annual follow-up are advised, including ABI/TBI measure­
ment and DUS for new or worsening symptoms.
8.1.2. Chronic limb-threatening ischaemia
8.1.2.1. Clinical presentation and diagnosis
Chronic limb-thretening ischaemia describes chronic lower-limb hypo­
perfusion responsible for ischaemic rest pain, or non-healing ulceration 
or gangrene (typically in distal segments).555,556 Ischaemic rest pain pri­
marily affects the patient’s forefoot and aggravates in a supine position, 
while lowering of the affected leg eases ischaemic symptoms.
8.1.2.1.1. Definition. Chronic limb-thretening ischaemia should be 
considered in the presence of one of the following lower-limb clinical 
signs or symptoms: 
• Ischaemic rest pain
• Non-healing lower-limb wound of ≥2 weeks’ duration
• Lower-limb gangrene
The following haemodynamic criteria may be used to guide diagnosis 
in patients with suspicion of CLTI: 
• Ankle pressure <50 mmHg
• TP <30 mmHg
• TcPO2 <30 mmHg
8.1.2.1.2. Initial assessment and risk of amputation. For patients 
with CLTI, initial diagnostic steps involve clinical examination and limb 
perfusion 
assessment 
through 
haemodynamic 
measurements. 
Regarding haemodynamic assessment in CLTI, standard ABI may be 
normal or falsely elevated due to non-compressible arteries related 
to medial sclerosis (common in diabetes or CKD),557 which can be 
overcome by estimation of ABI based on Doppler waveforms.124
Therefore, standard ankle pressure alone may not be reliable in esti­
mating limb loss risk.441,558 In addition, a large proportion of patients 
with ulcers may have below-the-ankle lesions.440 In patients with 
CLTI, TP, TBI, or TcPO2 should additionally be obtained.90,441,559
Particularly in patients with CLTI, the WIfI classification system 
should be applied. In addition to patients’ limb perfusion, the WIfI clas­
sification considers the wound size and the extent of foot infection to 
determine the individual risk of amputation.417,444–446
8.1.2.1.3. Imaging. In all patients with CLTI, comprehensive vascular 
imaging is mandatory to evaluate revascularization options. CLTI com­
monly affects more than one arterial segment of the lower limbs, involving 
infra-popliteal arteries (BTK and below-the-ankle arteries) in most cases. 
While non-invasive imaging (DUS, CTA, MRA) provides reliable results 
for above-the-knee arteries, imaging of BTK arteries, especially below 
the ankle, may be hampered by severe calcification.448,560,561 Therefore, 
in CLTI additional DSA with dedicated views of the foot should be con­
sidered for the assessment of BTK arteries.560 Even in patients who are 
not candidates for revascularization, DSA should be obtained to prevent 
unnecessary amputation or to minimize amputation extent.560,562
8.1.2.1.4. Mortality risk assessment. All-cause mortality and event 
rates of MI are more than two-fold higher in CLTI patients than in un­
selected patients with an ABI ≤0.90.431
In CLTI patients undergoing revascularization, the post-revascularization 
period is particularly associated with an increased risk of MALE and 
MACE.563 The management of patients with CLTI should therefore in­
clude an individual peri-procedural risk assessment. Referring to the peri- 
procedural risk patients can be categorized as average procedural risk 
(peri-procedural mortality <5% and 2 year survival >50%) or high proced­
ural risk (peri-procedural mortality ≥5% and 2 year survival ≤50%).564,565
Besides revascularization, it also needs to be considered that lower- 
limb amputation is associated with 30 day mortality rates of up to 
22%.566
Recommendation Table 16 — Recommendations for 
interventional treatment of patients with symptomatic 
peripheral arterial disease (per arterial bed)
Recommendations
Classa
Levelb
In femoro-popliteal lesions, drug-eluting treatment 
should be considered as the first-choice strategy.534–537
IIa
A
In iliac lesions, balloon angioplasty with or without 
stenting in external iliac arteries, or primary stenting in 
common iliac arteries, should be considered.545–548
IIa
B
In femoro-popliteal lesions, if revascularization is 
indicated, endovascular therapy should be 
considered.119,529–531
IIa
B
In femoro-popliteal lesions, if revascularization is 
indicated, an open surgical approach should be 
considered when an autologous vein (e.g. GSV) is 
available in patients with low surgical risk.119,529
IIa
C
In patients with severe IC undergoing endovascular 
femoro-popliteal revascularization, treatment of 
BTK arteries may be considered in the same 
intervention.549,550
IIb
C
© ESC 2024
BTK, below-the-knee; GSV, great saphenous vein; IC, intermittent claudication. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 17 — Recommendations in 
patients with peripheral arterial disease: follow-up of 
patients with peripheral arterial disease
Recommendations
Classa
Levelb
It is recommended to regularly, at least once a year, 
follow up patients with PAD, assessing clinical and 
functional status, medication adherence, limb 
symptoms, and CVRFs, with DUS assessment as 
needed.553,554
I
C
© ESC 2024
CVRFs, cardiovascular risk factors; DUS, duplex ultrasound; PAD, peripheral arterial 
disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3585


<!-- PAGE 49 -->

### Page 49

8.1.2.2. Medical treatment
Chronic limb-thretening ischaemia is associated with a high risk of is­
chaemic events,429,431 thus management of patients with CLTI must in­
clude OMT.
In addition, rest pain, optimal wound care, and infection control should 
be managed. A vascular team, including at least a vascular physician, a vas­
cular surgeon, and a radiologist, should be involved to prevent amputa­
tion.568 Lower-limb exercise training is contraindicated until ulcers are 
healed and aggressive offloading should be ensured to allow healing. 
Depending on infection extent, oral antibiotics may suffice, however, if 
extensive with systemic signs of inflammation, admission for intravenous 
(i.v.) antibiotic administration may be required.569,570
Good-quality evidence on the advantages of one type of wound 
dressing over others is lacking, while in selected patients individualized 
treatments with antimicrobial dressing,571 silver dressing,572 collagen 
dressing,573 honey- or iodine-based dressings,574 platelet-rich plasma, 
or negative pressure therapy575,576 may accelerate wound healing, 
shorten hospital stay, and prevent amputations. If deep-seated infection 
is suspected, X-ray or MRA are required to diagnose osteomyelitis, in 
which case a longer course of antibiotics may be necessary.577
Antibiotics for osteomyelitis treatment may be empirical, however, 
they should be adapted according to (preferably tissue) cultures.578–581
Ulcers require assessment of venous aetiology and potential for en­
dovenous therapy, while mixed ulcers require compression therapy 
after revascularization.582
8.1.2.3. Interventional treatment
8.1.2.3.1. Revascularization. In CLTI, revascularization should be at­
tempted to rapidly restore an inline direct blood flow to the 
foot.585–588 Three RCTs compared endovascular therapy with open 
surgery in infra-inguinal arteries. In the Bypass versus Angioplasty in 
Severe Ischaemia of the Leg (BASIL) trial, no significant difference 
was found regarding mortality or amputation-free survival at 2 years.589
However, surgery was associated with a significantly reduced risk of 
amputation, death, or both after 2 years.564,589 In the Best 
Endovascular versus Best Surgical Therapy for Patients with Critical 
Limb Ischemia (BEST-CLI) trial (median follow-up of 2.7 years), the in­
cidence of MALE or death was lower in patients in which one segment 
of the GSV was available for surgical revascularization than in patients 
who underwent endovascular revascularization. In the same trial, out­
comes of patients for whom an alternative bypass conduit was needed 
for surgical revascularization were similar to those of patients who 
underwent endovascular revascularization.567
In the BASIL-2 trial, which included patients requiring infra-popliteal, 
with or without additional further proximal infra-inguinal, revasculariza­
tion procedures, endovascular revascularization was associated with 
better amputation-free survival than surgical revascularization, which 
was primarily due to fewer deaths in this group.590 It is important to 
consider591 both revascularization options individually in each patient, 
considering the complexity of the diseased anatomical region.
Multilevel disease
Patients with CLTI commonly present with multilevel disease.592
Especially for complex lesions, comprehensive patient assessment, in­
cluding the individual patient’s clinical presentation, the lesion morph­
ology, and the peri-procedural risk, needs to be undertaken by a 
multidisciplinary vascular team to weigh the risks against the benefits 
of the respective methods of revascularization (endovascular vs. surgi­
cal).590,593–596 A structured approach is essential to achieve rapid and 
durable restoration of an inline flow to the foot. When possible, the an­
giosome concept can be considered, targeting the most affected ischae­
mic area.597 When CLTI leaves no viable revascularization options, 
transcatheter arterialization of deep veins may be considered.598
Aorto-iliac disease
An endovascular approach is the first choice, commonly employing 
bare metal or covered stents.599–603 Surgery is reserved for extensive 
obstructions and lesions treated unsuccessfully with an endovascular 
procedure.604 Hybrid revascularization should be considered in occlu­
sion of the common femoral artery or profunda femoris artery requir­
ing endarterectomy, in addition to inflow and/or outflow disease 
amenable to endovascular therapy. Hybrid procedures should be en­
couraged in a one-step modality.605
Femoro-popliteal disease
Chronic limb-threatening ischaemia is unlikely to be related to iso­
lated superficial femoral artery lesions; femoro-popliteal involvement 
in combination with aorto-iliac or infra-popliteal disease is frequently 
found. In 40% of cases, inflow treatment of femoro-popliteal disease 
is necessary.606 The revascularization strategy should be selected ac­
cording to lesion complexity.422 If endovascular therapy is chosen, land­
ing zones for potential bypass grafts should be preserved. When bypass 
surgery is decided, the bypass should be as short as possible, using the 
saphenous veins.567
Infra-popliteal disease
Extended infra-popliteal disease is mainly seen in patients with dia­
betes607–610 and CKD,611,612 often being associated with superficial 
femoral artery lesions. In short infra-popliteal lesions, endovascular 
Recommendation Table 18 — Recommendations for 
the management of chronic limb-threatening ischaemia
Recommendations
Classa
Levelb
For limb salvage in patients with CLTI, 
revascularization is recommended.564,567
I
B
Early recognition of CLTI and referral to the vascular 
team are recommended for limb salvage.417,560
I
C
In patients with CLTI, imaging of the entire affected 
limb should be considered.560
IIa
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 19 — Recommendations for 
medical treatment in patients with chronic limb- 
threatening ischaemia (see also Evidence Table 7)
Recommendations
Classa
Levelb
It is recommended that patients with CLTI are 
managed by a vascular team.568
I
C
In patients with CLTI and ulcers, offloading 
mechanical tissue stress is recommended to allow 
wound healing.583,584
I
C
It is recommended to treat infection with 
antibiotics.569,570
I
C
Lower-limb exercise training is not recommended in 
patients with CLTI and wounds.584
III
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 50 -->

### Page 50

therapy is the first choice.593 Drug-eluting balloons607 and bare metal 
stent implantation613 have shown no superiority over plain balloon 
angioplasty, although drug-eluting stents may be used for relatively 
short proximal lesions.614–616
8.1.2.3.2. Spinal cord stimulation. Spinal cord stimulation (SCS) may 
be considered in treating patients with CLTI and no viable revascular­
ization options. SCS offers modest pain relief and an 11% reduction 
in amputation rate compared with conservative management at 1 
year. No effect was seen in ulcer healing and benefits should be weighed 
against the high cost and possible complications.617 Recent technologic­
al advances in neuromodulation may improve the treatment value of 
this modality.618
8.1.2.3.3. Amputation. Minor amputation, usually up to the forefoot, 
is often needed for necrotic tissue removal with minor impact on patient 
mobility. Pre-amputation revascularization enhances wound healing. In 
cases of extensive necrosis or infectious gangrene, primary major ampu­
tation without revascularization may be preferable to avoid complica­
tions. Secondary amputation is indicated when revascularization fails, 
re-intervention is not possible, or limb deterioration persists despite a 
patent graft and optimal management. BTK amputation allows better 
mobility with a prosthesis. For bedridden patients, above-the-knee am­
putation may be the preferred choice.
8.1.2.4. Follow-up
In patients with CLTI, the incidence of CV events is increased.619,620
Follow-up should focus on general clinical CV condition, prevention 
of revascularization failure, wound healing, and contralateral limb status. 
After revascularization, at least an annual appointment with a vascular 
physician expert in CLTI management is warranted. Due to the lack of 
evidence, recommendations are largely based on consensus and expert 
opinions.128
First-year incidence of vein graft stenosis is 20%;621 however, if un­
eventful for 12 months, late issues are scarce.622 Clinical examination, 
ABI (or TBI) measurement, and DUS should be performed within 4– 
6 weeks and thereafter at 3, 6, 12, and 24 months after bypass 
surgery.128
After endovascular treatment, restenosis and occlusion ranges from 
5% in the pelvic region to >50% in the infra-popliteal arteries.623,624
Unlike after surgery, no plateau phase is seen, and the failure rate is con­
stant for at least 5 years. Surveillance includes clinical assessment looking 
for recurrent symptoms or signs, ABI measurement, and DUS based on 
the first check-up: if normal, DUS is recommended if symptoms reappear; 
if abnormal, initial DUS, re-intervention, or closer DUS follow-up on a 
case-by-case basis are recommended.128 Post-procedural ankle duplex- 
based estimated ABI of <0.90 predicts suboptimal wound healing, clinic­
ally driven target lesion revascularization (cdTLR), and MALE.625
After revascularization, closer follow-up and wound care are recom­
mended until healing. Thereafter, annual appointments with vascular 
physicians with expertise in CLTI management should be scheduled 
to check for symptoms, foot condition, ABI, and CVRFs, including avail­
ability for TP and TcPO2 if needed. Recurrence of symptoms may also 
be due to the progression of atherosclerotic disease above or below 
the bypass or angioplasty site.427
8.1.3. Acute limb ischaemia
8.1.3.1. Clinical presentation and diagnosis
Acute limb ischaemia is caused by an abrupt decrease in arterial limb per­
fusion. Potential causes are PAD progression, cardiac/aortic embolization, 
AD, graft thrombosis, aneurysm thrombosis, popliteal artery entrapment 
syndrome, trauma, phlegmasia cerulea dolens, ergotism, hypercoagulable 
states, and iatrogenic complications related to vascular procedures. ALI is 
a medical emergency and timely recognition is crucial to successful treat­
ment.629–632 Patients should be rapidly evaluated by a vascular specialist633
or rapidly transferred to a facility with such resources.
The time constraint is due to the period that skeletal muscle and 
nerves will tolerate ischaemia—roughly 4–6 h.634 Lower-extremity 
symptoms can include both pain and loss of function. The longer and 
the stronger these symptoms are, the less likely the possibility of limb 
salvage.
Recommendation Table 20 — Recommendations for 
interventional treatment of chronic limb-threatening 
ischaemia
Recommendation
Classa
Levelb
In CLTI patients, it is recommended to perform 
revascularization as soon as possible.564
I
B
In CLTI, it is recommended to use autologous veins 
as the preferred conduit for infra-inguinal bypass 
surgery.567,593
I
B
In multilevel vascular disease, it is recommended to 
eliminate inflow obstructions when treating 
downstream lesions.
I
C
An individual risk assessment (weighing the patient’s 
individual procedural risk of endovascular vs. surgical 
revascularization) by a multidisciplinary vascular team 
is recommended.
I
C
In CLTI patients with good autologous veins and low 
surgical risk (<5% peri-operative mortality, >50% 2 
year survival), infra-inguinal bypass may be 
considered.564,567,590
IIb
B
In CLTI patients, endovascular treatment may be 
considered as first-line therapy, especially in patients 
with increased surgical risk or inadequate autologous 
veins.564,567,590
IIb
B
© ESC 2024
CLTI, chronic limb-threatening ischaemia. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 21 — Recommendations for 
follow-up in patients with chronic limb-threatening 
ischaemia
Recommendations
Classa
Levelb
In patients with CLTI, following revascularization it is 
recommended to follow up patients on a regular 
basis.552,626,627
I
C
At follow-up, it is recommended to assess clinical, 
haemodynamic and functional status, limb symptoms, 
treatment adherence, and CVRFs.552,625–628
I
C
© ESC 2024
CLTI, chronic limb-threatening ischaemia; CVRFs, cardiovascular risk factors. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3587


<!-- PAGE 51 -->

### Page 51

8.1.3.1.1. Clinical examination. The emergency level and the choice 
of therapeutic strategy depend on the clinical presentation, mainly ac­
cording to neurological deficits. Clinical assessment must include symp­
tom duration as well as sensory and motor deficit severity to distinguish 
a threatened from a non-viable extremity. Neurological deficits (sen­
sory loss or especially motor deficit) are signs of limb threat and require 
emergency imaging and revascularization.635 Severe sensory deficit and 
paralysis suggest the limb may be unsalvageable. Clinical ALI categories 
are presented in Table 9.
8.1.3.1.2. Imaging and functional tests. The imaging method de­
pends on availability and aims to diagnose clot presence and assess 
haemodynamic severity. DSA, CTA, DUS, and contrast-enhanced 
(CE)-MRA are options based on local expertise, availability, and prefer­
ence.636 DUS helps determine treatment urgency when assessing 
neurological deficit is challenging. Loss of arterial signal suggests limb 
threat, while a present signal may indicate the limb is not immediately 
threatened, allowing for ABI measurement. The absence of both arter­
ial and venous Doppler signals, coupled with extensive motor deficit, 
suggests the limb may be irreversibly damaged (non-salvageable).637
In addition, biomarkers of muscle damage such as creatinine kinase 
(CK) or myoglobin may be useful as high levels indicate rhabdomyolysis, 
risk of amputation,638 kidney failure, and mortality.639 In limb ischaemia, 
CK and myoglobin elevations may be lower in chronic cases, possibly 
due to ischaemic pre-conditioning and collateral development.640
8.1.3.2. Medical treatment
Upon clinical diagnosis, initiate analgesia, anticoagulation, and i.v. fluids. 
Addressing acidosis and hyperkalaemia may be necessary. Administer 
i.v. unfractionated heparin (bolus 5000 IU or 70–100 IU per kg body 
weight, followed by continuous infusion with dose adjustment based 
on patient response, monitored by activated clotting time or activated 
partial thromboplastin time) or subcutaneous low molecular weight 
heparin (e.g. enoxaparin 1 mg per kg twice daily) to prevent further em­
bolization and thrombus propagation.
8.1.3.3. Surgical and interventional treatment
For a salvageable limb, urgent revascularization is essential. Diagnostic 
imaging, if it will not delay treatment, is recommended to guide therapy. 
If the limb is deemed unsalvageable, primary amputation or comfort 
care is indicated.
Different revascularization modalities can be applied, including per­
cutaneous catheter-directed thrombolytic therapy, percutaneous 
mechanical thrombus extraction or thrombo-aspiration (with or with­
out thrombolytic therapy), or surgical thrombectomy, bypass, and/or 
arterial repair.642 Moreover, these modalities can be combined, with 
the strategy determined by factors such as neurological deficit, ischae­
mia duration, localization, size, aetiology, comorbidities, type of conduit 
(artery or graft), and therapy-related risks and outcomes. Current en­
dovascular approaches to ALI boast high technical success rates.626 To 
reduce morbidity and mortality, an endovascular-first approach is often 
preferred, especially in patients with severe comorbidities. Thrombus 
extraction, thrombo-aspiration, and surgical thrombectomy are indi­
cated in cases of neurological deficit, while catheter-directed thrombo­
lytic therapy is more appropriate in less severe cases without 
neurological deficit. Modern catheter-based thrombectomy (CDT) is 
associated with 12-month amputation rates of <10% in Rutherford 
IIB.643 A meta-analysis showed that although CDT in the treatment 
of not immediately threatening ALI showed high angiographic success, 
the long-term outcomes were relatively poor, with low patency and a 
substantial risk of major amputation.644 Systemic thrombolysis has no 
role in the treatment of patients with ALI.
A meta-analysis showed that CDT and surgery have similar limb sal­
vage rates.645 Recent analyses indicate benefits of endovascular ap­
proaches in terms of mortality at similar amputation rates.646,647
A comparison of percutaneous thrombectomy vs. ultrasound- 
accelerated thrombolysis for the initial management of ALI showed 
no difference in terms of amputation, bleeding, clinical success, and ad­
verse events, with primary patency at 30 days of 82% and 71%, 
respectively.629,648,649
After thrombus removal, in cases of pre-existing arterial lesions, 
these should be treated by endovascular therapy or open surgery. If 
surgical treatment is required, it should be ideally performed in a hybrid 
room with capacity to allow sufficient completion angiographic imaging 
and initiation of local lysis if any remaining clot is visualized. 
Lower-extremity four-compartment fasciotomies should be per­
formed in patients with long-lasting ischaemia to prevent post- 
reperfusion compartment syndrome.637 The management of ALI is 
summarized in Figure 16.
Table 9 Clinical categories of acute limb ischaemia
Grade
Category
Sensory 
loss
Motor deficit
Arterial 
Doppler 
signal
Venous 
Doppler 
signal
Capillary 
refill
Biomarkers
Prognosis
I
Viable
None
None
Yes
Yes
Yes
Not elevated
No immediate 
threat
IIA
Marginally 
threatened
None or 
minimal 
(toes)
None
No
Yes
Salvageable if 
promptly treated
IIB
Immediately 
threatened
More than 
toes
Mild-moderate
No
Yes
Salvageable if 
promptly 
revascularized
III
Irreversible
Profound, 
anaesthetic
Profound 
paralysis (rigor)
No
No
No
Massively 
elevated
Major tissue loss, 
permanent nerve 
damage inevitable
© ESC 2024
Adapted with permission from.641


<!-- PAGE 52 -->

### Page 52

Neurological function
No sensory loss
Normal motor function
Sensory loss limited to toes
No muscle weakness
Sensory loss more than toes and rest pain
Mild-to-moderate muscle weakness
Complete sensory loss 
and loss of motor function
Capillary refill
Intact
Slow-intact
Slow-absent
Absent
Arterial Doppler
Audible
Inaudible
Venous Doppler
Audible
I: Viable
IIA: Marginally threatened
IIB: Immediately threatened
III: Irreversible
Inaudible
Muscle biomarkers
Elevated
Suspected ALI
Acutely cold and painful leg
Pain management
Medical management and follow-up
Imaging
(DUS, CTA, DSA, MRA)
Imaginga
(DUS, CTA, DSA, MRA)
Urgent revascularization
AND anticoagulation unless contraindicated
Emergency revascularization
AND anticoagulation unless contraindicated
Primary amputation or palliative care
Clinical evaluation by experienced clinician
Figure 16 Management of acute limb ischaemia. ALI, acute limb ischaemia; CTA, computed tomography angiography; DSA, digital subtraction angi­
ography; DUS, duplex ultrasound; MRA, magnetic resonance angiography. aShould not delay treatment.
ESC Guidelines                                                                                                                                                                                          3589


<!-- PAGE 53 -->

### Page 53

8.1.3.4. Follow-up
After revascularization or amputation, haemodynamic success should 
be established, aetiology of ALI investigated, and OMT ensured. 
Statins improve outcomes after revascularization.552,630 Since ALI is 
frequently caused by thrombo-embolism, Holter-ECG, echocardio­
gram, and aortic imaging are useful to allow initiation of appropriate 
therapy, in particular anticoagulation.650 Additionally, consider other 
prothrombotic syndromes, such as antiphospholipid syndromes and 
vasculitis, if clinically suspected. While there is only sparse evidence, 
the inclusion of PAD patients after revascularization into structured 
follow-up may improve their functional outcomes.627
8.2. Extracranial carotid and vertebral 
artery disease
8.2.1. Clinical presentation and diagnosis
8.2.1.1. Clinical presentation
Atherosclerotic CS represents one of the major causes of acute ischae­
mic stroke (20%).657
CS may be revealed by a cervical bruit, but also by a TIA or stroke.
8.2.1.2. Diagnosis
Atherosclerotic lesions are primarily located in specific arterial segments, 
including the carotid bifurcation, siphon, M1 segment of the middle cere­
bral artery, brachiocephalic trunk, subclavian artery, first and fourth seg­
ments of the vertebral artery, or first segment of the basilar artery. 
Carotid plaques (CP), originating in the intima, offer a better representa­
tion of the atherosclerotic process than carotid intima-media thickness 
(cIMT). CP may be diffuse or focal (protuberant). According to the 
Mannheim carotid plaque consensus, a CP is defined as a focal structure 
encroaching into the arterial lumen by ≥0.5 mm or ≥50% of the sur­
rounding vessel.658 The American Society of Echocardiography (ASE) re­
cently proposed a definition that includes any focal thickening considered 
atherosclerotic in origin and encroaching into the lumen of any carotid 
artery segment (protuberant-type plaque) or, in the case of diffuse vessel 
wall atherosclerosis, when cIMT measures ≥1.5 mm in any carotid artery 
segment.659 Plaques can progress to CS, defined as ≥50% narrowing of 
the extracranial internal carotid artery (ICA), with stenosis severity esti­
mated using the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) method or its non-invasive equivalent assessed by DUS 
(Figure 17).122,660 Other methods are described in the Supplementary 
data online, Section 1.5. The European Carotid Surgery Trial (ECST) 
and the area methods overestimate the severity of the CS and are not 
recommended.77
Carotid DUS is safe, accurate, and reliable if performed by a skilled vas­
cular specialist. It is the first-line imaging modality for screening, diagnosis, 
and surveillance of extracranial carotid arteries.77 The degree of stenosis 
is mostly based on Doppler analysis of blood flow in the common carotid 
artery (CCA), ICA, and external carotid artery (Table 10).661,662
Vertebral and subclavian arteries must also be checked. In some cases, 
indirect signs of severe stenosis have to be evaluated by transcranial 
and/or ophthalmic artery Doppler. Severe arterial calcification can de­
crease DUS accuracy.122
Recommendation Table 22 — Recommendations for 
the management of patients presenting with acute 
limb ischaemia (see also Evidence Table 8)
Recommendations
Classa
Levelb
In patients with ALI, it is recommended that an 
urgent evaluation is performed by a vascular clinician 
with sufficient experience to assess limb viability and 
implement appropriate therapy.635
I
C
In cases of neurological deficit, urgent 
revascularization is recommended; diagnostic 
imaging is recommended to guide treatment, 
provided it does not delay treatment, or if the need 
for primary amputation is obvious.422,635,651,652
I
C
In the absence of severe neurological deficit, 
revascularization is recommended within hours of 
initial imaging in a case-by-case decision.422,635,652
I
C
Treatment with analgesics is recommended as soon 
as possible for pain control.
I
C
It is recommended to monitor for compartment 
syndrome after revascularization and treat 
(fasciotomy).637,652
I
C
It is recommended to assess clinical and 
haemodynamic success following 
revascularization.627
I
C
In patients with ALI, it is recommended to obtain a 
comprehensive medical history and determine the 
cause of thrombosis and/or embolization.650
I
C
In patients with ALI, following revascularization if not 
on anticoagulation for other reasons, DAPT or 
rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) 
should be considered.514,653
IIa
C
Upon confirmation of ALI diagnosis, treatment with 
heparin may be considered.635,654–656
IIb
C
© ESC 2024
ALI, acute limb ischaemia; b.i.d., twice daily; DAPT, dual antiplatelet therapy; DPI, dual 
pathway inhibition; o.d., once daily. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 23 — Recommendations for 
carotid artery stenosis assessment
Recommendations
Classa
Levelb
It is recommended to use the NASCET method or its 
non-invasive equivalent to assess ICA 
stenosis.77,122,660
I
B
It is recommended to use DUS as first-line imaging to 
diagnose ICA stenosis.77,663
I
C
It is not recommended to use the ECST method for 
ICA stenosis assessment.77,122,660
III
C
© ESC 2024
DUS, duplex ultrasound; ECST, European Carotid Surgery Trial; ICA, internal carotid 
artery; NASCET, North American Symptomatic Carotid Endarterectomy Trial. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

8.2.2. Asymptomatic carotid artery stenosis
8.2.2.1. Medical treatment
Optimal medical treatment is based on CVRF correction through 
lifestyle intervention and pharmacological treatment, with the goal of 
reducing cerebrovascular and global CV events.19 Concerning hyper­
tension, similar target values as those presented in the general section 
are recommended for patients with asymptomatic CS.
8.2.2.1.1. Lipid-lowering therapy. See Section 7.
8.2.2.1.2. Antihypertensive therapy. See Section 7. 
8.2.2.1.3. Glucose-lowering therapy. See Section 7. 
8.2.2.1.4. Antithrombotic therapy. The clinical benefit of antithrom­
botic treatment in patients with asymptomatic CS remains 
unproven.664 The only RCT (the Asymptomatic Cervical Bruit 
Study [ACB]) addressing the issue enrolled only 188 patients per 
arm, and failed to show superiority of aspirin vs. placebo in reducing 
TIA, stroke, MI, or death.665 In observational studies, SAPT (mainly 
low-dose aspirin) was associated with reduced risk of MACE, 
although data were conflicting for moderate stenosis (i.e. 50%– 
75%);664 DAPT, combining aspirin and clopidogrel, has no benefit 
over SAPT.496,497
The Cardiovascular Outcomes for People Using Anticoagulation 
Strategies (COMPASS) trial reported a non-significant decrease in 
MACE in patients with either history of carotid revascularization or 
asymptomatic patients with >50% CS and CVRFs allocated to dual an­
tithrombotic therapy (aspirin 100 mg o.d. and rivaroxaban 2.5 mg b.i.d.) 
NASCET
(% stenosis)
ECST
(% stenosis)
50
75
60
80
70
85
80
91
90
97
A
C
B
Carotid artery stenosis equivalents between
NASCET and ECST criteria
ECST method
C
NASCET method x 100%
(C-A)
B
x 100%
(B-A)
Figure 17 North American Symptomatic Carotid Endarterectomy Trial/European Carotid Surgery Trial methods. ECST, European Carotid Surgery 
Trial; NASCET, North American Symptomatic Carotid Endarterectomy trial.
Table 10 Peak systolic velocity criteria for grading internal carotid artery stenosis
% stenosis
Reference
50%–69% (moderate stenosis)
≥70% (severe stenosis)
PSV threshold
SRUCC662
------------------------- 
Gornik et al.661
125–230 cm/s  
------------------------- 
≥180 cm/s 
or 
≥125 cm/s + PSV ICA/CCA ≥2
>230 cm/s  
------------------------- 
Overestimation with SRUCC criteria but no consensus
© ESC 2024
CCA, common carotid artery; ICA, internal carotid artery; PSV, peak systolic velocity; SRUCC, Society of Radiologists in Ultrasound.
ESC Guidelines                                                                                                                                                                                          3591


<!-- PAGE 55 -->

### Page 55

vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone. However, specific data 
on asymptomatic CS were not reported.
Since these patients present a two times higher risk of MI,30 lifelong 
low-dose aspirin should be considered in asymptomatic CS patients at 
increased risk for CV events (i.e. diabetic patients) and low bleeding 
risk497 to reduce stroke and CV risk.19,299,488,666
8.2.2.2. Interventional treatment
8.2.2.2.1. Open surgery vs. medical therapy. The rationale for carotid 
endarterectomy (CEA) in asymptomatic CS stems from two trials that 
were published some time ago. The Asymptomatic Carotid 
Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery 
Trial 1 (ACST-1) compared CEA with medical therapy in asymptomatic 
patients with 60%–99% CS.672–674 In ACAS, 5 year rates of ipsilateral 
stroke/death under CEA vs. medical therapy were 5.1% vs. 11.0%. 
ACST-1 reported 5 year rates of any stroke of 6.4% vs. 11.8%, respect­
ively. In a combined analysis of both trials, CEA conferred less benefit in 
women at 5 years.675 At 10 years, however, ACST-1674 reported that 
females benefit following CEA (absolute risk reduction [ARR] 5.8%) 
to the same extent as men (ARR 5.5%).
Medical treatment has advanced following the recruitment of patients 
in these trials.672–676 A 60%–70% decline in annual stroke rates was also 
observed in medically treated patients in both trials over 1995 to 2010.676
This reduction was attributed to better medical treatment and lower 
smoking incidence. The Stent Protected Angioplasty versus Carotid 
Endarterectomy study (SPACE-2) compared OMT alone against OMT 
plus CEA/carotid artery stenting (CAS) in asymptomatic patients with 
CS ≥70% according to ECST criteria. Due to slow recruitment, the study 
was underpowered. The 1 year rate of the major secondary endpoint was 
2.5% after CEA, 3.0% after CAS, and 0.9% after OMT.677 Incidence of any 
stroke or death from any cause within 30 days or any ipsilateral ischaemic 
stroke within 5 years (primary efficacy endpoint) was 2.5% with CEA plus 
OMT, 4.4% with CAS plus OMT, and 3.1% with OMT alone. Results from 
the Carotid Revascularization Endartectomy vs. Stenting Trial 2 
(CREST-2) are awaited to clarify whether intervention is beneficial in 
the treatment of asymptomatic CS compared with modern OMT.
The ARR in stroke favouring surgery over OMT was only 4.6% at 10 
years in ACST-1, indicating that 95% of asymptomatic patients ultim­
ately underwent unnecessary interventions.674,678
A recent meta-analysis confirmed the role of modern OMT in redu­
cing major stroke, combined stroke, and mortality in asymptomatic pa­
tients, suggesting that OMT has the potential to reduce the 
requirement for surgical intervention in patients with asymptomatic 
carotis stenosis.679
In conclusion, for invasive treatment of asymptomatic carotid sten­
osis, the overall risk reduction is low compared with OMT. Current 
data are not available to assess subgroups that may still benefit from 
intervention. However, there is a need to target revascularization in a 
subgroup of patients with clinical and/or imaging features that increase 
the risk for stroke on OMT (Table 11).678,680
Importantly, ACST-1 found no evidence that age >75 years at base­
line was associated with any ipsilateral stroke reduction at 5–10 
years.676–678,696 Neither the ACAS nor ACST-1 studies found any evi­
dence that stenosis severity or contralateral occlusion increased late 
stroke risk.672,674,697 In a recent meta-analysis, increasing stenosis was 
associated with late ipsilateral stroke only in the presence of concomi­
tant high-risk features.698 The general algorithm of CS management is 
presented in Figure 18.552
8.2.2.2.2. Carotid revascularization: surgery vs. stenting. In a recent 
meta-analysis update on RCTs in asymptomatic patients comparing 
CEA vs. CAS, including altogether 7092 patients, CAS was associated 
with significantly higher rates of 30 day ‘any’ stroke and 30 day death/ 
any stroke, while CEA was associated with significantly higher rates 
of 30 day MI. No significant differences were seen in 30 day death, 
30 day disabling stroke, 30 day death/disabling stroke, or 30 day 
death/any stroke/MI when CAS was compared with CEA.699 In the lar­
gest RCT, ACST-2, post-operative death and major stroke were similar 
(1.0%) between groups.700,701
No significant difference was found in the 5 and 10 year incidence of 
ipsilateral stroke and any stroke between CEA and CAS.696,702,703 The 
5 year non-procedural stroke rate in ACST-2 was 2.5% in each group 
for fatal/disabling stroke, and 5.3% with CAS vs. 4.5% with CEA for any 
stroke.700,701
Recommendation Table 24 — Recommendations for 
antithrombotic treatment in patients with carotid 
stenosis
Recommendations
Classa
Levelb
Carotid artery disease
In patients with symptomatic CS, not undergoing 
carotid endarterectomy or stenting, DAPT with 
low-dose aspirin and clopidogrel (75 mg) is 
recommended for the first 21 days or longer, 
followed by clopidogrel 75 mg or long-term aspirin 
to reduce the risk of stroke.667–669
I
A
In patients with asymptomatic >50% CS, long-term 
antiplatelet therapy (commonly low-dose aspirin) 
should be considered if bleeding risk is 
low.488,497,670,671
IIa
C
© ESC 2024
CS, carotid artery stenosis; DAPT, dual antiplatelet therapy. 
aClass of recommendation. 
bLevel of evidence.
Table 11 High-risk features associated with increased 
risk of stroke in patients with asymptomatic internal ca­
rotid artery stenosis on optimal medical treatment
Clinicala
Contralateral TIA/stroke681,682
Cerebral imaging
Ipsilateral silent infarction683–685
Ultrasound/CT 
imaging
Stenosis progression (>20%)340,684,685
Spontaneous embolization on transcranial Doppler 
(HITS)341,686
Impaired cerebral vascular reserve687,688
Large plaques689,690
Echolucent plaques136,691
Increased juxta-luminal black (hypoechogenic) 
area689,690
MRAb
Intraplaque haemorrhage692,693
Lipid-rich necrotic core694,695
© ESC 2024
CT, computed tomography; HITS, high-intensity transient signal; MRA, magnetic resonance 
angiography; TIA, transient ischaemic attack. 
aAge is not a predictor of poorer outcome. 
bMore than 40 mm2 on digital analysis.


<!-- PAGE 56 -->

### Page 56

Duplex ultrasound
Individual risk assessmenta
Average-to-high surgical risk
<60% carotid stenosis
60–99% carotid stenosis
100% carotid occlusion
Asymptomatic patient
OMT
(Class I)
Revascularization
 (Class III)
Revascularization
 (Class IIb)
CTA and/or MRA
 (incl. aortic arch)
CEA
or CAS/TCAR decision by vascular team based on an individual patient approach
Surgical/endovascular risk assessmenta
Routine revascularization
 (Class III)
OMT
(Class I)
Revascularization
 (Class III)
OMT
(Class I)
Vascular team 
and neurologist
N
Y
Duplex ultrasound
CTA and/or MRA
(incl. aortic arch)
<50% carotid stenosis
50–69% carotid stenosis
100% carotid occlusion
Symptomatic patient
OMT
(Class I)
Routine revascularization
 (Class III)
OMT
(Class I)
Revascularization
 (Class III)
OMT
(Class I)
Revascularization
 (Class IIa)
70–99% carotid stenosis
OMT
(Class I)
Revascularization
 (Class I)
CEA
or CAS/TCAR decision by vascular team based on an individual patient approach
Figure 18 Algorithm of carotid artery stenosis management. CAS, carotid artery stenting; CEA, carotid endarterectomy; CTA, computed tomog­
raphy angiography; MRA, magnetic resonance angiography; OMT, optimal medical treatment; TCAR, transcarotid artery revascularization; TIA, tran­
sient ischaemic attack. aAssess presence of high-risk features according to Table 11. If surgery/revascularization is considered, assess the overall risk 
related to surgery according to Table 12.
ESC Guidelines                                                                                                                                                                                          3593


<!-- PAGE 57 -->

### Page 57

The Stenting and Angioplasty with Protection in Patients at High Risk 
for Endarterectomy (SAPPHIRE) trial randomized symptomatic and 
asymptomatic patients deemed ‘high-risk for surgery’ to either CEA 
or CAS (using embolic protection devices).704 Overall, 71% of 
SAPPHIRE patients were asymptomatic, and in these patients the 30 
day rate of death/stroke after CAS was 5.8% vs. 6.1% after CEA704— 
both beyond the recommended 3%. If these procedural risk levels re­
flect contemporary practice, most ‘high-risk for surgery’ asymptomatic 
patients would be better treated medically.
A small sample size RCT has provided evidence that the use of a 
double-layer mesh stent can reduce the occurrence of peri-procedural 
diffusion-weighted imaging (DWI)-detected ischaemic lesion after ca­
rotid stents, when compared with conventional stents. At 1 year follow- 
up the use of a double-layer mesh stent was associated with a significant 
reduction in the composite endpoint of MACE and in-stent restenosis or 
occlusion. The clinical benefit of these findings has to be proven.705,706
Transcarotid artery revascularization (TCAR) has been introduced 
recently. Although no RCTs are available, large registry-based analyses 
report a 99.7% technical success rate and low 30 day complication rates 
(<3% in 30 day stroke/death and <1% MI).681
In a large-scale registry the 1 year rate of stroke or death was 6.4% 
for TCAR, 5.2% for CEA, and 9.7% for transfemoral carotid artery 
stenting (TFCAS).707
Properly conducted RCTs comparing TCAR with CEA in asymp­
tomatic patients are required to establish the true place of TCAR in ca­
rotid revascularization.708
8.2.3. Symptomatic carotid artery stenosis
8.2.3.1. Medical treatment
8.2.3.1.1. Lipid-lowering therapy. See Section 7.
8.2.3.1.2. Antihypertensive therapy. See Section 7.
8.2.3.1.3. Glucose-lowering therapy. See Section 7.
8.2.3.1.4. Antithrombotic therapy. Symptomatic CS is associated 
with a high risk of early recurrence of cerebrovascular ischaemic 
events.667–669,683 DAPT with low-dose aspirin and clopidogrel is re­
commended for all patients with symptomatic CS for at least 
3 months.669 Those undergoing surgical revascularization can stop clo­
pidogrel after surgery.711 Those undergoing endovascular revasculari­
zation should continue DAPT with clopidogrel and low-dose aspirin 
for 4 weeks after the procedure.488,666,711,712 In patients with stroke re­
lated to extracranial arterial disease, aspirin was more effective than 
VKAs in reducing recurrencies.687,713 Subgroup analysis from the 
Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or 
Ticagrelor and Patient Outcomes (SOCRATES) trial suggested a lower 
rate of MACE in patients receiving ticagrelor vs. aspirin;689 however, 
this analysis was underpowered to make any conclusions regarding 
the benefit of ticagrelor.
A combination of aspirin and clopidogrel in the early phase of symp­
tomatic carotid stenosis reduces asymptomatic cerebral embolization 
and stroke.692,694,714 It also reduces stroke recurrence after a minor 
stroke/TIA.667,668
Recently, the Acute Stroke or Transient Ischaemic Attack Treated 
with Ticagrelor and acetylsalicylic acid for Prevention of Stroke and 
Death (THALES) trial showed a 17% reduction in the risk of death 
or stroke when using ticagrelor and aspirin vs. aspirin alone in patients 
with minor stroke or high-risk TIA;715 however, bleeding events oc­
curred more frequently in the ticagrelor plus aspirin group.700,716 Of 
note, COMPASS data cannot be applied to symptomatic carotid sten­
osis since these patients were excluded because of intracranial bleeding 
risk.499
Recommendation Table 25 — Recommendations for 
interventional treatment in patients with asymptomatic 
carotid artery stenosis
Recommendations
Classa
Levelb
When ICA revascularization is considered, 
documented peri-operative stroke/death rates 
should be <3% and the patient’s life expectancy 
should be considered >5 years after careful 
consideration of the risks and benefits by a vascular 
team. 674,709
IIa
B
In ‘average surgical risk’ patients over 75 years of age 
with a CS of 60%–99%, in the presence of high-risk 
features, CEA, in addition to OMT, should be 
considered.674,709
IIa
B
In ‘high surgical risk’ patients with a CS of 60%–99%, 
in the presence of high-risk features, CAS, in addition 
to OMT, may be considered.699,701,704
IIb
B
In ‘average surgical risk’ patients with a CS of 60%– 
99%, in the presence of high-risk features, CAS, in 
addition to OMT, may be considered as an 
alternative to CEA.696,701,702,710
IIb
B
In asymptomatic patients with ICA stenosis, in the 
absence of high-risk features and with a life 
expectancy <5 years, routine revascularization is not 
recommended.674
III
A
© ESC 2024
CAS, carotid artery stenting; CEA, carotid endarterectomy; CS, carotid artery stenosis; 
ICA, internal carotid artery; OMT, optimal medical treatment. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 26 — Recommendations for 
evaluation and medical treatment in patients with 
symptomatic carotid artery stenosis
Recommendations
Classa
Levelb
DAPT is recommended in the early phase of minor 
strokes in patients with ICA stenosis, if not 
revascularized, for at least 21 days, considering the 
bleeding risk.667,668
I
A
It is recommended that symptomatic ICA stenosis 
patients are assessed by a vascular team including a 
neurologist.667,668
I
C
Long-term treatment with SAPT should be 
considered following ICA revascularization.667,668
IIa
C
DAPT may be considered in the early phase of minor 
stroke in patients with ICA stenosis for up to 90 days, 
considering the bleeding risk.667,668
IIb
B
© ESC 2024
DAPT, dual antiplatelet therapy (aspirin and clopidogrel); ICA, internal carotid artery; 
SAPT, single antiplatelet therapy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 58 -->

### Page 58

8.2.3.2. Interventional treatment
8.2.3.2.1. Open surgery. Optimal medical treatment is recommended 
for all symptomatic patients with CS. In recently symptomatic patients 
with <50% stenosis, CEA (plus OMT) did not prevent stroke. 
However, surgery reduced stroke risk in patients with moderate 
(50%–69%) and severe (70%–99%) stenosis. The benefit from surgery 
increased with increasing severity of stenosis, except for ‘near- 
occlusion’ lesions (95%–99% stenosis with distal ICA collapse or a nar­
row calibre lumen with ‘trickle flow’).660,717–720
Some features are associated with a higher increase of stroke in symp­
tomatic patients (50%–99% stenosis) medically treated: age (>75 years), 
symptoms within 14 days, male sex, hemispheric (vs. retinal) symptoms, 
cortical (vs. lacunar) stroke, increasing comorbidities, irregular stenosis, 
stenosis severity, contralateral occlusion, tandem intracranial stenosis, 
and failure to recruit intracranial collaterals.721
Large-scale registries suggest that CEA can be performed safely in 
the first 7 days after TIA/minor stroke.722–724 However, not all patients 
benefit from urgent revascularization, and controversy exists over the 
safety of performing CEA within the first 48 h after symptom onset due 
to an increased risk of haemorrhagic transformation. Higher-risk pa­
tients include those with acute carotid occlusion, a persisting major 
neurological deficit, an area of middle cerebral artery infarction exceed­
ing one-third, evidence of pre-existing parenchymal haemorrhage, and 
signs of impaired consciousness.724,725
The choice to perform carotid revascularization within 48 h from 
symptom onset is still debatable.726
8.2.3.2.2. Endovascular therapy vs. open surgery. Contemporary 
RCTs comparing CEA with CAS in symptomatic patients reported a 
significantly higher risk of 30 day ‘any stroke’ and ‘death/stroke’ follow­
ing CAS. This is mainly due to higher rates of minor stroke, which were 
non-disabling and resolved within 6 months.711,727
However, the occurrence of a peri-operative stroke is associated 
with three-fold poorer long-term survival,727 similar to a post- 
procedural MI (which was more frequent after CEA).728
In CAS patients, the risk increased in those aged >60 years, especially 
for those aged >80 years, who are four times more likely to experience 
a procedural stroke/death. When comparing CAS with CEA, the 
age-related effect became apparent in patients aged 60–65 years, and 
CEA is superior to CAS in patients aged >70 years.729,730
Elderly CAS patients may experience more peri-operative strokes, 
mainly minor ipsilateral strokes, possibly due to a higher burden of aor­
tic arch disease. In these cases, operator/institution experience may 
play a role in determining peri-procedural outcomes. CAS is associated 
with significantly lower risks for MI, transient cranial nerve injury, and 
haematoma.731,732
Beyond the 30 day peri-operative period, long-term data suggest that 
outcomes after CAS are similar to those with CEA.703,733 The pre­
dicted magnitude of 30 day risk (according to clinical/anatomical char­
acteristics and operator/centre experience) will thus largely 
determine whether CEA or CAS is preferable in individual patients.
Post-hoc trial analysis revealed enhanced benefits of CEA when per­
formed within 2 weeks of the ischaemic event,734 with reduced compli­
cations compared with CAS performed within 1 week of stroke/TIA. 
The Carotid Stenosis Trialists’ Collaboration found a higher stroke/ 
death rate (8.3% with CAS vs. 1.3% with CEA) for CAS in patients trea­
ted within 1 week of the last symptomatic event.735 These findings sup­
port a preference for early CEA in symptomatic patients. However, 
these trials, initiated over 30 years ago, lack evaluation of current 
OMT. Initially designed as an alternative for high surgical risk (HSR) pa­
tients,704,736 carotid stenting’s efficacy needs consideration in contem­
porary practice (Table 12).735
In conclusion, CEA is still the treatment choice for patients with 
symptomatic carotid stenosis. However, in patients eligible for ca­
rotid revascularization but deemed high surgical risk by a multidiscli­
plinary team, CAS may be preferred over CEA—the patient must be 
a suitable candidate for CAS, and the complication rate should not 
surpass 6%.
At present, TCAR results have been analysed in registries only. In 
these studies, in-hospital stroke/death has been significantly lower after 
TCAR compared with transfemoral CAS.707,737 Similar to the previous 
results established for CEA, symptomatic patients undergoing TCAR 
demonstrate similar outcomes if the procedure is performed >48 h 
after the neurological event.738 However, TCAR has not yet been eval­
uated in RCTs and has not been compared with CEA or OMT.
8.2.3.2.3. Vertebral arteries. The evidence on the use of lifestyle 
modifications and medical therapy in cases of symptomatic vertebral ar­
tery stenosis is lacking, but their use is reasonable given the overall CV 
risk in these patients.
Evidence on the use of preventive strategies and antithrombotic 
agents is lacking, but their use is reasonable in the presence of other 
CVRFs.
Surgery on extracranial vertebral stenosis (with transposition to CCA, 
trans-subclavian vertebral endarterectomy, distal venous bypass) can be 
performed with low stroke/death rates in experienced centres.739,740
However, with limited expertise in complex vertebral artery reconstruc­
tions, open surgery has been mostly replaced by endovascular interventions.
In a combined analysis of the the Vertebral Artery Ischaemia Stenting 
Trial (VIST), the Vertebral Artery Stenting Trial (VAST), and the 
Stenting and Aggressive Medical Management for Preventing 
Table 12 High-risk peri-operative features for carotid 
endarterectomy
Clinical
Congestive heart failure (NYHA functional class III/IV)
Unstable angina (CCS III/IV)
CAD with LM or >1 vessel with 70% stenosis
Recent MI (<30 days)
Planned open heart surgery (<30 days)
LVEF <30%
Severe pulmonary disease
Severe renal disease
Anatomical
Surgically inaccessible lesions 
• At or above C2
• Below the clavicle
Ipsilateral neck irradiation
Spinal immobility of the neck
Contralateral carotid artery occlusion (increases risk for stroke)
Contralateral laryngeal palsy
Tracheostomy
© ESC 2024
CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; LM, left main; LVEF, 
left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart 
Association.
ESC Guidelines                                                                                                                                                                                          3595


<!-- PAGE 59 -->

### Page 59

Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial,741 no clear 
benefit was shown for extracranial vertebral artery stenting.
Randomized controlled trials have not assessed surgical techniques 
like vertebral artery endarterectomy or transposition. While case ser­
ies exist, they often lack a control group following a consistent medical 
treatment protocol.742 As a result, the effectiveness of these proce­
dures remains uncertain.
8.2.3.3. Follow-up
Peri-operative and post-procedural medical management after carotid 
revascularization should include OMT. Post-operative hypertension is a 
risk factor for stroke and TIAs, wound bleeding, and intracranial haem­
orrhage.743 Therefore, proper pharmacological BP control is important 
in optimizing outcomes.744
Fluctuations of hypertension and hypotension are not uncommon 
and should be treated promptly.744,745
An intensive lipid-lowering therapy (ILT) aiming at >50% LDL-C re­
duction and LDL-C <1.4 mmol/L (55 mg/dL) is also recommended.19
Antiplatelet therapy should be tailored according to type of interven­
tion. In CEA, the reduction in peri-procedural and long-term ischaemic 
events under low-dose aspirin has been demonstrated.746,747 After ca­
rotid stenting, DAPT (aspirin and clopidogrel) is recommended, while 
optimal duration is debated.748 In the peri-operative period after 
CAS, DAPT should be prescribed and continued for at least 30 days 
post-procedure.77,749,750 Ticagrelor, when included in DAPT following 
CAS/TCAR, presents a drawback due to its elevated bleeding risk com­
pared with clopidogrel.751–753
Duplex ultrasound is the first-line technique to evaluate patients 
after CEA or CAS. CTA and MRA are alternative methods for deter­
mining restenosis.749,754
After CEA or CAS, DUS is recommended at baseline (<3 months) 
and annually thereafter until the patient is stable (i.e. until no restenosis 
is observed in two consecutive annual scans). Regular surveillance (e.g. 
every 2 years) can be performed based on the stenosis of the contra­
lateral ICA, risk profile, and patient’s life expectancy.749,754
For patients combining multiple CVRFs after the procedure, DUS 
may be beneficial every 6 months until a stable clinical pattern is estab­
lished, and annually thereafter.749,754
Early surveillance, especially within 1–3 months and particularly in 
cases where intraoperative completion imaging is absent (e.g. after 
CEA), aids in detecting technical errors and setting a baseline for future 
comparisons.
Follow-up enables the identification of ipsilateral carotid restenosis 
and contralateral disease progression, offering a chance for timely inter­
vention to minimize the risk of stroke. Nevertheless, this concept is fa­
cing growing challenges due to a reduced and selective role for 
intervention in asymptomatic patients. A surveillance protocol holds 
significance when anticipated outcomes are expected to cost- 
effectively influence a medical or interventional treatment plan.749,754
8.3. Other arterial locations
8.3.1. Subclavian artery disease
8.3.1.1. Clinical presentation and diagnosis
Atherosclerotic upper-limb artery disease (UEAD) is most frequently 
located in the subclavian artery.755,756 Digital ischaemia is most fre­
quently caused by non-atherosclerotic aetiologies, including thrombo- 
embolism, systemic sclerosis, idiopathic, thromboangiitis obliterans, 
iatrogenic, or cancer.757 Isolated subclavian stenosis (SS) is often 
asymptomatic and may be suspected because of an absolute inter-arm 
SBP difference >10–15 mmHg.758 In the Multi-Ethnic Study of 
Atherosclerosis (MESA), prevalence of asymptomatic SS was approxi­
mately 4.5% (male: 5.1%, female: 3.9%) in adults and more frequent in 
patients with PAD (11.4%).759 In patients attending CV clinics, a 
Recommendation Table 27 — Recommendations for 
interventions in patients with symptomatic carotid 
artery stenosis
Recommendations
Classa
Levelb
It is recommended to perform CEA of symptomatic 
70%–99% ICA stenosis provided a documented 30 
day risk of procedural death/stroke is <6%.660,719
I
A
If indicated, it is recommended to perform CEA 
within 14 days in symptomatic ICA stenosis 
patients.734
I
B
OMT is recommended for all symptomatic ICA 
stenosis patients.19
I
A
CEA of symptomatic 50%–69% ICA stenosis should 
be considered provided a documented 30 day risk of 
procedural death/stroke is <6%.660,719
IIa
A
For symptomatic patients at high risk for CEA with a 
70%–99% ICA stenosis, CAS should be considered 
provided a documented 30 day risk of procedural 
death/stroke is <6%.703
IIa
B
For symptomatic patients <70 years of age with a 
70%–99% ICA stenosis, CAS may be considered 
provided a documented 30 day risk of procedural 
death/stroke is <6%.703
IIb
A
Revascularization is not recommended in patients 
with ICA lesions <50%.660,719
III
A
© ESC 2024
CAS, carotid artery stenting; CEA, carotid endarterectomy; ICA, internal carotid artery; 
OMT, optimal medical treatment. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 28 — Recommendations for 
follow-up in patients with carotid artery stenosis
Recommendations
Classa
Levelb
Once-yearly follow-up is recommended to check for 
CVRFs and treatment compliance.754
I
A
After ICA stent implantation, DAPT with aspirin and 
clopidogrel is recommended for at least 1 
month.77,749,750
I
A
After ICA revascularization, long-term aspirin or 
clopidogrel is recommended.746,747
I
B
During follow-up, it is recommended to assess 
neurological symptoms, CVRFs, and treatment 
adherence at least yearly in patients with CS.754
I
C
After ICA revascularization, surveillance with DUS is 
recommended within the first month.749,754
I
C
© ESC 2024
CS, carotid artery stenosis; CVRFs, cardiovascular risk factors; DAPT, dual antiplatelet 
therapy; DUS, duplex ultrasound; ICA, internal carotid artery. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 60 -->

### Page 60

>25 mmHg SBP difference doubles prevalence and independently pre­
dicts mortality.32,758 As obstructive disease progresses, particularly af­
fecting vertebral vessels, the risk of ischaemia or steal symptoms 
significantly rises. Visual disturbances, syncope, ataxia, vertigo, dyspha­
sia, dysarthria, and facial sensory deficits during arm movements may 
indicate subclavian steal syndrome, correlating with inter-arm BP differ­
ence.760 Brachiocephalic occlusive disease can lead to stroke or TIA in 
carotid and vertebral territories, manifesting as exercise-induced fa­
tigue, pain, and arm claudication. Severe cases, especially with distal dis­
ease, may result in rest pain and digital ischaemia with necrosis.
Duplex ultrasound assessment of subclavian arteries enables the de­
tection of SS via intrastenotic high-velocity flows (50% stenosis: peak 
systolic velocity [PSV] ≥230 cm/s, PSV ratio [PSVr] ≥2.2; 70% stenosis 
PSV ≥340 cm/s and PSVr ≥3.0) or monophasic post-stenotic wave­
forms.761 The majority of patients (>90%) with at least 50% proximal 
SS have either intermittent or continuous flow reversal in the vertebral 
artery, though not all will be symptomatic.760,762 When subclavian steal 
syndrome is suspected, flow reversal should be assessed in the ipsilat­
eral extracranial vertebral artery by hyperaemia testing and if available 
transcranial Doppler.762 Severe stenosis or occlusion of the right bra­
chiocephalic trunk is associated with reduced flow velocities in the ip­
silateral subclavian artery and the CCA. Abnormal or doubtful DUS 
should lead to anatomic imaging (CTA/MRA).763 CTA is excellent for 
supra-aortic lesions and can provide extravascular information, espe­
cially when thoracic outlet syndrome is a differential diagnosis. MRA 
provides both functional and morphological information useful to dis­
tinguish antegrade from retrograde perfusion and to estimate stenosis 
severity.764 DSA is performed if endovascular therapy is indicated. PET 
is useful for the diagnosis of arteritis but not for assessment of athero­
sclerotic lesions in clinical practice.
8.3.1.2. Treatment strategy (medical and interventional)
Optimal medical treatment is recommended in all patients with symptom­
atic UEAD to reduce CV risk.32 Revascularization is indicated in symptom­
atic patients with TIA/stroke, coronary subclavian steal syndrome, 
ipsilateral haemodialysis access dysfunction, or impaired HRQoL. 
Revascularization should be considered in asymptomatic patients with 
planned coronary artery bypass grafting (CABG) using the internal mam­
mary artery and those with ipsilateral haemodialysis access, as well as 
asymptomatic patients with significant bilateral SS/occlusion for adequate 
BP surveillance. For revascularization, both endovascular and surgical pro­
cedures are available. There are no RCTs comparing endovascular vs. open 
repair but individual studies, including the Danish Vascular Registry, indicate 
similar long-term symptom resolution but higher general complication 
rates and hospital length of stay for open surgery.765 The risk of severe 
complications, including vertebrobasilar stroke, is low with both ap­
proaches. The post-procedural stroke rate is reported at 1.3% for endo­
vascular therapy765 and 0.9%–2.4% after open surgery.765–767
Percutaneous angioplasty for subclavian arterial stenosis is often used 
with stenting. There is no conclusive evidence to determine whether 
stenting is more effective than balloon angioplasty.768 Similar results 
were reported for endovascular therapy of the innominate artery.769
In heavily calcified ostial lesions, balloon-expandable stents give more ra­
dial force than nitinol stents. An endovascular approach is often the de­
fault strategy. However, in selected patients with low operative risk, 
with subclavian artery occlusion or after endovascular therapy failure, 
surgical subclavian–carotid transposition is safe with excellent long-term 
patency results (5 year patency 96%).766 Carotid–subclavian bypass sur­
gery with a prosthetic graft showed long-term benefit with low opera­
tive mortality and morbidity, especially in patients with extensive disease 
or re-occlusion after stenting (5 year patency 97%).770 Other options 
are extrathoracic extra-anatomic bypass procedures (axillo-axillary, ca­
rotid–axillary, or carotid–carotid bypass);771,772 however, axillo-axillary 
bypasses may occlude at 1 year in 14% of cases.773 The transthoracic ap­
proach is an option in patients with multivessel disease involving the aor­
tic arch and several supra-aortic vessels.767
While critical hand ischaemia owing to below-the-elbow atherosclerot­
ic occlusive disease is relatively uncommon, interventions are associated 
with a high rate of success, major amputations are rare, and many can 
be treated non-operatively.756 In appropriately selected patients, both en­
dovascular and open interventions have a high rate of success.755,756
In symptomatic patients with contraindications for endovascular ther­
apy or open surgery, prostanoid infusion or thoracic sympathectomy 
may be considered.774
8.3.1.3. Follow-up
Patients with UEAD should be followed up to ensure optimal CV 
prevention. Tighter follow-up is required in symptomatic patients to re- 
assess indication for revascularization as a large proportion of symptoms 
resolve spontaneously.775 After revascularization, patients should be fol­
lowed up to allow early detection and treatment of impending late proced­
ural failure.
Recommendation Table 29 — Recommendations for 
the management of subclavian artery stenosis (see also 
Evidence Table 9)
Recommendations
Classa
Levelb
Bilateral arm BP measurement is recommended for 
all patients with PAAD.32,758
I
B
In symptomatic patients with atherosclerotic 
subclavian artery disease (TIA/stroke, coronary 
subclavian steal syndrome, ipsilateral haemodialysis 
access dysfunction, severe ischaemia), both 
revascularization options (endovascular ± stenting 
or surgery) should be considered and discussed case 
by case by a vascular team.776
IIa
B
Endovascular revascularization may be considered 
over surgery, despite similar long-term outcomes, 
due to lower complication rates.765
IIb
B
In patients with atherosclerotic subclavian artery disease, 
revascularization:
Should be considered in cases of proximal stenosis in 
patients undergoing CABG using the ipsilateral 
internal mammary artery.777–781
IIa
C
Should be considered in cases of proximal stenosis in 
patients who already have the ipsilateral internal 
mammary artery grafted to coronary arteries with 
evidence of myocardial ischaemia.777,778,780
IIa
C
Should be considered in cases of ipsilateral 
haemodialysis arteriovenous access.778
IIa
C
Routine revascularization in patients with 
atherosclerotic subclavian artery disease is not 
recommended.776
III
C
© ESC 2024
BP, blood pressure; CABG, coronary artery bypass grafting; PAAD, peripheral arterial and 
aortic diseases; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3597


<!-- PAGE 61 -->

### Page 61

8.3.2. Renal artery disease
8.3.2.1. Clinical presentation and diagnosis
8.3.2.1.1. Epidemiology. In >90% of cases, RAS is caused by athero­
sclerosis and typically involves the ostial renal arterial segment 
(Table 13).782 Above 65 years of age, overall prevalence of ≥60% RAS 
is 6.8%, with a higher prevalence in men (9.1%) than in women 
(5.5%).783 In patients with PAD, RAS prevalence ranges between 7% 
and 42%, influenced by diagnostic criteria.784
8.3.2.1.2. Clinical presentation. Clinical presentation comprises reno­
vascular hypertension, renal function impairment and eventually, flash pul­
monary oedema (Table 13). RAS reduces the filtration capacity of the 
affected kidney, which activates the renin–angiotensin–aldosterone path­
way, potentially resulting in renovascular hypertension.782,785 In unilateral 
RAS, the functioning contralateral kidney may increase sodium excretion 
to prevent sodium retention and volume overload. In high-grade bilateral 
RAS or in unilateral RAS without a functioning second kidney, the risk of 
cardiorenal deterioration is higher than in unilateral disease.786
8.3.2.1.3. Diagnosis of renal artery disease. First diagnostic steps in­
clude laboratory tests to examine renal function, analysis of office and 
out-of-office BP recordings (ambulatory BP monitoring or home BP 
monitoring, as recommended by [upcoming] ESC/European Society 
of Hypertension [ESH] Guidelines for arterial hypertension), and non- 
invasive haemodynamic assessment of renal arteries by DUS.787
Renal artery PSV >200 cm/s measured by DUS allows the diagnosis of 
a >50% RAS (sensitivity 95%, specificity 90%).788 A renal-aortic peak flow 
velocity ratio (RAR = renal artery PSV/aortic PSV) >3.5 has 84%–91% 
sensitivity and 95%–97% specificity for the detection of ≥60% RAS.789
A side-to-side difference of the intrarenal resistance index ≥0.5 between 
both kidneys may serve as an additional haemodynamic criterion for 
haemodynamically relevant RAS.787,790 Other DUS criteria (acceleration 
time, acceleration index) have lower diagnostic accuracy.791
Sensitivity and specificity of contrast-enhanced MRA in the diagnosis 
of RAS is 88% and 100%, respectively;789 however, MRA overestimates 
the degree of RAS by 26%–32%.789 The advantages of MRA are the 
possibility of assessing renal parenchymal blood flow and freedom 
from radiation and iodinated contrast agents.
Spiral multidetector CTA allows renal artery diameter measure­
ments and provides information on vessel wall calcification and mural 
plaques. RAS diagnosis by CTA presents 64%–100% sensitivity and 
92%–98% specificity.789 CTA drawbacks include radiation exposure, 
the need for contrast media in patients with impaired renal function, 
and limited haemodynamic assessment of RAS.
Catheter angiography is the gold standard for diagnosing RAS, enab­
ling additional haemodynamic measures (Figure 19).792 Considering the 
potential risks of invasive procedures, DUS and other non-invasive mo­
dalities (CTA or MRA) should precede catheter angiography and inva­
sive haemodynamic measurements (Figure 19).
Renal scintigraphy, plasma renin measurements before and after 
ACEI provocation, and venous renin measurements are not considered 
for RAS evaluation.
8.3.2.1.4. Prognosis. Atherosclerotic RAS progresses with respect to 
the degree of stenosis, while total renal artery occlusions occur less 
frequently.793 The presence of significant RAS is a strong predictor for 
mortality794 and renovascular disease is an important risk factor for the 
development of end-stage renal disease (ESRD).795 The risk of RAS- 
related ESRD is higher in men than in women and increases with age.795
8.3.2.2. Treatment strategy (medical and interventional)
8.3.2.2.1. Medical therapy. Optimal medical treatment is recom­
mended in RAS patients.785 Data on antithrombotic therapy in patients 
with atherosclerotic RAS are scarce and retrospective.796 However, 
the use of an antiplatelet agent is reasonable in atherosclerotic RAS.
No prospective study has specifically examined antithrombotic ther­
apy post-RAS stenting, and information from existing RAS stenting 
trials is limited.797 Following the antithrombotic treatment approach 
in non-coronary arterial beds, it is suggested to use DAPT for at least 
1 month after RAS stent implantation.666
8.3.2.2.2. Revascularization. Revascularization in atherosclerotic RAS
Prospective RCTs comparing endovascular revascularization with 
OMT in atherosclerotic RAS favoured renal artery stenting over bal­
loon angioplasty.792
However, renal artery stenting showed no superiority over OMT in 
reducing BP, CV events, renal events, or mortality in unilateral athero­
sclerotic RAS.788,798,799 A trial suggested a potential benefit of renal ar­
tery angioplasty for BP in bilateral RAS, but subsequent RCTs did not 
confirm this.800–802 Data on the benefit of renal artery stenting in spar­
ing antihypertensive drugs are inconsistent.324,800,801,803,804
In specific circumstances or RAS aetiologies, revascularization should 
be considered (Figure 19). Open surgical renal artery revascularization 
appears comparable to endovascular treatment regarding BP and renal 
function.805,806 Thus, open surgery can be an alternative approach in 
cases with a revascularization indication and complex anatomy or failed 
endovascular repair.
Table 13 Clinical signs suggestive of renal artery 
disease
Hypertension onset before 30 years of age
Severe hypertension after the age of 55 years, when associated with CKD or 
heart failure
Hypertension and abdominal bruit
Rapid and persistent worsening of previously controlled hypertension
Resistant hypertension 
• Three antihypertensive drugs including a diuretic agent 
or
• ≥4 antihypertensive drugs 
and
• Other secondary form unlikely
Hypertensive crisis (i.e. acute renal failure, acute heart failure, hypertensive 
encephalopathy, or grade 3–4 retinopathy)
New azotaemia or worsening of renal function after treatment with RAAS 
blockers
Unexplained atrophic kidney or discrepancy in kidney size, or unexplained 
renal failure
Flash pulmonary oedema
© ESC 2024
CKD, chronic kidney disease; RAAS, renin–angiotensin–aldosterone system.


<!-- PAGE 62 -->

### Page 62

N
N
N
N
N
N
Patient with suspicion of RAS
Duplex ultrasound
Renal artery revascularization
(Class III)
Diagnostic
Kidney viablea
Catheter-based angiography
>70% RAS or haemodynamically relevant 50–70% RASc
Evaluation of high-risk
 features after confirmed OMTb
Presence of high-risk featuresb
Kidney viablea
Kidney viablea
No RAS
RAS exclusion
RAS exclusion
PSV ≥200 cm/s (>50% RAS), RAR >3.5 (≥60%)
 side-to-side difference of intrarenal resistance index ≥0.5
Morphologically significant RAS
Bilateral high-grade atherosclerotic
 RAS (>70%)
Non-atherosclerotic RAS and
 special populations
Unilateral atherosclerotic
 RAS (>70%)
Inconclusive DUS or 
suspicion of haemodynamically significant RAS
MRA/CTA
(Class I)
OMT
 (Class I)
OMT
 (Class I)
Renal artery revascularization
(Class III)
Renal artery revascularization
(Class IIa)
OMT
 (Class I)
Y
Y
Y
Y
Y
Y
Figure 19 Diagnostic and treatment algorithm for renal artery stenosis. CTA, computed tomography angiography; MRA, magnetic resonance angi­
ography; OMT, optimal medical treatment; Pd/Pa, distal coronary pressure to aortic pressure ratio; PSV, peak systolic velocity; RAR, renal-aortic peak 
flow velocity ratio; RAS, renal artery stenosis.  
asee table below   
aKidney viability in RAS
Signs of viability
Signs of non-viability
Renal size
>8 cm
<7 cm
Renal cortex
Distinct cortex (>0.5 cm)
Loss of corticomedullar differentiation
Proteinuria
Albumin-creatinine ratio <20 mg/mmol
Albumin-creatinine ratio >30 mg/mmol
Renal resistance index
<0.8
>0.8
© ESC 2024
bRapidly progressive, treatment-resistant arterial hypertension; rapidly declining renal function; flash pulmonary oedema; solitary kidney. 
cResting mean pressure gradient >10 mmHg; systolic hyperaemic pressure gradient >20 mmHg; renal PdPa ≤ 0.9 (or 0.8).
ESC Guidelines                                                                                                                                                                                          3599


<!-- PAGE 63 -->

### Page 63

8.3.2.3. Follow-up
Following the diagnosis of significant RAS and the implementation of 
OMT and/or renal artery revascularization, regular follow-up exams 
are crucial. Monitoring should encompass laboratory tests to assess re­
nal function, analysis of office and out-of-office BP recordings (ambula­
tory or home BP monitoring per upcoming ESC/ESH Guidelines for 
arterial hypertension), and renal artery DUS. DUS, comprising renal 
PSV, RAR, side-to-side difference of the resistance index, and kidney 
size, is the preferred imaging modality during follow-up.787
In conservatively managed RAS patients, follow-up assessment 
should re-evaluate potential indications for renal artery revasculariza­
tion (Figure 19).
After renal artery stenting, the initial follow-up is recommended at 1 
month and subsequently every 12 months or when new signs or symp­
toms arise.807 Re-intervention may be considered for in-stent resten­
osis ≥60% detected by DUS, recurrent signs and symptoms (diastolic 
BP >90 mmHg on >3 antihypertensive drugs, or a >20% increase in 
serum creatinine).787,808
8.3.3. Visceral artery disease
8.3.3.1. Acute mesenteric ischaemia
Acute mesenteric ischaemia can be caused by arterial embolism or 
thrombosis in situ, non-occlusive mesenteric ischaemia (usually due 
to superior mesenteric artery [SMA] vasoconstriction), and venous 
thrombosis. In recent decades, embolism decreased from 46% to 
35%, while arterial thrombosis increased from 20% to 35%.815–817
Acute thrombo-embolic occlusion most frequently affects the SMA. 
Due to extensive collaterals, it infrequently leads to intestinal infarction.
8.3.3.1.1. Clinical presentation and diagnosis. Clinical examination
Early diagnosis of AMI is based on high clinical suspicion. Embolic AMI 
typically manifests as sudden onset intense abdominal pain, accompan­
ied by minimal physical findings, bowel emptying (vomiting, diarrhoea), 
and a common embolic source (primarily AF).818–820 Emboli may also 
lodge in other locations, aiding diagnosis. Acute arterial thrombosis 
tends to occur in areas with pre-existing atherosclerotic disease, result­
ing in a less dramatic clinical presentation. Patients may have previous 
symptoms of chronic mesenteric ischaemia (CMI) or other atheroscler­
otic manifestations.821
Laboratory tests are unreliable for the diagnosis of AMI, although ele­
vated levels of l-lactate, leucocytosis, and D-dimer (DD) may exist.822–825
Imaging
Computed tomography angiography is the gold standard for diagno­
sis,826,827 allowing the detection of thrombi and/or emboli in the SMA 
trunk or its branches together with the recognition of intestinal ischae­
mic signs. A plain abdominal X-ray lacks specificity. A normal result does 
not rule out the diagnosis.828
8.3.3.1.2. Treatment strategy. Most patients require immediate re­
vascularization to survive. There are no RCTs comparing surgical vs. en­
dovascular intervention in AMI. Two meta-analyses found endovascular 
revascularization to be superior to surgical intervention in terms of in- 
hospital mortality and rates of bowel resection.829,830 An open surgical 
approach is most appropriate in centres where endovascular interven­
tions are less available and in patients with peritonitis.831 Retrograde 
open mesenteric stenting (ROMS) is an alternative that offers shorter 
operative time; the SMA is punctured in the open abdomen, followed 
by stenting.832
Recommendation Table 30 — Recommendations for 
diagnostic strategies for renal artery disease
Recommendations
Classa
Levelb
DUS is recommended as the first-line imaging 
modality in patients with suspicion of RAS.787,789–791
I
B
In cases of DUS-based suspicion of RAS or 
inconclusive DUS, MRA, or CTA are 
recommended.789,791
I
B
In patients with atherosclerotic RAS, it is 
recommended to assess clinical high-risk features and 
kidney viability when evaluating renal artery 
revascularization.809,810
I
B
© ESC 2024
CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic 
resonance angiography; RAS, renal artery stenosis. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 31 — Recommendations for 
treatment strategies for renal artery disease (see also 
Evidence Table 10)
Recommendations
Classa
Levelb
Medical therapy
In patients with atherosclerotic RAS the use of 
low-dose aspirin may be considered.811
IIb
C
Revascularization
In patients with atherosclerotic unilateral >70% RAS, 
concomitant high-risk features, and signs of kidney 
viability, renal artery revascularization should be 
considered after OMT has been 
established.798,809,810
IIa
B
In patients with atherosclerotic bilateral (>70%) RAS 
or RAS in a solitary kidney, concomitant high risk 
features, and signs of kidney viability, renal artery 
revascularization should be considered.800–802
IIa
B
Continued 
In patients with hypertension and/or signs of renal 
dysfunction due to RAS caused by fibromuscular 
dysplasia, concomitant high-risk features, and signs of 
kidney viability, revascularization with primary 
balloon angioplasty and bailout stenting should be 
considered.812,813
IIa
B
In patients with an indication for renal artery 
revascularization and complex anatomy, or after 
failed endovascular revascularization, open surgical 
revascularization should be considered.805,806
IIa
B
In patients with atherosclerotic unilateral RAS, 
routine revascularization is not 
recommended.324,800–804,814
III
A
© ESC 2024
RAS, renal artery stenosis. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 64 -->

### Page 64

8.3.3.1.3. Follow-up. Most patients treated for AMI require lifelong 
anticoagulant/antiplatelet therapy to prevent recurrence. Patients 
undergoing revascularization should have surveillance with CTA or 
DUS within 6 months,833 as recurrent AMI after mesenteric revascular­
ization accounts for 6%–8% of late deaths.834 Current Society for 
Vascular Surgery (SVS) Guidelines recommend DUS at 1, 6, and 12 
months after the intervention, and then annually thereafter.754
8.3.3.2. Chronic mesenteric artery disease
Occlusive CMI is mostly caused by atherosclerosis and more frequently 
affects females (65%–72%).835,836 Symptoms typically manifest when at 
least two mesenteric vessels are involved due to extensive collaterals. 
Prevalence of asymptomatic coeliac artery and/or SMA stenosis is 3% 
in patients under 65 years of age and 18% in those aged >65.837
However, inadequate anastomoses can result in symptomatic ischae­
mia even with a single-vessel atherosclerotic occlusion.838,839
8.3.3.2.1. Clinical presentation and diagnosis. Clinical examination
Like AMI, early diagnosis of CMI relies on clinical suspicion. Classic 
symptoms include post-prandial abdominal pain, weight loss, and 
gastrointestinal disturbances like diarrhoea or constipation. Patients 
may develop food aversion to avoid pain, but their appetite remains 
Patient with suspected CMI
Exclude other causes
Diagnosis
Functional test
Confirmed
Isolated CA or SMA stenosis
No stenosis
Chronic NOMI
MALS
Atherosclerosis
Multidisciplinary meeting for consensus treatment
Endovascular or 
surgical revascularization
Secondary prevention 
of atherosclerosis
Therapy of underlying condition
Multi-vessel stenosis
CTA
(Class I)
Figure 20 Algorithm of chronic mesenteric ischaemia management. CA, coeliac artery; CMI, chronic mesenteric ischaemia; CTA, computed tom­
ography angiography; MALS, median arcuate ligament syndrome; NOMI, non-occlusive mesenteric ischaemia; SMA, superior mesenteric artery.
ESC Guidelines                                                                                                                                                                                          3601


<!-- PAGE 65 -->

### Page 65

unaffected, distinguishing them from individuals with malignancies. An 
abdominal examination might reveal a bruit.
Lactate, lactate dehydrogenase, and/or leucocyte count are unhelpful 
in CMI diagnosis.840,841 Functional testing (tonometry, visible light spec­
troscopy) is applicable in patients with symptomatic mesenteric sten­
osis and single-vessel disease.842
Imaging
Duplex ultrasound is valuable due to its low costs, absence of the 
need for contrast agents, and no radiation. However, skilled investiga­
tors in specialized centres are required for the examination. Despite 
suggested diagnostic criteria, consensus is lacking.843,844 Anatomical 
mapping for treatment planning typically involves CTA or MRA, 
845,846 with DSA reserved only for therapeutic purposes (Figure 20).
8.3.3.2.2. Treatment strategy. Optimal medical treatment is the basis 
of CMI management. Prophylactic revascularization is not recom­
mended for asymptomatic CMI. In symptomatic cases, a meta-analysis 
favoured endovascular over open surgery due to fewer complications 
and a trend towards lower 30 day mortality.835 However, open surgery 
showed superior long-term results, with fewer symptom recurrences 
and higher 1 and 5 year primary patency rates in two additional 
meta-analyses.847,848 Despite the growing use of endovascular therapy, 
open surgery remains indicated after failed endovascular therapy with­
out the option for repeat intervention, and in cases with extensive oc­
clusions, calcifications, or technical challenges.
8.3.3.2.3. Follow-up. Following CMI revascularization, lifelong medical 
treatment, including lifestyle changes and OMT for atherosclerosis, is 
recommended. SVS guidelines propose mesenteric DUS surveillance 
for recurrent stenosis. A potential follow-up schedule involves controls 
within 1 month post-procedure, biannually for the first 2 years, and an­
nually thereafter.849
9. Aorta
9.1. Atheromatous disease of the aorta
9.1.1. General concepts
Atheromatous disease of the aorta has an estimated incidence of 
40%–51.3%, being complicated in 7.6% of cases.850–853 Earlier stages of ath­
erosclerosis, presenting as plaque inflammation, can be present in 48% of 
asymptomatic individuals.850 Atherosclerotic plaque classification is based 
on plaque thickness and the presence of ulceration or mobile components 
(Table 14).159,171,854 This classification is crucial because severe or complex 
atherosclerotic plaques in the aortic arch or ascending aorta are strongly 
linked to cerebrovascular events (odds ratio [OR] 4–9.1 for plaques 
≥4 mm).855–860 Additionally, the annual incidence of stroke recurrence re­
mains high (up to 16%) despite antiplatelet or anticoagulant therapy.855,861
9.1.2. Treatment
9.1.2.1. Primary prevention
Asymptomatic non-severe/non-complex aortic plaques (Table 14) should 
not mandate antiplatelet therapy. Nonetheless, in severe/complex plaques, 
statins should be indicated to decrease plaque progression or CV 
events,862 and SAPT with clopidogrel or low-dose aspirin should be con­
sidered after risk/benefit evaluation.493,666,861,863 However, in this scenario, 
anticoagulation861 or DAPT (low-dose aspirin and clopidogrel) are not in­
dicated.666,863 Floating aortic thrombi and complex mobile plaques are 
rare, with limited large-scale trials on their management. Guidance relies 
on case reports, observational studies, and expert opinions, yet there is evi­
dence favouring anticoagulation, particularly for symptomatic cases.864
9.1.2.2. Secondary prevention
Secondary prevention with antiplatelet therapy after an embolic event is 
recommended to prevent recurrences.666,865,866 While the value of 
DAPT vs. SAPT remains uncertain, recent studies indicate that prolonged 
DAPT raises bleeding risk without added antithrombotic bene­
fits.667,863,867 Treatment duration is unclear and must strike a balance be­
tween early benefit (notably within 7 days post-emboli) and steady 
bleeding risk. Statins (LDL target below 1.4 mmol/L [55 mg/dL]) prove ef­
fective in preventing strokes regardless of the aetiology.862,865,868
Additionally, a healthy lifestyle is crucial for improving CV health and redu­
cing complications.
Recommendation Table 32 — Recommendations in 
patients with visceral artery stenosis
Recommendations
Classa
Levelb
In patients with acute mesenteric ischaemia due to 
acute occlusion of the SMA, endovascular 
revascularization is recommended.829–831
I
B
In patients with suspected acute or chronic 
mesenteric ischaemia, CTA is 
recommended.826,827,845,846
I
C
In patients with acute or chronic mesenteric 
ischaemia, assessment by a vascular team is 
recommended.
I
C
Revascularization of asymptomatic atherosclerotic 
visceral artery stenosis is not recommended.
III
C
© ESC 2024
CTA, computed tomography angiography; SMA, superior mesenteric artery. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 33 — Recommendations for 
primary and secondary prevention in aortic atheroma­
tous plaques
Recommendations
Classa
Levelb
Primary prevention
In patients with severe/complex aortic atheromatous 
plaques, statins should be considered to decrease 
progression and risk of CV events.862
IIa
C
SAPT with clopidogrel or low-dose aspirin should be 
considered in severe/complex plaques.493,666,861,863
IIa
C
Anticoagulation861 or DAPT863 are not 
recommended in aortic plaques since they present 
no benefit and increase bleeding risk.666
III
C
Secondary prevention after an embolic event related to aortic 
atherosclerosis
In patients with an embolic event and evidence of an 
aortic arch atheroma, intensive lipid management to 
an LDL-C target <1.4 mmol/L (<55 mg/dL) is 
recommended to prevent recurrences.242,862,865,868
I
A
In patients with an embolic event and evidence of an 
aortic arch atheroma, SAPT is recommended to 
prevent recurrences.666,865,866
I
C
© ESC 2024
CV, cardiovascular; DAPT, dual antiplatelet therapy; LDL-C, low-density lipoprotein 
cholesterol; SAPT, single antiplatelet therapy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 66 -->

### Page 66

9.2. Aortic aneurysms
9.2.1. General concepts
9.2.1.1. Definitions
Aortic dilatation, the second most frequent aortic disease after athero­
sclerosis, is defined as an aortic diameter >2 standard deviations of 
the predicted mean diameter depending on age, sex, and body size 
(z-score >2). However, in clinical practice, aortic root dilatation 
can be suspected in male adults when aortic diameter is >40 mm and 
in females at >36 mm,138,149,869 or with an indexed diameter/BSA 
(aortic size index [ASI]) >22 mm/m2. In extreme BSA and age values, 
use of z-scores is recommended (see Section 5.4 for their calculation).
Arterial aneurysm is defined as a diameter >1.5 times (>50%) lar­
ger than the predicted one. This definition, as well as the use of 
z-scores, introduces the need for normal values and correction for 
age, sex, and body size. However, correcting for BSA can lead to 
underestimation in overweight patients,870 therefore a correction 
for height (aortic height index [AHI]) is becoming more popular.153
In terms of clinical risk, both ASI and AHI have been shown to improve 
risk stratification for AAE.153,871 Since in many cases of aortic dilata­
tion the surgical indication is established before achieving this aneur­
ysmal diameter, we strongly recommend the use of significant aortic 
dilation specifying the diameter or the indexed diameter value rather 
than the term ‘aneurysm’.
Thoracic aortic aneurysms (TAAs) are more prevalent in men than in 
women (ratio 4:1);872 however, the growth rate is greater in women 
(0.96 ± 1.00 mm per year) than in men (0.45 ± 0.58 mm per year), 
and thus the risk of AAE.873
Aneurysms can be fusiform or saccular based on morphology. 
Saccular aneurysms relate to infection, penetrating atherosclerotic 
ulcer (PAU), trauma, or inflammatory diseases, while fusiform aneur­
ysms connect with degenerative and connective tissue conditions. 
Although evidence about their natural course is limited, saccular aneur­
ysms are considered more malignant in terms of AAE. Based on loca­
tion, aortic aneurysms are classified into TAA and abdominal aortic 
aneurysm (AAA) (Figure 21). They differ in treating specialists, causes, 
age at onset, risk factors, and complications. However, this binary clas­
sification is artificial due to the prevalence of thoracoabdominal aortic 
aneurysms (TAAA) and tandem lesions (20%–30% of AAA patients 
also have TAA),874,875 emphasizing the importance of comprehensive 
aortic and vascular assessments at diagnosis. When detecting an aortic 
aneurysm at any site, it is advisable to conduct a thorough evaluation of 
the entire aorta initially and during subsequent follow-ups. Specifically, 
when diagnosing a TAA, it is crucial to assess the aortic valve, particu­
larly in cases of BAV. Data on peripheral aneurysms in TAA, particularly 
in femoro-popliteal segments, is less clear compared with AAA. 
However, cerebral aneurysms, notably prevalent in women and those 
with HTAD, warrant thorough screening, particularly in symptomatic 
cases.876–878
9.2.2. Thoracic aortic aneurysms
9.2.2.1. Aetiology, risk factors, and natural history
Thoracic aortic aneurysms occur in 5–10/100 000 person-years,884
with an approximate predominance of root and/or ascending aorta 
of ∼60%, arch of ∼10%, and descending aorta of ∼30%.885,886
Hypertension is the main risk factor (80%); however, genetics may be 
involved in 20% of cases.887 The decision to refer patients for genetic 
evaluation should consider age, family history, and presence of syn­
dromic features,25,888 as reported in more detail in Section 10.1.
9.2.2.2. Ascending thoracic aorta and arch aneurysms
(1) Aortic root aneurysms (including sinuses of Valsalva: annulo- 
aortic ectasia). They can be idiopathic, associated with HTAD (syn­
dromic/non-syndromic), or found in 20%–30% of BAV patients 
(see Section 10).879,880 Patients are usually younger (30–50 years 
of age), with aortic regurgitation, and with a 1:1 sex ratio.
(2) Supra-coronary aortic aneurysms (above sinuses of 
Valsalva). Caused by atherosclerosis in relation to hypertension af­
fecting older patients (59–69 years) and males (ratio 3:1),880 or re­
lated to medial degeneration (isolated or associated with aortic 
valve disease, including BAV) (see Section 10). Primary bacterial in­
fection or syphilis are uncommon. Arteritis is rare, but Takayasu’s 
and giant cell arteritis can lead to aneurysm formation.
(3) Aortic arch aneurysms. Often accompanying adjacent ascend­
ing or descending aorta aneurysms, aortic arch aneurysms present 
surgical challenges due to potential neurological and CV risks. They 
are typically linked to atherosclerosis, with cystic medial degener­
ation primarily affecting ascending aorta-related arch aneurysms. 
Deceleration injuries or coarctation may extend into the aortic 
arch.889
Recommendation Table 34 — Recommendations for 
initial evaluation of thoracic aortic aneurysm and 
abdominal aortic aneurysm
Recommendations
Classa
Levelb
When an aortic aneurysm is identified at any 
location, assessment of the entire aorta is 
recommended at baseline and during 
follow-up.874,875
I
C
When a TAA is identified, assessment of the aortic 
valve (especially for BAV) is recommended.879,880
I
C
When an AAA is identified, evaluation of the 
presence of aneurysm in the femoro-popliteal 
arterial segment should be considered.876–878,881
IIa
C
Patients with aortic aneurysm are at increased risk of 
CVD, thus general CV prevention should be 
considered.26,882,883
IIa
C
© ESC 2024
AAA, abdominal aortic aneurysm; BAV, bicuspid aortic valve; CV, cardiovascular; CVD, 
cardiovascular disease; TAA, thoracic aortic aneurysm. 
aClass of recommendation. 
bLevel of evidence.
Table 14 Grading of atherosclerotic aortic plaques
Grade
Severity (atheroma 
thickness)
Description
1
Normal
Intimal thickness <2 mm
2
Mild
Intimal thickening of 2 to <3 mm
3
Moderate
Atheroma ≥3 to <4 mm (no 
mobile/ulcerated components)
4
Severe
Atheroma ≥4 mm (no mobile/ 
ulcerated components)
5
Complex
Grade 2, 3, or 4 atheroma plus 
mobile/ulcerated components
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3603


<!-- PAGE 67 -->

### Page 67

Thoracic aortic aneurysm patients are usually asymptomatic, diagnosed 
incidentally during unrelated imaging or screenings. Symptoms such as 
chest pain, aortic regurgitation, and compression-related issues may oc­
cur.890 Patients with aortic root involvement (as seen in HTAD) are 
more prone to suffer from AAE.891,892
Thoracic aortic aneurysm growth rate is variable, associated with 
aetiology, location, and baseline aortic diameter.893–895 Degenerative 
TAAs grow faster in women than men and are associated with a three- 
fold higher risk of AAE.24,873,896 When the aorta reaches 57.5 mm in 
size, reported yearly rates of rupture, dissection, and death are 3.6%, 
3.7%, and 10.8%, respectively.897–899
9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta 
aneurysms
They can involve different parts of the DTA and may extend to the AA: 
TAAA. TAAAs are divided into five groups900 according to the modi­
fied TAAA classification scheme (Figure 22), which is crucial for risk stra­
tification. By classifying aneurysm extent, surgeons can anticipate 
procedure complexity, select suitable techniques, and reduce risks dur­
ing surgical planning.
Most DTA aneurysms and TAAA are degenerative with calcification, 
although other causes include trauma, infection, inflammation, or gen­
etic factors901,902 (Figure 21). Patients with HTAD rarely develop 
Media degeneration
Inflammation
Genetic disorders
Infection
Thoracic aortic aneurysm (TAA)
Aetiology
Screening 
Diagnostic
TTE
TTE or TOE plus CCT or CMR
Root and ascending aorta
Descending aorta
HTAD
BAV
Sporadic TAA
Atherosclerosis
Aortitis (infectious or not)
Trauma
Abdominal aortic aneurysm (AAA)
Aetiology
Screening 
Diagnostic
DUS
DUS or CEUS, CCT or CMR
Atherosclerosis
Coarctation
Atherosclerosis
Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, screening and diagnostic methods. AAA, abdominal aortic aneurysm; BAV, bicuspid 
aortic valve; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced Doppler ultrasound; CMR, cardiovascular magnetic resonance; 
DUS, Doppler ultrasound; HTAD, heritable thoracic aortic disease; TAA, thoracic aortic aneurysm; TOE, transoesophageal echocardiography; TTE, 
transthoracic echocardiography.


<!-- PAGE 68 -->

### Page 68

Suprarenal AAA
Pararenal AAA
Juxtarenal AAA
Infrarenal AAA
Type I
Type III
Type IV
Type V
Type II
SMA
IMA
Left renal artery
Coeliac trunk
Innominate artery
Left carotid artery
Left subclavian artery
Classification of thoracoabdominal aortic aneurysms
Classification of abdominal aortic aneurysms
Figure 22 Classification of thoracoabdominal900 and abdominal aortic aneurysms. AAA, abdominal aortic aneurysm; IMA, inferior mesenteric artery; 
SMA, superior mesenteric artery.
ESC Guidelines                                                                                                                                                                                          3605


<!-- PAGE 69 -->

### Page 69

thoracoabdominal aortic aneurysms without dissection. Mean age at 
diagnosis is 59–69, with a male predominance of 2–4:1. Aneurysm 
growth rate is 1.9–3.4 mm per year,902,903 but tends to increase notably 
with diameters over 50 mm or post-proximal aorta surgery in patients 
with MFS. In this population, debate continues as to whether this re­
flects a more vulnerable aorta associated to the genetic disease or 
haemodynamic changes post-surgery.
For untreated DTA aneurysm patients, 5 year survival is about 54%, 
with aortic rupture as the leading cause of death.904 Rupture risk factors 
include HTAD, a diameter over 50 mm, hypertension, smoking, chronic 
obstructive pulmonary disease (COPD), symptoms, chronic aortic dis­
section, and age. A significant rise in AAE risk occurs at a 60 mm diam­
eter. Although dissection can occur in smaller aortas, the individual risk 
is low.899 High-risk features for rupture are represented in Figure 23.
High-risk features for TAAA rupture beyond aortic diameter
Aortic root and ascending aorta
Thoracoabdominal aorta
Radiological signs of AAA rupture
Retroperitoneal haematoma
Contrast extravasation
High crescent sign
Paraortic fat stranding
Tangential calcification
Calcification discontinuity
Thrombus fissuration
Draped aorta sign
Relation with patient’s height
Upper normal limits of aortic diameter by age
Uncontrolled resistant hypertension
Saccular aneurysm associated to PAU
Uncontrolled resistant hypertension
COPD
Aortic length measurement
Yearly rate of diameter growth
Root vs 
ascending phenotype
Genetic predisposition
Aortic growth rate:
Ascending aorta and arch ≥ 3mm/year
DTAA ≥ 10mm/year (or ≥ 5mm/6 months) 
AAA ≥ 10mm/year (or ≥ 5mm/6 months)
Symptoms
Descending thoracic aorta
Figure 23 Risk factors for thoracic and abdominal aneurysm rupture. AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; 
DTAA, descending thoracic aorta aneurysm; PAU, penetrating atherosclerotic ulcer; TAAA, thoracoabdominal aortic aneurysm.905–908


<!-- PAGE 70 -->

### Page 70

9.2.2.4. Surveillance
Patients with TAA who do not meet surgical criteria require chronic 
follow-up that includes clinical evaluation and imaging techniques. 
The best imaging modality depends on aneurysm location: TTE, 
CCT, or CMR when affecting the aortic root and the ascending aorta; 
CMR and CCT when involving the distal ascending aorta, the aortic 
arch, or the DTA.159,171 Follow-up should be conducted with the 
same imaging technique and in the same centre.909 If a TAA is only 
moderate in size and remains relatively stable over time, CMR rather 
than CCT is reasonable to minimize radiation exposure.172,910
Follow-up for aortic aneurysms associated with HTAD is described 
in Section 10.1.3.2.
Figure 24 proposes a follow-up algorithm for patients with TAA. In 
cases of aortic root or proximal ascending aorta dilatation, after ini­
tial diagnosis by TTE the basal diameter and extension must be con­
firmed by CMR or CCT. If there is agreement between techniques, 
TTE can be used for follow-up; however, if there is a difference of 
≥3 mm, surveillance must be performed by CMR or CCT. After 
the initial diagnosis, imaging is required at 6–12 months, depending 
on aetiology and baseline diameter (Figure 24); see Sections 5.4.2
and 9.2.1 about indexed values of aortic dimensions, to ensure sta­
bility.159,911 Subsequently, imaging can be performed annually if there 
is no expansion/extension or customized according to the underlying 
condition. If the aorta shows rapid expansion (≥3 mm per year) or 
approaches the surgery/endovascular repair threshold, a closer evalu­
ation is recommended every 6 months. In contrast, stability in aortic 
diameters over years could lengthen these intervals (especially in 
non-genetic aneurysms and those <45 mm). In cases of dilatation 
of aortic arch or DTA, diameters obtained by TTE are deemed 
less precise and need confirmation by CMR or CCT. In those types 
of aneurysms, follow-up frequency will depend on the baseline diam­
eter and aetiology and will follow the same criteria established in the 
algorithm in Figure 24 for the 40–49 mm range. However, for the 
50–55 mm range, the aorta should be re-imaged every 6 months un­
til the threshold for intervention is reached (see Sections 9.2.5.3 and 
9.2.5.4).
9.2.3. Abdominal aortic aneurysms
9.2.3.1. General concepts
An AAA is defined as a focal dilation at least 1.5 times its normal diam­
eter, generally ≥30 mm. Most AAAs are fusiform, and many are lined 
with laminated thrombi.916 Their prevalence increases with age, with 
a 4:1 male/female ratio.872 They are commonly classified based on their 
relation to renal arteries (Figure 22) because of the complexity of sur­
gical treatment. AAA extends to the common iliac arteries in 25% of 
cases and in up to 20% of patients is associated with peripheral femoral 
and/or popliteal artery aneurysm.876–878
9.2.3.2. Aetiology, risk factors, and natural history
Smoking, age, male sex, and familial history of aneurysmal disease are ma­
jor risk factors,917–921 whereas diabetes is associated with a decreased 
risk922,923 and slower growth rate924 (Figure 21, see also Section 5). 
Other aetiologies include inflammation (5%–10% of all AAA),925 genetic 
disorders, and infection. The mean growth rate is around 3 mm per year 
(1–6 mm)906,926 and depends on sac diameter, presence of genetic disor­
ders, continuous smoking, metabolism (presence of inflammation), and 
aortic wall calcification.927–929 Risk of rupture rises exponentially de­
pending on diameter, being higher in women.930,931
AAAs are asymptomatic in two-thirds of cases and if they become 
symptomatic, rupture is the main manifestation. They often represent 
incidental imaging findings, as the sensitivity of clinical examination— 
especially palpation of an abdominal mass—is generally poor. 
Symptoms may include acute abdominal or back pain, and in some 
cases, hypovolaemic shock. However, contained rupture may present 
with atypical low flank or abdominal pain (see Figure 23 for high-risk fac­
tors and radiological signs or AAA rupture).932–935 Independently of 
risk of rupture, patients with AAA have impaired survival: the 5 year 
mortality rate is higher (×4 in women, ×2 in men) despite AAA repair, 
likely due to the presence of cardiovascular disease in other areas.936
9.2.3.3. Surveillance
Those with an aortic diameter <25 mm present low risk of developing 
large AAA in 10 years, whereas a diameter of 25–29 mm deserves re­
assessment after 4 years.937,938 DUS is the standard imaging technique 
for surveillance; however, CCT provides superior visualization of the 
AA and its branches, especially for pre-operative planning. CMR is rea­
sonable in selected patients (young and female) when a long follow-up is 
considered, to avoid radiation.
Recommendation Table 35 — Recommendation 
for the surveillance of patients with thoracic aortic an­
eurysms (non-heritable thoracic aortic disease)
Recommendations
Classa
Levelb
In thoracic aortic dilatation, TTE is recommended at 
diagnosis to assess aortic valve anatomy and function, 
aortic root, and ascending aorta diameters. 
Additionally, a global aortic evaluation using all 
echocardiographic views is recommended.159
I
C
CMR or CCT is recommended for surveillance of 
patients with aneurysm at the distal ascending aorta, 
aortic arch, DTA, or TAAA.70,159,172,912–915
I
C
In thoracic aortic dilatation, CCT or CMR is 
recommended to confirm TTE measurements, rule 
out aortic asymmetry, and determine baseline 
diameters for follow-up.137,143,144
I
C
Continued 
Follow-up imaging with TTE, CCT, or CMR (based 
on aneurysm location) should be considered annually 
if there is no expansion/extension or customized 
according to baseline aortic diameter and the 
underlying condition.70,159,172
IIa
C
TTE is not recommended for the surveillance of 
aneurysms in the distal ascending aorta, aortic arch, 
or DTA.159,171
III
C
© ESC 2024
CCT, Cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DTA, descending thoracic aorta; TAAA, thoracoabdominal aortic aneurysm; TTE, 
transthoracic echocardiography. 
See proposed algorithm in Figure 24. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3607


<!-- PAGE 71 -->

### Page 71

Surveillance of AAA
N
Y
Root or ascending dilatation with TAV or BAV (and normal valve function)
at first or susbsequent echocardiography
40–44 mmª
45–49 mm
50–52 mm
Ascending
Ascending
53–54 mm
≥55 mm
<3 mm/y
≥3 mm/y
<3 mm/y
≥3 mm/y
Surgery if low operative risk
(Class IIb)
Otherwise
Surgery if low operative risk
(Class IIa)
Otherwise
Confirm by
CCT or CMR
Confirm by
CCT or CMR
Baseline CCT/CMR
and reimage by
TTE in one year
Reimage by CCT/
CMR 6 months later to define projected growth rate
Reimage by TTE yearly
(or every 6 months if growth rate ≥3 mm/y)
Reimage by TTE
every
2 or 3 years
Reimage every 6 months
Confirm by
CCT or CMR
Confirm by
CCT or CMR
Aortic diameter
Phenotype
High-risk featuresb
Root
TAV
BAV
Growth rate
Growth rate
Phenotype
TAV/BAV
Every
4 years
Every
4 years
Consider follow-up
Follow-up
Every
3 years
Every
3 years
Every 12
months
Every 12 months
Every 6
months
Consider intervention
(Class I)
Every 6
months
Surgery
(Class I)
Surgery
(Class I)
AAA size 
(mm)
Women
Men
25
30
35
40
45
50
55
Consider intervention
(Class I)
Figure 24 Surveillance of patients with non-heritable thoracic aortic disease and abdominal aortic aneurysms. AAA, abdominal aortic aneurysm, 
BAV, bicuspid aortic valve; CCT, cardiovascular computed tomography; HTAD, heritable thoracic aortic disease; CMR, cardiovascular magnetic res­
onance; TAV, tricuspid aortic valve; TTE, transthoracic echocardiography. a36–44 mm in women. bFor TAV and BAV: age <50 years; height 
<1.69 m; ascending length >11 cm; uncontrolled hypertension; and, for BAV: coarctation; family history of acute aortic events.


<!-- PAGE 72 -->

### Page 72

A meta-analysis advises follow-up intervals for AAAs based on size: 3 
years for 30–39 mm, 1 year for 40–44 mm, and 6 months for 45– 
54 mm in men, with <1% rupture risk.938 Women have similar growth 
rates but a four-fold higher rupture risk.938 A proposed follow-up algo­
rithm is displayed in Figure 24. Consider shorter intervals for rapid 
growth (≥10 mm per year or ≥5 mm per 6 months), in which case re­
pair may be considered.
9.2.4. Optimal medical treatment of aortic aneurysms
In patients with aortic aneurysms, the role of antithrombotic therapy is 
uncertain. In complicated aortic atherosclerotic plaques, concomitant 
CAD is common (OR 2.99) and SAPT should be considered (see 
Section 9.1). In patients with AAA, results of observational studies 
are conflicting in relation to aneurysm growth. Low-dose aspirin is 
not associated with a higher risk of AAA rupture but could worsen 
prognosis in cases of rupture.944 In an RCT of patients with AAA 
(35–44 mm), ticagrelor did not reduce growth rate.945
Optimal medical treatment for aortic aneurysms aims to lower CV 
morbidity, slow growth rate, delay surgery, reduce peri-operative 
risk, and prevent AAE. Aneurysm patients face elevated CV risk due 
to common CVRFs, and the 10 year CV event mortality risk (heart at­
tacks or strokes) is 15 times higher than AAE risk, even after re­
pair.882,883 According to the SMART risk score algorithm, optimal 
implementation of risk management guidelines would reduce the 10 
year risk of MACE from 43% to 14% in patients with AAA.936 Thus, life­
style modification, exercise, smoking cessation, and treatment of risk 
factors are crucial (see Section 7).
Risk factors and possible drug treatment to reduce AAA growth and/ 
or the risk of rupture have been thoroughly discussed in a recent review 
paper.946 Their meta-analysis suggested a possible effect of ACEIs (but 
not ARBs) on the risk of rupture, whereas another meta-analysis947 did 
not indicate an effect of ACEIs on AAA growth. A reduction of AAA 
growth by statins is indicated in a recent meta-analysis.352
Furthermore, reduced AAA growth by the antidiabetic drug metformin 
has been suggested in several meta-analyses352,948,949 and there are sev­
eral ongoing RCTs to explore this. For BP, follow general hypertension 
guidelines. Aim for BP below 140/90 mmHg, with a target of 120/80 
mmHg, if tolerated.300,302,305 Data on the specific positive effects of 
beta-blockers and ARBs in TAA and AAA are limited (mostly derived 
from MFS populations). However, it is reasonable to use BBs and/or 
ARBs as first-line antihypertensive drugs in TAA and AAA.
Consider moderate/high-intensity statins in TAA patients but skip 
for those with low CV risk and non-atherosclerotic (HTAD). In 
AAA, consider statins to reduce aneurysm risks, including growth, rup­
ture, and peri-operative mortality.330,347,348 Low-dose aspirin is de­
bated but may be reasonable given elevated CV risk factors in TAA 
and AAA patients.666,950 Additionally, apply all CVD secondary preven­
tion measures to these patients (see Section 7).
Some evidence suggests that fluoroquinolones could be associated 
with an increased risk for aneurysm progression and dissection,951–956
but conflicting analyses do not support this association. The cautious 
use of fluoroquinolones should not be discouraged when there is a clin­
ical indication, even considering concerns regarding aortic aneurysm 
and dissection (AA/AD). Note that AA/AD risk (both thoracic and ab­
dominal) may increase due to infection itself, regardless of the antibiotic 
chosen. Infectious disease specialists discourage routine fluoroquino­
lone use as a first-line antibiotic if equally effective alternatives exist. 
Hence, do not withhold this therapy in aortic disease cases when clin­
ically necessary. All medical and lifestyle recommendations are summar­
ized in Figure 7.
9.2.5. Surgical management of aortic aneurysms
9.2.5.1. Surgical treatment of aortic root and ascending aorta
In isolated dilatation of the ascending tubular (supra-coronary) aorta, a 
supra-commissural tubular graft is inserted with the distal anastomosis 
just before the aortic arch. For aneurysms extending proximally below 
the sinotubular junction (STJ) with involvement of aortic sinuses, the 
surgical approach depends on the aortic annulus and valve condition. 
If the aortic valve cusps are pliable, experienced centres may recom­
mend aortic valve-sparing techniques,961–965 such as David’s procedure 
(reimplantation) or the Yacoub technique (remodelling).890,966–968
Recommendation Table 36 — Recommendations for 
surveillance of patients with abdominal aortic aneurysm
Recommendations
Classa
Levelb
DUS surveillance is recommended every 6 months in 
men with AAA of 50–55 mm and in women with 
AAA of 45–50 mm.938
I
B
CCT or CMR is recommended if DUS does not 
allow adequate measurement of AAA 
diameter.148,939–942
I
B
DUS is recommended for AAA surveillance.943
I
C
DUS surveillance every 3 years should be considered 
in patients with AAA of 30–<40 mm.938
IIa
B
DUS surveillance should be considered annually in 
women with AAA of 40–<45 mm and in men with 
AAA of 40–<50 mm.938
IIa
B
DUS surveillance should be considered every 4 years 
in patients with aortic diameter ≥25 mm and 
<30 mm and life expectancy >2 years.937,938
IIa
C
© ESC 2024
AAA, abdominal aortic aneurysm; CCT, Cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; DUS, duplex ultrasound. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 37 — Recommendations for 
medical treatment in patients with thoracic aorta or 
abdominal aortic aneurysms
Recommendations
Classa
Levelb
In patients with aortic aneurysm (TAA and/or AAA), 
optimal implementation of CV risk management and 
medical treatment (see detailed recommendations in 
dedicated Tables of Recommendationsc) are 
recommended to reduce MACE.936
I
C
Fluoroquinolones, while generally discouraged for 
patients with aortic aneurysms, may be considered if 
there is a compelling clinical indication and no other 
reasonable alternative.951–960
IIb
B
© ESC 2024
AAA, abdominal aortic aneurysm; CV, cardiovascular; MACE, major adverse cardiovascular 
events; TAA, thoracic aortic aneurysm. 
aClass of recommendation. 
bLevel of evidence. 
csee Tables of Recommendations 7 to 10.
ESC Guidelines                                                                                                                                                                                          3609


<!-- PAGE 73 -->

### Page 73

Otherwise, composite replacement of the aortic root and valve with 
the Bentall procedure is indicated.
Pre-operative evaluation890 and initial follow-up of patients is defined 
in Figure 25. Patients with a bioprosthetic valve should be monitored by 
TTE annually. However, in patients with mechanical prosthesis or na­
tive aortic valve, clinical evaluation and TTE should be performed as 
soon as possible if new heart symptoms develop.969 SAPT with low- 
dose aspirin (75–100 mg per day) should be considered for the first 
3 months after conservative aortic valve surgery if there are no indica­
tions for OAC. Lifelong OAC with a VKA is recommended for all pa­
tients with a Bentall mechanical prosthesis.970,971 However, in 
patients with no baseline indications for OAC, low-dose aspirin (75– 
100 mg/day) or OAC using a VKA should be considered for the first 
3 months after Bentall surgery with a bioprosthesis.972,973
TTE and TOE
Aortic valve assessment
CCT or CMR
Annulus/root/
ascending aorta assessment
Supracommisural tubular graft
Aortic valve sparing
Annuloplasty
Bentall procedure
Pre-surgery
STJ dilatation
(Ia)
STJ and aortic root dilatation (Ib)
Annulus dilatation
(Ic)
Aortic valve disease
TTE 
Immediate cardiac complications
(i.e. pericardial effusion...)
CCT or CMR
Rule out aortic complications
Before discharge
1 month
From
1 year
TTE 
Aortic valve function and gradients 
Aortic root and proximal ascending aorta assessment
TTE 
Aortic valve function and gradients 
Aortic root and proximal ascending aorta assessment
Mechanical prosthesis or native valve:
Bioprosthesis:
TTE/year
CCT or CMR
Evaluation of aortic disease progression and rule out complications
Aorta totally repaired:
Follow-up at 2 years and then every 5 years link with aneurysm 
follow-up algorithm
TTE based on gradients,
symptoms or residual AR
Aorta not fully repaired:
Figure 25 Peri-operative algorithm for the management of patients with surgically treated aortic root and ascending aortic aneurysm. AR, aortic 
regurgitation; CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; STJ, sinotubular junction; TOE, transoesophageal 
echocardiography; TTE, transthoracic echocardiography.


<!-- PAGE 74 -->

### Page 74

Although many risk factors associated with AAE have been described 
(such as elongation, angulation, and unfavourable biomechanics), aortic 
diameter is still the main determinant of aortic complications and 
death.974–976 AAE rates decreased with prophylactic aortic surgery 
over a decade,977 and additionally, surgical risk for ascending aortic/aor­
tic root surgery dropped significantly.978–980 Now, experienced cardiac 
surgery centres report <1% mortality with elective surgery.980,981
Most acute type A aortic dissections (acute TAAD) occur at diameters 
below 55 mm. However, the risk exceeds 1% between 50 and 54 mm,982
with a critical point at 52–53 mm.153,981,983 Pre-dissection aortic diam­
eter at the tubular level is 25%–30% smaller than post-dissection. 
Over 60% of non-MFS, non-BAV acute TAAD patients have a non- 
dilated ascending aorta before dissection.984,985 Additionally, the ‘root 
phenotype’ has been reported to be more malignant than those with as­
cending phenotype, with higher velocity of progression and AAE 
risk.154,891,892,986
Novel parameters, like ascending aortic length (AAL) and the 
ascending-arch angle, correlate with acute TAAD risk.155,976 AAL 
≥13 cm links to nearly five-fold higher yearly AAE rates compared 
with AAL <9 cm, with a threshold of >11 cm as a risk indicator.155
Indexing aortic diameters to anthropometric parameters has been sug­
gested and a proportional increase in the risk of AAE has been retro­
spectively demonstrated for increasing diameter indexed to BSA,904
diameter indexed to patient height,153 or cross-sectional area indexed 
to patient height.154 However, these diameter-based indexing methods 
share the same limitations in risk prediction as the absolute diameter in 
the general population,984,985 whereas they can be advantageous in pa­
tients with small body size.153,154 These additional risk factors (beyond 
the diameter) are summarized in Figure 23.
9.2.5.2. Surgical treatment of aortic arch aneurysms
Surgery for arch aneurysms is challenging, primarily due to risks like 
hypothermic circulatory arrest and the need for brain protection, re­
sulting in higher mortality and stroke rates. Isolated aortic arch surgery 
is appropriate for asymptomatic degenerative aortic arch aneurysms 
≥55 mm in diameter or symptoms or signs of local compression. 
Hemi-arch or total arch replacement are frequently required in patients 
who have an indication for surgery on an adjacent aneurysm of the as­
cending aorta. In specific cases, supra-aortic vessel transposition via off- 
pump debranching followed by TEVAR of the arch can be an alternative 
to traditional surgery, particularly when avoiding hypothermic circula­
tory arrest is a concern.992–996 When the disease involves the proximal 
descending aorta or future need for treatment of the descending aorta 
is anticipated, the frozen elephant trunk (FET) technique is a good op­
tion.997 Assessment of patency and morphology of the circle of Willis is 
recommended when treatment involves the aortic arch.998,999
Recommendation Table 38 — Recommendations for 
surgery in aortic root and ascending aorta dilatation 
associated with tricuspid aortic valve (see also 
Evidence Table 11)
Recommendations
Classa
Levelb
Surgery is recommended in patients with dilatation 
of the aortic root or ascending aorta with a tricuspid 
aortic valve and a maximum diameter of 
≥55 mm.172,894,899,904
I
B
Valve-sparing aortic root replacement is 
recommended in patients with aortic root dilatation 
if performed in experienced centres and durable 
results are expected.961–965
I
B
VKAs are recommended lifelong for all patients with 
a Bentall procedure with an MHV prosthesis.970,971
I
B
In patients with dilatation of the tubular ascending 
aorta who can be offered surgery with low predicted 
risk,c ascending aortic replacement should be 
considered at a maximum diameter 
>52 mm.153,981,983
IIa
B
In patients undergoing surgery for tricuspid aortic 
valve disease who have concomitant dilatation of the 
aortic root or ascending tubular aorta, and low 
predicted surgical risk, ascending aorta or root 
replacement should be considered at a maximum 
diameter ≥45 mm, otherwise ≥50 mm.70,987–989
IIa
B
Continued 
SAPT with low-dose aspirin (75–100 mg per day) 
should be considered for the first 3 months after 
valve-sparing aortic surgery when there are no other 
baseline indications for OAC.
IIa
C
In patients undergoing non-aortic-valve cardiac 
surgery who have concomitant dilatation of the 
ascending aorta or aortic root with a maximum 
diameter ≥50 mm, concomitant aortic surgery 
should be considered.70,990,991
IIa
C
Ascending aortic or root replacement may be 
considered at a maximum diameter of ≥50 mm in 
patients with proximal aorta dilatation who can be 
offered surgery with low predicted riskc and present 
with any of the following:153–155,891,892
• Growth of the aortic diameter ≥3 mm per year
• Resistant hypertensiond
• Short stature <1.69 m
• Root phenotype
• Aortic lengthe >11 cm
• Age <50 years
• Desire for pregnancy
• Aortic coarctation
IIb
B
© ESC 2024
MHV, mechanical heart valve; OAC, oral anticoagulation; SAPT, single antiplatelet therapy; 
VKA, vitamin K antagonist. 
For heritable thoracic aortic disease and bicuspid aortic valve-related thoracic aortic 
aneurysm refer to Section 10. 
aClass of recommendation. 
bLevel of evidence. 
cIndividual patient’s risk <3%. 
dHypertension that cannot be adequately controlled despite use of three or more agents 
recommended by a physician with expertise in the management of hypertension. 
eCurvilinear distance at aortic centreline between the ventriculo-aortic junction and the 
origin of the innominate artery.
Recommendation Table 39 — Recommendations for 
surgery in aortic arch aneurysms
Recommendations
Classa
Levelb
In patients with low or intermediate operative risk with 
an aortic arch aneurysm and recurrent episodes of 
chest pain not attributable to non-aortic causes, open 
surgical replacement of the arch is recommended.70,172
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3611


<!-- PAGE 75 -->

### Page 75

9.2.5.3. Surgical treatment of the thoracic descending aorta
9.2.5.3.1. General considerations. At 60 mm diameter, a DTA aneur­
ysm has a 10% annual rupture risk, justifying intervention at 
≥55 mm.902,1002 Intervention at a diameter <55 mm may not bring 
any further survival benefit except for women,904,1003 patients with 
connective tissue disorders,904 or rapid growth (≥10 mm per year or 
≥5 mm every 6 months),1004 (for high-risk factors see Figure 23). 
This threshold may be increased in high surgical risk patients.1005 It is 
advisable to centralize complex procedures in centres with expertise 
in aortic diseases and a multidisciplinary team for effective patient 
management.
9.2.5.3.2. Open repair. Thoracic endovascular aortic aneurysm 
repair is recommended as first-choice intervention for DTA aneur­
ysms,1006–1010 thus open repair is limited to patients with unsuitable 
anatomy for TEVAR1011 or connective tissue disorders.1012 The early 
mortality benefit of TEVAR seems to decrease after 1 year, and there­
after long-term survival (10 years) seems better with open repair.1013
Therefore, open repair is advisable for young, healthy patients with un­
suitable TEVAR anatomy and prolonged life expectancy, particularly 
when symptoms from aneurysm rupture or compression arise.
However, open repair involves significant post-operative risks, ne­
cessitating thorough pre-operative evaluations for cardiac, pulmonary, 
renal function, carotid, and peripheral arterial diseases. Risks include 
stroke, mesenteric and renal ischaemia due to clamping dur­
ation,1014,1015 and paraplegia tied to the extent of aneurysmal dis­
ease.1016,1017 Outside experienced centres, outcomes have shown 
minimal improvement in recent years, with mortality rates around 
10% and spinal cord ischaemia rates at 11%–15%.1016,1018
9.2.5.3.3. Endovascular repair. Comparative studies favour TEVAR 
over open repair, showing lower mortality (6%) and morbid­
ity.1006,1019,1020 However, TEVAR’s survival advantage is balanced by 
an increased risk of follow-up re-intervention. It reduces spinal cord in­
jury risk (3%).1021–1024 Left subclavian artery (LSA) coverage during 
TEVAR for proximal sealing is required in up to 50% of cases.1025
This is associated with an increased risk of cerebrovascular events, 
spinal cord ischaemia (SCI), and upper-limb ischaemia,1026,1027 justifying 
previous surgical or concomitant endovascular (with branched or fene­
strated grafts) revascularization of the LSA in an elective set­
ting.1026,1028,1029 In cases of inadequate distal zone sealing, safe 
coverage of the coeliac artery has been proposed when sufficient col­
lateral circulation exists,1030,1031 but results are controversial.1032
9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms
9.2.5.4.1. General considerations. Since AAEs increase when TAAA 
diameter exceeds 60 mm,902,1002,1033 and there are more technical sur­
gical challenges in TAAA repair (compared with DTA aneurysm or 
AAA), TAAA repair, in low-moderate surgical risk patients, is proposed 
if the aortic diameter is ≥60 mm. However, surgical repair should be 
considered at diameters ≥55 mm if patients present with high-risk fea­
tures (Figure 24) or are at very low risk and under the care of experi­
enced surgeons in a multidisciplinary aorta team.1004,1033,1034 HTAD, 
distal location, chronic dissection, and BAV903 are associated with rapid 
growth rate and will require closer follow-up.
9.2.5.4.2. Open repair. Open TAAA repair is a complex aortic pro­
cedure. Post-operative mortality risk increases with left ventricular 
(LV) dysfunction, renal insufficiency, and advanced age.1035–1037 Since 
organs and tissues distal to the aortic clamp will suffer from prolonged 
ischaemia, extracorporeal circulation is mandatory to reduce complica­
tions,1011,1038 especially SCI (2.5%–15%).1011,1039–1044 The mortality 
rate after open TAAA repair varies between 6% and 8% in high-volume 
centres1006,1011,1039 vs. 30% in less experienced centres,1045,1046 raising 
the recommendation to perform these complex procedures only in 
specialized institutions.
9.2.5.4.3. Endovascular repair. Endovascular repair is a promising al­
ternative for treating challenging aortic anatomy like juxta-renal AAA 
(Figure 22).1047,1048 The use of fenestrated and branched endografts 
has shown excellent results, allowing perfusion of visceral ves­
sels.1049–1053 While direct comparison studies with open TAAA repair 
are lacking,1054 the increasing adoption of endovascular procedures is 
notable, especially for high-risk patients, with low post-operative mor­
tality rates (<10%).1051,1052,1055–1058 A recent meta-analysis confirms 
these excellent outcomes, endorsing endovascular repair for 
TAAA.1059 The incidence of post-operative SCI (around 5%) is similar 
between endovascular and open repair.1052,1057,1060,1061 Thus, at 
mid-term follow-up, endovascular repair is durable with acceptable 
secondary re-intervention rates, which remain one of the major limita­
tions.1052,1057,1058,1060,1061 Factors favouring endovascular vs. open re­
pair in TAAA are presented in Table 15.
In patients with an isolated aortic arch aneurysm who 
are asymptomatic and have low operative risk, open 
surgical replacement should be considered at an arch 
diameter of ≥55 mm.70,172,899
IIa
B
In patients undergoing open surgical repair of an 
ascending aortic aneurysm, concomitant hemi-arch 
replacement should be considered if the dilatation 
extends into the proximal aortic arch 
(>50 mm).70,172,1000
IIa
C
In patients undergoing open surgical repair of an 
aortic arch aneurysm, an elephant trunk or frozen 
elephant trunk procedure should be considered if the 
aneurysmal disease extends into the proximal 
descending thoracic aorta.70,172,997,1001
IIa
C
In patients undergoing open surgical repair of an 
ascending aortic aneurysm, concomitant hemi-arch 
or arch replacement may be considered in 
experienced centres if the dilatation extends into the 
aortic arch (>45 mm).70,172,1001
IIb
C
In patients with an aortic arch aneurysm who meet 
criteria for intervention but have high surgical risk, a 
hybrid or endovascular approach may be 
considered.70,172
IIb
C
© ESC 2024
For heritable thoracic aortic disease refer to Section 10. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 76 -->

### Page 76

9.2.5.5. Surgical treatment of abdominal aorta aneurysms
9.2.5.5.1. General considerations. Rupture remains the most feared 
AAA complication, and is associated with the maximum diameter,1063
as well as other risk factors (Figure 23). Different studies1064–1071 (in­
cluding the United Kingdom Small Aneurysm Trial [UKSAT] and 
American Aneurysm Detection and Management [ADAM] trial) re­
ported no benefits from open or endovascular interventions (despite 
lower peri-operative complication rates) in asymptomatic AAA pa­
tients with a maximal diameter <55 mm in men and <50 mm in wo­
men. Evidence that women are more likely to rupture under 
surveillance and at a smaller aortic diameter justified a lower 
(50 mm) threshold. Another interesting method to quantify the risk 
of rupture based on body size, which seems a better predictor in wo­
men, has been proposed.1072 However, in the absence of recent stud­
ies, thresholds for intervention have not changed in recent years. 
Considering the complexity of patient management, it is advisable to 
centralize complex procedures in centres with a high level of expertise 
in aortic diseases and a multidisciplinary team.
9.2.5.5.2. Pre-operative cardiovascular evaluation and choice of 
treatment. Coronary artery disease is the leading cause of early mor­
tality after AAA repair,937,1073 and is associated with a 5%–10% rate of 
peri-operative CV complications such as death, MI, or stroke.1074,1075
Since endovascular repair is associated with lower mortality (<1%) 
and CV complications,1076–1079 the need for pre-operative cardiac 
Recommendation Table 40 — Recommendations for 
the management of patients presenting with descending 
thoracic aortic and thoracoabdominal aortic aneurysms
Recommendations
Classa
Levelb
In patients with unruptured DTA aneurysm (without 
HTAD), elective repair is recommended if diameter 
≥55 mm.902,1002
I
B
In patients without HTAD with unruptured DTA 
aneurysm, when elective repair is indicated and 
anatomy is suitable, TEVAR is recommended over 
open repair.1006,1019,1020
I
B
In patients with DTA aneurysm who undergo 
TEVAR with planned LSA coverage, it is 
recommended to revascularize the LSA before 
TEVAR to reduce the risk of SCI and 
stroke.1026,1028,1029
I
B
In patients with unruptured degenerative TAAA, 
elective repair is recommended when the diameter is 
≥60 mm.902,1002,1033
I
B
In patients without significant comorbidities and with 
unruptured DTA aneurysm, when elective repair is 
indicated and anatomy is unsuitable for TEVAR, open 
repair should be considered if life expectancy 
exceeds 2 years.1013
IIa
B
In TAAA, surgical repair should be considered at 
diameters ≥55 mm if patients present with high-risk 
features, are at very low risk, and are under the care 
of experienced surgeons in a multidisciplinary aorta 
team.1004,1033,1034
IIa
B
In patients with unruptured degenerative TAAA and 
suitable anatomy, when elective repair is indicated, 
endovascular repair using fenestrated and/or 
branched endografts should be considered in 
experienced centres.1051,1052,1055–1059
IIa
B
Continued 
In patients with unruptured DTA aneurysm (without 
HTAD) and high-risk features,c elective repair may 
be considered if the diameter is 
<55 mm.904,1003,1004,1033,1034
IIb
B
© ESC 2024
DTA, descending thoracic aorta; HTAD, heritable thoracic aortic disease; LSA, left 
subclavian artery; SCI, spinal cord ischaemia; TAAA, thoracoabdominal aortic aneurysm; 
TEVAR, thoracic endovascular aortic aneurysm repair. 
For heritable thoracic aortic disease refer to Section 10. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 23 for high-risk features.
Table 15 Overview of factors favouring open vs. endovascular repair in thoracoabdominal aortic aneurysm
Characteristic
Favours open repair
Favours endovascular repair
Biological age and life 
expectancy
• Younger age
• Considerable life expectancy with acceptable 
quality of life
• Older age
• Limited life expectancy
Anatomical considerations
• If aortic and branch anatomy preclude endovascular 
approach
• Poor vascular access
• Suitable proximal and distal landing zones
• Favourable visceral and renal configuration
• Vascular access obtainable
Pathological
• Chronic dissection
• Acute dissection
Background/causal factor
• Hereditary aortic disease
• Degenerative aortic disease
Cardiopulmonary condition
• Good cardiopulmonary reserve
• Poor cardiopulmonary reserve
Fitness
• No significant comorbidities
• Successful rehabilitation likely
• Severe organ impairment (renal, kidney, pulmonary)
• Obesity
• Limited mobility, unlikely to rehabilitate successfully
Urgency
• Elective repair
• Emergency repair without a viable endovascular 
solution
• Elective repair
• Emergency repair with time for custom-made graft or suitable for 
standard grafts
© ESC 2024
Adapted from Ouzounian et al. with permission.1062
ESC Guidelines                                                                                                                                                                                          3613


<!-- PAGE 77 -->

### Page 77

Patients with abdominal aortic aneurysm
Aortic aneurysm
Graft
Aortic aneurysm
Stent graft
Surveillance
(See aneurysm follow-up algorithm)
N
N
Low/medium
High
Prohibitive
Either of the following:
Life expectancy 2 years
Operative mortality risk
Elective repair
Anatomy appropriate for EVAR
Open repair
(Class I)
If suitable anatomy,
EVAR (Class IIa) 
Optimal medical treatment
Elective repair
(Class III)
EVAR
(Class IIa)
Fusiform AAA ≥55 mm (men), ≥50 mm (women)
Saccular aneurysm 45 mm
N
Y
Y
Y
A
B
Figure 26 Algorithm for individual decision-making process in the treatment of patients with abdominal aortic aneurysm. (A) Illustration of open 
repair (graft). (B) Illustration of endovascular treatment (EVAR). AAA, abdominal aortic aneurysm; EVAR, endovascular aortic aneurysm repair.


<!-- PAGE 78 -->

### Page 78

work-up will depend on procedure risk, symptoms, and patient-specific 
CVRFs (see Sections 4 and 12, and the 2022 ESC Guidelines on cardiovas­
cular assessment and management of patients undergoing non-cardiac sur­
gery).1080 Coronary revascularization before elective aortic surgery in 
patients with stable cardiac symptoms cannot be recommended, since 
there is evidence that this strategy does not improve outcomes or re­
duce the 30 day MI rate.1080,1081
A complete vascular evaluation (that includes not only the AA but 
also the entire aorta: ascending, arch, and descending aorta) is manda­
tory to determine the best strategy in AAA management, CCT being, 
by consensus, the optimal pre-operative imaging modality.1082,1083
When CCT is contraindicated, consider CMR, though calcification as­
sessment is challenging. Pre-operative planning should determine 
EVAR feasibility by sizing the aorto-iliac system, yet adherence to 
device-specific instructions remains uncertain.1084–1090 DUS assess­
ment of the femoro-popliteal segment is advocated since femoro- 
popliteal aneurysms are commonly associated with AAA.1091,1092
Additionally, the technique of choice should be discussed between 
the treating physician and the patient based on the patient’s life expect­
ancy and preferences, operator and hospital volumes, and surveillance 
compliance.910,1093–1097 Elective AAA repair is not recommended in 
frail patients or those with life expectancy <2 years.1098,1099 The indi­
vidual decision-making process in AAA patients is displayed in Figure 26.
Different studies have demonstrated a significant short-term survival 
benefit for EVAR, but with similar long-term outcomes compared with 
open repair (up to 15 years)1100–1103 also reported in females.1104
However, loss of early benefit is associated with an increased rate of 
late complications occurring after 8 years, especially late ruptures.1079
These trials used earlier-generation EVAR devices, so the durability 
of the latest-generation devices remains uncertain. Recent data, how­
ever, suggest a reduced risk of late complications and fewer re- 
interventions.1105–1108
9.2.5.5.3. Open abdominal aorta aneurysm repair. Open AAA re­
pair through mid-line laparotomy (with <30 min clamping time) 
with a Dacron graft has been the preferred choice for years, despite 
notable CV morbidity1078,1100,1109–1113 and a 2%–5% mortality 
rate.1110,1111,1113,1114 In ruptured AAA, open repair results are worse 
than those of elective surgery, with an unchanged complication rate 
of around 48%.1115 Thus, endovascular repair is recommended to re­
duce peri-operative morbidity and mortality.1116–1118
Open AAA repair raises incisional hernia risk, particularly in obese 
patients, suggesting prophylactic mesh use in high-risk cases.1119–1121
9.2.5.5.4. Endovascular abdominal aorta aneurysm repair.
Endovascular abdominal aorta aneurysm repair reduces peri-operative 
mortality to <1%, although it implies higher risk of re-intervention in 
the long term.1122–1124 Current devices offer features like active fix­
ation, repositioning ability, low-profile design, and polymer-filled rings 
for improved sealing.1106,1125–1128 New devices demonstrate similar 
long-term outcomes with reduced re-intervention risk,1090 expanding 
treatment possibilities to 60%–70% of infrarenal AAA cases.1129,1130
In cases of juxta- or para-renal AAA (Figure 22), both open and en­
dovascular treatment can be proposed in high-volume centres, with 
similar short- and long-term results. The choice between open surgical 
repair and endovascular repair depends on various factors, including the 
patient’s anatomy, overall health, and the extent of the aneurysm 
(see Table 15). In cases of complex endovascular treatment, a fene­
strated or branch stent endograft should be considered.1096,1131
A percutaneous femoral approach is suitable since it provides quick­
er access, reduced invasiveness, and allows local anaesthesia. Some evi­
dence supports the use of ultrasound-guided percutaneous access for 
EVAR due to a lower rate of access-related complications and a shorter 
operation time.1132–1135
As patients treated by EVAR are more prone to late complications 
(endoleaks, migration, or rupture) and re-interventions, lifelong surveil­
lance is currently mandatory.1096,1136–1140
9.2.6. Endoleaks
Endoleaks are defined as the persistence of blood flow outside the graft 
but inside the aneurysm sac, preventing complete thrombosis 
(Figure 27). They are the most common complication, with an incidence 
up to one-third of either early or late procedures (those appearing after 
1 year).1145 Chronic anticoagulation constitutes a risk factor for 
re-intervention, late conversion surgery, or mortality.1146 Endoleaks 
exposing the aneurysm sac to systemic pressure and expansion will 
require re-intervention to prevent rupture.
Five types of endoleaks have been described, as detailed in Figure 27. 
Type I and type III require correction with a new (endovascular) pro­
cedure. Type II is present in about 25% of patients but may seal 
Recommendation Table 41 — Recommendations for 
the management of patients presenting with abdominal 
aortic aneurysm
Recommendations
Classa
Levelb
Elective repair is recommended if AAA diameter is 
≥55 mm in men or ≥50 mm in women.1064–1067
I
A
In ruptured AAA with suitable anatomy, 
endovascular repair is recommended over open 
repair to reduce peri-operative morbidity and 
mortality.1116–1118
I
B
Prior to AAA repair, DUS assessment of the 
femoro-popliteal segment, to detect concomitant 
aneurysms, should be considered.1091,1092
IIa
B
In patients with AAA with suitable anatomy and 
reasonable life expectancy (>2 years), EVAR should 
be considered as the preferred therapy, based on 
shared decision-making.910,1096,1141–1143
IIa
B
In patients with unruptured AAA and aneurysm 
growth ≥5 mm in 6 months or ≥10 mm per year, 
repair may be considered.1064,1065
IIb
C
Elective repair for patients presenting with a saccular 
aneurysm ≥45 mm may be considered.1144
IIb
C
In patients with AAA and limited life expectancy 
(<2 years), elective AAA repair is not 
recommended.1098,1099
III
B
Prior to AAA repair, routine evaluation with 
coronary angiography and systematic 
revascularization in patients with chronic coronary 
syndromes is not recommended.1080,1081
III
C
© ESC 2024
AAA, abdominal aortic aneurysm; DUS, duplex ultrasound; EVAR, endovascular aortic 
aneurysm repair; TAA, thoracic aortic aneurysm. 
See also Figure 23. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3615


<!-- PAGE 79 -->

### Page 79

Y
N
Classification of endoleak types
Type Ia
Type Ib
Type II
Type III
Type IV
Type V
Surveillance after TEVAR/EVAR and management of endoleaks
CCT and DUS/CEUSa at 1 month and 1 year post-op
No new endoleak
Type I or type III endoleak
Consider re-intervention
(Class I)
Type II endoleak
Detected at
1 month post-op
CCT re-evaluation at 6–12 months
Annual surveillance with
CCT or DUS/CEUSa 
for the first 5 years
<10 mm or shrinking
Consider open surgery,
if growing aneurysm sac
CCT or DUS/CEUSa surveillance every 6 months for 24 months
New endoleak or growing aneurysm sac
CCT, or non-contrast CCT with
DUS/CEUS every 5 yearsa
Growing aneurysm sac
Consider embolization,
if feasible
(Class IIa)
CCT
Proceed to endoleak type
CCT or DUS/CEUSa surveillance at 6–12 months
New endoleak
≥10 mm
Y
N
Figure 27 Algorithm for follow-up after thoracic endovascular aortic aneurysm repair, and management of endoleaks and their classification. CEUS, 
contrast-enhanced ultrasound; CCT, cardiovascular computed tomography; DUS, duplex ultrasound; TEVAR, thoracic endovascular aortic aneurysm repair; 
EVAR: Endovascular aortic repair. aIn cases of TEVAR, CCT is the preferred imaging technique since DUS/CEUS does not permit the correct evaluation of the 
thoracic aorta. In cases of renal failure, non-contrast CCT is a good alternative to monitor aneurysm sac growing and is associated to DUS/CEUS for EVAR 
monitoring. Endoleaks are classified into five types: Type Ia, proximal attachment site endoleak; Type Ib, distal attachment site endoleak; Type II, backfilling of 
the aneurysm sac through branch vessels of the aorta; Type III, graft defect or component misalignment; Type IV, leakage through the graft wall attributable to 
endograft porosity; and Type V; caused by ‘endotension’, possibly resulting from aortic pressure transmitted through the graft/thrombus to the aneurysm sac. 
Adapted from Rokosh et al. with permission.1147


<!-- PAGE 80 -->

### Page 80

spontaneously in approximately 50% of cases. Risk factors for type II 
endoleaks include patent collaterals, presence of accessory arteries, 
and anticoagulation. In cases of significant sac expansion (≥10 mm), 
re-intervention should be considered, preferably by vessel or sac em­
bolization. Type IV, attributed to device porosity, is rare with modern 
devices and no intervention is needed. Type V induces sac expansion 
without any visible endoleak. Treatment may be considered for signifi­
cant sac growth (≥10 mm) and consists of stent graft relining or defini­
tive endograft explant and open surgical repair.
Cardiovascular computed tomography with(out) contrast, and DUS 
and/or CEUS, are the main imaging modalities for TEVAR/EVAR follow- 
up. Imaging within the first 30 days is recommended to assess treat­
ment success and/or complications. For TEVAR, contrast-enhanced 
CCT is the preferred imaging technique for follow-up and should be 
performed regularly (shorter or longer intervals are based on the ex­
pansion rate). In renally impaired patients, combined follow-up using 
DUS and non-contrast enhanced CCT is a suitable alternative (see 
follow-up algorithm, Figure 27). For EVAR, CCT and DUS/CEUS are re­
commended at 1 month following repair. Thereafter, surveillance 
should be based on the risk of late complications and includes DUS 
and/or CEUS (Figure 27).
9.2.7. Long-term follow-up after aortic repair
Long-term success in the management of aortic aneurysms depends 
also on strict post-treatment surveillance, for both secondary preven­
tion of the aortic disease and early identification of post-repair 
complications.
In endovascularly treated patients, surveillance aims to detect endo­
leaks, aneurysmal sac dilatation, and graft structural failure or migra­
tion.1150 Surgical treatments, while carrying higher operative risks, 
often yield more durable results with rarer late complications mostly 
related to laparotomy.1151
After intervention on the thoracic aorta, TTE, TOE, CCT, and CMR 
are used for follow-up, CCT being the most used and available method 
for both endovascular and surgical treatments.1150–1152 After interven­
tion on the AA, CCT, CMR, and DUS/CEUS are used. DUS/CEUS can 
detect the most common drawbacks of EVAR, except for graft struc­
tural issues. For chronic and periodic monitoring, the use of CMR, es­
pecially in young women, should be considered (to reduce radiation 
exposure). However, the choice between these modalities should con­
sider patient factors, potential artefacts, and local imaging expertise and 
availability. Both for the thoracic and abdominal aorta, due to the lack of 
studies systematically comparing different surveillance time intervals, 
recommendations are mostly based on consensus or evidence from 
single-centre observational studies.70,1153
9.2.7.1. Follow-up after thoracic aortic aneurysm treatment
Complications after ascending aorta graft replacement, though rare, 
include pseudo-aneurysms and graft infections. Pseudo-aneurysms, 
occurring in roughly 5% of cases, are most common within the first 2 
post-operative years, linked to aortic dissection surgery, HTAD, and 
synthetic glues.1154
CMR studies systematically following peri- 
anastomotic haematomas have reported higher rates (15%).1155
Graft infections can occur in 0.5%–6% of surgical patients with high 
morbidity and mortality rates, requiring rapid diagnosis. Treatment typ­
ically involves surgery and antibiotics, tailored to factors like overall 
health, infection severity, and underlying conditions.1156 Residual aortic 
disease progression depends on the underlying condition, such as 
HTAD, and requires individualized surveillance.
After TEVAR for DTA aneurysm, late complications are higher 
than with surgery (up to 38%), leading to re-operation in 24% of 
cases.1150 However, over 80% of TEVAR complications arise within 
the initial post-operative years.1157 Notably, FET results in fewer stent 
graft-related complications: 2% stent-induced intimal tear, 3% endo­
leak, and 7% need for additional TEVAR.1158
After surgical treatment of TAAs, the protocol is a first CCT scan at 
discharge or 1 month, then another in the first post-operative year (at 
6, 9, or 12 months), followed by a 2 year scan, and if no issues arise, 
scans every 5 years thereafter (Figure 25).1062,1159 Stricter lifelong sur­
veillance is recommended after TEVAR: after first imaging at 1 month, 
yearly controls are recommended for at least the first 5 post-operative 
years, then less frequently if no complications are detected (Figure 27).
Cardiovascular risk profile modification, cardiac rehabilitation, and 
lifestyle adjustments are an integral part of post-aneurysm repair 
follow-up (Figure 7).24
9.2.7.2. Follow-up after abdominal aortic aneurysm treatment
Evidence for follow-up after AAA is more robust than after TAA re­
pair.70,1096 Post-surgery, anastomotic or para-anastomotic complica­
tions are rare (2%–4%).1160
In contrast, EVAR has higher 
complication rates (16%–30%), necessitating lifelong surveil­
lance.1079,1150 EVAR’s survival advantage over surgery diminishes after 
8 years, with higher aneurysm-related mortality risk for EVAR.1079
However, most failures are detectable early, and complications seldom 
occur later in patients with normal early controls.1161,1162 CCT effect­
ively detects early EVAR abnormalities,1163 but DUS/CEUS surveillance 
proves accurate, reducing the need for radiation and nephrotoxic 
agents, and lowering costs (Figure 27).1164–1167
Interestingly, a meta-analysis found low compliance of patients to 
post-operative surveillance without differences in all-cause mortality, 
aneurysm-related mortality, and re-intervention between compliant 
and non-compliant patients.1168 Altogether, the above-mentioned evi­
dence supports stratified methods of surveillance,1096
with 
Recommendation Table 42 — Recommendations for 
the management of patients presenting with endoleaks
Recommendations
Classa
Levelb
It is recommended to perform 30 day imaging after 
TEVAR/EVAR, by CCT and DUS/CEUS, to assess the 
success of intervention.1096
I
B
It is recommended to re-intervene to achieve a seal 
in patients with type I endoleak after TEVAR/ 
EVAR.1137,1148
I
B
It is recommended to re-intervene, principally by 
endovascular means, to achieve a seal in patients with 
type III endoleak after TEVAR/EVAR.1139
I
B
Re-intervention, principally with an endovascular 
approach or embolization, should be considered in 
patients with type II or V endoleak and significant sac 
expansion ≥10 mm or significantly decreasing 
proximal or distal seal.1096,1149
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; CEUS, contrast-enhanced ultrasound; DUS, 
Duplex ultrasound; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3617


<!-- PAGE 81 -->

### Page 81

identification of high-risk situations (e.g. older patients, inadequate seal­
ing, type II endoleaks, no early post-procedural shrinkage of the aneur­
ysmal sac) for which more frequent evaluation should be 
planned.1161,1169,1170
Follow-up of OMT is highly important in AAA patients (Figure 7).24
Statin use after AAA repair (surgical or EVAR) is associated with de­
creased short- and long-term mortality.1171 In addition, surveillance 
for aneurysm development in other arterial locations is recommended.
9.3. Acute thoracic aortic syndromes
9.3.1. General concepts
Acute aortic syndromes are life-threatening emergencies, including classic 
AAD, IMH, PAU, aortic pseudo-aneurysm, and traumatic aortic injuries 
(TAI). They involve aortic wall damage and share a dynamic, overlapping 
pathophysiology, clinical presentation, and diagnostic and therapeutic ap­
proaches.24,172,174,910 AAS may also be iatrogenic following open or endo­
vascular/percutaneous procedures, or cardiac surgery.1172
To guide AAS management, several anatomical classifications have 
been developed, the Stanford and the DeBakey systems being the 
most widely used. The Stanford system classifies AAS according to 
whether the ascending aorta is involved (type A or DeBakey type I 
and type II) or not (type B or DeBakey type IIIa and type IIIb) regardless 
of the site of origin of the intimal tear.172,174,910,1173 This classification 
considers not only anatomical and treatment aspects, but also prognos­
tic implications, since patients with DeBakey type II AAS will probably 
be left without structural aortic wall lesions after surgery (Figure 28).
Furthermore, if time elapsed from symptom onset to diagnosis is con­
sidered, AAS can be divided into hyperacute (<24 h), acute (1–14 days), 
subacute (15–90 days), and chronic (>90 days) (Figure 28).1174–1176
A new classification considers the intimal tear’s entry site and dissec­
tion extension (Figure 29).136 Subscript P describes the proximal in­
volved aorta, and subscript D indicates the distal zone. This 
classification guides treatment decisions for sealing the entry tear. 
AADs limited to the aortic arch or originating as retrograde dissections 
from the descending aorta that extend into the arch and stop before 
the ascending aorta are termed as non-A non-B AD.1177–1179
Recently, a European update of the Stanford classification—Type 
Entry Malperfusion (TEM) classification—has been proposed.1180 This 
combines information about the type of dissection, its extent, and 
the presence of complications (malperfusion), thus providing greater 
prognostic insights (Figure 29). This classification is recommended by 
the European Association for Cardio-Thoracic Surgery. The TEM and 
other classifications are described in the Supplementary data online, 
Section 1.6.
9.3.1.1. Epidemiology and risk factors
Classic AAD (comprising 80%–90% of AAS; incidence of 2.6–3.5 cases 
per 100 000 person-years)24,1181 is characterized by the presence of an 
intimal flap separating the true from the false lumen (FL).24,172,910
Recommendation Table 43 — Recommendations for 
follow-up after treatment of aortic aneurysms (see 
also Evidence Table 12)
Recommendations
Classa
Levelb
Thoracic aortic aneurysm
After open repair of TAA, an early CCT is 
recommended within 1 month, and then yearly CCT 
follow-up for the first 2 post-operative years and 
every 5 years thereafter is recommended if findings 
are stable.c,70,1153,1159
I
B
After TEVAR, follow-up imaging is recommended at 
1 and 12 months post-operatively, then yearly until 
the fifth post-operative year if no abnormalitiesd are 
documented.70,1153,1158
I
B
After 5 post-operative years without complications, 
continuing long-term follow-up of TEVAR by CCT 
every 5 years should be considered.70,1153,1158
IIa
B
If growth of the excluded aneurysm is observed, 
without evidence of type I or III endoleak, repeating 
CCT every 6–12 months, depending on the growth 
rate observed, should be considered.1150
IIa
C
When frequent controls are required in TAA 
patients treated either by open or endovascular 
repair, CMR should be considered instead of CCT 
after the first year of follow-up. However, the choice 
between these imaging modalities should be based 
on individual patient factors, the potential for 
artefacts, and the local availability and expertise in 
specific imaging techniques.1155
IIa
C
Abdominal aortic aneurysm
After open repair of AAA, first follow-up imaging is 
recommended within 1 post-operative year, and 
every 5 years thereafter if findings are stable.1079,1096
I
A
After EVAR, follow-up imaging is recommended with 
CCT (or CMR) and DUS/CEUS at 1 month and 12 
months post-operatively, then, if no abnormalitiesd 
are documented, DUS/CEUS is recommended every 
year, repeating CCT or CMR (based on potential 
artefacts) every 5 years.70,1079,1100,1163–1165,1167
I
A
In higher-risk patients, i.e. with inadequate sealing or 
type II endoleak at first CCT control, more frequent 
DUS/CEUS imaging should be 
considered.e,1096,1161,1164,1165,1167
IIa
B
In low-riskf patients, from 1 year post-operatively 
after EVAR, repeating DUS/CEUS every 2 years 
should be considered.1096
IIa
B
Continued 
If any abnormality during DUS/CEUS is found, 
confirmation should be considered using additional 
CCT or CMR (based on potential artefacts).1163,1166
IIa
B
In post-treatment surveillance, administration of 
OMT (see 8.1.2.2 and 8.2.4) and assessment of 
aneurysm development/growth in other arterial 
segments should be considered.
IIa
C
© ESC 2024
AAA, abdominal aortic aneurysm; CCT, cardiovascular computed tomography; CEUS, 
contrast-enhanced ultrasound; CMR, cardiovascular magnetic resonance; DUS, Duplex 
ultrasound; EVAR, endovascular aortic repair; OMT, optimal medical treatment; TAA, 
thoracic aortic aneurysm; TEVAR, thoracic endovascular aortic repair. 
aClass of recommendation. 
bLevel of evidence. 
cBoth at the level of the treated segment and in the residual native aorta. 
dIncluding: endoleak (any type), enlargement of the excluded aneurysm, and stent graft 
migration/separation/fracture. 
ee.g. imaging every 6 months during the first year, thereafter every 2–3 years. 
fLow-risk: early sac shrinkage >10 mm, relatively younger age (<70 years), proximal and 
distal sealing >10 mm, no endoleak.


<!-- PAGE 82 -->

### Page 82

Acute aortic dissection occurs mostly in males (∼65%) and in the 
seventh decade of life (∼63 years).1175,1182 Multiple risk factors often 
coexist directly linked to factors like wall stress (with systemic hyper­
tension being the most common) and/or aortic media abnormalities, 
including syndromic and non-syndromic genetic diseases. HTAD, 
BAV, prior aortic surgery, and larger aortic dimensions are more fre­
quent among young patients (<40 years).24,1182,1183 Systemic hyperten­
sion and cocaine abuse are more common among African-American 
Classification of timing 
Frequency of acute aortic syndrome
Classification of acute aortic syndromes
DeBakey I 
Stanford A
Stanford B
DeBakey II 
DeBakey IIIa
DeBakey IIIb 
60%
10–15%
25–30%
Hyperacute
AAS
Time
Acute
AAS
Subacute
AAS
Chronic
AAS
AAS
onset
24 hours post-AAS
14 days post-AAS
90 days post-AAS
Figure 28 Anatomical and temporal classification of acute aortic syndrome. AAS, acute aortic syndrome.
ESC Guidelines                                                                                                                                                                                          3619


<!-- PAGE 83 -->

### Page 83

than among white patients.1184,1185 Of note, the incidence of iatrogenic 
AD during cardiac catheterization is very low (around 0.01%–0.02%) 
and during cardiac surgery is 0.06%–0.23%, with favourable in-hospital 
and long-term prognosis.1186,1187
9.3.1.1.1. Sex differences. A specific female sex phenotype appears to 
be evident in acute TAAD. At admission, acute TAAD female patients 
are usually older but have lower body mass index (BMI), BSA, and cre­
atinine plasma levels. They present less frequently with active smoking, 
Proximal extent
Distal extent
Type
AD
Entry tear:
Zone 0
0
1
2
3
4
5
6
7
8
9
10
11
12
0
1
2
3
4
5
6
7
8
9
10
11
12
BPD
Entry tear:
≥Zone 1
ID
Unidentified entry tear involving
Zone 0
Type
Entry
0
1
2
3
4
5
6
7
8
9
10
11
11
10
A
B
Non-A non-B
M0 - no malperfusion
M1 - coronary
M2 - supra-aortic
M3 - spinal, visceral, iliac
(-) no clinical symptoms
(+) clinical symptoms
E0
E1
E
E
E
E2
E3
E
E0
E3
E
E
E0
E3
E2
Malperfusion
T
E
M
TEM aortic dissection classification
Figure 29 Aortic dissection classification system based on the 2020 Society for Vascular Surgery/Society of Thoracic Surgeons Reporting Standards 
and the European update of the Stanford classification—Type Entry Malperfusion classification. A, type A aortic dissection; B, type B aortic dissection; 
non-A, non-B, aortic dissection limited to the aortic arch or retrograde dissection extending into the arch (but not in the ascending aorta). Upper panel: 
Classification of AAD considering the intimal tear’s entry site and dissection extension. Subscript P describes the proximal involved aorta, and subscript 
D indicates the distal zone. Lower panel: The TEM classification is the European update of the Stanford classification combining information about the 
Type of dissection (T), the Entry site (E), and the presence of Malperfusion (M). Also refer to Supplementary data online, Section 1.6. Society for Vascular 
Surgery/Society of Thoracic Surgeons (SVS/STS). Reproduced with permission from.136,1180


<!-- PAGE 84 -->

### Page 84

BAV, and previous cardiac surgery,1188 but diabetes mellitus is more 
common in women than in men. In-hospital surgical mortality does 
not differ between sexes, although 10 year survival appears to be higher 
in men. Among only medically treated acute TAAD patients, prohibitive 
high in-hospital mortality has been equally registered for both sexes 
(men 58.6% vs. women 53.8%).1188 However, further studies are 
needed to explore AAD sex differences to design appropriate diagnos­
tic and therapeutic interventions and preventive strategies.1189
Pregnancy increases the risk of AAS, more often in the last trimester 
(50%) or post-partum (33%).1190
9.3.1.1.2. Chronobiology. Acute aortic dissection presents chrono­
biological patterns, with a higher incidence in morning hours (peak be­
tween 8 am and 9 am) and winter (peak in January in the Northern 
Hemisphere).24,1175
9.3.1.1.3. Outcomes. For acute TAAD, in-hospital mortality has de­
creased from 31% to 22% due to better surgical outcomes; for acute 
type B aortic dissection (acute TBAD), in-hospital mortality has remained 
stable over the years (14%).1175,1182 Including deaths before admission, 30 
day mortality for AAD ranges from 23% to 55.8% in Western Europe.1181
D-dimer and chest X-Ray
D-dimer
Chest X-Ray
POCUS
High risk: ADD-RS ≥2
AAS confirmed
AAS excluded
+
+
+
–
Low risk: ADD-RS <2
Clinical suspicion of AAS: determine ADD-RSa
ECG: exclude STEMI (2023 ESC ACS Guidelines)
Chest X-Ray and laboratory test and POCUS (if available)
Consider alternative diagnosis
CCT neck-pelvis without delay and/or focused TTEa + ECG
CCT
Aortic dissection detection-risk score (ADD-RS)a
High-risk examination feature
High-risk pain feature
High-risk condition
If one present = 1 ADD-RS point
If present = 1 ADD-RS point
If one present = 1 ADD-RS point
Marfan syndrome
Family history of aortic disease
Known aortic valve disease
Recent aortic manipulation
Known aortic aneurysm
Haemodynamic instability
(hypotension/shock)
Perfusion deficit (pulse deficit,
differential systolic blood pressure)
Focal neurological deficit
New AR murmur
Chest, back, or abdominal pain described as abrupt onset,  severe intensity, or ripping/tearing
+
–
Figure 30 Multiparametric diagnostic work-up of acute aortic syndrome. AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk 
score; CCT, cardiovascular computed tomography; ECG, electrocardiogram; POCUS, point-of-care ultrasound; STEMI, ST elevation myocardial infarc­
tion; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; +, findings compatible with AAS. aIn haemodynamically unstable 
patients: consider TTE and/or TOE as first-line imaging technique depending on local expertise and availability.
ESC Guidelines                                                                                                                                                                                          3621


<!-- PAGE 85 -->

### Page 85

Non-A, non-B dissection patients tend to be younger (median age 59 
years) and have a lower mortality than acute TAAD patients.1180,1191
The 30 day mortality in patients medically treated is around 14%,1179
and 4.4% for those successfully treated surgically.1177
9.3.1.2. Clinical presentation
Acute TAAD typically presents with sudden, severe chest/back pain, 
often described as ‘sharp’, alongside a history of arterial hypertension. 
However, around 6.4% of patients do not experience pain.1182,1192,1193
Hypotension and shock are frequent. Unique clinical features specific to 
acute TAAD include pericardial effusion, aortic regurgitation, and cor­
onary artery involvement leading to ACS (particularly the right coron­
ary artery).1194 Stroke may occur when supra-aortic branches are 
involved. Additional complications encompass paraplegia (resulting 
from spinal ischaemia), acute kidney injury, intestinal ischaemia, or 
limb ischaemia. Isolated abdominal aortic dissection occurs in about 
1.3% of acute TBAD cases when the intimal flap originates below or 
at the renal arteries.1195
A complete clinical evaluation is mandatory, consisting of a central 
neurological evaluation, heart and lung auscultation (aortic diastolic 
murmur, pericardial rubbing, etc.), abdominal palpation (tenderness, 
etc.), and assessment of peripheral pulsations as well as mobility and 
sensibility in upper and lower limbs. SBP differences (pulse deficit) 
should be sought.
9.3.1.3. Diagnostic work-up
Early diagnosis is still a major pitfall in managing AAD patients, there­
fore, a diagnostic multiparametric algorithm is proposed (Figure 30). 
It combines the aortic dissection detection-risk score (ADD-RS) with 
D-dimer (DD) and has been validated with an excellent capacity to 
rule out AAS.1196–1200
In patients presenting with chest pain, a routine chest radiography 
and ECG are recommended to exclude other aetiologies; however, 
the absence of these findings should not delay further investigations.163
Laboratory tests should be obtained, but awaiting results should not 
delay imaging if there is a high probability of AAD. The most common 
finding is an increase in DD level, which is the case in several other con­
ditions such as pulmonary embolism or infections. When DD levels are 
below 500 ng/mL, AAD is unlikely.172,1201
A focused TTE at the emergency department, if available, is recom­
mended1202,1203 to assess pericardial effusion, wall motion abnormal­
ities, aortic regurgitation, and aortic diameters. Sometimes a 
dissection flap can be visualized, especially when using contrast.165
When AAD is suspected, ECG-gated CCT from neck to pelvis is the 
preferred imaging technique, with 100% sensitivity and 98% specificity, 
and should be performed as soon as possible to confirm diagnosis, lo­
calize entry tear, extension (type A vs. type B), and malperfu­
sion.170,172,1182,1204 When ACS or pulmonary embolism are still in 
the differential diagnosis, a triple rule-out ECG-gated CCT scan proto­
col can be performed be performed to avoid motion artefacts mimick­
ing acute TAAD.170,1205,1206 However, this strategy is associated with 
higher contrast and radiation doses, might be less accurate for AAS, 
and does not reduce the need for additional imaging tests.170,1207 If 
CCT is not available or in haemodynamically unstable patients, TOE 
can confirm diagnosis. TOE is especially useful pre-, intra, and post- 
operatively to monitor changes in the anatomical AAD configuration 
or surgical complications. CMR could be a valuable alternative for 
CCT, however, it is less available, requires a longer examination time, 
relies on patient collaboration, and consequently, is less frequently 
used in the acute setting. CCT, CMR, and TOE all provide good diagnos­
tic accuracy172,1204 (See Supplementary data online, Table S4).
9.3.1.4. Therapeutic intervention in acute aortic dissection
9.3.1.4.1. Initial treatment. Acute aortic syndrome care should be 
centralized in experienced centres and managed by aorta teams.1211
The cornerstone in AAS is initial reduction of the pulse pressure by low­
ering SBP below 120 mmHg and heart rhythm ≤60 beats per minute 
(b.p.m.). The aim is to decrease aortic wall stress to avoid further exten­
sion of dissection with possible rupture or malperfusion.174,1212–1216
Intravenous beta blockade (labetalol as a first choice due to its alpha- 
and beta-blocking properties) is generally accepted as the best option. 
Also, esmolol, an ultra-short-acting beta-blocker, can be titrated quickly 
and easily, making it particularly useful in the acute setting. If contraindi­
cated, i.v. non-dihydropyridine CCBs could be used for heart rate control. 
If the BP target is not reached after initiating beta-blockers, i.v. vasodilators 
such as nitrates or dihydropyridine CCBs (e.g. nicardipine) can be adminis­
tered concomitantly with rate-controlling agents first to avoid reflex 
tachycardia. In cases of malperfusion, higher BP could be tolerated to op­
timize perfusion to the threatened region. Early placement of an arterial 
line to monitor BP invasively is mandatory and admission to an intensive 
care unit is advisable (including ECG and urine output monitor­
ing).1205,1217,1218 Antihypertensive treatment can be gradually switched 
to oral therapy once BP and heart rate targets are reached and the patient 
has normal gastrointestinal transit. Adequate pain control is necessary to 
help reach these haemodynamic goals. Intravenous morphine can be cau­
tiously titrated to induce pain relief (Figure 31).
In-hospital mortality, reaching 60%, correlates with AAS type, loca­
tion, patient comorbidities, and treatment. Risk rises with complications 
like pericardial tamponade, coronary involvement, or malperfusion. 
Figure 32 describes the main signs and symptoms of complications and 
the mortality rate associated with them.1219–1223
Recommendation Table 44 — Recommendations for 
diagnostic work-up of acute aortic syndromes
Recommendations
Classa
Levelb
In unstable patients who cannot be transferred to CCT, 
TOE is recommended for diagnosis1204,1208,1209 and 
evaluation of the coeliac trunk and mesenteric artery.1210
I
B
In patients presenting with clinical features compatible 
with possible AAS, a multiparametric algorithm for 
ruling in or out AAS using the ADD-RS is 
recommended.1196–1200
I
B
ECG-gated CCT from neck to pelvis is recommended 
as the first-line imaging technique in patients with a 
suspected AAS since it is widely available, accurate, 
and provides information about the entry tear, 
extension, and possible complications (malperfusion, 
dilatation, or rupture).170
I
C
In patients with suspected AAS, focused TTE (with 
use of contrast if feasible) is recommended during the 
initial evaluation.170
I
C
In patients with suspected AAS, TOE is 
recommended to guide peri-operative management 
and detect complications.170
I
C
In patients with suspected AAS, CMR should be 
considered as an alternative imaging technique if CCT 
is not available.170
IIa
C
© ESC 2024
AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk score; CCT, 
cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; ECG, 
electrocardiogram; TOE, transoesophageal echocardiography; TTE, transthoracic 
echocardiography. 
See also Figure 30. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 86 -->

### Page 86

Interventional treatment in acute TAAD and acute TBAD is de­
scribed in the next sections and summarized in Figure 33.
9.3.1.4.2. Type A aortic dissection interventional treatment.
Immediate surgical repair is recommended for acute TAAD, however, 
a high mortality rate (∼50% and 1%–2% per hour) within the first 48 h 
is described if managed medically only.1232 Despite advances in surgi­
cal and anaesthetic techniques, there is still a high risk of peri- 
operative mortality (17%–25%) and neurological complications 
(18%).1233 In recent reports from the International Registry of 
Acute Aortic Dissection (IRAD), medically managed patients had a 
23.7% mortality rate (0.5% per hour) compared with 4.4% (0.09% 
per hour) for those undergoing surgery.1234 Analyses of pre- and 
post-July 2007 IRAD data showed no difference in 48 h mortality 
for medically treated patients, but surgical mortality decreased 
(from 5.5% to 3.9%).1234 As surgical techniques have improved, data 
have shown improved post-operative survival rates.1235 The use of 
the GERAADA (German Registry of Acute Aortic Dissection Type 
A) score1236 should be considered in patients undergoing surgery to 
determine 30 day mortality (https://www.dgthg.de/de/GERAADA_ 
Score).
Surgical intervention surpasses conservative therapy in long-term 
follow-up,1237 even for challenging cases. Thus, all acute TAAD pa­
tients should receive surgical treatment; however, cardiogenic shock 
secondary to pericardial tamponade, malperfusion of coronary arter­
ies, mesenteric circulation, lower extremities, kidneys, or brain, and/ 
or coma are major predictors for post-operative mortality 
(Figure 32).1234,1238 Among octogenarians, in-hospital mortality 
was lower after surgery than with conservative treatment 
(37.9% vs. 55.2%), but with a non-significant difference due to small 
sample size.1239 While some have reported excellent surgical and 
quality of life (QoL) outcomes in elderly patients,1239 others found 
(Class I)
(Class I)
(Class I)
+
1
2
3
Intravenous labetalol or esmolol
(if contraindication to beta-blockade,
substitute with diltiazem or verapamil)
Titrate to heart rate ≤60 b.p.m.
Intravenous opiates
Titrate to pain control
Intravenous vasodilator (nitroprusside or angiotensin-converting enzyme inhibitor)
(Goal is lowest possible BP that maintains adequate organ perfusion)
Continue to step 3
if systolic
BP ≥ 120mmHg
Titrate to BP <120 mmHg
Rate/pressure control
Pain control
Pressure control
Figure 31 Medical management of acute aortic syndrome. BP, blood pressure; b.p.m: beats per minute.
Recommendation Table 45 — Recommendation for 
medical treatment in acute aortic syndromes
Recommendations
Classa
Levelb
In patients with AAS, immediate anti-impulse 
treatment targeting SBP <120 mmHg and heart rate 
≤60 b.p.m. is recommended. In cases of spinal 
ischaemia or concomitant brain injury, maintaining 
higher MAP is recommended.1214–1216
I
B
Intravenous BBs (e.g. labetalol or esmolol) are 
recommended as first-line agents. If necessary, i.v. 
vasodilators (e.g. dihydropyridine calcium blockers or 
nitrates) could be added.174,1224
I
B
Invasive monitoring with an arterial line and continuous 
three-lead ECG recording, as well as admission to an 
intensive care unit, is recommended.1205,1217,1218,1225
I
B
In patients with AAS who can be managed 
conservatively and who achieved haemodynamic 
targets with i.v. anti-impulse therapy, switching to 
oral BBs and, if necessary, up-titration of other 
BP-lowering agents, is recommended after 24 h if 
gastrointestinal transit is preserved.174,1216
I
B
Adequate pain control to achieve haemodynamic 
targets is recommended.174
I
C
If the patient has a contraindication for BBs, a 
non-dihydropyridine calcium blocker should be 
considered.174,1224
IIa
B
© ESC 2024
AAS, acute aortic syndrome; BB, beta-blocker; BP, blood pressure; b.p.m., beats per minute; ECG, 
electrocardiogram; i.v., intravenous; MAP, mean arterial pressure; SBP, systolic blood 
pressure. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3623


<!-- PAGE 87 -->

### Page 87

a higher rate of post-operative neurological complications.1240 Based 
on the current evidence, age per se should not be considered an ex­
clusion criterion for surgery.
For optimal repair of acute TAAD regarding long-term outcomes, 
including risk of late death and late re-operation, the following points 
need to be addressed. First, in most cases of aortic regurgitation as­
sociated with acute TAAD, the aortic valve is essentially normal and 
can be preserved.1241–1243 Alternatively, valve replacement can be 
performed in cases of pre-existent structural valve disease. The de­
cision whether to replace the aortic root is based on the presence of 
tears in the sinuses, extensive dissection of sinuses/coronary ostia, 
or significant dilatation of the root. The risk of late dilatation of 
the aortic sinuses when spared should be considered.1242,1244
Additionally, the distal extent of aortic repair is a topic of debate. 
Ascending aortic replacement or hemi-arch replacement alone is technic­
ally easier and effectively closes the entry site but leaves a large part of the 
diseased aorta untreated. In acute TAAD with visceral or renal malperfu­
sion, the primary entry tear is often in the descending aorta. Consider ex­
tended therapies like FET repair for these patients, offering a complete 
repair with a low chance of late re-intervention despite increased tech­
nical complexity.1245–1247
For potential cardiac arrest from pericardial tamponade, consider an 
emergency pericardial puncture as a temporary life-saving measure be­
fore transferring to the operating room.1248,1249
The frozen elephant trunk technique
The FET technique addresses complex aortic and aortic arch 
issues in a single operation,1260–1263 creating a secure landing zone 
for future interventions. Recent advances involve ‘proximalization’— 
placing the FET in the aortic arch’s zone 0 or 1, treating proximal 
arch aortic issues, and enhancing the landing zone for downstream 
procedures—which surpasses the standard elephant trunk 
technique.1264,1265
Malperfusion in type A aortic dissection
In acute TAAD with malperfusion, operative mortality correlates 
with the number of affected organs. Around 30% of patients develop 
malperfusion syndrome due to elevated pressure in the FL caused by 
substantial proximal inflow and insufficient distal outflow, leading to 
visceral organ and limb ischaemia.1175 The intimal flap may extend 
into peripheral arteries, causing a static ‘stenosis-like’ blockage. 
Malperfusion typically combines dynamic and static obstructions, ne­
cessitating surgical and hybrid interventions for affected patients 
(Figure 34).
Mesenteric malperfusion, a life-threatening complication with a 
mortality rate of 65%–95%, leads to diverse treatment approaches. 
Some centres prefer early direct reperfusion before aortic surgery, 
Recommendation Table 46 — Recommendations for 
intervention in type A acute aortic dissection
Recommendations
Classa
Levelb
In patients with acute TAAD, emergency 
surgical consultation and evaluation 
and immediate surgical intervention 
is recommended.1182,1250
I
B
In patients with acute TAAD who have 
extensive destruction of the aortic root, a 
root aneurysm, or a known genetic aortic 
disorder, aortic root replacement is 
recommended with a mechanical or 
biological valved conduit.1251–1255
I
B
In patients presenting with acute TAAD, transfer 
from a low- to a high-volume aortic centre with the 
presence of a multidisciplinary team should be 
considered to improve survival if transfer can be 
accomplished without significant delay in 
surgery.1256,1257
IIa
B
In selected patients, a valve-sparing root repair may 
be considered, when performed by experienced 
surgeons.1251,1258,1259
IIb
B
© ESC 2024
TAAD, type A aortic dissection. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 47 — Recommendations for 
aortic repair strategies in type A acute aortic dissection
Recommendations
Classa
Levelb
In patients with acute TAAD and a partially dissected 
aortic root but no significant aortic valve leaflet 
pathology, aortic valve resuspension is 
recommended over valve replacement.1251–1255
I
B
In patients with acute TAAD undergoing aortic 
repair, an open distal anastomosis is recommended 
to improve survival and increase FL thrombosis rates. 
1266–1269
I
B
In patients with acute TAAD without an intimal tear 
in the arch or a significant arch aneurysm, hemi-arch 
repair is recommended over more extensive arch 
replacement.1270–1272
I
B
In patients with acute TAAD and a secondary intimal 
tear in the arch or proximal DTA, an extended aortic 
repair with stenting of the proximal DTA (e.g. by 
using the frozen elephant trunk technique) may be 
considered to reduce late distal aortic complications 
(e.g. aneurysm evolution of the remaining dissected 
descending aorta).1273,1274
IIb
C
© ESC 2024
DTA, descending thoracic aorta; FL, false lumen; TAAD, type A aortic dissection. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 88 -->

### Page 88

while others favour conventional central aortic repair.1275
The IRAD registry highlights the superiority of a surgical and hybrid 
approach over medical or endovascular therapy alone. Central aor­
tic repair effectively restores perfusion, showing promising results 
for renal malperfusion, extremity malperfusion, uncomplicated 
mesenteric malperfusion, or combinations.
Cerebral malperfusion, equally grave, triggers treatment debates ne­
cessitating a multidisciplinary strategy. Evidence supports surgical 
Hypotension/shock
Cardiogenic shock related to:
Tamponade (pulsus paradoxus)
Aortic regurgitation (diastolic murmur)
Major coronary occlusion by compression or dissection flap
Hypovolaemic shock (aortic rupture)
Branch vessel involvement
Bowel ischaemia
Lactic acidosis
Elevation liver function test
Hemiplegia, hemiparesis or paraplegia
Stroke, coma or altered mental status
Acute kidney injury or oliguria
Peri-aortic haematoma
Mortality
56%
28.6%
10.5%
4.4% 
N
N
N
Y
Y
Y
Figure 32 Complications in acute aortic syndromes, clinical evidence associated with malperfusion syndrome, and in-hospital mortality associated 
with these complications.
ESC Guidelines                                                                                                                                                                                          3625


<!-- PAGE 89 -->

### Page 89

Initial diagnosis based on CCT
Type A AAD
Type B AAD
Favourable TEVAR anatomyc
Favourable TEVAR anatomyc
 + life expectancy >5 years
OMT + surveillance
Complicated type B AAD
Uncomplicated type B AAD
Open cardiac surgery
(Class I)
Endovascular repair
(Class I)
Open surgical repair
(Class I)
Endovascular repair in the subacute phased
(Class IIa) 
OMT + more frequent surveillance
One of the following:
Contained or free aortic rupture
Organ malperfusion
Extension of the dissectionª
Progressive aortic enlargementª
One of the following:
High-risk features at CCT or CMR
Ao diameter >40 mm
FL diameter >20–22 mm
Entry tear >10 mm
Entry tear at lesser curvature
Haemorrhagic pleural effusion
Evidence of malperfusion
High-risk clinical features
Refractory hypertensionb
Refractory pain >12 h
Need for readmission
   Total Ao diameter >5 mmª
Y
N
Y
N
Y
N
Y
N
Reappearance of pain/symptoms
Figure 33 Interventional treatment algorithm in acute aortic dissection. AAD, acute aortic dissection; Ao, aorta; CCT, cardiovascular computed tom­
ography; OMT, optimal medical treatment; TEVAR, thoracic endovascular aortic repair. aOn serial imaging in the acute phase during the hospital stay. 
bOngoing hypertension despite more than three classes of antihypertensive drugs. cDefined as the presence of adequate proximal and distal landing 
zones for the prosthesis and adequate iliac/femoral vessels for vascular access. dBetween 14 and 90 days after dissection onset.172,1226–1231


<!-- PAGE 90 -->

### Page 90

(Class I)
(Class IIa)
(Class IIa)
(Class I)
Acute type A aortic dissection
Acute type B aortic dissection
Check for presence of acute type A aortic dissection complications
Aortic rupture or CPR
Tamponade
Consider pericardial drainage
Cerebral malperfusion or stroke
Mesenteric malperfusion
Lower extremity malperfusion
Invasive diagnostics  and/or percutaneous malperfusion repair or TEVAR/EVAR
If not performed before aortic surgery and malperfusion persists, optional angiographic control and/or percutaneous malperfusion repair/TEVAR/EVAR
Direct admission to hybrid-OR with onsite aortic team
Anaesthesiological monitoring and intraoperative TOE (if feasible) and preparation for surgery
Immediate aortic surgery (ascending and consider aortic arch or FET based on extension)
Angiographic control and/or percutaneous malperfusion repair or TEVAR or EVAR
Check for presence of acute type B aortic dissection complications
If malperfusion persists
Aortic rupture/
tamponadea
Cerebral 
malperfusion/strokea
Mesenteric malperfusion
Lower extremity malperfusion
TEVAR or EVAR and/or percutaneous malperfusion repair
Static thrombus thrombus
Dynamic
Static + dynamic
F
T
thrombus
Consider pericardial drainage
In case of retrograde aortic dissection, immediate aortic surgery (ascending aorta, aortic arch or
FET, based on extension)
Consider extra-anatomic bypass if lower extremity malperfusion persists
Figure 34 Mechanisms and clinical management of aortic branch obstruction in acute aortic dissection. CPR, cardiopulmonary resuscitation; F, false 
lumen; FET, frozen elephant trunk; OR, operating room; T, true lumen; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular 
aortic aneurysm repair. aDevelops only in retrograde type A dissection.
ESC Guidelines                                                                                                                                                                                          3627


<!-- PAGE 91 -->

### Page 91

intervention, reducing mortality rates to 25%–27%, compared with 
76% with medical management alone.1255,1276 Close monitoring and ra­
pid intervention are essential to achieve optimal outcomes and minim­
ize the risk of permanent neurological damage. A recommended 
algorithm for malperfusion management is displayed in Figure 34.
Endovascular treatment in type A aortic dissection
Endovascular therapy alone has been attempted in highly selected 
cases and the concept of a single endovascular valve-carrying conduit 
was suggested recently but has not yet been validated.1281,1282
Treatment in non-A non-B aortic dissection
Conservative management leads to high mortality (malperfusion, 
aortic rupture); thus, surgery or endovascular therapy is favoured 
within 14 days of symptom onset. For complicated non-A non-B 
aortic dissection with an arch tear, consider FET repair, though if 
feasible, stent-graft implantation for primary tear coverage is an 
alternative.1179,1283
9.3.1.4.3. Acute type B aortic dissection interventional treatment.
Acute TBAD presents without complications (uncomplicated) in 
around 50% of cases.1250 Complicated acute TBAD includes aortic rup­
ture, malperfusion-related issues, rapid aortic expansion, paraplegia/ 
paraparesis, aortic haematoma, refractory pain, and hypertension des­
pite optimal therapy, which associates with an approximately 50% mor­
tality risk with conservative treatment.1193,1250,1284,1285
Open surgery used to be the sole option for complicated acute 
TBAD but carried a mortality rate of 25%–50%. Consequently, 
medical management, now considered the standard for uncompli­
cated cases, significantly reduces mortality. Goals include lowering 
SBP and heart rate with BBs (see Section 9.3.1.4.1). However, adher­
ence is the main limitation of chronic medical treatment, with a rate 
below 50%.1286,1287 Compliance increases with previous aortic sur­
gery, severity of hypertension, and understanding of the disease pro­
cess. Thus, surveillance and disease awareness are imperative for 
these patients.
Endovascular therapy for complicated acute TBAD is now the first- 
line treatment, provided there is favourable anatomy, due to positive 
short- and long-term outcomes.1288–1294 Open surgery is reserved 
for unsuitable cases, and fenestration could be considered as an ultima 
ratio. In selected instances, correcting side branch compression before 
proximal sealing may be considered.136
In recent years, the ADSORB (Acute Dissection Stentgraft OR Best 
Medical Treatment) and INSTEAD-XL (Investigation of Stent Grafts in 
Aortic Dissection with extended length of follow-up) trials1219,1226,1295
have reported that early intervention for uncomplicated acute and sub­
acute TBAD is beneficial compared with medical management, and there 
is important debate on whether to treat patients with uncomplicated 
acute TBAD to improve their life expectancy.1296–1298 Intervention is con­
sidered early within 90 days after onset of symptoms and may be safer 
when performed in the subacute phase (>14 days after onset of symp­
toms), but data are scarce.1298–1300 The Society of Thoracic Surgeons/ 
American Association for Thoracic Surgery (STS/AATS) 2022 
guidelines1294 state that prophylactic TEVAR may be considered also in pa­
tients with suitable anatomy and high-risk features (Figure 33) to reduce 
late aortic-related adverse events. However, this matter is not entirely 
settled, and the Improving outcomes in vascular disease—aortic dissection 
(IMPROVE-AD trial) is currently underway. This trial aims to evaluate clin­
ical outcomes in patients with subacute (from 48 h to 6 weeks) uncompli­
cated type B aortic dissection (uTBAD), comparing upfront TEVAR plus 
medical therapy against medical therapy with surveillance for deterioration.
Aortic characteristics change over time, and endovascular treatment in 
the chronic phase offers limited potential for aortic remodelling. 
Identifying specific characteristics at the time of acute TBAD diagnosis 
that predict a complicated course has been attempted. Independent pre­
dictors of TBAD outcomes include a primary entry tear >10 mm located 
at the inner aortic curvature,1301 initial aortic diameter >40 mm,1301,1302
initial FL diameter >20 mm,1301 number/size of fenestrations between the 
true lumen and FL,1303 stent graft-induced new entry tear,1304,1305 and 
partial FL thrombosis.1306,1307 These parameters are summarized in a 
new system for the categorization of AD, DISSECT (Duration from onset 
of symptoms, Intimal tear location, Size of the aorta based on maximum 
trans-aortic diameter, Segmental Extent, Clinical complications related to 
the dissection, Thrombosis of the FL),1308 which serves as a guide to sup­
port a therapeutic decision (Figure 33).1308 A recent meta-analysis found 
TEVAR to be superior to best medical therapy in uncomplicated acute 
TBAD. Early outcomes were similar, but TEVAR was associated with few­
er long-term events and better aortic remodelling.1297,1298,1309 Thus, in 
stable TBAD with suitable anatomy and high-risk features, pre-emptive 
TEVAR to improve the late outcome should be considered.
Accurate endograft sizing is vital for TEVAR success, as errors may lead 
to complications. Disease-specific factors, such as acute thoracic aortic 
syndromes, pose challenges due to fluctuations in aorta diameter from 
haemorrhagic shock and resuscitation. Sizing decisions must account 
for these changes. Measuring the thoracic aorta based on admission 
CCT may be imprecise, even with proper centreline measurements. 
Real-time imaging, especially IVUS, enhances accuracy, particularly in 
hypovolaemic cases. However, further research is required to clarify 
the role of intraoperative imaging methods (e.g. IVUS, TOE, 3D CCT) 
in endograft sizing and long-term outcomes for optimal patient care.194
Recommendation Table 48 — Recommendations for 
the management of malperfusion in the setting of acute 
aortic dissection
Recommendations
Classa
Levelb
In patients with acute TAAD presenting with 
malperfusion (cerebral, mesenteric, lower limb, or 
renal), immediate aortic surgery is 
recommended.1275,1277
I
B
In patients with acute TAAD presenting with 
cerebral malperfusion or non-haemorrhagic stroke, 
immediate aortic surgery should be considered to 
improve neurological outcome and reduce 
mortality.1255,1276,1278
IIa
B
In patients with acute TAAD presenting with clinically 
significant mesenteric malperfusion syndrome, 
immediate invasive angiographic diagnostics to evaluate 
percutaneous malperfusion repair before or directly 
after aortic surgery, in aortic centres with expertise, 
should be considered.1278–1280
IIa
C
© ESC 2024
TAAD, type A aortic dissection. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 92 -->

### Page 92

9.3.1.4.4. Chronic type B aortic dissection interventional treatment.
Type B aortic dissection is considered as chronic 3 months after the onset 
of symptoms, but it also includes residual type B dissection after repair of 
TAAD. Aortic complications, especially aneurysmal degeneration, will oc­
cur in up to 50% of these patients.1302,1313 Therefore, in chronic TBAD, 
indications for treatment include the onset of new aortic symptoms such 
as rapid expansion, malperfusion, or rupture.1314 In asymptomatic pa­
tients, aneurysmal dilatation is the most important risk factor for rupture, 
reaching 20% when the diameter exceeds 55 mm.1302,1315 Risk of rupture 
increases with diameter; it has been reported a risk of 15.3% and 18.8% 
between 50–55 mm and 54–56 mm, respectively, thus suggesting 
50–55 mm as a threshold for elective surgery.1316 However, smaller 
diameters should be considered in patients with HTAD. According to sev­
eral studies, mortality in the chronic phase is high (40%–70%) and it is 
mainly related to patients’ comorbidities, such as heart disease and stroke.
Open repair
Despite the lack of data comparing open repair vs. TEVAR in chronic 
TBAD, open surgery remains the first-line treatment in low-risk pa­
tients or those with HTAD. The STS/AATS guidelines1294 state that 
open repair should be considered in chronic TBAD patients with indi­
cation for intervention, unless comorbidities are prohibitive or anatomy 
is not suitable for TEVAR. The surgical technique for chronic TBAD is 
like those for degenerative aneurysms, but repair is more complex due 
to the dissection flap.1317 Surgical mortality rates between 6% and 11% 
and SCI rates between 3% and 11% have been reported.1317–1321
Patients treated in low-volume centres present higher mortality rates 
(up to 20%), which reinforces the recommendation for centralization 
in experienced centres.
Endovascular repair
Thoracic endovascular aortic aneurysm repair (TEVAR) is the pre­
ferred treatment for eligible chronic TBAD patients, offering low early 
mortality (<5%), with stroke and SCI rates below 3%. It is also suitable 
for high-risk patients who are not candidates for open repair. The pri­
mary goal is to close the entry tear, induce FL thrombosis, and promote 
aortic remodelling to mitigate growth and rupture risk.1322,1323 A sys­
tematic review showed 90% immediate technical success and 86% 
complete FL thrombosis. However, FL thrombosis usually occurs 
above the coeliac trunk, necessitating lifelong distal FL surveillance.1324
Coverage of the LSA is often necessary and should be associated with 
revascularization. In a recent meta-analysis1325 comparing TEVAR to 
open repair in chronic TBAD, TEVAR showed lower early mortality, 
stroke rates, SCI, and respiratory complications but a higher re- 
intervention rate. Long-term survival rates were similar, but open re­
pair offered greater durability.1326
Adequate distal sealing poses a challenge due to the dissection extend­
ing to the iliac artery, with additional re-entries, allowing retrograde flow 
into the thoracic aneurysm. In chronic TBAD patients with AA enlarge­
ment, insufficient distal landing, or large re-entry tears, TEVAR alone is 
discouraged. Instead, a comprehensive repair involving the visceral aorta, 
infra-renal aorta, and iliac artery is needed. Recent studies have shown 
favourable results using custom or improvized fenestrated/branched en­
dografts with careful patient selection.1062,1327–1329 A multidisciplinary 
team-based approach in experienced centres is necessary for good 
outcomes.1330
9.3.1.4.5. Management during pregnancy. Management of AD dur­
ing pregnancy requires a multidisciplinary team and specialized centres. 
Initial care should consider general medical recommendations (as pre­
viously described), using drugs with the lowest teratogenic impact.
In cases of type A dissection, if the foetus is viable, caesarean delivery 
will be performed before aortic repair. If the foetus is not viable, surgery 
will be done with the foetus in place.1335,1336 In uncomplicated type B 
Recommendation Table 49 — Recommendations for 
the management of patients presenting with acute 
type B aortic dissection
Recommendations
Classa
Levelb
Medical therapy including pain relief and blood 
pressure control is recommended in all patients with 
acute TBAD.1215,1219,1310,1311
I
B
In patients with complicated acute TBAD, 
emergency intervention is 
recommended.1193,1250,1284,1285,1288,1289,1291–1293
I
B
In patients with complicated acute TBAD, TEVAR is 
recommended as the first-line therapy.c,910,1288–1293
I
B
In patients with acute TBAD, BBs should be 
considered as the first-line medical therapy.1216,1312
IIa
B
In patients with uncomplicated acute TBAD, TEVAR 
in the subacute phase (between 14 and 90 days) 
should be considered in selected patients with 
high-risk featuresd to prevent aortic 
complications.1219,1226,1295,1297,1298,1308,1309
IIa
B
© ESC 2024
BBs, beta-blockers; HTAD, heritable thoracic aortic disease; TBAD, type B aortic 
dissection; TEVAR, thoracic endovascular aortic repair. 
See also Figure 33. 
aClass of recommendation. 
bLevel of evidence. 
cExcept in patients with known or suspected HTAD. 
dFor high-risk features see Figure 33.
Recommendation Table 50 — Recommendations for 
the management of patients presenting with chronic 
type B aortic dissection
Recommendations
Classa
Levelb
Antihypertensive therapy is recommended in all 
patients with chronic TBAD.1331–1333
I
B
In chronic TBAD with acute symptoms of 
malperfusion, rupture, or progression of disease, 
emergency intervention is 
recommended.1302,1313,1314
I
C
In patients with chronic TBAD and a descending 
thoracic aortic diameter ≥60 mm, treatment is 
recommended in patients at reasonable surgical 
risk.1302,1315,1334
I
B
In patients with chronic TBAD and a descending 
thoracic aortic diameter ≥55 mm, an indication for 
intervention should be considered in patients with 
low procedural risk.1302,1316
IIa
C
In patients with chronic post-dissection 
thoracoabdominal aortic aneurysms, the use of 
fenestrated/branched stent grafts may be considered, 
when treatment is indicated.1062,1327–1329
IIb
C
© ESC 2024
TBAD, type B aortic dissection. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3629


<!-- PAGE 93 -->

### Page 93

dissections, strict control of the pregnant patient and foetus with con­
servative medical management is recommended.1224,1335 Although lim­
ited to selected cases, successful TEVAR has been described in 
complicated TBAD.1227 More information is detailed in the 2018 ESC 
Guidelines for the management of cardiovascular diseases during 
pregnancy.1337
9.3.2. Intramural haematoma
Intramural haematoma, constituting 5%–25% of AAS cases, involves 
vasa vasorum haemorrhage within the aortic media, with or without in­
timal disruption (ID).70,172,1338 Most cases (60%–70%) involve the DTA 
(ascending aorta ∼30%, aortic arch ∼10%).70,172,1192 Although it usually 
occurs at an older age than AAD, risk factors and symptoms are simi­
lar;70,172,1192,1338 however, aortic regurgitation, malperfusion syn­
drome, and pulse deficits are less frequent in type A IMH than in 
TAAD.70,172
9.3.2.1. Diagnostic work-up
Diagnostic IMH work-up should be similar to that proposed for AAS 
(Figure 30), but with different morphological features in the imaging 
techniques.
CCT and CMR (followed by TOE) are the leading techniques for 
diagnosis.70,159,171–173 Unenhanced followed by contrast-enhanced 
CCT represents the most used tool in the acute setting (hyperin­
tense signal of aortic wall before contrast administration).70,171,172
The IMH diagnostic hallmark consists of crescentic or circular aortic 
wall thickening in the absence of an intimal flap or aortic wall en­
hancement following contrast administration.70,171,172 CMR is an ex­
cellent imaging technique to detect small IMHs and for the 
differentiation of IMH (hyperenhanced images in T1-weighted 
images) from atherosclerotic thickening of the aorta, thrombus, or 
thrombosed dissection.172 TTE yields low sensitivity (<40% for 
IMH cut-off limit of 5 mm).171
9.3.2.2. Clinical outcomes
Intramural haematoma may evolve into AAD (12% of patients), saccu­
lar (8%) or fusiform aneurysm (22%), and/or ID (54%).1192,1339–1342
Partial or total regression is reported in 34% of patients.70,1192,1343
Outcomes are comparable to those in AAD. In-hospital mortality for 
type A IMH is 26.6% (surgical 24.1% and medical 40.0%). In this regard, 
higher mortality for IMH involving the aortic valvular complex has been 
observed.1175 In-hospital mortality for type B IMH is 4.4% but worsens 
once surgery is indicated (surgical 20.0% vs. medical 3.8%).1175,1344
9.3.2.3. Geographical variations
Reports from South Korea and Japan reveal notable disparities with 
Western nations in IMH incidence (28.9% vs. 5.7% of overall AAD as 
reported by IRAD), treatment strategies, and outcomes. In Eastern 
regions, the majority (80.8%) of type A IMH patients received med­
ical treatment, resulting in significantly improved clinical outcomes 
(in-hospital mortality 6.6% [5.9% for medical and 9.4% for surgi­
cal]).1345 These results may be partially explained by the detection 
of early-stage IMH (mild, uncomplicated cases) at primary cen­
tres.1345–1347
9.3.2.4. Management
Current IMH therapeutic interventions are similar to AAD, with the 
first step consisting mainly of pain and BP control regardless of the ana­
tomopathological features (Figure 31).
9.3.2.4.1. Type A intramural haematoma. As in AAD, type A IMH 
involves the ascending aorta. Surgery (emergency or urgent depend­
ing on clinical status) is recommended. In selected patients with in­
creased operative risk (i.e. multiple comorbidities) and uncomplicated 
type A IMH without high-risk imaging features (Table 16) a 
‘wait-and-see strategy’ in a reference/experienced centre may be 
reasonable.70,172,1348,1349
9.3.2.4.2. Type B intramural haematoma. In type B IMH, the disease 
is in the descending aorta, distal to the left subclavian artery. For un­
complicated type B IMH, initial management involves medical treat­
ment and thorough clinical and imaging monitoring.70,172
If 
uncomplicated type B IMH presents high-risk imaging characteristics 
(see Table 16), the multidisciplinary team should consider endovascu­
lar repair as an option. In contrast, complicated type B IMH warrants 
consideration of TEVAR.1350,1351 However, in unfavourable anat­
omy, open surgery remains an alternative.
ID has been described in 54% of type B IMH cases.1192,1339–1342
Approximately 28% of them are tiny intimal disruptions (≤3 mm) 
that are not related to AAEs. However, 14% of them evolve into focal 
intimal disruptions (FID) (>3 mm), with prognostic implications; thus, 
all patients with ID require close follow-up with imaging techniques. 
In the acute phase, FID has a poor prognosis owing to the high risk 
of aortic rupture and should be treated early and invasively, especially 
large FID (≥10 mm length and ≥5 mm depth).1342,1352 However, in 
the chronic phase, most FIDs evolve with slow aortic dilatation and 
without complications, and they can be managed with medical treat­
ment and close imaging surveillance.1352
Table 16 High-risk features of intramural haematoma 
type A and B
Ascending aorta involvement
Difficult BP control
Persistent/recurrent pain despite aggressive BP control
Maximum aortic diameter: 
• Type A: >45–50 mm
• Type B: >47–50 mm
Progression to aortic dissection
Focal intimal disruption with ulcer-like projection
Haematoma thickness >10 mm (type A) or >13 mm (type B)
Enlarging haematoma thickness
Enlarging aortic diameter
Pericardial effusion at admission (type A)
Recurrent pleural effusion
Detection of organ malperfusion
© ESC 2024
BP, blood pressure. 
Adapted with permission from.172


<!-- PAGE 94 -->

### Page 94

9.3.3. Penetrating atherosclerotic ulcer
Penetrating atherosclerotic ulcer (2%–7% of all AAS cases) is character­
ized by localized ulceration of an aortic atherosclerotic plaque penetrat­
ing through the internal elastic lamina into the media, frequently 
associated with IMH and diffuse atherosclerosis.70,172,174,910,1338,1343
Often, multiple PAUs are present, ranging from 5 to 25 mm in diam­
eter and 4 to 30 mm in depth.70,172,174,1338 They occur mostly in the 
middle and lower DTA, with the aortic arch and AA less involved. 
The ascending aorta is rarely affected,70,172,910,1192 but when this occurs, 
especially complicated with IMH, the risk of rupture is 33%–75% and 
progression to dissection is associated with a high mortality rate.
Most patients are older males, smokers, aged >65, with multiple co­
morbidities like systemic hypertension, CAD, COPD, renal insuffi­
ciency, and concurrent abdominal aneurysm.24,172,910,1357
Symptoms are like those in AAD and may manifest in older age after a 
long asymptomatic phase (often PAU is diagnosed as an incidental finding 
during an imaging examination).24,172,910,1357 It should be highlighted that 
symptom onset may indicate PAU expansion (tunica adventitia involve­
ment); thus, urgent imaging (CCT or CMR) and appropriate therapeutic 
intervention are needed to prevent aortic rupture.70,171,172,174
9.3.3.1. Diagnosis
Diagnostic work-up is described in Figure 30. CCT represents the tech­
nique of choice for diagnosis. TOE and CMR represent possible valid 
alternatives considering availability and local expertise.70,159,171–173 Of 
note, 18FDG-PET-CT is a promising technique since it can detect in­
creased glucose uptake in PAUs as a marker of increased metabolic 
activity and inflammation, which has been associated with major ad­
verse events.1358,1359 This information may be used to guide treatment 
decisions, such as the selection of patients who may benefit from endo­
vascular or surgical intervention.1360
9.3.3.2. Treatment
Medical treatment as described for AD is recommended (Figure 31). 
Management of incidental cases is not clearly defined.174 Small series 
suggest that isolated, asymptomatic, small PAUs may be safely managed 
conservatively with regular surveillance.1361,1362
Surgery is recommended in type A PAU with the option of a 
‘wait-and-see strategy’ in highly selected high-risk patients with no high- 
risk features (Figure 35). However, in uncomplicated type B PAU, med­
ical treatment along with careful clinical and imaging surveillance is re­
commended.174,1350 When intervention is needed, endovascular 
treatment (early and 3 year aortic mortality 7.2% and 10.4%, respect­
ively)1350 should be preferred to open surgery (early and 3 year aortic 
mortality of 15.9% and 25.0%, respectively).174,1350 In cases of uncom­
plicated PAU with high-risk imaging features1363–1365 (Figure 35), endo­
vascular treatment should also be considered. The natural history of 
PAU of the abdominal aorta (AA) with associated IMH is less known. 
In a review of PAU of the AA, endovascular stenting was the preferred 
treatment of choice (62%), followed by open surgical repair (35%) and 
conservative therapy (3%).1366
Recommendation Table 51 — Recommendations for 
the management of intramural haematoma
Recommendations
Classa
Levelb
In patients with IMH, medical therapy including pain 
relief and blood pressure control is 
recommended.24,172
I
C
In type A IMH, urgent surgery is 
recommended.172,1175,1192
I
C
In type B IMH, initial medical therapy under careful 
surveillance is recommended.1175,1192,1347,1350,1353
I
C
In uncomplicatedc type B IMH, repetitive imaging 
(CCT or CMR) is indicated.1175,1192,1347,1350,1353
I
C
In complicatedc type B IMH, TEVAR is 
recommended.1175,1192,1347,1350,1353
I
C
In uncomplicatedc type B IMH but with high-risk 
imaging featuresd, TEVAR should be 
considered.1347,1350
IIa
C
In complicatedc type B IMH, surgery may be 
considered in patients with anatomy unfavourable 
for TEVAR.1175,1192,1347,1350,1353
IIb
C
In selected patients with increased operative risk and 
uncomplicatedc type A IMH without high-risk 
imaging featuresd, a ‘wait and see’ strategy may be 
considered.1348,1354–1356
IIb
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
IMH, intramural haematoma; TEVAR, thoracic endovascular aortic repair. 
aClass of recommendation. 
bLevel of evidence. 
cUncomplicated/complicated IMH refers to the absence or presence of recurrent pain, 
expansion of the IMH, periaortic haematoma, and intimal disruption. 
dHigh-risk features of intramural hematoma type A and B are described in Table 16.
Recommendation Table 52 — Recommendations for 
the management of penetrating atherosclerotic ulcer
Recommendations
Classa
Levelb
In all patients with PAU, medical therapy including 
pain relief and blood pressure control is 
recommended.24,172
I
C
In cases of type A PAU, surgery is recommended.172
I
C
In cases of type B PAU, initial medical therapy under 
careful surveillance is recommended.1347,1350
I
C
In uncomplicated type B PAU, repetitive imaging 
(CMR, CCT, or TOE) is recommended.1347,1350
I
C
In complicated type B PAU, endovascular treatment 
(TEVAR) is recommended.1347,1350,1357
I
C
In uncomplicated type B PAU with high-risk imaging 
features,c endovascular treatment should be 
considered.1347,1350
IIa
C
In selected patients with increased operative risk and 
uncomplicated type A PAU without high-risk imaging 
features,c a ‘wait-and-see’ strategy may be 
considered.1367
IIb
C
In complicated type B PAU, surgery may be 
considered based on anatomy and medical 
comorbidities.1347,1350
IIb
C
In isolated, asymptomatic, small PAUs with no 
high-risk features,c conservative management with 
regular surveillance and medical treatment may be 
considered.24,1361
IIb
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
PAU, penetrating atherosclerotic ulcer; TOE, transoesophageal echocardiography; 
TEVAR, thoracic endovascular aortic repair. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 35 for high-risk imaging features of PAU.
ESC Guidelines                                                                                                                                                                                          3631


<!-- PAGE 95 -->

### Page 95

9.3.4. Aortic pseudo-aneurysm
Aortic pseudo-aneurysms, or false aneurysms, result from aortic wall disrup­
tion, typically caused by factors like trauma,1368 surgery, or infections. They 
are often symptomless, detected incidentally during post-aortic procedure 
imaging. Symptoms may include chest pain, compression, and if untreated, 
they can lead to fatal rupture or other severe complications.1369,1370
Type B PAU
Acute or symptomatic PAU
Chronic or asymptomatic PAU
Follow-up
Appearance of symptoms or signs of impending rupture
Endovascular treatment
(Class IIa)
Optimal medical treatment
(Class I)
Endovascular treatment
(Class I)
Haemodynamic instability
Rupture, contained rupture or signs of impending rupture
Refractory pain
Aortic diameter 55 mm (C)
Large pseudoaneurysm
Presence of IMH or high-risk imaging features (see box below)
High-risk imaging features of PAUs
Maximum PAU width (A) 13–20 mm
Maximum PAU depth (B) 10 mm
Significant growth of PAU width
(A) or depth (B) >5 mm/year
PAU associated with a saccular aneurysm
PAU with an increasing pleural effusion
Significant growth of PAU width
(A) or depth (B) >5 mm/yr 
Aortic diameter 55 mm (C)
High-risk imaging features 
(see box below)
N
Y
Y
Y
N
N
A
B
C
Presence of any of the following
Presence of any of the following
Figure 35 High-risk features in penetrating atherosclerotic ulcer and management of patients with type B penetrating atherosclerotic ulcer. IMH, 
intramural haematoma; PAU, penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair. (A) Maximum PAU width. (B) 
Maximum PAU depth; (C) Maximal aortic diameter at the site of the PAU.910


<!-- PAGE 96 -->

### Page 96

Pseudo-aneurysm repair seems always indicated regardless of size or 
position to prevent progression and rupture. Nevertheless, in some cir­
cumstances and under close follow-up, patients could be moni­
tored by CCT, CMR, or TOE and intervention could be 
postponed unless size expansion, symptoms, or compression of 
surrounding structures occur.1371 Pseudo-aneurysms could be 
treated by open surgery or endovascular treatment (occluders, 
stent grafts, or coils). There is no randomized study comparing 
open surgery vs. TEVAR; however, treatment of choice is com­
monly based on anatomical features, clinical presentation, and 
the patient’s comorbidities and decided by a multidisciplinary 
team in specialized centres.1045,1371
9.3.5. Traumatic aortic injury
Traumatic aortic injury (TAI), commonly from high-speed motor 
accidents or falls, involves partial or complete aorta transection. It 
results from rapid deceleration causing torsion and shearing forces, 
often affecting relatively immobile aorta segments like the aortic isth­
mus (90%), aortic root (5%), or diaphragmatic hiatus (5%).24,70,172
Traumatic aortic injury is classified based on the degree of lesion 
in the aortic wall (Figure 36): grade I (intimal tear), grade II (IMH), 
grade III (pseudo-aneurysm), and grade IV (aortic rupture). In the 
Crash Injury Study, 130/613 deaths (21%) were associated with TAI 
(mortality associated with aortic rupture 91%; at-scene survival 
9%).1372
9.3.5.1. Diagnosis and therapeutic interventions
Due to non-specific symptoms and signs (often obscured by con­
comitant multiple organ injury) a timely diagnosis relies on a high level 
of clinical suspicion.70,172 CCT (accuracy close to 100%) represents 
the technique of choice, acting as a ‘one-stop shop’ to rapidly assess 
the entire skeletal system and internal organs.70,171,172 TOE may be 
an alternative, although limited by availability, local expertise, and po­
tentially a patient’s multiple traumas.24,70,172 Therapeutic interven­
tions are dependent on the extent of aorta lesion and patient 
clinical status as assessed by a multidisciplinary team. Generally, ag­
gressive fluid administration should be avoided because it may ex­
acerbate bleeding, coagulopathy, and hypertension. To reduce risk 
of rupture, mean BP should not exceed 80 mmHg.172 Minimal aortic 
injury (grades 1 and 2) may be managed medically along with strict 
clinical and imaging surveillance; moderate aortic injury (grade 3) 
with semi-elective repair (within 24–72 h) to allow patient stabiliza­
tion (though in some patients urgent repair is needed);24,1373 and se­
vere aortic injury (grade 4) with immediate repair.1374 If there is 
progression of the IMH (grade 2), semi-elective repair (within 
24–72 h) may be considered. TEVAR is preferred (if feasible) to 
open surgery (in-hospital mortality 7.9% vs. 20% and 1 year mortality 
8.7% vs. 17%). In semi-elective repair, if the LSA needs to be covered, 
prior LSA revascularization before TEVAR is suggested to reduce the 
risk of paraplegia 172,1373,1374
9.3.5.2. Long-term surveillance in traumatic aortic injury
In addition to clinical assessment, CCT is the imaging choice for follow- 
up.70,171,172 Cumulative exposure to radiation and iodinated contrast 
medium remains the major limitation in young patients, especially in 
women. A combination of a chest X-ray and CMR (if no graft artefacts) 
would be a valid alternative.24,171,172
9.3.6. Iatrogenic aortic injuries
Iatrogenic aortic lesions are those associated with invasive procedures 
(cardiac surgery, most commonly dissection type A, or coronary angi­
ography, with a similar proportion of type A and B dissections) (see 
Section 9.3.2.1). Incidence is low and ADs are the most common lesions. 
Main risk factors are advanced age, presence of CVRFs, atherosclerosis, 
aortic aneurysms, or PAD (Figure 37). Patients with iatrogenic AAS are 
often painless with correspondingly less chest or back pain.1375
While historically associated with high mortality,1375 recent registries 
like the German GERAADA indicate a mortality rate similar to that for 
spontaneous dissections.1186
Clinical management is based on the underlying lesion (AAD, IMH) 
and location; however, conservative management has been described 
with good results in type A iatrogenic dissection if the coronary flow 
is preserved and the dissection is small.1376 Iatrogenic lesion classifica­
tion is depicted in Figure 37.1377 Although scarce, data support a conser­
vative approach based on evolution in type 1 and 2 lesions (Dunning 
classification), and surgery in type 3.1377 In cases of coronary involve­
ment, stent implantation sealing the flap may be proposed.1376,1377
9.3.7. Long-term follow-up of acute aortic syndrome
Imaging modalities and time intervals for surveillance vary according to le­
sion location (ascending/descending aorta), type of treatment (medical, en­
dovascular, surgical), and underlying disease (HTAD).70,1062,1153Compared 
with the chronic disease setting, follow-up of AAS patients is characterized 
by a higher risk of complications and need for re-operation.1378 Patients re­
ceiving TEVAR for AAS involving the descending aorta are more prone 
Recommendation Table 53 — Recommendations for 
traumatic aortic injury
Recommendations
Classa
Levelb
In cases of severe aortic injury (grade 4), immediate 
repair is recommended.24,1373,1374
I
A
In cases of TAI with suitable anatomy requiring 
intervention, TEVAR is recommended over open 
surgery.24,1373,1374
I
A
In all TAI patients, medical therapy including pain 
relief, and blood pressure and heart rate control, is 
recommended.24,172
I
C
In cases of TAI suspicion, CCT is 
recommended.159,172
I
C
In cases of moderate aortic injury (grade 3), repair is 
recommended.24,1373
I
C
If CCT is not available, TOE should be 
considered.159,172
IIa
C
In minimal aortic injury (grades 1 or 2), initial medical 
therapy under careful clinical and imaging surveillance 
should be considered.24,1374
IIa
C
In cases of progression of the IMH (grade 2), 
semi-elective repair (within 24–72 h) should be 
considered.24,1374
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; IMH, intramural haematoma; TAI, traumatic 
aortic injury; TOE, transoesophageal echocardiography; TEVAR, thoracic endovascular 
aortic repair. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3633


<!-- PAGE 97 -->

### Page 97

(27%–49%) to requiring a second intervention than patients undergoing 
surgical repair.1379,1380 However, need for re-intervention at follow-up 
(after initial treatment of AAD) seems to have a significant impact on sur­
vival for TAAD1381 but not for TBAD.1380
9.3.7.1. Follow-up after invasive treatment
Following surgery for AAS, imaging surveillance will focus on persist­
ence/obliteration of the FL, anastomotic dehiscence, progressive dilata­
tion of residual native aorta (with or without residual dissection), or 
graft infection. CCT is the most used modality, but in patients requiring 
frequent examinations CMR can be considered to reduce radiation.
Compared with outcomes of open surgery for aortic aneurysms, time 
to re-intervention in patients developing complications is significantly 
shorter,1159 also due to the faster average growth of the dissected aorta 
(about 1 mm per year).70 Considering the reported incidence rates 
(around 10%) of complications requiring re-operation, it is reasonable 
to follow patients every 6 months in the first year (including an 
early—within 1 month—echocardiography to follow native or pros­
thetic aortic valve function), then yearly up to the third post-operative 
GRADE
I
GRADE
II
GRADE
III
GRADE
IV
MedTX
(Class IIa)
Med
TX/TEVAR
(Class IIa)
TEVAR/OR
(Class I)
TEVAR/OR
(Emergent)
(Class I)
Intimal tear
Intramural haematoma
Pseudoaneurysm
Rupture
Figure 36 Classification and treatment of traumatic aortic injuries. Med, medical; OR, open surgery repair; TEVAR, thoracic endovascular aortic re­
pair; Tx, treatment.


<!-- PAGE 98 -->

### Page 98

Grade 1
Grade 2
Grade 3
Dunning classification
Older age
Cardiovascular risk factors
Atherosclerosis
Aortic aneurysm
PAD
Risk factors
Aortic canulation
Coronary angiography
4 cm
Aetiology
4 cm
4 cm
Figure 37 Aetiology, risk factors, and classification of iatrogenic aortic injuries. PAD, peripheral arterial disease. Dunning classification of iatrogenic 
aortic dissection:1377: type 1, dissection limited to the sinuses of Valsalva; type 2, dissection of the ascending aorta outside the sinuses but < 40 mm from 
the aortic annulus. type 3, dissection > 40 mm from the annulus.
ESC Guidelines                                                                                                                                                                                          3635


<!-- PAGE 99 -->

### Page 99

year and then every 2–3 years if there are no complications 
(Figure 38).1153,1159
TEVAR implies a higher risk for late re-interventions,1159,1378 and a 
sequence of imaging intervals at 1, 6, 12, 24, 36, 48, and 60 months is 
recommended if no abnormality is detected (shorter intervals should 
be considered in high-risk patients). Thereafter, controls can be per­
formed every 2–3 years. Compared with the time points after surgery, 
an adjunctive early control at 1 month is necessary to exclude asymp­
tomatic retrograde type A dissection induced by TEVAR (70% of cases 
occurring within 30 post-operative days).1382
Besides imaging surveillance, clinical follow-up is aimed at achieving 
strict BP control, limiting the burden of CVRFs, and providing patients 
with counselling for lifestyle modifications and prescriptions for sport 
activity.24 There is evidence that statin treatment may improve survival 
in AAS patients under medical treatment, whereas BBs may improve 
survival in surgically treated patients.1333
9.3.7.2. Follow-up under medical treatment (chronic type B aortic 
dissection, intramural haematoma, penetrating atherosclerotic ulcer)
Around 70% of TBAD patients survive the hyperacute phase. If there is 
no malperfusion, uncontrolled hypertension, or impending rupture, ini­
tiate anti-impulse therapy alongside surveillance.
Chronic aortic dilatation, reaching 55 mm, is the leading cause (about 
40%) of intervention, while acute complications necessitating immediate 
treatment are rare.1301,1383 Imaging controls should be performed at least 
at 1, 6, and 12 months after discharge and yearly thereafter; however, one 
additional earlier scan, e.g. within 3 months, may reveal important changes 
occurring in the subacute phase, when the dissected aorta remains suc­
cessfully amenable to early TEVAR.1383 During surveillance, late complica­
tions may be predicted by imaging features, including the number and 
location of the entry tear(s), and dimensions of the FL, total (true + false) 
lumen, or entry tear.1383 This might help in risk stratification to modulate 
the stringency of surveillance in the individual patient (Figure 33).1213
Concerning findings
Stable
1
6
months
3
1
year
2
years
3
years
4
years
5
years
6
years
Pre-discharge
(1 month)
Pre-discharge
Recommendation for CCT or CMR
From this point on, extend the time intervals for monitoring according to the clinical context
Residual false lumen
No false lumen
Stable
(AD or IMH)
PAU or concerning findings
Treated AAS
(open or endovascular repair)
Medically treated AAS
Figure 38 Algorithm for follow-up after acute aortic syndrome. AAS, acute aortic syndrome; AD, aortic dissection; CMR, cardiovascular magnetic 
resonance; CCT, cardiovascular computed tomography IMH, intramural haematoma; PAU, penetrating atherosclerotic ulcer.


<!-- PAGE 100 -->

### Page 100

Type B IMH and PAU are usually conservatively treated with antihyper­
tensive therapy and watchful monitoring. Most of the medically treated 
IMHs have a favourable course, whereas PAUs are less predictable in terms 
of risk of acute TBAD or rupture.1350 Therefore, for IMH the same surveil­
lance criteria as for medically treated uncomplicated TBAD can be em­
ployed; for PAU more frequent controls are advisable, i.e. one every 6 
months instead of every year. Selectively, in asymptomatic patients with 
2 year growth-rate stabilization and no high-risk features, intervals be­
tween controls can be longer (every 1–2 years) (Figures 35 and 38).70,1384
10. Genetic and congenital diseases 
of the aorta
10.1. Genetic and chromosomal diseases
This section discusses genetic and congenital aortic diseases. 
Aortic root and ascending aortic disease is commonly linked to 
congenital or hereditary factors, while descending aortic pro­
blems, especially in the AA, often result from atherosclerosis.1385
Unless noted otherwise, recommendations provided herein are 
intended for adults.
Genetic diseases affecting the thoracic aorta are grouped under 
the broader term of HTAD. HTAD comprises a clinically and genet­
ically heterogeneous group of disorders sharing the common de­
nominator of aneurysm or dissection of the thoracic aorta. 
Familial forms (thoracic aortic disease [TAD] affecting ≥2 individuals 
in one family) or confirmed genetic entities (familial or sporadic) as 
well as syndromes conferring a risk for TAD fall under the definition 
of HTAD.70 Due to the rarity of these conditions, robust evidence 
for many scenarios, such as intervention thresholds, surgical meth­
ods, open surgery vs. endovascular approaches, and pregnancy plan­
ning, is lacking. Thus, a multidisciplinary and individualized approach 
is advisable.70,1386,1387
Clinically, HTADs can manifest as either syndromic or non- 
syndromic entities. The genes identified to date may underly both 
entities and predominantly show autosomal dominant inheritance 
patterns. While TAD is the primary feature in HTAD, extra-aortic 
features (skeletal/ocular) may be key to diagnosing certain syndrom­
ic cases. In some cases, the presence of extra-aortic manifestations 
may aid in risk stratification and hence in defining optimal manage­
ment.1388–1390 The main clinical and genetic data on syndromic 
and non-syndromic HTADs are summarized in the Supplementary 
data online, Table S5.
Numerous underlying gene defects have been discovered in both 
syndromic and non-syndromic cases, leading to the constitution of 
three major molecular groups: genes encoding components of: (i) the 
extracellular matrix; (ii) the transforming growth factor-beta (TGF-ß) 
signalling pathway; and (iii) the smooth muscle cell contractile appar­
atus. Clinical and CV outcomes vary between these groups and will 
Recommendation Table 54 — Recommendations for 
follow-up after treatment of acute aortic syndrome
Recommendations
Classa
Levelb
After TEVAR for AAS, follow-up imaging is 
recommended at 1, 6, and 12 months 
post-operatively, then yearly until the fifth 
post-operative year if no abnormalitiesc are 
documented.1159,1378,1382
I
B
In medically treated type B AAS or IMH, follow-up 
imaging is recommended at 1, 3, 6, and 12 months 
after onset, then yearly if imaging findings are 
stable.1301,1383
I
C
In medically treated PAU, follow-up imaging is 
recommended at 1 month after diagnosis, then every 
6 months if imaging findings are stable.70,1350,1384
I
C
After open surgery for AAS, follow-up imaging by 
CCT and TTE within 6 months, then CCT at 12 
months and then yearly if findings are stable,d should 
be considered.1153,1159,1383
IIa
B
If no complicationsc occur within the first 5 years, 
CCT every 2 years thereafter should be 
considered.1159,1378
IIa
B
If no residual patent FL is documented for 3 
post-operative years, subsequent surveillance by 
CCT every 2–3 years should be 
considered.1153,1159,1383
IIa
C
If abnormalitiesc are documented at any time of 
follow-up after TEVAR for AAS, then CCT should be 
considered every 3–6 months.1159,1378,1382
IIa
C
When frequent controls are required in AAS 
patients treated either by open or endovascular 
repair, CMR should be considered instead of CCT 
after the first-year follow-up.70,1153
IIa
C
In the follow-up of medically treated PAU, after 2 
years of imaging stability, larger intervals should be 
considered in low-risk patientse.70,1350,1384
IIa
C
© ESC 2024
AAS, acute aortic syndrome; CCT, cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; FL, false lumen; IMH, intramural haematoma; PAU, 
penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair; TTE, 
transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cIncluding: pseudo-aneurysm, graft infection, endoleak (any type), enlargement of the 
excluded aneurysm, and stent graft migration/separation/fracture. 
dBoth in terms of extent of residual FL and of aortic diameters at any level. 
eLow-risk: based on width and depth of PAU (See Figure 35 for high-risk features).
Recommendation Table 55 — Recommendations for 
the management of patients with heritable thoracic aor­
tic disease
Recommendations
Classa
Levelb
It is recommended that medical management of 
patients with HTAD is individualized and based on 
shared decision-making.1386
I
C
It is recommended that patients with known or 
suspected syndromic or non-syndromic HTAD are 
evaluated in a centre with experience in the care of 
this patient group.888
I
C
© ESC 2024
HTAD, heritable thoracic aortic disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3637


<!-- PAGE 101 -->

### Page 101

help pave the way to precision medicine in HTAD.1391 Extensive clinical 
and imaging studies in HTAD revealed arterial vasculature involvement 
beyond the thoracic aorta. Patients may develop aneurysms and/or dis­
sections beyond the aorta in diseases such as MFS, Loeys–Dietz or vas­
cular Ehlers–Danlos syndrome (vEDS),1390,1392,1393 or can be prone to 
occlusive vascular disease in the setting of alpha-actin gene (ACTA2) var­
iants.1394 Large clinical variability is observed within families carrying an 
identical variant and instances of incomplete penetrance (a ‘skipped 
generation’) are observed. All HTAD entities display cystic medial de­
generation, hindering precise diagnosis using pathology.
Both genetic testing and imaging (mainly by TTE, but also consider 
CMR or CCT if the aortic root/ascending aorta are not properly visua­
lized) in patients and family members are important in the diagnosis of 
HTAD. In those patients in whom no genetic cause is identified, but in 
whom there is a high suspicion of an underlying genetic defect, genetic 
re-evaluation needs to be considered after 3–5 years. Genetic testing 
should always be accompanied with appropriate counselling. 
Furthermore, appropriate assessment of HRQoL and psychological 
support should be offered to patients and families.1395 Indications for 
genetic testing and aortic screening in HTAD are illustrated in the algo­
rithm in Figure 39.
Although isolated AAA is less frequently associated with a genetic ba­
sis, patients with high-risk features (syndromic features, early onset of 
disease, absence of CVRFs, and/or family history of TAD or AAA) 
should be evaluated in centres with experience in HTAD to evaluate 
the need for genetic testing and specific surveillance, including active 
clinical screening in family members.
10.1.1. Turner syndrome
10.1.1.1. Diagnosis, clinical presentation, and natural history
Turner syndrome (TS), resulting from partial or complete monosomy 
of the X-chromosome, affects 1 in 2500 live-born females.
About 50% of patients experience CV issues like ascending aortic dila­
tation, BAV, aortic coarctation, elongated aortic arch, and partial abnormal 
pulmonary venous return.1417–1419 All women present with generalized ar­
teriopathy and TS itself is an independent risk factor for thoracic aortic dila­
tation. AD risk (type A in 85% and type B in 15%) is elevated in this 
population,1420–1422 although recent studies indicate that this risk may 
be lower with proper treatment guidelines.1423–1426 Risk factors include 
aortic dilatation, BAV, coarctation, and arterial hypertension. Defining aor­
tic dilatation in TS requires adjustment for anthropometric parameters and 
aortic growth data for dissection risk estimation.1427 Z-scores used in the 
general population are equivalent to Turner-specific z-scores.1428
Imaging surveillance
In newly diagnosed TS, TTE and CMR are recommended at baseline for 
the evaluation of congenital heart defects and aortic anatomy/diameters. 
For women aged 15 years and older with TS, adjusting for their smaller 
body size is essential when assessing aortic dimensions. Utilize metrics 
like the ascending aortic size index (ASI), aortic height index (AHI), or aor­
tic z-scores to gauge aortic dilation and dissection risk. Further follow-up 
is dictated by baseline aortic diameters, age, and risk factors (Figure 40).
Recommendation Table 57 — Recommendations for 
imaging in women with Turner syndrome
Recommendations
Classa
Levelb
To take the smaller body size of women (≥15 years) 
with TS into account, the use of the ascending ASI 
(ratio of aortic diameter [mm] to BSA [m2]), AHI 
(ratio of aortic diameter [mm] to height [m]), or 
aortic z-score is recommended to define the degree 
of aortic dilatation and assess the risk of aortic 
dissection.153,1417,1421,1423,1428,1429
I
C
It is recommended to define imaging and clinical 
surveillance intervals according to the estimated risk 
for dissection, based on the ascending ASI and 
concomitant lesions.c,1420,1421
I
C
© ESC 2024
AHI, aortic height index; ASI, aortic size index; BSA, body surface area; TS, Turner 
syndrome. 
aClass of recommendation. 
bLevel of evidence. 
cConcomitant lesions: hypertension, aortic coarctation, bicuspid aortic valve (Figure 40).
Recommendation Table 56 — Recommendations for 
genetic testing and aortic screening in aortic disease
Recommendations
Classa
Levelb
Genetic testing
In patients with aortic root/ascending aneurysms or 
thoracic aortic dissection, gathering family history 
information for at least three generations about 
TAD, unexplained sudden deaths, and peripheral 
and intracranial aneurysms is 
recommended.880,1396–1402
I
B
In patients with aortic root/ascending aortic 
aneurysms or thoracic aortic dissection and risk 
factors for HTAD,c genetic counselling at an expert 
centre and subsequent testing, if indicated, is 
recommended.1399,1403–1408
I
B
In patients with HTAD who have a pathogenic/likely 
pathogenic variant, genetic testing of at-risk biological 
relatives (i.e. cascade testing) is recommended, 
irrespective of age.70,1407,1409
I
C
In patients with HTAD, guidance of clinical 
management by the underlying gene/variant, when 
known, should be considered.70,1391,1410–1416
IIa
B
Aortic imaging screening
In patients with TAD with risk factors for HTAD,c 
with a negative family history of TAD and in whom 
no (likely) pathogenic variant is identified, TTEd 
screening aortic imaging of FDRse is 
recommended.1396,1402
I
B
Continued 
Imaging screening of family members of patients with 
TAD with risk factors for HTADc in whom no (likely) 
pathogenic variant is identified should be considered 
starting at age 25, or 10 years below the youngest 
case, whichever is younger. If the initial screening is 
normal, continued screening every 5 years until the 
age of 60 should be considered.25
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
FDR, first-degree relative; HTAD, heritable thoracic aortic disease; TAD, thoracic aortic 
disease; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 39. 
dCMR/CCT may be indicated if the aortic root/ascending aorta cannot be visualized 
adequately. 
eParents, siblings, children.


<!-- PAGE 102 -->

### Page 102

≤ 60 years
HTN
HTN
Patient with TAD
Aortic dilatation
Aortic dissection
Aortic root/ascending
 z-score ≥3 or any additional risk feature
(see box below)
Aortic root/ascending z-score ≥3
 or aortic dissection
Genetic testing
(Class I)
Re-evaluate genetic testing
 in the proband (after 3–5 years)
Cascade screening
(Class I)
Gene-based management
(Class IIa)
Reimaging of FDRs (after 5 years)
(Class IIa)
Aortic imaginga screening of FDRs
(Class I)
No further
 investigation for HTAD
No further
 investigation for HTAD
Referral to a centre with
 experience in the care of this patient group
(Class I)
Any additional risk feature
(see box below)
Syndromic features of:
Y
N
Y
N
Y
N
Y
N
Y
N
Marfan syndrome
Loeys-Dietz syndrome
Vascular Ehlers-Danlos syndrome
Family history of (either one):
TAD
Peripheral/intracranial artery aneurysm
Unexplained Sudden death <60 years
Positive
Negative or VUS
Any additional risk feature 
Figure 39 Algorithm for genetic and imaging screening in patients with thoracic aortic disease. CCT, cardiovascular computed tomography; CMR, 
cardiovascular magnetic resonance; FDR, first-degree relative; HTAD, heritable thoracic aortic disease; HTN, arterial hypertension; TAD, thoracic aor­
tic disease; TTE, transthoracic echocardiography; VUS, variant of uncertain significance. amainly by TTE, but also consider CMR or CCT if the aortic 
root/ascending aorta are not properly visualized.
ESC Guidelines                                                                                                                                                                                          3639


<!-- PAGE 103 -->

### Page 103

10.1.1.2. Medical treatment
In the absence of clinical trials, a pragmatic approach in a shared-decision 
model is adopted regarding TS medical treatment. Adoption of the 
strategy for inhibition of aortic growth with BBs and/or ARBs as in 
MFS may be considered. Hypertension should be treated according 
to general guidelines.300
Hormonal treatment with growth hormone (in childhood), sex (oestro­
gen and/or progesterone), and thyroid hormones needs to be discussed in a 
multidisciplinary team with the paediatrician and endocrinologist.1430–1434
10.1.1.3. Surgery of aortic aneurysms
Aortic aneurysm surgery in TS should be informed, individualized, and 
consider factors beyond aortic diameter (indexed). These include BAV, 
coarctation, uncontrolled hypertension (despite more than three 
classes of antihypertensive drugs), rapid aortic growth (≥3 mm per 
year) and planned pregnancy.
10.1.1.4. Pregnancy and physical exercise
Turner syndrome often involves fertility challenges, but assisted 
reproductive therapy has increased pregnancy rates. However, preg­
nancy in TS can elevate the risk of AD, particularly with additional 
risk factors (Figure 40). Recent studies suggest improved pregnancy out­
comes due to better guideline adherence.1435,1436 Prophylactic aortic 
root surgery in women with TS contemplating pregnancy is recom­
mended when the ASI reaches 25 mm/m2.1337 These decisions should 
be made by an expert team in a shared-decision process.
Physical exercise has a beneficial impact on CVD risk and HRQoL 
in TS.1437 Structural congenital heart defects and aortic diameters 
(ASI, AHI and z-score) (Figure 40) need to be considered in the recom­
mendations on the level of sports practice.1418
ASI
AHI
Z-score
Risk group
Low
Moderate
Moderate
Moderate
High
High
<20 mm/m2
≥20–<23 mm/m2
≥23–25 mm/m2
>25 mm/m2
>25 mm/m
>4
≥23–25 mm/m
≥20–<23 mm/m
<20 mm/m
3.5–4
23 mm/m2
>23 mm/m2
>23 mm/m
23 mm/m
-
-
>3.5
-
Every 5–10
years:
Cardiology evaluation and
TTEb
Every 3–5
years:
Cardiology evaluation and
TTEb
Every 2–3
years:
Cardiology evaluation and
TTEb
Every year:
Cardiology evaluation and
TTEb
Consider surgery
(Class IIb)
Consider surgery
(Class IIa)
None of CoA, BAV,  HTNa
CoA, BAV, HTNa or aortic growth ≥3 mm/year
Figure 40 Algorithm for surveillance in women (≥15 years) with Turner syndrome. AHI, aortic height index (ratio of aortic diameter [mm] to height 
[m]); ASI, aortic size index (ratio of aortic diameter [mm] to BSA [m2]); BAV, bicuspid aortic valve; BSA, body surface area; CCT, Cardiovascular 
Computed Tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; HTN, arterial hypertension; TTE, transthoracic 
echocardiography. aHTN: arterial hypertension, not under control despite more than three classes of antihypertensive drugs. bCMR (preferably) or 
CCT if inadequate visualization of the ascending aorta.
Recommendation Table 58 — Recommendations for 
aortic surgery in women with Turner syndrome
Recommendations
Classa
Levelb
Elective surgery for aneurysms of the aortic root and/ 
or ascending aorta should be considered in women 
with TS who are ≥15 years of age, have an ascending 
ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, 
and have associated risk factors for aortic dissectionc 
or are planning pregnancy.70,1417,1421
IIa
C
Continued 
Elective surgery for aneurysms of the aortic root and/ 
or ascending aorta may be considered for women 
with TS who are ≥15 years of age, have an ascending 
ASI >25 mm/m2, an AHI >25 mm/m, a z-score >4, 
and who do not have associated risk factors for 
aortic dissectionc.70,1417,1421
IIb
C
© ESC 2024
AHI, aortic height index (ratio of aortic diameter [mm] to height [m]); ASI, aortic size index 
(ratio of aortic diameter [mm] to BSA [m2]); TS, Turner syndrome. 
aClass of recommendation. 
bLevel of evidence. 
cBicuspid aortic valve, elongation of the transverse aorta, coarctation of the aorta, and/or 
uncontrolled hypertension (despite more than three classes of antihypertensive drugs). See 
Figure 40.


<!-- PAGE 104 -->

### Page 104

10.1.2. Vascular Ehlers–Danlos syndrome
10.1.2.1. Diagnosis, clinical presentation, and natural history
Vascular Ehlers–Danlos syndrome is a rare (prevalence of 1/50 000 to 
1/200 000) autosomal dominant disease caused by pathogenic variants 
in the COL3A1 gene, which encodes the pro-alpha1 chains of type III 
procollagen. The most common COL3A1 variants provoke a disruption 
in the assembly of type III collagen fibrils, causing an important loss of 
mechanical strength of arteries and other hollow organs, especially 
the bowel and uterus.1438 Identification of a causal COL3A1 variant is 
a requirement for the diagnosis of vEDS.1439
vEDS is the most severe form of Ehlers–Danlos syndrome because 
of its clinical life-threatening vascular complications, making early iden­
tification and a thorough family inquiry particularly crucial.
Clinical complications may start during adolescence and repeat at un­
predictable time intervals. The most common complications involve 
medium-sized arteries: dissections, aneurysms, arterial ruptures, and 
arteriovenous fistulas. AD (both type A and B) occurs in up to 10% 
of patients.1440
Prognosis depends on the type of COL3A1 variant, with null variants 
(no gene product or absence of function) showing a better out­
come.1441 The rate of recurrence of organic complications in patients 
with vEDS is 1.6 events per 5 year period. Life expectancy is reduced 
to an average of 51 years.1442
10.1.2.2. Surveillance and imaging
Management of vEDS is complex and requires a multidisciplinary ap­
proach. Recommendations include: lifestyle modification to minimize 
injury and risk of vessel/organ rupture, identification of a care team, in­
dividualized emergency care plans, maintaining BP in the normal range, 
aggressive hypertension treatment, and annual surveillance of the vas­
cular tree by DUS, CCT (low radiation alternatives), or CMR (if feas­
ible).1439 A recent survey among European expert centres indicated 
that arterial monitoring is standard clinical practice and that frequency 
of follow-up should be adapted individually.1443 The prognosis im­
proves when patients are properly managed.1441
10.1.2.3. Medical treatment
Medical management is based on optimal BP control. Celiprolol, a BB 
with vasodilatory properties, has been shown to reduce vascular mor­
bidity in two retrospective studies1441,1444 and one randomized, open- 
label trial.1445 There is no consensus about the age at which to start 
treatment, but starting after 10 years of age is considered reasonable 
by many experts.
10.1.2.4. Surgical treatment
Acute, unexplained pain requires urgent imaging to exclude arterial 
rupture. Acute arterial complications usually require hospitalization 
and a conservative approach in most cases. Interventional vascular or 
intestinal procedures are limited to vital risk. Procedures requiring or­
gan inflation should be avoided or performed with extreme caution. 
There are no clear recommendations regarding aortic/arterial dia­
meters at which to intervene in patients with vEDS. Thus, decisions 
need to be made on a case-by-case basis.
10.1.2.5. Pregnancy
Pregnancy in vEDS incurs a risk of (fatal) arterial and uterine complica­
tions. Pregnancy does not appear to affect overall mortality compared 
with nulliparous vEDS women.1446 However, patients need to be en­
gaged in a shared-decision process, informed by vascular status and 
underlying variant type.
10.1.3. Marfan syndrome
10.1.3.1. Diagnosis, clinical presentation, and natural history
Marfan syndrome, the most common syndromic HTAD condition 
(prevalence of 1/5000–1/10 000), arises from pathogenic fibrillin-1 
gene (FBN1) variants. Beyond the CV system, multiple organ systems 
are often affected, including the eyes and skeleton. Diagnosis relies 
on recognizing clinical features in line with the revised Ghent nosology, 
which includes genetic testing.1447
Aortic aneurysm and dissection involving the aortic root are a 
hallmark of the disease. Less commonly, the descending thoracic 
and abdominal aorta may be involved. With increasing survival 
and age in MFS, the prevalence of TBAD seems to be increasing, ex­
ceeding type A dissection rates in recent reports.1448,1449 TBAD 
will often occur at diameters below surgical thresholds. Previous 
aortic root replacement, mitral valve surgery, and a longer life 
span are associated with TBAD. Additional CV features include mi­
tral valve prolapse, extra-aortic arterial involvement, myocardial 
dysfunction, and arrhythmias.1393,1450–1452 Thanks to improved 
diagnosis in earlier stages, proper management including surveil­
lance, medical treatment, and timely prophylactic aortic surgery, 
life expectancy in MFS patients is now approaching that of the gen­
eral population.1416,1453
The major determinant of TAAD is the aortic root diameter, with 
increased risk of rupture when it exceeds 50 mm.1454 Other risk fac­
tors include family history of AAS at low diameter, aortic root growth 
rate (annualized growth rate ≥3 mm or more in adults), pregnancy, and 
hypertension (hypertension persisting notwithstanding three or more 
antihypertensive medications prescribed by a physician with experience 
in hypertension treatment). Increasing evidence for variant-based dif­
ferences in aortic risk is emerging and may be considered.1413,1416
10.1.3.2. Imaging surveillance
Transthoracic echocardiography is the appropriate imaging modality 
for initial evaluation and follow-up of the aortic root in most patients 
and allows evaluation of the distal segments of the aorta in many. 
Also, TTE is useful for assessing mitral and aortic valve regurgitation, mi­
tral valve prolapse with/out annular disjunction, and LV dysfunction. In 
some cases (especially when pectus abnormalities are present) TTE 
windows may be suboptimal, and CMR (preferably)/CCT may be pre­
ferred. Periodical evaluation of the global aorta and peripheral arteries 
with CMR/CCT and DUS (every 3–5 years based on the patient’s evo­
lution) is indicated since they also present a higher incidence of 
Recommendation Table 59 — Recommendations for 
medical treatment in patients with vascular Ehlers– 
Danlos syndrome (see also Evidence Table 13)
Recommendations
Classa
Levelb
In patients with vEDS, regular vascular surveillance of 
the aorta and peripheral arteries by DUS, CCT, or 
CMR is recommended.1439,1443
I
C
Treatment with celiprolol should be considered in 
patients with vEDS.1441,1444,1445
IIa
B
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DUS, duplex ultrasound; vEDS, vascular Ehlers–Danlos syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3641


<!-- PAGE 105 -->

### Page 105

peripheral aneurysms,1455 which are associated with more aggressive 
forms of the disease.1393 CMR is preferred over CCT to avoid radiation 
exposure; however, its use should be adapted to local availability/ex­
pertise. Additionally, CMR allows evaluation of biomechanical and 
haemodynamic parameters that can be useful in risk stratifica­
tion.181,1456,1457 Given its superior spatial resolution, CCT may be re­
commended for pre-operative planning and in cases of measurement 
inconsistency. Imaging of intracerebral vessels is indicated in cases of 
symptoms and/or clinical manifestations of aneurysms/rupture. 
Recommendations for imaging surveillance are illustrated in Figure 41
and should be adjusted to the individual patient, taking the history 
and presence of abnormalities during preceding studies into account.
10.1.3.3. Medical treatment
Medical treatment is described in Recommendation Table 61. Some 
caution may be warranted with the use of CCBs: these have shown an 
increased aortic risk in a mouse model and in retrospective case con­
trol studies,1460 and alternatives are preferred for hypertension 
treatment.
10.1.3.4. Aortic surgery
Open surgery is preferred over endovascular procedures in patients 
with MFS. Endovascular procedures may be considered in selected 
cases in emergency settings and/or in centres with a high level of ex­
pertise.1465 The thresholds for aortic root surgery need to take add­
itional risk factors, as well as the expertise of the team, into account.1466
Recommendation Table 60 — Recommendations for 
vascular imaging in Marfan syndrome
Recommendations
Classa
Levelb
In patients with MFS, TTE is 
recommended:70,171,1458,1459
• At least annually in patients with an aortic root 
diameter <45 mm in the absence of additional risk 
factorsc
• At least every 6 months in patients with an aortic 
root diameter <45 mm in the presence of 
additional risk factorsc
• At least every 6–12 months in patients with an 
aortic root diameter ≥45 mm in the absence of 
additional risk factorsc
I
C
In patients without previous aortic surgery, complete 
peripheral vascular and thoracoabdominal aorta 
imaging by CMR or CCT and DUS is recommended 
at the first evaluation, and subsequently every 3–5 
years if stable.70,1455,1459
I
C
In patients with MFS who have undergone aortic root 
replacement, surveillance imaging of the thoracic 
aorta by CMR (or CCT) is recommended at least 
every 3 years.70,1458
I
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DUS, duplex ultrasound; MFS, Marfan syndrome; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cRisk factors: aortic root diameter >40 to ≤45 mm and family history of aortic dissection at 
small aortic dimensions (i.e. <50 mm); resistant hypertension (hypertension persisting 
notwithstanding three or more antihypertensive medications prescribed by a physician 
with experience in hypertension treatment); and rapid growth of the aorta (annualized 
growth rate ≥3 mm or more in adults).
Recommendation Table 62 — Recommendations for 
aortic surgery in Marfan syndrome
Recommendations
Classa
Levelb
Surgery is indicated in patients with MFS who have 
aortic root disease with a maximal aortic sinus 
diameter ≥50 mm.70,172,1466–1468
I
B
Surgery to replace the aortic root and ascending 
aorta, using the valve-sparing surgery technique, is 
recommended in patients with MFS or related 
HTAD with aortic root dilatation when anatomical 
features of the valve allow its preservation and the 
surgeon has specific expertise.70,1466,1469
I
B
Surgery should be considered in patients with MFS 
who have an aortic root aneurysm with a maximal 
aortic sinus diameter ≥45 mm and additional risk 
factors.c,1467,1469
IIa
C
In patients with MFS and an aneurysm of the 
ascending aorta, aortic arch, descending thoracic 
aorta, or abdominal aorta of ≥50 mm, surgical 
replacement of the aneurysmal segment by a surgeon 
with specific expertise should be considered.1467,1469
IIa
C
© ESC 2024
HTAD, heritable thoracic aortic disease; MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence. 
cFamily history of aortic dissection at small aortic dimensions (i.e. <50 mm); resistant 
hypertension (hypertension persisting notwithstanding three or more antihypertensive 
medications prescribed by a physician with experience in hypertension treatment); and 
rapid growth of the aorta (annualized growth rate ≥3 mm or more in adults).
Recommendation Table 61 — Recommendations for 
medical treatment in Marfan syndrome (see also 
Evidence Table 14)
Recommendations
Classa
Levelb
In patients with MFS, treatment with either a BB or 
an ARB, in maximally tolerated doses (unless 
contraindicated), is recommended to reduce the rate 
of aortic dilatation.1461,1462
I
A
In patients with MFS, the use of both a BB and an 
ARB, in maximally tolerated doses (unless 
contraindicated), should be considered to reduce the 
rate of aortic dilatation.1463,1464
IIa
A
© ESC 2024
ARB, angiotensin receptor blocker; BB, beta-blocker; MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 106 -->

### Page 106

10.1.3.5. Pregnancy and physical exercise
In pregnant MFS women, the risk of AD increases up to eight times 
relative to the general population.1470 The risk for TAAD is deter­
mined by the aortic diameter, but type B dissections tend to occur 
even more commonly and may occur without prior dilata­
tion.1470,1471 Patients should be aware of the persisting risk of 
TBAD after aortic root replacement.1471 Women unaware of the 
diagnosis are at the highest risk of dissection.1470–1472
The Registry Of Pregnancy And Cardiac disease (ROPAC) indicates 
that women managed according to guidelines are at low risk of 
pregnancy-related complications and major effects of BBs on foetal 
growth were not shown, although this needs to be carefully 
monitored.70,1337,1435,1471,1472
Exercise is potentially associated with an increased risk of aortic dila­
tation and AAD. It is recommended to individualize physical activity in 
MFS based on aortic diameter, family history of dissection or sudden 
death, and pre-existing fitness status.71 Although competitive sports 
are contraindicated, moderate aerobic exercise is recommended 
with a level of intensity based on aortic diameters.71
Two studies1481,1482 showed that mild-moderate dynamic exercise 
improved aortic wall structure and function and reduced aortic growth 
rate in MFS mouse models. Recent data in MFS children and young adults 
indicate that adhering to daily physical exercise (10 000 steps a day) had 
a beneficial effect on aortic root growth.1483 Although a limited number 
of clinical studies have evaluated physical activity rehabilitation 
programmes, two studies1484,1485 evidenced that physical activity, up 
to a moderate specific intensity, may be recommended. Thus, although 
physical activity poses a dilemma, individualized adapted programmes 
are most likely successful in encouraging exercise in MFS.
10.1.4. Other syndromic and non-syndromic 
heritable thoracic aortic diseases and/or arterial 
disorders
Main clinical and genetic data of known syndromic and non-syndromic 
HTAD entities are summarized in the Supplementary data online, 
Table S5. The two most prevalent diseases for each entity include 
Loeys–Dietz syndrome and ACTA2-related HTAD, respectively. Given 
the rarity of these entities, specific recommendations regarding surveillance 
and treatment are lacking and largely adopted from the recommendations 
for MFS. Some disease-specific recommendations are mentioned below.
10.1.4.1. Loeys–Dietz syndrome
10.1.4.1.1. Diagnosis, clinical presentation, and natural evolution.
The spectrum of clinical presentations in Loeys–Dietz syndrome is very 
wide. Some patients fulfil criteria for MFS,1447 while some features such 
as bifid uvula and hypertelorism are very specific to the disease. Clinical 
manifestations are listed in the Supplementary data online, Table S5. 
There is a tendency for AD and rupture at lower vessel dimensions 
than is typically seen in other similar conditions.1390,1487 Pathogenic var­
iants in six genes (TGFBR1 and TGFBR2, TGFB2 and TGFB3, SMAD2 and 
SMAD3), all encoding components of the TGF-ß signalling pathway, cause 
Loeys–Dietz syndrome. Differences in clinical manifestations and aortic 
outcome according to the underlying gene and the extent of extra-aortic 
features have been reported and need to be considered in surveillance 
and defining thresholds for surgery.1388,1390,1391
Surveillance 
in 
Loeys–Dietz 
syndrome 
is 
described 
in 
Recommendation Table 65 and Figure 41. Although the indication for 
surgery must be considered according to the underlying genetic defect 
and the presence of risk factors (Recommendation Table 66 and 
Figure 42), a 45 mm aortic diameter threshold should be considered 
(≥40 mm in cases of associated high-risk features).
Recommendation Table 63 — Recommendations for 
pregnancy in women with Marfan syndrome
Recommendations
Classa
Levelb
It is recommended that all women with MFS: 
• Have a pre-conception evaluation to address the 
risks of maternal CV and other complications
• Have follow-up in a centre with access to a 
pregnancy heart and vessel team.1473
I
C
It is recommended that couples in which a partner 
has or is at risk for HTAD be offered pre-conception 
genetic counselling.
I
C
Imaging of the whole aorta (by CMR/CCT) is 
recommended prior to pregnancy.
I
C
Follow-up during pregnancy is recommended with a 
frequency determined by aortic diameter and 
growth.1337,1474,1475
I
C
Intake of BBs during pregnancy is recommended.1476
I
C
Prophylactic aortic root surgery is recommended in 
women desiring pregnancy with aortic diameters 
>45 mm.1435,1472
I
C
Prophylactic aortic root surgery may be considered 
in women desiring pregnancy with aortic diameters 
of 40–45 mm.1472,1475,1477
IIb
C
ARBs are not recommended during pregnancy.1478–1480
III
B
© ESC 2024
ARBs, angiotensin receptor blockers; BBs, beta-blockers; CCT, cardiovascular computed 
tomography; CMR, cardiovascular magnetic resonance; CV, cardiovascular; HTAD, 
heritable thoracic aortic disease; MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 64 — Recommendations for 
physical exercise in patients with Marfan syndrome
Recommendations
Classa
Levelb
It is recommended to individualize physical activity in 
patients with MFS based on aortic diameter, family 
history of aortic dissection, and pre-existing fitness.
I
C
Regular moderate aerobic exercise with a level of 
intensity informed by aortic diameter is 
recommended in most patients with MFS.
I
C
For patients who present with aortic dissection and/ 
or have undergone aortic surgery, post-operative 
cardiac rehabilitation aiming at improving both 
physical and mental health should be 
considered.73,1483,1484,1486
IIa
B
© ESC 2024
MFS, Marfan syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3643


<!-- PAGE 107 -->

### Page 107

CCTa
Surgery if risk factorsb
(Class IIa)
Aortic root/
ascending diameter (mm)
Marfan/FBN1
Loeys-Dietz/
TGF-ß genes
ACTA2/
SMC genes
TTE Follow-up
Every 6–12 months
Surgery
(Class I)
CMR/CCT head-to-pelvis every 1–3 years
Baseline CMR/CCT
Baseline CMR/CCT
Baseline CMR/CCT
TTE yearly
TTE yearly 
CMR/CCT every 3–5 years
CMR/CCT every 3–5 years
CCTa
CCTa
CCTa
35 mm
40 mm
42 mm
45 mm
50 mm
CCTa
Surgery if risk factorsb
(Class IIb)
Every 6–12 months
TTE yearly
Surgery
(Class IIa)
Surgery
(Class IIa)
Figure 41 Algorithm for imaging surveillance in patients with syndromic and non-syndromic heritable thoracic aortic disease. CCT, cardiovascular 
computed tomography; CMR, cardiovascular magnetic resonance; DUS, duplex ultrasound; HTAD, heritable thoracic aortic disease; SMC, smoth mus­
cle cell; TTE, transthoracic echocardiography. aPre-surgical CCT. bSee respective tables of recommendations for aortic surgery in Marfan (Table 62) and 
Loeys-Dietz syndrome (Table 66).
Recommendation Table 66 — Recommendations for 
aortic root surgery in Loeys–Dietz syndrome
Recommendations
Classa
Levelb
Aortic root replacement should be considered 
for patients with Loeys–Dietz syndrome if the 
aortic root diameter exceeds 
45 mm.1388,1390,1489–1492
IIa
C
It may be considered to adjust the threshold for 
surgery according to the underlying gene, taking 
associated risk featuresc into account.1391
IIb
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence. 
cHigh-risk features include certain specific pathogenic variants; women with TGFBR2 
variants and small body size; severe extra-aortic features; family history of aortic 
dissection (especially at young age or relatively small aortic diameter); and aortic growth 
rate ≥3 mm per year.
Recommendation Table 65 — Recommendations for 
imaging follow-up in Loeys–Dietz syndrome
Recommendations
Classa
Levelb
In patients with Loeys–Dietz syndrome, TTE at baseline 
and subsequently every 6–12 months, depending on 
aortic diameter and growth,c is recommended.70,1390,1488
I
C
In patients with Loeys–Dietz syndrome, a baseline 
arterial imaging study from head to pelvis with CMR or 
CCT and subsequent surveillance with CMR or CCT or 
DUS every 1–3 years is recommended.70,1488
I
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
DUS, duplex ultrasound; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cMore frequent imaging if aortic root/ascending diameter >42 mm and aortic growth rate 
≥3 mm per year.


<!-- PAGE 108 -->

### Page 108

10.1.4.2. ACTA2-related heritable thoracic aortic disease
Pathogenic variants in the ACTA2 gene, encoding for smooth muscle- 
specific alpha-actin (a critical component of the vascular smooth 
muscle cell contractile apparatus), lead to aortic aneurysms and dis­
sections in non-syndromic patients.1496 Patients primarily present 
with type A or B aortic dissection, and with aneurysms that involve 
the root and/or ascending aorta. A subset of pathogenic variants pre­
disposes to occlusive vascular diseases.1497 Surveillance is summarized 
in Recommendation Table 67 and Figure 41. TAAD may occur at 
aortic diameters <45 mm, and consideration of surgery at diameters 
<45 mm should be informed by the presence of additional clinical and 
genetic risk factors.1410 Genetic and imaging cascade screening of 
first-degree family members is an essential element of care, as treat­
able disease may otherwise be missed in family members—with fatal 
consequences.
High risk features include:
Known high risk genetic variants (R528H/C in TGFBR2)
Women with TGFBR2 variants and small body size
Severe extra-aortic features
 Aortic root surgery if 
risk factors
(see box below)
 Aortic root surgery
Family history of aortic dissection (especially at young age or relatively small aortic diameter)
Aortic growth rate ≥3mm per year
TGFBR2a,b
35 mm
40 mm
45 mm
50 mm
55 mm
TGFBR1a
TGFBR2a
TGFBR1a
 Consider aortic root surgery
Consider aortic root surgery
SMAD3c,d
TGFB2e,f,g
TGFB3h,i
Figure 42 Suggested thresholds for prophylactic aortic root/ascending replacement in Loeys–Dietz syndrome. From a1388, b1391, c1492, d1491, e1490, 
f1489, g1493, h1494, i1495.
Recommendation Table 67 — Recommendations for 
imaging and surgery in ACTA2-related heritable thoracic 
aortic disease (see also Evidence Table 11)
Recommendations
Classa
Levelb
Annual monitoring of the aortic root/ascending aorta 
with TTE to evaluate aortic root/ascending aorta 
enlargement is recommended.1498
I
C
Imaging of the aorta with CMR/CCT every 3–5 years 
is recommended.1498
I
C
Prophylactic aortic root surgery should be 
considered with an aortic diameter ≥45 mm, or 
lower in cases with other risk factors.c,1499
IIa
C
© ESC 2024
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; 
TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cRisk factors for aortic dissection: family history of dissection with no or minimal dilatation 
or young age; rapid growth ≥3 mm per year.
ESC Guidelines                                                                                                                                                                                          3645


<!-- PAGE 109 -->

### Page 109

10.2. Aortic disease associated with 
bicuspid aortic valves
Bicuspid aortic valves, the most common congenital heart defect 
(0.5%–2% of live births), besides being a risk factor for aortic valve dis­
ease, is associated with a peculiar form of aortopathy, characterized by 
morphological and clinical heterogeneity (bicuspid valvulo-aortopathy). 
Its inheritance is high, with autosomal dominant transmission of BAV in 
a minority of cases, but no single-gene model clearly explaining BAV 
inheritance.1500–1502 Several genes, generally implicated in embryogenesis 
and cell differentiation, have been associated with BAV/BAV-related aor­
topathy, but each of them explained <5% of cases.1503–1507 Therefore, 
1
2a
2b
Ascending phenotype
(70–75%)
Fused BAV (90–95% of BAV) 3 phenotypes
2-sinus BAV (5–7% of BAV) 2 phenotypes
Partial-fusion BAV - short fusion of 1 commisure
Right - left cusp fusion
(70–80%)
Right - non cusp fusion
(20–30%)
Left - non cusp fusion
(3–6%)
Root phenotype
(15–20%)
Extended phenotype
(5–10%)
BAV morphologies
Aortic phenotypes
L
A
A
P
P
L
Laterolateral
Anteroposterior
Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature. Modified from Michelena et al.1510 A, anterior; BAV, bicuspid aortic valve; L, lateral; 
P, posterior. Although preferential associations exist, each of the three valve types—‘fused BAV’, ‘2-sinus BAV’, and ‘partial-fusion BAV’—can be vari­
ably associated with dilatation predominantly located at the sinuses of Valsalva (‘root phenotype’, 15%–20%) or at the tubular (supra-coronary) tract 
(‘ascending phenotype’, 70%–75%). A minor proportion of patients present with equal dilatation of the sinusal and tubular segments or ascending dila­
tation extending into the proximal arch (‘extended phenotype’, 5%–10%).


<!-- PAGE 110 -->

### Page 110

genetic testing is not indicated for isolated BAV disease, but reserved 
for patients with syndromic features, family history of aortic disease, 
or aneurysms/dissections of medium-sized arteries other than the 
thoracic aorta, and may be considered in patients with the root 
phenotype.1389,1508,1509
We recommend adopting a new international consensus nomencla­
ture and classification, established by a panel of experts, to replace the 
previous various concurrent nomenclatures used1510 (Figure 43). 
Aneurysm prevalence reaches 40% in clinical series and 0.85 per 100 
patient-years in population studies. AAEs are rare, but 8- to 10-fold 
more frequent than in the general population.1001,1511 The longest 
available follow-up of BAV subjects was recently reported,1512 showing 
a total lifetime morbidity burden as high as 86%, a predominant part of 
which was driven by valve-related complications (aortic stenosis, endo­
carditis, HF).
When a BAV is first detected, a complete study of the thoracic aorta 
is necessary; vice versa, in every patient with ascending aortic dilatation, 
valve morphology should be ascertained.70,969 When TTE detects 
BAV-associated aortic dilatation, CCT or CMR is recommended to 
confirm measurements, exclude coarctation, and record baseline dia­
meters at different levels for subsequent periodic assessments.137,1001
Surveillance by TTE becomes necessary when the maximum diameter 
exceeds 40 mm. In mixed tricuspid aortic valve (TAV) and BAV series, 
AAEs occurred in 2/10 000 patient-years with a diameter >40 mm (vs. 
0.1–0.3/10 000 patient-years in the general population)894 (Figure 43). 
Considering average aortic diameter growth of 0.2–0.6 mm per 
year,893,1513 once fast progression is excluded, follow-up can be sched­
uled every 2–3 years (according to risk profile). In 5%–15% of cases, 
BAV patients have at least one FDR with either BAV or ascending aortic 
dilatation; root phenotype and aortic regurgitation in the proband pre­
dict ascending dilatation in FDRs.1514 FDR screening is considered cost- 
effective, but the age at which relatives should undergo TTE remains to 
be determined.1515,1516
A diameter exceeding 55 mm at any level mandates sur­
gery.70,969,1001 However, the historically known relation between diam­
eter and acute complications has been recently reappraised. Both in 
large mixed153 and purely BAV series,981 an ascending diameter of 
about 52 mm already marked an AAE risk increase from ∼1% to 
4%–5%. Additionally, early post-operative mortality for elective surgery 
of the proximal aorta ranges today between 0.25% and 2%.980,981
Therefore, aortic surgery in low surgical risk (<3%) patients with an as­
cending diameter >52 mm implies a lower risk than observed in the 
natural history of the disease. For aortic root dilatation in BAV patients, 
the ‘hinge point’ was at 50 mm;981 this phenotype is associated with fas­
ter growth rate,893 higher risk of events following isolated aortic valve 
replacement,1517 worse survival if not operated,1518 and higher risk of 
acute TAAD.976,1519
Surgery should be considered when the diameter is ≥50 mm in se­
lected ascending phenotype patients (Figures 23, 24 and 43).70,1001
Among those factors, family history of AAEs, poorly controlled hyper­
tension, aortic coarctation, and rapid (≥3 mm per year) diameter 
growth should be noted. Surgery at >50 mm may also be considered 
in a shared decision with the patient, taking lifestyle and psychological 
factors into consideration,70,1001 since 50 mm should correspond to 
an approximately 10-fold increase in the risk of AAEs.894 In a study 
of patients with aortic diameter ≥40 mm, those with diameters of 
50 mm faced a 1% risk of AAEs within 5 years, compared with 
0.1% for those with 40 mm diameters, explaining the 10-fold differ­
ence; however, this study did not exclusively involve BAV patients.894
Another recent study1520 specifically focused on BAV patients found 
a 0.4% incidence of AAEs per patient-year for diameters above 
50 mm, in contrast to the general BAV population’s 0.03% inci­
dence.1521 Previous guidelines also suggested aortic repair for a 
cross-sectional area-to-height ratio (CSA/h) >10 cm2/m;70 neverthe­
less, more recently, it has been suggested that the CSA/h threshold 
for the ascending tract in BAV should be 13 cm2/m.981 For the aver­
age height of male and female Europeans (1.8 m and 1.67 m, respect­
ively), a CSA/h of 10 cm2/m would correspond to a diameter of 
48 mm or 46 mm, respectively, whereas 13 cm2/m means 54 mm 
or 53 mm. It is reasonable to refer to the 13 cm2/m CSA/h cut-off 
for ascending aortic repair, especially in individuals ≤1.69 m in height 
(since 13 cm2/m corresponds to ≤52 mm diameter). Recently, be­
sides dilatation, aortic elongation is also considered a risk factor,974
and a curvilinear length >11.5 cm at the vessel’s centreline increases 
the yearly risk of AAEs.155 Age is another factor to consider: at 50 
years, a 40 mm ascending aorta corresponds to the upper normal 
limit for patients with large body size,149 and therefore the same 
diameter at a higher age could imply a lower risk of AAEs.
Recommendation Table 68 — Recommendations for 
bicuspid aortic valve-associated aortopathy management
Recommendations
Classa
Levelb
When a BAV is first diagnosed, initial TTE to assess 
diameters of the aorta at several levels is 
recommended.1001,1510,1522
I
B
Surgery for bicuspid aortopathy is recommended 
when the maximum aortic diameter is 
≥55 mm.70,172,899,969,1001
I
B
Surgery for bicuspid aortopathy of the root 
phenotypec is recommended when the maximum 
aortic diameter is ≥50 mm.70,893,981,986,1001,1519,1523
I
B
CCT or CMR of the entire thoracic aorta is 
recommended at first diagnosis and when important 
discrepancies in measurements are found between 
subsequent TTE controls during surveillance, or when 
the diameter of the aorta exceeds 45 mm.1001,1510
I
C
Screening by TTE in FDRs of BAV patients with root 
phenotypec aortopathy and/or isolated aortic 
regurgitation is recommended.1001,1510,1514
I
C
Surveillance serial imaging by TTE is recommended in 
BAV patients with a maximum aortic diameter 
>40 mm, either with no indication for surgery or 
after isolated aortic valve surgery, after 1 year, then if 
stability is observed, every 2–3 years.70,1001
I
C
Screening by TTE in FDRs of all BAV patients should 
be considered.70,1001,1500,1510,1515
IIa
B
In patients with low surgical risk, surgery for bicuspid 
aortopathy of ascending phenotyped should be 
considered when the maximum aortic diameter is 
>52 mm.153,172,981
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3647


<!-- PAGE 111 -->

### Page 111

10.3. Coarctation of the aorta and aortic 
arch variants
10.3.1. Coarctation of the aorta
This topic is extensively discussed in the ESC 2020 Guidelines for the man­
agement of adult congenital heart disease.1468 Coarctation of the aorta 
(CoA) manifests as a discrete stenosis or a hypoplastic segment typically 
located at the insertion of the ductus arteriosus. More distal locations 
are known as mid-aortic syndrome and require dedicated manage­
ment.1524 Associated lesions include BAV (up to 50%–85%), intracereb­
ral aneurysms (10%), and ascending aortic aneurysms.1525,1526 CoA may 
be associated with syndromes such as TS. Research indicates that up to 
12.6% of females diagnosed with CoA also have TS, and coarctation is 
observed in 7%–18% of patients with TS.1417,1468,1527
10.3.1.1. Diagnostic work-up
Mild cases of CoA may only become evident in adulthood. Symptoms 
reflect pre-stenotic hypertension (e.g. headache, nosebleeds) and post- 
stenotic hypoperfusion (e.g. abdominal angina and claudication). The 
natural course is largely driven by hypertension-related complications, in­
cluding HF, intracranial haemorrhage, premature coronary/cerebral artery 
disease, and aortic rupture/dissection.1528 Presently, there is no evidence 
supporting screening for intracerebral aneurysms in asymptomatic patients.
A systolic non-invasive gradient between upper and lower extremities, an 
abnormal ABI, or an invasive peak-to-peak gradient ≥20 mmHg indicates 
significant CoA. In the presence of collaterals or decreased LV function, gra­
dients or ABI may underestimate severity. A diastolic tail in the DTA or ab­
dominal diastolic antegrade flow by TTE is suggestive of significant 
narrowing. Criteria to consider significant CoA are listed in Figure 44. TTE 
is also useful to detect LV hypertrophy, which is a marker of disease. 
CMR and CCT are the preferred imaging techniques, depicting the narrow­
ing as well as the surrounding anatomy, necessary for interventional 
decision-making.
10.3.1.2. Treatment and follow-up
In native CoA and re-coarctation (Figure 44) covered stenting is the first- 
choice treatment. Interposition of a tube graft is the preferred surgical 
therapy if stenting is less suitable.1529 Hypertension remains an important 
complication, even after successful treatment, and is more common when 
the initial repair is performed in adulthood.1528 Right arm 24 h ambulatory 
BP measurement or exercise tests better detect hypertension.1530,1531
All CoA patients require lifelong follow-up.1532 Imaging of the aorta with 
CMR/CCT every 3–5 years, adjusted to previous imaging findings and type 
of intervention, is required to document post-repair or post-interventional 
complications (such as re-coarctation). Patch repairs are at particular risk 
of repair-site para-anastomotic aneurysms or pseudo-aneurysms, the lat­
ter possibly occurring following interposition grafts as well.1533
Recommendation Table 69 — Recommendations for 
evaluation and medical treatment of patients with 
coarctation of the aorta
Recommendations
Classa
Levelb
In patients with native or repaired coarctation, lifelong 
follow-up is recommended, including regular imaging 
of the aorta with CCT/CMR every 3–5 years (adapted 
to clinical status and previous imaging findings).1534,1535
I
B
Coarctation or re-coarctation repair (either surgical or 
endovascular) is indicated in patients with hypertension 
with an increased non-invasive gradient between the 
upper and lower limbs (decreased ABI) confirmed with 
invasive measurement (peak-to-peak >20 mmHg), with 
a preference for stenting when technically feasible.1536
I
C
In patients with coarctation, BP measurements at both 
arms and one lower extremity are recommended.
I
C
It is recommended to treat hypertension in patients 
with coarctation according to ESC hypertension 
guidelines.300
I
C
Endovascular treatment should be considered in 
patients with hypertension with >50% narrowing 
relative to the aortic diameter at the diaphragm, even 
if the invasive peak-to-peak gradient is <20 mmHg, 
when technically feasible.1537
IIa
C
Endovascular treatment should be considered in 
normotensive patients with an increased non-invasive 
gradient confirmed with invasive peak-to-peak gradient 
>20 mmHg, when technically feasible.1468
IIa
C
© ESC 2024
ABI, ankle–brachial index; BP, blood pressure; CCT, cardiovascular computed tomography; 
CMR, cardiovascular magnetic resonance; ESC, European Society of Cardiology. 
aClass of recommendation. 
bLevel of evidence.
In patients with low surgical risk and ascending 
phenotype bicuspid aortopathy, surgery should be 
considered at a maximum diameter ≥50 mm if any of 
the following is the case:70,153,155,981,1001
• Age <50 years
• Shorter staturee
• Ascending aortic length ≥11 cmf
• Aortic diameter growth rate ≥3 mm per yearg
• Family history of acute aortic syndrome
• Aortic coarctation
• Resistant hypertensionh
• Concomitant non-aortic-valve cardiac surgery
• Desire for pregnancy
IIa
C
Surgery for bicuspid aortopathy in patients 
undergoing aortic valve surgery should be considered 
at a root or ascending diameter ≥45 mm.70,172,969
IIa
C
© ESC 2024
BAV, bicuspid aortic valve; BP, blood pressure; CCT, cardiovascular computed tomography; 
CMR, cardiovascular magnetic resonance; CSA/h, cross-sectional area-to-height ratio; FDRs, 
first-degree relatives; TTE, transthoracic echocardiography. 
aClass of recommendation. 
bLevel of evidence. 
cRoot phenotype = aortic dilatation with sinus diameter > tubular diameter. 
dAscending phenotype = aortic dilatation with tubular diameter > sinus diameter. 
ePatient height between 1.50 and 1.69 m (yielding a CSA/h ratio >13 cm2/m). 
fCurvilinear distance at aortic centreline between the ventriculo-aortic junction and the origin 
of the innominate artery. 
gIn order to ascertain real rapid growth, side-by-side re-evaluation of images obtained with the 
same modality and technique should be performed. 
hHypertension persisting notwithstanding three or more antihypertensive medications 
prescribed by a physician with experience in hypertension treatment, including diuretics.


<!-- PAGE 112 -->

### Page 112

Y
N
≥20 mmHg
<20 mmHg
Perform catheterization
(Re)coarctation not likely
Surveillance: TTE every year and CMR or CCT 3–5 years
BP measurement and investigationa
Intervention
(Class IIa)
Intervention
(Class IIa)
Intervention
(Class I)
BP measurement and investigationa
≥50% narrowing on any imaging modality
HTN
HTN
N
Y
N
Y
N
Y
Suspicion of significant (re)coarctation: any of the following:
Non invasive (right arm-to-leg)
BP gradient >20 mmHg
>50% narrowing on any imaging modality
Abdominal antegrade diastolic flow on DUS
Diastolic run off in the descending thoracic aorta on DUS
Mean gradient >20 mmHg across the CoA region on DUS
Collateral flow >30%
on phase contrast CMR
A
A
B
B
C
C
E
E
D
D
F
F
D
>35 mmHg peak gradient
>20 mmHg mean gradient
Post CoAo
Pre CoAo mL/s
>30% increase
Figure 44 Criteria for significant coarctation/re-coarctation of the aorta and management algorithm. BP, blood pressure; CCT, cardiovascular com­
puted tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; DUS, duplex ultrasound; HTN, hypertension; TTE, trans­
thoracic echocardiography. aDiagnosis of hypertension may require confirmation with ambulatory BP measurement and should also be considered in 
cases of exercise-induced hypertension and/or left ventricular hypertrophy on TTE.
ESC Guidelines                                                                                                                                                                                          3649


<!-- PAGE 113 -->

### Page 113

10.3.2. Aortic arch anatomic variants
A type I arch, where the three great vessels directly arise from the aor­
ta, is the most common form, occurring in about 70% of the population. 
The type II (bovine) arch is the most frequent variant: type II-A (9% of 
the population) has the left common carotid artery arising from the in­
nominate artery, and type II-B (13% of the population) has both the in­
nominate and left common carotid arteries originating from a common 
point on the aortic arch.1538,1539 Limited data suggest that a bovine arch 
is associated with a higher risk of aortic dilation and aortic events/com­
plications.1540,1541 These variations are important to report as they can 
impact specific medical procedures and diagnostic interpretations.
10.3.3. Aberrant subclavian artery and Kommerell’s 
diverticulum
The most common variant is the aberrant right subclavian artery, where 
the right subclavian artery arises as the last branch of the aortic arch, 
usually after the left subclavian artery, and often passes behind the 
oesophagus through the mediastinum, potentially causing dysphagia 
lusoria, respiratory symptoms, or recurrent laryngeal nerve palsy. 
The less common variant, the aberrant left subclavian artery, is typically 
associated with congenital heart defects, such as a right aortic arch. 
However, in adulthood, both variations are often incidental findings.1542
Kommerell’s diverticulum is a remnant of the fourth dorsal aortic 
arch due to incomplete regression, found in 20%–60% of those with 
an aberrant subclavian artery.1543 Surgical intervention is advised for 
a diverticulum orifice >30 mm or combined diverticulum and adjacent 
descending aorta diameter >50 mm, or both.1544 Successful repair has 
been described using open, endovascular, or hybrid approaches de­
pending on anatomy, comorbidities, and expertise.1543
11. Polyvascular peripheral arterial 
disease and peripheral arterial 
disease in patients with 
cardiac diseases
11.1. Polyvascular disease
Polyvascular disease is defined as the simultaneous presence of clinically 
relevant obstructive atherosclerotic lesions in at least two major arter­
ial territories.
11.1.1. Epidemiology and prognosis
Approximately 1 in 4–6 patients with atherosclerosis have PVD 
(Figure 45).620,1545 According to the REACH registry, patients with 
PAD were most likely both to have PVD at baseline and to develop 
PVD over the observational period.1546,1547
PVD independently increases major CV event risk, roughly doubling 
it compared with single arterial bed symptoms.1547–1549 Event rates rise 
with the number of affected arterial beds.1546,1550
11.1.2. Screening for atherosclerosis in other arterial 
territories
Screening for PVD in atherosclerotic patients relies on medical 
history, clinical exam, and ABI measurement. If suspected, start with 
non-invasive DUS, followed by CTA/MRA if needed.1557 Assessing 
concurrent atherosclerosis in other vascular regions is detailed in 
Table 17.
CAD
Carotid stenosis >70%
PAD (ABI ≤0.90)
RAS >70%
9%
5%
16%
4%
61%
39%
22%
18%
7%
15%
25%
70%
60%
40%
20%
0%
19%
14%
23%
10%
CAD
Carotid stenosis >70%
PAD (ABI ≤0.90)
Figure 45 Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease. The graph reports the rates of 
concomitant arterial diseases in patients presenting an arterial disease in one territory (e.g. in patients with CAD, 5%–9% of cases have concomitant 
carotid stenosis >70%). Adapted from 2017 ESC Guidelines on PAD.77,493,784,1549,1551–1556 ABI, ankle–brachial index; CAD, coronary artery disease; 
PAD, peripheral arterial disease; RAS, renal artery stenosis.


<!-- PAGE 114 -->

### Page 114

11.1.2.1. Screening for coronary artery disease in patients with 
symptomatic peripheral arterial disease
The morbidity and mortality of patients with PAD is high due to CV 
complications. Given high CAD event rates in patients with PAD, 
CAD screening may be helpful to optimize medical treatment and is 
not intended to increase the rate of coronary interventions.431
Evaluation can be performed by stress testing or CCT; however, there 
is no evidence that systematic screening for CAD in stable PAD im­
proves outcomes. Coronary angiography is less suitable due to invasive­
ness. In patients requiring lower-limb revascularization, CAD 
management should be based on the 2022 ESC Guidelines on cardiovas­
cular assessment and management of patients undergoing non-cardiac 
surgery.1080
11.1.2.2. Screening for peripheral arterial disease in patients with 
coronary artery disease
In high-risk CAD patients with three-vessel disease or recent ACS, sys­
tematic screening for multisite atherosclerotic disease through ABI and 
DUS of carotids, lower-extremity, and renal arteries did not improve 
outcomes.1563 However, a subgroup analysis of the COMPASS trial 
suggests potential benefits when adding vascular-dose rivaroxaban to 
aspirin in stable patients with CAD and PAD, raising the question of 
whether identifying PAD in stable CAD patients could be advanta­
geous.429,1559 In patients undergoing CABG, the presence of concomi­
tant PAD is associated with a three-fold risk of subsequent CV events 
after CABG.1560,1561 The GSV should be spared whenever possible, 
since the success of peripheral arterial revascularization in complex le­
sions is strongly associated with the availability of sufficient autologous 
venous segments.567,1564
11.1.2.3. Screening for coronary artery disease in patients with 
carotid stenosis
Due to the high prevalence of CAD among patients scheduled for elect­
ive CEA,1565,1566 pre-operative CAD screening, including coronary 
angiography, may be considered in suspected patients.1558 CAD re­
quires prioritization of revascularization according to the patient’s clin­
ical status and the severity of carotid disease and CAD. Coronary 
revascularization should generally be performed first; the exception is 
recently symptomatic patients with unstable neurological symptoms 
in whom carotid revascularization should be prioritized.680
11.1.2.4. Screening for carotid stenosis in patients with coronary 
artery disease
Carotid artery stenosis screening may be useful in patients undergoing 
elective CABG. Ischaemic stroke after CABG is multifactorial,1567 but 
also depends on the degree of carotid disease.1556 Two studies suggest 
that limiting DUS to patients with at least one risk factor (age >65 
years, history of cerebrovascular disease, presence of a carotid bruit, 
multivessel CAD or PAD) identifies most patients with significant 
(≥70%) CS.1555,1562 Nevertheless, addition of CEA to CABG is unlikely 
to provide significant stroke reduction. In a study in patients with CAD 
with >80% CS undergoing staged or synchronous carotid procedures 
(two-thirds were neurologically asymptomatic and 73% had unilateral 
asymptomatic carotid stenosis), in-hospital stroke rates and 30 day 
mortality were similar in patients treated with CABG + CEA and in 
those treated with isolated CABG.1568 Another study suggests that se­
lective use of DUS should be considered before CABG in patients with 
a history of neurological events or PAD.1569
11.1.3. Management of patients with polyvascular 
disease
Polyvascular disease requires proactive management of all modifiable 
risk factors through lifestyle changes and drug therapy. Scientific evi­
dence suggests the benefit of intensified antithrombotic therapy, with 
no increase in risk of bleeding.1570 ILT offers comparable benefits for 
PVD patients and those with single arterial territory disease. 
However, the benefits of ILT in patients with PVD are not dependent 
on baseline LDL-C.1571
Revascularization should be reserved for symptomatic arterial terri­
tories, using the least invasive strategy in a multidisciplinary vascular 
team approach.
11.2. Peripheral arterial disease and heart 
failure
Left ventricular (LV) dysfunction is observed in 20%–30% of PAD pa­
tients,1572,1573 mostly associated with CAD.1574 High aortic stiffness 
Table 17 Need for assessment of associated atherosclerotic disease in additional vascular territories in symptomatic pa­
tients with coronary artery disease, peripheral arterial disease, or carotid stenosis
Leading disease
Assessment in 
other vascular 
territories
CAD
PAD
Carotid stenosis
CAD
May be helpful to optimize medical treatment431 and 
to be considered in patients scheduled for open 
vascular surgery with poor functional capacity or 
significant risk factors or symptoms. 1080
Consider in patients scheduled for 
carotid endarterectomy and 
suspected CAD.1558
PAD
Potential benefits in identifying 
high-risk patients and guiding 
treatment decisions.429,1559–1561
Carotid stenosis
Useful in patients undergoing elective 
CABG.1555,1562
© ESC 2024
CABG, coronary artery bypass grafting; CAD, coronary artery disease; PAD, peripheral arterial disease.
ESC Guidelines                                                                                                                                                                                          3651


<!-- PAGE 115 -->

### Page 115

can increase LV afterload and impair coronary blood flow, resulting in 
hypertension, LV hypertrophy, LV diastolic dysfunction, and 
HF.1575,1576 Skeletal muscle involvement and deconditioning due to 
PAD may aggravate HF severity.1577,1578
Peripheral arterial disease and HF are independently associated with 
poor outcomes and those with concomitant HF have a 30% higher risk 
of MACE and 40% higher risk of all-cause mortality.1574 Evaluation of 
LV function in patients with PAD may be useful for better CV risk strati­
fication and comprehensive management of their CV disease.1579 This is 
of particular importance when an intermediate- or high-risk vascular 
intervention is planned. Expectedly, the presence of PAD in patients 
with HF is also associated with poor outcomes.1580–1584 These patients 
represent a high-risk group in which intense risk-factor modification 
strategies and optimization of HF therapy are warranted.
11.3. Peripheral arterial disease and AF
The prevalence of AF among patients with PAD is around 12%.1585–1590
A meta-analysis revealed that in patients with AF and PAD, risk of all- 
cause mortality, CV mortality, and MACE is 40%, over 60%, and over 
70% higher, respectively compared with patients with AF without 
PAD.1591 PAD is included in the CHA2DS2-VASc (congestive heart fail­
ure, hypertension, age ≥75 [doubled], diabetes, stroke [doubled], vas­
cular disease, age 65 to 74 and sex category [female]) risk score, which 
underlies the prognostic importance of PAD in patients with AF.1592
11.4. Peripheral arterial disease and aortic 
stenosis
Peripheral arterial disease frequently accompanies symptomatic aortic 
stenosis, especially among patients not eligible for surgical aortic valve 
replacement (20%–30%).198,1593–1595 In these patients, pre-procedural 
CCT/CTA or CMR1596 of the aorta and major peripheral arteries is 
mandatory to evaluate the access site for transcatheter aortic valve im­
plantation (TAVI) and plan a closure strategy for the access site. 
Patients with PAD have increased risk of all-cause mortality and vascu­
lar complications after TAVI,198 thus, screening for PAD in these pa­
tients may be helpful.
12. Key messages
Peripheral arterial and aortic diseases are highly prevalent, often asymp­
tomatic, and linked to increased morbidity and mortality. Early diagnosis 
is crucial for better outcomes and management requires a multidiscip­
linary team. CVRF control is crucial to prevent progression and compli­
cations. Despite the benefit of medical therapy, lifestyle changes, 
healthy diet, abstinence from smoking, exercise/rehabilitation, and edu­
cation are essential for effective management. Patient empowerment is 
essential to improve adherence and close/regular monitoring is essen­
tial to improve prognosis. Use of web- or app-based calculators for es­
timation of CV risk in the secondary prevention of ASCVD may aid 
patient motivation for lifestyle changes and adherence to medication.
Peripheral arteries
Atherosclerotic lower-extremity PAD is a chronic disease needing 
lifelong follow-up.
Assessment of walking impairment, functional status, and amputation 
risk is crucial in PAD management.
Ankle–brachial index should be the initial diagnostic test for screen­
ing and diagnosing PAD, and serves as a surrogate marker for CV and 
all-cause mortality. DUS is the first-line imaging method to confirm 
PAD lesions.
Supervised exercise training or, if not available, HBET, improves 
walking and functional performances, and reduces CV risk. Exercise 
training remains underused and increased awareness is warranted.
In asymptomatic PAD patient revascularization is not recommended. 
In symptomatic PAD patient need for interventional treatment, follow­
ing a period of optimal medical treatment and exercise, should be dis­
cussed in a multidisciplinary setting.
Chronic limb-threatening ischaemia increases the risk of CV events, 
needs early diagnosis, rapid referral to a multidisciplinary vascular team, 
and revascularization for limb salvage.
Acute limb ischaemia warrants rapid clinical assessment by a vascular 
team and urgent revascularization.
Duplex ultrasound is the first-line diagnostic modality for carotid 
stenosis. Routine revascularization is not recommended if asymp­
tomatic. In symptomatic patients multidisciplinary assessment is 
recommended.
Recommendation Table 70 — Recommendations for 
screening and management of polyvascular disease and 
peripheral arterial disease with cardiac diseases (see 
also Evidence Table 15)
Recommendations
Classa
Levelb
In patients with PVD, an LDL-C reduction by ≥50% 
from baseline and an LDL-C goal of <1.4 mmol/L 
(<55 mg/dL) are recommended.242,1571
I
A
In patients with PAD and newly diagnosed AF with a 
CHA2DS2-VASc score ≥2, full oral anticoagulation is 
recommended.1597
I
C
Screening for ilio-femoral PAD is recommended in 
patients undergoing TAVI.198,1598
I
B
Carotid DUS should be considered for stable 
patients scheduled for CABG with TIA/stroke within 
the past 6 months without carotid 
revascularization.1556,1569
IIa
B
Continued 
In patients with stable PVD who are symptomatic in 
at least one territory and without high bleeding risk,c 
treatment with a combination of rivaroxaban (2.5 mg 
b.i.d.) and aspirin (100 mg o.d.) should be 
considered.429,1559
IIa
A
Carotid DUS may be considered for stable patients 
scheduled for CABG without TIA/stroke within the 
past 6 months.1555,1562
IIb
C
© ESC 2024
AF, atrial fibrillation; b.i.d., twice daily; CABG, coronary artery bypass grafting; 
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, 
stroke (doubled), vascular disease, age 65 to 74 and sex category (female); DUS, duplex 
ultrasound; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein 
cholesterol; o.d., once daily; PAD, peripheral arterial disease; PVD, polyvascular disease; 
TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack. 
aClass of recommendation. 
bLevel of evidence. 
cPrior history of intracerebral haemorrhage or ischaemic stroke, history of other 
intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible 
gastrointestinal blood loss, other gastrointestinal pathology associated with increased 
bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, 
or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.


<!-- PAGE 116 -->

### Page 116

Atherosclerotic UEAD is most frequently located in the subclavian 
artery and may be suspected because of an absolute inter-arm SBP dif­
ference >10–15 mmHg. DUS is first-line imaging and routine revascu­
larization is not recommended.
The key to early diagnosis of acute and chronic mesenteric ischae­
mia is a high level of clinical suspicion—laboratory tests are unreli­
able for the diagnosis. Acute SMA occlusion requires immediate 
revascularization.
Aorta
Aortic aneurysms are managed based on size, location, and growth 
rate. Small aneurysms are monitored regularly (Guidelines provide 
disease-specific follow-up algorithms), while larger ones may require 
surgical/endovascular repair to prevent rupture.
In aortic root aneurysms, aortic replacement may be considered at 
>52 mm in low-risk patients and at experienced centres.
Aortic diameter is the primary risk factor for aortic events. However, 
evidence supports diameter indexation (especially in extreme BSA po­
pulations) and the use of aortic length (>11 cm), the AHI (>32.1 mm/m), 
growth rate (≥3 mm per year for ascending aorta and arch or >5 mm 
per 6 months in the thoracoabdominall aorta), and age/sex for risk 
assessment.
Multidisciplinary collaboration, hybrid operating rooms, and ad­
vanced stent technology have increased the adoption of hybrid ap­
proaches and endovascular therapies for different thoracoabdominal 
aortic diseases.
Acute aortic syndrome management involves medical treatment in 
critical care units and selective surgical intervention based on location 
and complications. The main problem in these conditions continues 
to be a delay in diagnosing patients or transferring them to an aortic 
centre. Improved diagnostic algorithms and reduced surgical complica­
tions have lowered mortality rates. Surgical/endovascular treatment in 
the subacute phase is advised for high-risk patients with type B aortic 
syndrome.
Suspected genetic aortic conditions require evaluation at experi­
enced centres to assess both the patient and their FDRs for genetic 
studies. Genetic aortic conditions should be considered based on family 
history, syndromic features, age <60 years, and no CVRFs (Guidelines 
offer a screening algorithm for thoracic aorta disease). A comprehen­
sive evaluation of the entire aorta and other vascular territories is re­
commended in HTAD. Recent advances in genetics are enabling 
personalized and patient-centred assessment. This includes using differ­
ent aortic diameter thresholds to indicate surgery and implementing di­
verse surveillance algorithms.
13. Gaps in evidence
There are several areas where robust evidence is still lacking and which 
deserve to be addressed in future clinical research. 
(1) Epidemiology and risk factors in PAAD: 
(a) Improve PAAD risk definition.
(b) Provide contemporary data on PAAD prevalence in Europe.
(c) Inflammation biomarkers, metabolomics, and proteomics may 
have prognostic value in PAAD.
(2) Evaluation of peripheral arteries and aorta: 
(a) Follow-up algorithms can assist PAAD patient management 
but have limitations and evidence on cost-effectiveness is 
needed.
(b) The best methodology for aortic measurements remains to be 
elucidated.
(3) Screening for carotid, peripheral arterial, and aortic diseases: 
(a) Screening in specific populations: research is needed to under­
stand the nuances of screening in particular populations and 
whether modifications to current guidelines are necessary.
(b) Patient outcomes and benefits of screening: impact of screen­
ing on patient outcome should be assessed.
(4) OMT and PAAD: 
(a) Research needed on QoL and workability.
(b) Research needed for optimal preventive strategies.
(c) Exercise therapy and rehabilitation for PAAD should be more 
accessible and employed.
(d) Anti-inflammatory therapy should be investigated.
(e) Antithrombotic therapies in specific risk groups of PAAD and 
patients undergoing revascularization should be addressed.
(5) Aortic aneurysms: 
(a) Discovering novel individualized risk stratification parameters 
beyond well-established markers.
(b) Assessing the safety of fluoroquinolone use in patients with 
aortic aneurysm.
(6) Acute aortic syndromes: 
(a) Assess the management of pregnancy-related AAS.
(b) Identify diagnostic biomarkers other than D-dimer.
(c) Management in uncomplicated TBAD and IMH should be 
assessed.
(7) Genetic aortic diseases: 
(a) Need to refine risk estimation in AD, particularly in HTAD, es­
pecially the risk of type B aortic dissection.
(b) There is insufficient evidence to support the efficacy of any 
medication in reducing the risk of AD.
(8) Sex differences in PAAD: 
(a) Investigate sex and age differences.
(b) Assess the optimal parameter or indexed parameter to guide 
intervention decisions in women with aortic and PAD diseases.
14. Sex differences
Sex differences have been evaluated and discussed in the specific 
sections.
15. ‘What to do’ and ‘What not to 
do’ messages from the guidelines
Table 18 ‘What to do’ and ’What not to do’. ‘What to do and What not 
to do’ lists all Class I and Class III recommendations from the text.
ESC Guidelines                                                                                                                                                                                          3653


<!-- PAGE 117 -->

### Page 117

Table 18 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for clinical and laboratory, and for functional and quality of life, assessment in patients with peripheral arterial and 
aortic disease
When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of arterial circulation.
I
B
To assess PAAD, it is recommended to perform thorough clinical, vascular, and CVRF laboratory evaluation.
I
C
Recommendations for diagnostic tests in patients with peripheral arterial disease
Measurement of the ABI is recommended as the first-line non-invasive test for screening and diagnosis of PAD, using an ABI ≤0.90 as a 
diagnostic criterion.
I
B
In the case of non-compressible ankle arteries or ABI >1.40, additional methods such as TP, TBI or Doppler waveform analysis are 
recommended.
I
B
Recommendations for imaging of the aorta
It is recommended that aortic diameters are measured at prespecified anatomical landmarks, and the largest diameter of the section be 
perpendicular to the longitudinal axis.
I
C
It is recommended in cases of serial imaging of the aorta over time to use the same imaging modality with the same measurement method.
I
C
It is recommended to consider renal function, pregnancy, age, and history of allergy to contrast media to select the optimal imaging modality 
with minimal radiation exposure and lowest iatrogenic risk, except for emergency cases.
I
C
Recommendations for thoracic aortic measurements
TTE is recommended as the first-line imaging technique in evaluating thoracic aortic diseases.
I
B
It is recommended to report aortic diameters using the leading-to-leading edge convention in end-diastole by echocardiography.
I
C
It is recommended to report aortic diameters using the inner-to-inner edge convention in end-diastole by CCT or CMR.
I
C
It is recommended to report aortic diameters from images obtained with the double-oblique technique (not axial images) by CCT or CMR.
I
C
ECG-triggered CCT is recommended for comprehensive diagnosis, follow-up, and pre-invasive treatment assessment of the entire aorta, 
particularly the root and ascending aorta.
I
C
CMR is recommended for diagnosis and follow-up of thoracic aortic diseases, especially when chronic follow-up is required.
I
C
Recommendations for abdominal aortic aneurysm screening
Screening is recommended in men aged ≥65 years and with a history of smoking to reduce the risk of death from ruptured AAA.
I
A
Screening is recommended in FDRs of patients with AAA aged ≥50, unless an acquired cause can be clearly identified.
I
C
Recommendations for lifestyle, physical activity, and patient education
In patients with PAAD, cessation and abstinence from smoking of any kind is recommended to reduce the risk of AD, MI, death, and limb 
ischaemia.
I
A
A healthy diet rich in legumes, dietary fibre, nuts, fruits, and vegetables, with a high flavonoid intake (Mediterranean diet), is recommended 
for CV disease prevention in patients with PAAD.
I
A
Low- to moderate-intensity (or high if tolerated) aerobic activities are recommended in patients with PAD to increase overall and pain-free 
walking distance.
I
A
In patients with PAAD, behavioural counselling to promote healthy diet, smoking cessation, and physical activity is recommended to 
improve the CV risk profile.
I
B
It is recommended to promote patient and caregivers’ education and empowerment through tailored guidance on lifestyle adjustments and 
the importance of regular physical activity.
I
C
Recommendations for antihypertensive therapy in patients with peripheral and aortic disease
In patients with PAAD and hypertension an SBP target towards 120–129 mmHg, if tolerated, is recommended.
I
A
In unilateral RAS patients, it is recommended that antihypertensive medication include ACEIs/ARBs.
I
B
Recommendations for lipid-lowering therapy for patients with peripheral arterial and aortic diseases
In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended.
I
A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with 
atherosclerotic PAAD.
I
A
Statins are recommended in all patients with PAD.
I
A
If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to 
achieve the given target values.
I
B
Continued


<!-- PAGE 118 -->

### Page 118

If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in 
patients with atherosclerotic PAAD, to achieve target values.
I
A
For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is 
recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.
I
B
Fibrates are not recommended for cholesterol lowering.
III
B
Recommendations for the medical management of patients with peripheral arterial and aortic diseases and diabetes
It is recommended to apply tight glycaemic control (HbA1c <53 mmol/mol [7%]) to reduce microvascular complications in patients with 
PAAD.
I
A
SGLT2i with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or 
target HbA1c and concomitant glucose-lowering medication.
I
A
GLP-1RAs with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or 
target HbA1c and concomitant glucose-lowering medication.
I
A
It is recommended to avoid hypoglycaemia in patients with PAAD.
I
B
It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy.
I
C
It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits, followed by agents with proven CV safety, over 
agents without proven CV benefit or safety.
I
C
Recommendations for diagnostic tests in patients with peripheral arterial disease and diabetes, renal failure and wounds
Measuring TP or TBI is recommended in patients with diabetes or renal failure if resting ABI is normal.
I
C
Recommendations for imaging in patients with peripheral arterial disease
DUS is recommended as first-line imaging method to confirm PAD lesions.
I
C
In symptomatic patients with aorto-iliac or multisegmental/complex disease, CTA and/or MRA are recommended as adjuvant imaging 
techniques for preparation of revascularization procedures.
I
C
Analysis of anatomical imaging tests in conjunction with symptoms and haemodynamic tests prior to an invasive procedure is 
recommended.
I
C
Recommendations for exercise therapy in patients with peripheral arterial disease
In patients with symptomatic PAD, SET is recommended.
I
A
In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy.
I
A
Recommendations for antithrombotic therapy in patients with peripheral arterial disease
Use of antiplatelet therapy with aspirin alone (range 75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is recommended for the reduction of 
MACE in patients with symptomatic PAD.
I
A
Long-term DAPT in patients with PAD is not recommended.
III
A
Oral anticoagulant monotherapy for PAD (unless for another indication) is not recommended.
III
A
The routine use of ticagrelor in patients with PAD is not recommended.
III
A
It is not recommended to systematically treat patients with asymptomatic PAD without any sign of clinically relevant ASCVD with 
antiplatelet drugs.
III
B
Recommendations on interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)
In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended.
I
B
It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general 
patient condition.
I
C
In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI.
III
B
In patients with asymptomatic PAD, revascularization is not recommended.
III
C
Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease
It is recommended to regularly, at least once a year, follow-up patients with PAD, assessing clinical and functional status, medication 
adherence, limb symptoms, and CVRFs, with DUS assessment as needed.
I
C
Recommendations for the management of chronic limb-threatening ischaemia
For limb salvage in patients with CLTI, revascularization is recommended.
I
B
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage.
I
C
Recommendations for medical treatment in patients with chronic limb-threatening ischaemia
It is recommended that patients with CLTI are managed by a vascular team.
I
C
In patients with CLTI and ulcers, offloading mechanical tissue stress is recommended to allow wound healing.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3655


<!-- PAGE 119 -->

### Page 119

It is recommended to treat infection with antibiotics.
I
C
Lower-limb exercise training is not recommended in patients with CLTI and wounds.
III
C
Recommendations for interventional treatment of chronic limb-threatening ischaemia
In CLTI patients, it is recommended to perform revascularization as soon as possible.
I
B
In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery.
I
B
In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions.
I
C
An individual risk assessment (weighing the patient’s individual procedural risk of endovascular vs. surgical revascularization) by a 
multidisciplinary vascular team is recommended.
I
C
Recommendations for follow-up in patients with chronic limb-threatening ischaemia
In patients with CLTI, following revascularization it is recommended to follow-up patients on a regular basis.
I
C
At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs.
I
C
Recommendations for the management of patients presenting with acute limb ischaemia
In patients with ALI, it is recommended that an urgent evaluation is performed by a vascular clinician with sufficient experience to assess limb 
viability and implement appropriate therapy.
I
C
In cases of neurological deficit, urgent revascularization is recommended; diagnostic imaging is recommended to guide treatment, provided 
it does not delay treatment, or if the need for primary amputation is obvious.
I
C
In the absence of severe neurological deficit, revascularization is recommended within hours of initial imaging in a case-by-case decision.
I
C
Treatment with analgesics is recommended as soon as possible for pain control.
I
C
It is recommended to monitor for compartment syndrome after revascularization and treat (fasciotomy).
I
C
It is recommended to assess clinical and haemodynamic success following revascularization.
I
C
In patients with ALI, it is recommended to obtain a comprehensive medical history and determine the cause of thrombosis and/or 
embolization.
I
C
Recommendations for carotid artery stenosis assessment
It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis.
I
B
It is recommended to use DUS as first-line imaging to diagnose ICA stenosis.
I
C
It is not recommended to use the ECST method for ICA stenosis assessment.
III
C
Recommendations for antithrombotic treatment in patients with carotid stenosis
In patients with symptomatic CS, not undergoing carotid endarterectomy or stenting, DAPT with low-dose aspirin and clopidogrel (75 mg) 
is recommended for the first 21 days or longer, followed by clopidogrel 75 mg or long-term aspirin to reduce the risk of stroke.
I
A
Recommendations for interventional treatment in patients with asymptomatic carotid artery stenosis
In asymptomatic patients with ICA stenosis, in the absence of high-risk features and with a life expectancy <5 years, routine 
revascularization is not recommended.
III
A
Recommendations for evaluation and medical treatment in patients with symptomatic carotid artery stenosis
DAPT is recommended in the early phase of minor strokes in patients with ICA stenosis, if not revascularized, for at least 21 days, 
considering the bleeding risk.
I
A
It is recommended that symptomatic ICA stenosis patients are assessed by a vascular team including a neurologist.
I
C
Recommendations for interventions in patients with symptomatic carotid artery stenosis
It is recommended to perform CEA of symptomatic 70%–99% ICA stenosis provided a documented 30 day risk of procedural death/stroke 
is <6%.
I
A
If indicated, it is recommended to perform CEA within 14 days in symptomatic ICA stenosis patients.
I
B
OMT is recommended for all symptomatic ICA stenosis patients.
I
A
Revascularization is not recommended in patients with ICA lesions <50%.
III
A
Recommendations for follow-up in patients with carotid artery stenosis
Once-yearly follow-up is recommended to check for CVRFs and treatment compliance.
I
A
After ICA stent implantation, DAPT with aspirin and clopidogrel is recommended for at least 1 month.
I
A
After ICA revascularization, long-term aspirin or clopidogrel is recommended.
I
B
During follow-up, it is recommended to assess neurological symptoms, CVRFs, and treatment adherence at least yearly in patients with CS.
I
C
After ICA revascularization, surveillance with DUS is recommended within the first month.
I
C
Continued


<!-- PAGE 120 -->

### Page 120

Recommendations for the management of subclavian artery stenosis
Bilateral arm BP measurement is recommended for all patients with PAAD.
I
B
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended.
III
C
Recommendations for diagnostic strategies for renal artery disease
DUS is recommended as the first-line imaging modality in patients with suspicion of RAS.
I
B
In cases of DUS-based suspicion of RAS or in inconclusive DUS, MRA or CTA are recommended.
I
B
In patients with atherosclerotic RAS, it is recommended to assess clinical high-risk features and kidney viability when evaluating renal artery 
revascularization.
I
B
Recommendations for treatment strategies for renal artery disease
In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended.
III
A
Recommendations in patients with visceral artery stenosis
In patients with acute mesenteric ischaemia due to acute occlusion of the SMA, endovascular revascularization is recommended.
I
B
In patients with suspected acute or chronic mesenteric ischaemia, CTA is recommended.
I
C
In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended.
I
C
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended.
III
C
Recommendations for primary and secondary prevention in aortic atheromatous plaques
Anticoagulation or DAPT are not recommended in aortic plaques since they present no benefit and increase bleeding risk.
III
C
In patients with an embolic event and evidence of an aortic arch atheroma, intensive lipid management to an LDL-C target <1.4 mmol/L 
(<55 mg/dL) is recommended to prevent recurrences.
I
A
In patients with an embolic event and evidence of an aortic arch atheroma, SAPT is recommended to prevent recurrences.
I
C
Recommendations for initial evaluation of thoracic aorta aneurysm and abdominal aortic aneurysm
When an aortic aneurysm is identified at any location, assessment of the entire aorta is recommended at baseline and during follow-up.
I
C
When a TAA is identified, assessment of the aortic valve (especially for BAV) is recommended.
I
C
Recommendation for the surveillance of patients with thoracic aortic aneurysms (non-heritable thoracic aortic disease)
In thoracic aortic dilatation, TTE is recommended at diagnosis to assess aortic valve anatomy and function, aortic root, and ascending aorta 
diameters. Additionally, a global aortic evaluation using all echocardiographic views is recommended.
I
C
CMR or CCT is recommended for surveillance of patients with aneurysm at the distal ascending aorta, aortic arch, DTA, or TAAA.
I
C
In thoracic aortic dilatation, CCT or CMR is recommended to confirm TTE measurements, rule out aortic asymmetry, and determine 
baseline diameters for follow-up.
I
C
TTE is not recommended for the surveillance of aneurysms in the distal ascending aorta, aortic arch, or DTA.
III
C
Recommendations for surveillance of patients with abdominal aortic aneurysm
DUS surveillance is recommended every 6 months in men with AAA of 50–55 mm and in women with AAA of 45–50 mm.
I
B
DUS is recommended for AAA surveillance.
I
C
CCT or CMR is recommended if DUS does not allow adequate measurement of AAA diameter.
I
B
Recommendations for medical treatment in patients with thoracic aorta or abdominal aortic aneurysms
In patients with aortic aneurysm (TAA and/or AAA), optimal implementation of CV risk management and medical treatment (see detailed 
recommendations in dedicated Tables of Recommendations) are recommended to reduce MACE.
I
C
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
Surgery is recommended in patients with dilatation of the aortic root or ascending aorta with a tricuspid aortic valve and a maximum 
diameter of ≥55 mm.
I
B
Valve-sparing aortic root replacement is recommended in patients with aortic root dilatation if performed in experienced centres and 
durable results are expected.
I
B
VKAs are recommended lifelong for all patients with a Bentall procedure with an MHV prosthesis.
I
B
Recommendations for surgery in aortic arch aneurysms
In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to 
non-aortic causes, open surgical replacement of the arch is recommended.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3657


<!-- PAGE 121 -->

### Page 121

Recommendations for the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic  
aneurysms
In patients with unruptured DTA aneurysm (without HTAD), elective repair is recommended if diameter ≥55 mm.
I
B
In patients without HTAD with unruptured DTA aneurysm, when elective repair is indicated and anatomy is suitable, TEVAR is 
recommended over open repair.
I
B
In patients with DTA aneurysm who undergo TEVAR with planned LSA coverage, it is recommended to revascularize the LSA before 
TEVAR to reduce the risk of SCI and stroke.
I
B
In patients with unruptured degenerative TAAA, elective repair is recommended when the diameter is ≥60 mm.
I
B
Recommendations for the management of patients presenting with abdominal aortic aneurysm
Elective repair is recommended if AAA diameter is ≥55 mm in men or ≥50 mm in women.
I
A
In ruptured AAA with suitable anatomy, endovascular repair is recommended over open repair to reduce peri-operative morbidity and 
mortality.
I
B
In patients with AAA and limited life expectancy (<2 years), elective AAA repair is not recommended.
III
B
Prior to AAA repair, routine evaluation with coronary angiography and systematic revascularization in patients with chronic coronary 
syndromes is not recommended.
III
C
Recommendations for the management of patients presenting with endoleaks
It is recommended to perform 30 day imaging after TEVAR/EVAR, by CCT + DUS/CEUS, to assess the success of intervention.
I
B
It is recommended to re-intervene to achieve a seal in patients with type I endoleak after TEVAR/EVAR.
I
B
It is recommended to re-intervene, principally by endovascular means, to achieve a seal in patients with type III endoleak after TEVAR/EVAR.
I
B
Recommendations for follow-up after treatment of aortic aneurysms
After open repair of TAA, early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years 
and every 5 years thereafter is recommended if findings are stable.
I
B
After TEVAR, follow-up imaging is recommended at 1 and 12 months post-operatively, then yearly until the fifth post-operative year if no 
abnormalities are documented.
I
B
After open repair of AAA, first follow-up imaging is recommended within 1 post-operative year, and then every 5 years thereafter if findings 
are stable.
I
A
After EVAR, follow-up imaging is recommended with CCT (or CMR) and DUS/CEUS at 1 month and 12 months post-operatively, then, if 
no abnormalities are documented, DUS/CEUS is recommended every year, repeating CCT or CMR (based on potential artefacts) every 5 
years.
I
A
Recommendations for diagnostic work-up of acute aortic syndrome
In unstable patients who cannot be transferred to CCT, TOE is recommended for diagnosis and evaluation of the coeliac trunk and 
mesenteric artery.
I
B
In patients presenting with clinical features compatible with possible AAS, a multiparametric algorithm for ruling in or out AAS using the 
ADD-RS is recommended.
I
B
ECG-gated CCT from neck to pelvis is recommended as the first-line imaging technique in patients with a suspected AAS since it is widely 
available, accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).
I
C
In patients with suspected AAS, focused TTE (with use of contrast if feasible) is recommended during the initial evaluation.
I
C
In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications.
I
C
Recommendation for medical treatment in acute aortic syndromes
In patients with AAS, immediate anti-impulse treatment targeting SBP <120 mmHg and heart rate ≤60 b.p.m. is recommended. In cases of 
spinal ischaemia or concomitant brain injury, maintaining higher MAP is recommended.
I
B
Intravenous BBs (e.g. labetalol) are recommended as first-line agents. If necessary, i.v. vasodilators (e.g. dihydropyridine calcium blockers or 
nitrates) could be added.
I
B
Invasive monitoring with an arterial line and continuous three-lead ECG recording, as well as admission to an intensive care unit, is 
recommended.
I
B
In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching 
to oral BBs and, if necessary, up-titration of other BP-lowering agents, is recommended after 24 h if gastrointestinal transit is preserved.
I
B
Adequate pain control to achieve haemodynamic targets is recommended.
I
C
Continued


<!-- PAGE 122 -->

### Page 122

Recommendations for intervention in type A acute aortic dissection
In patients with acute TAAD, emergency surgical consultation and evaluation and immediate surgical intervention is recommended.
I
B
In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic 
root replacement is recommended with a mechanical or biological valved conduit.
I
B
Recommendations for aortic repair strategies in type A acute aortic dissection
In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is 
recommended over valve replacement.
I
B
In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL 
thrombosis rates.
I
B
In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more 
extensive arch replacement.
I
B
Recommendations for the management of malperfusion in the setting of acute aortic dissection
In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is 
recommended.
I
B
Recommendations for the management of patients presenting with acute type B aortic dissection
Medical therapy including pain relief and blood pressure control is recommended in all patients with acute TBAD.
I
B
In patients with complicated acute TBAD, emergency intervention is recommended.
I
B
In patients with complicated acute TBAD, TEVAR is recommended as the first-line therapy.
I
B
Recommendations for the management of patients presenting with chronic type B aortic dissection
Antihypertensive therapy is recommended in all patients with chronic TBAD.
I
B
In chronic TBAD with acute symptoms of malperfusion, rupture, or progression of disease, emergency intervention is recommended.
I
C
In patients with chronic TBAD and a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable 
surgical risk.
I
B
Recommendations for the management of intramural haematoma
In patients with IMH, medical therapy including pain relief and blood pressure control is recommended.
I
C
In type A IMH, urgent surgery is recommended.
I
C
In type B IMH, initial medical therapy under careful surveillance is recommended.
I
C
In uncomplicated type B IMH, repetitive imaging (CCT or CMR) is indicated.
I
C
In complicated type B IMH, TEVAR is recommended.
I
C
Recommendations for the management of penetrating atherosclerotic ulcer
In all patients with PAU, medical therapy including pain relief and blood pressure control is recommended.
I
C
In cases of type A PAU, surgery is recommended.
I
C
In cases of type B PAU, initial medical therapy under careful surveillance is recommended.
I
C
In uncomplicated type B PAU, repetitive imaging (CMR, CCT, or TOE) is recommended.
I
C
In complicated type B PAU, endovascular treatment (TEVAR) is recommended.
I
C
Recommendations for traumatic aortic injury
In cases of severe aortic injury (grade 4), immediate repair is recommended.
I
A
In cases of TAI with suitable anatomy requiring intervention, TEVAR is recommended over open surgery.
I
A
In all TAI patients, medical therapy including pain relief, and blood pressure and heart rate control, is recommended.
I
C
In cases of TAI suspicion, CCT is recommended.
I
C
In cases of moderate aortic injury (grade 3), repair is recommended.
I
C
Recommendations for follow-up after treatment of acute aortic syndrome
After TEVAR for AAS, follow-up imaging is recommended at 1, 6, and 12 months post-operatively, then yearly until the fifth post-operative 
year if no abnormalities are documented.
I
B
In medically treated type B AAD or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging 
findings are stable.
I
C
In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3659


<!-- PAGE 123 -->

### Page 123

Recommendations for the management of patients with heritable thoracic aortic disease
It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making.
I
C
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in 
the care of this patient group.
I
C
Recommendations for genetic testing and aortic screening in aortic disease
In patients with aortic root/ascending aneurysms or thoracic aortic dissection, gathering family history information for at least three 
generations about TAD, unexplained sudden deaths, and peripheral and intracranial aneurysms is recommended.
I
B
In patients with aortic root/ascending aortic aneurysms or thoracic aortic dissection and risk factors for HTAD, genetic counselling at an 
expert centre and subsequent testing, if indicated, is recommended.
I
B
In patients with HTAD who have a pathogenic/likely pathogenic variant, genetic testing of at-risk biological relatives (i.e. cascade testing) is 
recommended, irrespective of age.
I
C
In patients with TAD with risk factors for HTAD, with a negative family history of TAD and in whom no (likely) pathogenic variant is 
identified, TTE screening aortic imaging of FDRs is recommended.
I
B
Recommendations for imaging in women with Turner syndrome
To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to 
BSA [m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and 
assess the risk of aortic dissection.
I
C
It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending 
ASI and concomitant lesions.
I
C
Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome
In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended.
I
C
Recommendations for vascular imaging in Marfan syndrome
In patients with MFS, TTE is recommended: 
• At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factors
• At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factors
• At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factors
I
C
In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aorta imaging by CMR or CCT and DUS is 
recommended at the first evaluation, and subsequently every 3–5 years if stable.
I
C
In patients with MFS who have undergone aortic root replacement, surveillance imaging of the thoracic aorta by CMR (or CCT) is 
recommended at least every 3 years.
I
C
Recommendations for medical treatment in Marfan syndrome
In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to 
reduce the rate of aortic dilatation.
I
A
Recommendations for aortic surgery in Marfan syndrome
Surgery is indicated in patients with MFS who have aortic root disease with a maximal aortic sinus diameter ≥50 mm.
I
B
Surgery to replace the aortic root and ascending aorta, using the valve-sparing surgery technique, is recommended in patients with MFS or 
related HTAD with aortic root dilatation when anatomical features of the valve allow its preservation and the surgeon has specific expertise.
I
B
Recommendations for pregnancy in women with Marfan syndrome
It is recommended that all women with MFS: 
• Have a pre-conception evaluation to address the risks of maternal CV and other complications
• Have follow-up in a centre with access to a pregnancy heart and vessel team
I
C
It is recommended that couples in which a partner has or is at risk of HTAD be offered pre-conception genetic counselling.
I
C
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy.
I
C
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth.
I
C
Intake of BBs during pregnancy is recommended.
I
C
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm.
I
C
ARBs are not recommended during pregnancy.
III
B
Recommendations for physical exercise in patients with Marfan syndrome
It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and 
pre-existing fitness.
I
C
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS.
I
C
Continued


<!-- PAGE 124 -->

### Page 124

### 16 Evidence tables

Evidence tables are available on the European Heart Journal website.
17. Data availability statement
No new data were generated or analysed in support of this research.
18. Author information
Author/task 
force 
Member 
Affiliations: 
Gisela 
Teixido-Tura, Cardiovascular Imaging section and Aortic diseases 
Unit (VASCERN), Department of Cardiology, Vall d’Hebron Hospital 
Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′ 
Hebron Institut de Recerca (VHIR), Barcelona, Spain, Centro de 
Investigación Biomédica en Red de Enfermedades Cardiovasculares, 
Instituto de Salud Carlos III, Madrid, Spain; Stefano Lanzi, 
Department of Angiology, Lausanne University Hospital, University of 
Lausanne, Lausanne, Switzerland; Vinko Boc, Department of 
Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, 
Slovenia; Eduardo Bossone, Department of Public Health, 
University of Naples “Federico II”, Naples, Italy, Department of 
Translational Medical Sciences, University of Naples “Federico II”, 
Naples, Italy; Marianne Brodmann, Division of Angiology, Medical 
Recommendations for imaging follow-up in Loeys–Dietz syndrome
In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth, is 
recommended.
I
C
In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance 
with CMR or CCT or DUS every 1–3 years is recommended.
I
C
Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease
Annual monitoring of the aortic root/ascending aorta with TTE to evaluate aortic root/ascending aorta enlargement is recommended.
I
C
Imaging of the aorta with CMR/CCT every 3–5 years is recommended.
I
C
Recommendations for bicuspid aortic valve-associated aortopathy management
When a BAV is first diagnosed, initial TTE to assess diameters of the aorta at several levels is recommended.
I
B
Surgery for bicuspid aortopathy is recommended when the maximum aortic diameter is ≥55 mm.
I
B
Surgery for bicuspid aortopathy of the root phenotype is recommended when the maximum aortic diameter is ≥50 mm.
I
B
CCT or CMR of the entire thoracic aorta is recommended at first diagnosis and when important discrepancies in measurements are found 
between subsequent TTE controls during surveillance, or when the diameter of the aorta exceeds 45 mm.
I
C
Screening by TTE in FDRs of BAV patients with root phenotype aortopathy and/or isolated aortic regurgitation is recommended.
I
C
Surveillance serial imaging by TTE is recommended in BAV patients with a maximum aortic diameter >40 mm, either with no indication for 
surgery or after isolated aortic valve surgery, after 1 year, then if stability is observed, every 2–3 years.
I
C
Recommendations for evaluation and medical treatment of patients with coarctation of the aorta
In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR 
every 3–5 years (adapted to clinical status and previous imaging findings).
I
B
Coarctation or re-coarctation repair (either surgical or endovascular) is indicated in patients with hypertension with an increased 
non-invasive gradient between the upper and lower limbs (decreased ABI) confirmed with invasive measurement (peak-to-peak 
>20 mmHg), with a preference for stenting when technically feasible.
I
C
In patients with coarctation, BP measurements at both arms and one lower extremity are recommended.
I
C
It is recommended to treat hypertension in patients with coarctation according to ESC hypertension guidelines.
I
C
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.
I
A
In patients with PAD and newly diagnosed AF with a CHA2DS2-VASc score ≥2, full oral anticoagulation is recommended.
I
C
Screening for ilio-femoral PAD is recommended in patients undergoing TAVI.
I
B
© ESC 2024
AAA, abdominal aortic aneurysm; AAS, acute aortic syndrome; ABI, ankle–brachial index; ACEI, angiotensin-converting enzyme inhibitor; AD, aortic dissection; ADD-RS, aortic dissection 
detection-risk score; AF, atrial fibrillation; AHI, aortic height index; ALI, acute limb ischaemia; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; ASI, aortic 
size index; BAV, bicuspid aortic valve; BB, beta-blocker; BP, blood pressure; b.p.m., beats per minute; CCT, cardiovascular computed tomography; CEA, carotid endarterectomy; CEUS, 
contrast-enhanced ultrasound; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category 
(female); CLTI, chronic limb-threatening ischaemia; CMR, cardiovascular magnetic resonance; CS, carotid artery stenosis; CTA, computed tomography angiography; CV, cardiovascular; 
CVRF, cardiovascular risk factor; DAPT, dual antiplatelet therapy; DTA, descending thoracic aorta; DUS, duplex ultrasound; ECG, electrocardiogram; ECST, European Carotid Surgery 
Trial; ESC, European Society of Cardiology; FDR, first-degree relative; FL, false lumen; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HTAD, 
heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; i.v., intravenous; LDL-C, low-density lipoprotein cholesterol; LSA, left subclavian artery; 
MACE, major adverse cardiac event; MAP, mean arterial pressure; MFS, Marfan syndrome; MHV, mechanical heart valve; MI, myocardial infarction; MRA, magnetic resonance 
angiography; NASCET, North American Symptomatic Carotid Endarterectomy Trial; o.d., once daily; OMT, optimal medical treatment; PAAD, peripheral arterial and aortic diseases; 
PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; PCSK9, proprotein convertase subtilisin/kexin type 9; PVD, polyvascular disease; RAS, renal artery stenosis; 
QoL, quality of life; SAPT, single antiplatelet therapy; SBP, systolic blood pressure; SCI, spinal cord ischaemia; SET, supervised exercise training; SGLT2i, sodium-glucose co-transporter-2 
inhibitor; SMA, superior mesenteric artery; T2DM, type 2 diabetes mellitus; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm; TAAD, type A aortic dissection; 
TAD, thoracic aortic disease; TAI, traumatic aortic injury; TAVI, transcatheter aortic valve implantation; TBAD, type B aortic dissection; TBI, toe–brachial index; TOE, transoesophageal 
echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TP, toe pressure; TS, Turner syndrome; TTE, transthoracic echocardiography; vEDS, vascular Ehlers– 
Danlos syndrome; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3661


<!-- PAGE 125 -->

### Page 125

University Graz, Graz, Austria; Alessandra Bura-Rivière, Vascular 
Medicine Department, Toulouse University Hospital, Toulouse, France, 
Faculty of Medicine, University Toulouse 3, Toulouse, France; Julie De 
Backer, Cardiology and Center for Medical Genetics, Ghent 
University 
Hospital, 
Ghent, 
Belgium; 
Sebastien 
Deglise, 
Department of Vascular Surgery, University Hospital Lausanne 
(CHUV), Lausanne, Switzerland; Alessandro Della Corte, 
Department of Translational Medical Sciences, University of 
Campania “Luigi Vanvitelli”, Naples, Italy, Unit of Cardiac Surgery, 
Monaldi Hospital, Naples, Italy; Christian Heiss, Department of 
Clinical and Experimental Medicine, University of Surrey, Guildford, 
United Kingdom, Vascular Medicine Department, Surrey and Sussex 
Healthcare 
NHS 
Trust, 
Redhill, 
United 
Kingdom; 
Marta 
Kałużna-Oleksy, 1st Department of Cardiology, Poznan University 
of Medical Sciences, Poznan, Poland; Donata Kurpas, Division of 
Research Methodology, Department of Nursing, Faculty of Nursing 
and Midwifery, Wroclaw Medical University, Poland; Carmel 
M. McEniery, Medicine, University of Cambridge, Cambridge, 
United Kingdom; Tristan Mirault, Vascular Medicine Department, 
Université Paris Cité, Paris, France, Vascular Medicine Department, 
Assistance Publique Hôpitaux de Paris-APHP, Hôpital Européen 
Georges-Pompidou, Paris, PARCC U970 team 5 Innate and 
Adaptative Immunity in Vascular Diseases, INSERM, Paris, France; 
Agnes A. Pasquet, Department of Cardiovascular Diseases, 
Cliniques Universitaires Saint Luc, Brussels, Belgium, IREC/CARD, 
UCLouvain, Brussels, Belgium; Alex Pitcher, The Heart Centre, 
Oxford University NHS Foundation Trust, Oxford, United Kingdom; 
Hannah A.I. Schaubroeck, Department of Intensive Care 
Medicine, Ghent University Hospital, Ghent, Belgium; Oliver 
Schlager, Division of Angiology, Department of Medicine II, Medical 
University of Vienna, Vienna, Austria; Per Anton Sirnes, 
Cardiology Practice, Kardiokonsult, Son, Norway, Cardiology section, 
Volvat Medical Centre, Moss, Norway; Muriel G. Sprynger, 
Cardiology, University Hospital of Liège, Liège, Belgium; Eugenio 
Stabile, Division of Cardiology, Health Science Department, 
Università della Basilicata, Potenza, Italy; Françoise Steinbach 
(France), ESC Patient Forum, Sophia Antipolis, France; Matthias 
Thielmann, Department of Thoracic and Cardiovascular Surgery, 
West-German Heart and Vascular Center, University Hospital Essen, 
University Duisburg-Essen, Essen, Germany; Roland R.J. van 
Kimmenade, Department of Cardiology, Radboud University 
Medical Center, Nijmegen, Netherlands; and Maarit Venermo, 
Department of Vascular Surgery, University of Helsinki and Helsinki 
University Hospital, Helsinki, Finland.
19. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers:
Alessia Gimelli (CPG Review Co-ordinator) (Italy), Jean-Baptiste 
Ricco (CPG Review Co-ordinator) (France), Elena Arbelo (Spain), 
Christian-Alexander Behrendt (Germany), Michael Böhm (Germany), 
Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio 
Buccheri (Sweden), Gill Louise Buchanan (United Kingdom), Christina 
Christersson (Sweden), Gert J. de Borst (Netherlands), Marco De 
Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United 
Kingdom), Lynne Hinterbuchner (Austria), Borja Ibanez (Spain), 
Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan 
(Sweden), Klaus Kallenbach2 (Luxemburg), Lars Køber (Denmark), 
Konstantinos C. Koskinas (Switzerland), Juraj Madaric1 (Slovakia), 
Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer 
(Israel), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen 
(Denmark), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), 
Barbara Rantner (Germany), Bianca Rocca (Italy), Xavier Rossello 
(Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland), 
Sabine Steiner (Germany), Isabella Sudano (Switzerland), Martin 
Teraa 
(Netherlands), 
Ilonca 
Vaartjes 
(Netherlands), 
Rafael 
Vidal-Perez (Spain), Christiaan Vrints (Belgium), and Katja Zeppenfeld 
(Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2024 ESC Guidelines for the management of peripheral ar­
terial and aortic diseases:
Algeria: Algerian Society of Cardiology, Mohammed El Amine 
Bouzid; Armenia: Armenian Cardiologists Association, Arsen 
A. Tsaturyan; Austria: Austrian Society of Cardiology, Georg Delle 
Karth; Azerbaijan: Azerbaijan Society of Cardiology, Fuad Samadov; 
Belgium: Belgian Society of Cardiology, Antoine Bondue; Bosnia 
and Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Alden Begić; Bulgaria: Bulgarian Society of Cardiology, 
Ivo Petrov; Croatia: Croatian Cardiac Society, Majda Vrkic 
Kirhmajer; Cyprus: Cyprus Society of Cardiology, Georgios 
P. Georghiou; Czechia: Czech Society of Cardiology, Pavel 
Procházka; Denmark: Danish Society of Cardiology, Torsten 
B. Rasmussen; Egypt: Egyptian Society of Cardiology, Yasser 
A. Sadek; Estonia: Estonian Society of Cardiology, Jaagup Truusalu; 
Finland: Finnish Cardiac Society, Petri Saari; France: French Society 
of Cardiology, Guillaume Jondeau; Germany: German Cardiac 
Society, Christiane Tiefenbacher; Greece: Hellenic Society of 
Cardiology, Kimon Stamatelopoulos; Hungary: Hungarian Society 
of Cardiology, Endre Kolossváry; Iceland: Icelandic Society of 
Cardiology, Elín Hanna Laxdal; Ireland: Irish Cardiac Society, Monica 
Monaghan; Israel: Israel Heart Society, Jonathan Koslowsky; Italy: 
Italian Federation of Cardiology, Ciro Indolfi; Kazakhstan: 
Association of Cardiologists of Kazakhstan, Nursultan Kospanov; 
Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera 
Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova; 
Latvia: Latvian Society of Cardiology, Ainars Rudzitis; Lithuania: 
Lithuanian Society of Cardiology, Andrius Berūkštis; Luxembourg: 
Luxembourg Society of Cardiology, Katja Lottermoser; Malta: 
Maltese Cardiac Society, Maryanne Caruana; Morocco: Moroccan 
Society of Cardiology, Raissuni Zainab; North Macedonia: 
National Society of Cardiology of North Macedonia, Marijan 
Bosevski; Norway: Norwegian Society of Cardiology, Stein Samstad; 
Portugal: Portuguese Society of Cardiology, Ana Teresa Timoteo; 
Romania: Romanian Society of Cardiology, Ovidiu Dragomir 
Chioncel; San Marino: San Marino Society of Cardiology, Pier 
Camillo Pavesi; Slovakia: Slovak Society of Cardiology, Maria 
Rasiova; Slovenia: Slovenian Society of Cardiology, Borut Jug; 
Spain: Spanish Society of Cardiology, Ariana González Gomez; 
Sweden: 
Swedish 
Society 
of 
Cardiology, 
Stefan 
James; 
Switzerland: Swiss Society of Cardiology, Marc Righini; Tunisia: 
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Amine 
Tarmiz; Turkey: Turkish Society of Cardiology, Eralp Tutar; and 
Ukraine: Ukrainian Association of Cardiology, Maksym Sokolov.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom),


<!-- PAGE 126 -->

### Page 126

Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez 
(Spain), 
Lars 
Køber 
(Denmark), 
Konstantinos 
C. 
Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
